

As. 118.258

Señor

**DIRECTOR DIVISIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO**

E.

S.

D.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 11-130828- -00010-0000

Fecha: 2013-12-02 15:55:50 Dep. 2020 DIR.NUEVASCREAC
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 523 RESPUESTA Folios: 119

REF: Expediente No. **11 130.828-** solicitud de patente de invención a favor de **EISAI R&D MANAGEMENT CO., LTD.** Título **COMPOSICIÓN DE LIPOSOMA QUE CONTIENE ERIBULINA Y/O SU SAL FARMACOLÓGICAMENTE PERMISIBLE.**

RESPUESTA A EXAMEN DE FONDO

JUAN PABLO CADENA SARMIENTO, portador de la tarjeta profesional No. 57.492 del C.S.J., obrando como apoderado de la sociedad solicitante me permito dar respuesta al oficio número 13262 relacionado con la patentabilidad de la presente invención y notificado por fijación en lista el 30 de Julio de 2013.

De manera atenta nos permitimos remitir a su Despacho los siguientes documentos, adjuntos al presente memorial:

- i. Un nuevo capítulo descriptivo, en donde se modificaron las expresiones "*hidruro de sodio*", "*hidruro de potasio*" y "*ácido glutamínico*", reemplazándolas respectivamente por "*hidróxido de sodio*", "*hidróxido de potasio*" y "*ácido glutámico*", lo cual soluciona tales errores de traducción, lo cual no supone ninguna ampliación de la materia divulgada en concordancia con la respectiva solicitud internacional (Párrafos [0018], [0027], [0042] y [0050] de la solicitud PCT/JP2010/055770).
- ii. Un nuevo pliego reivindicatorio compuesto de catorce (14) reivindicaciones, las cuales encuentran total sustento en el capítulo descriptivo y no exceden en ningún momento el alcance de la invención inicialmente divulgada.

- iii. Anexo 1: DRUMMOND DC (1999) "Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors" *Pharmacological Reviews*, 51(4), 691-743.
- iv. Anexo 2: Apéndice I - Tabla de composiciones liposomales comercializadas hasta Septiembre de 2013, según información de la FDA (*Food and Drug Administration*) de los Estados Unidos.

Como consideración inicial, y atendiendo a las sugerencias del señor Examinador, nos permitimos modificar el título de la presente solicitud, el cual ahora define una "Composición de liposoma que contiene eribulina y/o su sal farmacológicamente permisible", guardando estrecha relación con la materia reivindicada, más específicamente el compuesto activo de la invención.

Igualmente, consideramos pertinente destacar que el nuevo pliego reivindicatorio contiene únicamente dos reivindicaciones independientes (reivindicaciones 1 y 13), considerando que el señor Examinador objetó el anterior pliego por contener un excesivo número de reivindicaciones independientes. Así pues, afirmamos que el nuevo pliego reivindicatorio define claramente el objeto a proteger, el cual corresponde a una composición de liposoma y el método de preparación de la misma.

En cuanto a las objeciones de claridad, consideramos que el nuevo pliego reivindicatorio soluciona y supera cada una de ellas toda vez que no incluye las objetadas reivindicaciones 4, 5-9, 12-18, 26 y 30, por tanto nos permitimos asegurar que el actual pliego reivindicatorio es completamente claro y conciso.

Novedad

La reivindicación 1 fue considerada no novedosa en vista de las enseñanzas del documento D2 ("*Lipid membrane structure containing anti-mt-mmp monoclonal antibody*", US2007112176), el cual divulga una estructura de membranas lipídicas que contiene un anticuerpo monoclonal anti-metaloproteinasa de matriz de tipo membrana, el cual puede ser empleado como sistema de entrega de fármacos para entregar eficientemente ingredientes activos y/o genes a células tumorales.

Con el fin de superar tal objeción, las características técnicas divulgadas en las anteriores reivindicaciones 3 y 12 fueron incorporadas en la nueva reivindicación 1, la cual ahora divulga:

“Una composición de liposoma caracterizada porque contiene un liposoma, y (i) eribulina y/o su sal farmacológicamente permisible, (ii) al menos una sal de amonio (NH_4^+) y (iii) ácido cítrico en la fase interna del liposoma.”

De acuerdo con lo anterior, nos permitimos afirmar que la materia reclamada en la nueva reivindicación 1 es novedosa en comparación con lo divulgado por el documento D2, ya que éste falla en divulgar la combinación de al menos una sal de amonio (NH_4^+) y ácido cítrico, según lo establecido previamente las reivindicaciones 3 y 12.

Consecuentemente, partiendo de que dicho documento D2 únicamente revela una composición que comprende un anticuerpo monoclonal, mesilato de eribulina y sulfato de amonio, respetuosamente solicitamos sea reconocido el cumplimiento del requisito de novedad por parte de la actual reivindicación 1.

Nivel inventivo

Las reivindicaciones dependientes 12, 13 y 26 fueron objetadas por ser obvias en vista de las enseñanzas del documento D1 (“*Liposomes useful for drug delivery*”, US2007116753) en combinación con los documentos D2 (“*Lipid membrane structure containing anti-mt-mmp monoclonal antibody*”, US2007112176) y D3 (Peleg-Shulman, T., et al. “*Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance*” Biochimica et Biophysica Acta 1510 (2001) 278-291).

Teniendo en cuenta que las reivindicaciones objetadas fueron removidas del actual pliego reivindicatorio, procederemos a demostrar el cumplimiento del requisito en mención por parte de las nuevas reivindicaciones independientes (reivindicaciones 1 y 13), las cuales divulgan:

“1. Una composición de liposoma caracterizada porque contiene un liposoma, y (i) eribulina y/o su sal farmacológicamente permisible, (ii) al menos una sal de amonio (NH₄⁺) y (iii) ácido cítrico en la fase interna del liposoma.”

“13. Un método para preparar una composición de liposoma que contiene eribulina y/o su sal farmacológicamente permisible, que comprende:

(a) preparar un liposoma, en donde la fase interna del liposoma contiene sulfato de amonio y ácido cítrico;

(b) preparar una solución que contiene eribulina y/o su sal farmacológicamente permisible; y

(c) combinar el liposoma preparado en (a) con la solución preparada en (b) para obtener una composición de liposoma que contiene eribulina y/o su sal farmacológicamente permisible atrapada en la fase interna del liposoma.”

Teniendo en cuenta las anteriores reivindicaciones, consideramos pertinente agregar que las mismas encuentran sustento en los ejemplos consignados en el capítulo descriptivo de la presente solicitud, guardando concordancia específicamente con la modalidad 9.

Centrándonos entonces en el documento D1, el cual divulga composiciones liposomales que contienen amonios sustituidos y/o polianiones, nos permitimos afirmar que a pesar de que dicha anterioridad divulga liposomas y sus respectivos métodos de fabricación, sus enseñanzas están enfocadas en liposomas que contienen sales de amonio sustituidas y polianiones junto a una ingrediente activo como el agente antitumoral doxorubicina.

En este sentido, encontramos que dicho documento D1 sugiere fuertemente el uso de una sal de amonio “en donde al menos uno de los radicales R1, R2, R3 y R4 es un grupo orgánico” (Párrafo [0006] del documento D1) lo cual se opone de manera concreta a la materia reivindicada.

En contraste, la presente invención comprende **sales de amonio (NH_4^+)** las cuales claramente se encuentran sin sustituir, por lo tanto afirmamos que la presente invención no habría podido derivarse de manera obvia a partir de tales enseñanzas, las cuales son opuestas a lo reivindicado.

De hecho, además de que el documento D1 no enseña ni sugiere la utilización de una sal de amonio libre de la forma (NH_4^+), es notorio que dicha anterioridad califica de inapropiado el uso de dichas sales, tal y como se puede evidenciar en el Párrafo [0066] de tal documento:

"Los compuestos de amonio que poseen átomos de hidrógeno que pueden reaccionar fácilmente mediante sustitución nucleofílica, y por demás reaccionar químicamente con las entidades atrapadas en el liposoma, son por lo tanto capaces de perjudicar la integridad química de dichas entidades durante o posterior al proceso de carga (atrapamiento) de los liposomas. En consecuencia, es deseable que un compuesto de amonio sustituido se encuentre químicamente más inerte, careciendo entonces de funciones químicas inestables y que reaccionen fácilmente con los demás componentes del liposoma, incluida la entidad encapsulada."

Así pues, en vista del anterior fragmento del documento D1, concluimos que tal anterioridad alejaría al versado en la materia de la presente invención, ya que –aparte de recomendar el uso de sales de amonio sustituidas–, manifiesta y expone las presuntos **inconvenientes** de incluir sales de amonio (NH_4^+), oponiéndose a la materia divulgada por la presente invención.

Adicionalmente, la misma anterioridad menciona lo siguiente respecto a los resultados positivos e inesperados alcanzados mediante el uso de sales de amonio poco reactivas:

"Inesperadamente, descubrimos que las composiciones liposomales que comprenden en su espacio interior un amonio sustituido terciario y cuaternario que no tenga un hidrógeno sustituible, o un amonio primario o secundario estéricamente impedido, en el cual se impida el acceso a un hidrógeno del amonio

*mediante un grupo orgánico voluminoso vecino (...) presenta no sólo una sorprendente **capacidad de carga**, sino también **estabilidad mejorada de la entidad atrapada, impidiendo su liberación prematura del liposoma en el cuerpo humano.***

De acuerdo con lo anterior, además de fallar en anticipar el uso de sales de amonio de la forma (NH₄⁺), el documento D1 reporta resultados excelentes al incluir sales de amonio sustituidas en la composición de liposoma que divulga.

A la luz de tales resultados, consideramos que la anterioridad descrita en D1 falla en motivar la sustitución de dicha sal por cualquier otra, y por tanto el versado en la materia preferiría conservar la composición divulgada en dicho documento, en lugar de cambiarla o combinarla con las enseñanzas de cualquier otra anterioridad.

En consecuencia, nos permitimos afirmar que un versado en la materia, al consultar dicho documento D1, se vería motivado más bien a concebir una composición de liposoma incluyendo preferentemente una sal de amonio terciaria, cuaternaria o estéricamente impedida para su preparación, y no una sal de amonio (NH₄⁺) como la reivindicada, la cual podría perjudicar los excelentes resultados que reporta el documento D1.

Considerando lo anterior, es evidente que la composición de liposoma reivindicada, al incluir sales de amonio no sustituidas (NH₄⁺) (como lo son el sulfato de amonio, el citrato de amonio y el tartrato de amonio) rompe con el **prejuicio técnico** que se deriva de las enseñanzas de D1, lo cual deseamos sea considerado como un indicio adicional de nivel inventivo, ya que la composición reivindicada demostró una excelente relación de atrapamiento, según expone la siguiente tabla:

Tabla 6 de la presente solicitud

No.	Fase acuosa interna	pH de fase externa	Relación de atrapamiento (%)
1	Sulfato de amonio 100 mM ácido cítrico 30 mM pH = 7.5	7.5	72.9
2		8.0	79.8
3		8.5	86.4
4		9.0	92.8
5		9.5	98.5
6		10.0	100.0
7		10.5	99.3

Como se puede apreciar en la anterior tabla, la relación de atrapamiento (%) lograda por la composición reivindicada que comprende sulfato de amonio –una sal de amonio no sustituida, valga aclarar– nunca es inferior al 72.9 %, y logra un atrapamiento total del fármaco (100 %) a un pH 10.0.

Ahora bien, considerando los demás documentos que el señor Examinador cita (documentos D2 y D3), encontramos que ninguno de ellos brinda enseñanzas suficientes que motiven, por encima de los resultados alcanzados por la composición del documento D1, llevar a cabo modificación alguna a tal anterioridad.

Luego entonces, una persona versada en la materia que consulte los documentos D1, D2 y D3, ya sea independientemente o en combinación, no encontraría motivación o sugerencia alguna que lleve a modificar la composición divulgada en D1, y mucho menos concebiría la inclusión de una sal de amonio del tipo NH_4^+ , cuyo uso no es divulgado en D2 o D3, y es claramente indebido según las enseñanzas de D1.

A pesar de lo anterior, y suponiendo que dichas anterioridades sí brindaran motivos suficientes al versado en la materia para desarrollar una nueva composición liposomal a partir de tales enseñanzas, nos permitimos afirmar que el versado en la materia no sería capaz de alcanzar de manera obvia la presente invención, en la medida que los documentos D1, D2 y D3 no divulgan todas y cada una de las características técnicas reivindicadas.

Enfocándonos ahora en el principio activo que comprende la presente invención (eribulina y/o una sal farmacéuticamente permisible de la misma), nos permitimos afirmar que un versado en la materia no tendría ninguna motivación ni esperanza de éxito relacionada con modificar el activo doxorubicina de la composición de D1, por un agente activo diferente. Tal conclusión se deriva del estudio titulado “*Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors*”, llevado a cabo por los mismos inventores de la anterioridad descrita en D1 (Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D), el cual se encuentra adjunto al presente memorial bajo el nombre de Anexo 1.

En tal publicación científica, Drummond DC, et al. revelan *“la importancia de mantener una formulación estable para el uso efectivo de liposomas como sistemas de entrega de fármacos y que una composición de lípidos particular no es necesariamente la mejor para todos los fármacos, incluso si ambos tienen naturaleza anfipática. Cada fármaco deberá considerarse de modo individual”* (Anexo 1, página 717).

Así pues, considerando que el cambio aleatorio del fármaco contenido en una composición liposomal constituye una acción incierta de la cual puede derivarse un resultado positivo o negativo, nos permitimos afirmar que el versado en la materia no cuenta en ningún momento con alguna motivación o expectativa de éxito derivada de la presunta sustitución del activo doxorubicina por eribulina y/o su sal farmacológicamente permisible, ni dicha sustitución podría concebirse de manera obvia a partir de las enseñanzas de cualquiera de los documentos citados por su Despacho.

Retomando la Tabla 6 incluida previamente, nos permitimos agregar también que dichos resultados, notoriamente positivos, no podrían haberse alcanzado fruto de una modificación insensata o azarosa de alguna composición liposomal divulgada en el estado de la técnica. Muy por el contrario, la materia reivindicada obedece a un estudio juicioso que involucra la elección cuidadosa de cada uno de los componentes, estudios farmacocinéticos y estudios de estabilidad asociados con la composición reivindicada, lo cual claramente es muestra del uso de la actividad inventiva.

Adicionalmente, dicho Anexo 1 menciona que *“los resultados obtenidos con DOX (doxorubicina) no pueden extrapolarse necesariamente a otro fármaco, incluso si presentara una estructura química similar”* (Anexo 1, página 727), en referencia a los resultados de atrapamiento, estabilidad y liberación alcanzados por la anterioridad en estudio. En concordancia, el Anexo 1 recomienda llevar a cabo un análisis del comportamiento de la composición liposomal en combinación con cada fármaco específico, mencionando la posibilidad de que, por cuestiones netamente químicas, la estabilidad de una composición puede resultar desfavorable al cambiar el fármaco que ésta comprende, involucrando de manera negativa el comportamiento de la composición final.

Ahora bien, retomando lo mencionado en dicho Anexo 1 con referencia a la estructura química de un agente activo, nos permitimos reproducir a continuación las estructuras de los compuestos doxorubicina (Figura 1) y eribulina (Figura 2), para posterior análisis:




Figura 1. Estructura de doxorubicina.




Figura 2. Estructura de la eribulina.

Según las anteriores Figuras, es posible notar que no hay ninguna similitud estructural entre los dos fármacos en mención, por tanto ni siquiera podría afirmarse que por su similitud estructural o de comportamiento químico, sería obvio reemplazar el activo doxorubicina por eribulina, siendo esta una molécula mucho más voluminosa y por tanto, representa un reto mayor al buscar atraparlo en un sistema de entrega liposomal efectivo.

Igualmente, consideramos que el hecho de que ambos activos presenten una actividad antitumoral demostrada, no constituye motivación o argumento suficiente para decidir el reemplazo de uno por otro, toda vez que la eficacia de la composición liposomal –en términos de atrapamiento, estabilidad y liberación– podría verse perjudicada.

Partiendo entonces de que los documentos D2 y D3 únicamente se limitan a mencionar el uso del fármaco eribulina, y no proporcionan ejemplos ni sugieren la manera en la que sería posible preparar una composición de liposoma que contenga dicho fármaco, consideramos que tales documentos no complementan de manera adecuada las enseñanzas del ya analizado documento D1, y por tanto no sería posible derivar de manera obvia la invención aquí reivindicada a partir del arte previo.

Por otra parte, consideramos pertinente agregar que la afirmación de Drummond DC, et al. respecto a la necesidad de adaptar una composición liposomal a cada fármaco distinto a doxorubicina, encuentra total sustento en evidencias actuales del tipo de composiciones liposomales desarrolladas y actualmente comercializadas con el aval de la *Food and Drug Administration* (FDA) de los Estados Unidos, las cuales se describen abiertamente en el Anexo 2 adjunto al presente memorial.

De acuerdo con dicho Anexo 2, es posible notar que en el mercado se encuentran disponibles únicamente trece composiciones liposomales, de las cuales ninguna comprende exactamente la misma formulación de activos y excipientes, y además **no se ha aprobado** ninguna composición liposomal que contenga el activo **eribulina**, lo cual soporta y evidencia aún más la total patentabilidad de la composición de liposoma que se reivindica.

Partiendo entonces de las enseñanzas de los citados Anexos 1 y 2, es posible concluir que para un versado en la materia **no existían expectativas de éxito** que motivaran el desarrollo de una composición de liposoma incluyendo el fármaco eribulina, sobre todo teniendo en cuenta que no existen en el mercado formulaciones similares a la reivindicada, y que Drummond DC, et al. afirman que no es posible extrapolar una composición liposomal exitosa –en términos de atrapamiento, estabilidad y liberación– a cualquier otro fármaco, y que por tanto es necesario llevar a cabo estudios pertinentes para cada fármaco diferente.

A este respecto, consideramos pertinente agregar que no basta con identificar de manera aislada e inconexa las diferentes características esenciales reivindicadas en documentos del arte previo para concluir que la invención habría podido derivarse de manera obvia, sino que de acuerdo con el Instructivo de Examen de Solicitudes de Patentes de Invención y Modelo de Utilidad (Numeral 2.13.5 del Capítulo II), tales anterioridades deben indicar al versado en la materia cómo llevar a cabo la presente invención, lo cual evidentemente no sucede en el presente caso.

Así pues, encontramos que la afirmación del señor Examinador, referente a que *“la persona del oficio normalmente versada en la materia incluiría el fármaco eribulina mesilato en la fase interna de un liposoma que incluye sulfato de amonio revelada en el documento D2 en la composición liposomal divulgada en el documento D1”* carece de todo sustento, ya que se deriva de un análisis en retrospectiva que no permite establecer un juicio subjetivo sobre la invención, y que adicionalmente –como se ha demostrado ya– la combinación de las enseñanzas de los documentos citados por su Despacho se opone completamente a los conocimientos generales de dicho versado en la materia en vista del estado de la técnica.

En contraste, consideramos que el versado en la materia no habría podido imaginar o predecir que el fármaco eribulina podría formularse exitosamente en una composición de liposoma, y que tras desarrollar dicha composición podrían alcanzarse los favorables resultados previamente descritos en la Tabla 6, proporcionando así un eficaz sistema de entrega para dicho fármaco, el cual reiteramos es completamente novedoso e inventivo.

Es así que, de acuerdo con los motivos y evidencias ya discutidas, nos permitimos concluir que:

- i. Ninguna de las anterioridades revela o sugiere una composición de liposoma que comprende la combinación de al menos una sal de amonio (NH_4^+) y ácido cítrico, como revela la **reivindicación 1** así como las ventajas previamente discutidas.
- ii. Ninguno de dichos documentos divulga o anticipa un método para la preparación de una composición de liposoma, en donde la fase interna del liposoma contiene sulfato de amonio y ácido cítrico, de acuerdo con la **reivindicación 13**.

Por tanto consideramos que la invención descrita en la totalidad del pliego reivindicatorio, cumple a cabalidad con el requisito de novedad y nivel inventivo, el cual solicitamos sea reconocido por su Despacho.

En vista de lo anteriormente expuesto, respetuosamente solicitamos el retiro de las objeciones de la presente solicitud y la concesión del privilegio solicitado, ya que en opinión del solicitante cumple con todos los requisitos establecidos en la decisión 486.

Atentamente,



JUAN PABLO CADENA SARMIENTO

T.P. No. 57.492 del C.SJ.

C.C. 80.410.337 de Usaquén

Calle 70 A No. 4 - 41

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800.176.089-2

-/-

118258



Industria y Comercio
SUPERINTENDENCIA

RECIBO DE CAJA

No. 13 - 111930

Bogotá D.C., Noviembre 01 de 2013 - 17:23:38

RECIBIDO DE : BRIGARD & CASTRO S.A.

NI 860.047.372

***** Soporte del Pago *****

TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	VR PAGO
RECIBO DE CA	999999999	111914	01/11/2013		33.315.000.00

***** Conceptos Pagados *****

CANT.	RENTISTICO	CONCEPTO	Vr. UNDITARIO	Vr. CONCEPTO
4	50005-01-01 SOLICITUDES	1607 REIVINDICACION PATENTE UNITARIA ADICIONAL A LAS 10 INIC	30.000.00	120.000.00
				\$120.000.00

SON: **CIENTO VEINTE MIL PESOS MONEDA CORRIENTE**

Responsable: _____

Recibo de Caja Aplicado al Expediente No. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 11-130828- -00010-0000

Fecha: 2013-12-02 15:55:50
Tra. 11 PATENTE IYII
Act. 523 RESPUESTA

Dep. 2020 DIR. NUEVAS CREAC
Eve: 378 FASE NACIONAL I
Folios: 119

Sede Centro: Carrera 13 No. 27 - 00 Pisos 3,4,5 y 10 Bogotá, D.C.- Colombia

Web: www.sic.gov.co e-mail: Info@sic.gov.co Conmutador: (571) 5870000 Fax: (571) 5870284 Línea: 018000-910165 Call Center: (571) 6513240

, Noviembre 1 de 2013 - 17:23:45

REIVINDICACIONES

1. Una composición de liposoma caracterizada porque contiene un liposoma, y (i) eribulina y/o su sal farmacológicamente permisible, (ii) al menos una sal de amonio (NH_4^+) y (iii) ácido cítrico en la fase interna del liposoma.
2. La composición de liposoma de acuerdo con la reivindicación 1, en donde dicha sal de amonio (NH_4^+) se selecciona de sulfato de amonio, citrato de amonio y tartrato de amonio.
3. La composición de liposoma de acuerdo con la reivindicación 1 o 2, en donde la fase interna del liposoma contiene además al menos un ajustador de pH.
4. La composición de liposoma de acuerdo con la reivindicación 3, en donde dicho ajustador de pH se elige de una base.
5. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 4, en donde dicha eribulina y/o su sal farmacológicamente permisible es mesilato de eribulina.
6. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde la composición de liposoma es en forma líquida.
7. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde el liposoma contiene fosfatidilcolina hidrogenada.
8. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde el liposoma contiene colesterol.
9. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde el liposoma contiene condensado de metoxipolietilenglicol.

10. La composición de liposoma de acuerdo con la reivindicación 9, en donde dicho condensado de metoxipolietilenglicol corresponde a condensado de diestearoilfosfatidil etanolamino polietilenglicol.

11. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 6, en donde el liposoma contiene fosfatidilcolina hidrogenada, colesterol y condensado de diestearoilfosfatidil etanolamino polietilenglicol.

12. La composición de liposoma de acuerdo con cualquiera de las reivindicaciones 1 a 6, en donde el liposoma contiene fosfatidilcolina hidrogenada de soya, colesterol y polietilenglicol 2000-fosfatidiletanolamina.

13. Un método para preparar una composición de liposoma que contiene eribulina y/o su sal farmacológicamente permisible, que comprende:

(a) preparar un liposoma, en donde la fase interna del liposoma contiene sulfato de amonio y ácido cítrico;

(b) preparar una solución que contiene eribulina y/o su sal farmacológicamente permisible; y

(c) combinar el liposoma preparado en (a) con la solución preparada en (b) para obtener una composición de liposoma que contiene eribulina y/o su sal farmacológicamente permisible atrapada en la fase interna del liposoma.

14. El método para preparar una composición de liposoma de acuerdo con la reivindicación 13, que comprende además:

(d) ajustar el pH de la fase externa del liposoma a un valor suficiente para lograr el atrapamiento de dicha eribulina o su sal farmacológicamente permisible en la fase interna del liposoma, en donde dicho pH de la fase externa del liposoma es de 7 a 10.

COMPOSICIÓN DE LIPOSOMA

Campo Técnico

La presente invención se relaciona a una composición de liposoma novedosa que contiene eribulina o su sal farmacológicamente permisible. La presente invención también se relaciona a un método de manufactura de la composición de liposoma.

Técnica Antecedente

Los liposomas son vesículas cerradas microscópicas que tienen una fase interna encerrada por una o más bicapas de lípido, y son capaces de contener material soluble en agua en la fase interna, y material lipofílico en la bicapa de lípido. Cuando se atrapa un compuesto activo en el liposoma, y se suministra al tejido objetivo, como atrapar el compuesto activo en el liposoma con alta eficiencia y como asegurar la retención estable del compuesto activo por el liposoma constituyen puntos importantes.

Cuando se atrapan compuestos lipofílicos en el liposoma, una alta relación de atrapamiento puede ser lograda de manera relativa fácilmente, pero excepto en casos de compuestos que tienen muy alta afinidad de membrana tal como anfotericina B (el agente principal en el fármaco liposomal AmBisome), la estabilidad de retención en el suero sanguíneo es ordinariamente baja, y es difícil obtener mejora suficiente en la farmacocinética. Con respecto a métodos para atrapar compuestos solubles en agua en el liposoma, hay varios métodos tal como el método de película de lípido (método de Vórtice), método de evaporación de fase inversa, método de remoción de surfactante, método de congelación-descongelación y métodos de carga remotos (método de gradiente de pH, método de gradiente de ión). Sin embargo, es solamente los métodos de carga remotos que proporcionan una relación de atrapamiento cercana al 100%; una relación de atrapamiento en el orden de solamente 5 a 30% se obtiene de los otros métodos.

Como métodos de carga remotos, se conocen aquellos que usan un gradiente de pH y gradiente de ión de sulfato de amonio. El método de gradiente de pH, que es un método de carga remoto usando un gradiente de pH, es una técnica para incorporar compuestos en el liposoma al usar el movimiento del equilibrio de disociación molecular/iónico debido al pH del compuesto objetivo.

Como un ejemplo de un compuesto atrapado en el liposoma por el

método de gradiente de pH, se puede mencionar, por ejemplo, doxorubicina (DOX, pKa; 8.2). Después de preparar una solución de liposoma con una solución reguladora de pH 4, la fase externa del liposoma se reemplaza con una solución reguladora de pH 7. En el caso donde se adiciona DOX a esta solución de liposoma, como la DOX molecular en la solución de pH es lipofílica, esta migra a la membrana de liposoma antes que a la fase acuosa. En el caso donde la DOX que ha migrado a la membrana de liposoma además hace contacto con la fase interna de pH 4 de liposoma, ésta llega a ser iónica, y se incorpora en la fase interna del liposoma. De esta manera, DOX se transporta de la fase externa a la fase interna de liposoma por un movimiento de equilibrio de disociación (ver la Literatura no de Patente 1, Literatura no de Patente 2 y Literatura de Patente 1).

Una variedad de técnicas se han reportado para mejorar este tipo de método de carga remoto. En la Literatura no de Patente 3, se divulga una técnica para mejorar la relación de atrapamiento de compuestos activos al adicionar etanol junto con el compuesto activo a la fase externa del liposoma, cuando el método de gradiente de pH se conduce en el liposoma de la composición especial llamada liposoma libre de colesterol.

En la Literatura de Patente 2, además del gradiente de pH, se divulga una técnica para mejorar la relación de atrapamiento de compuestos activos al tener iones de cobre existentes en la fase interna del liposoma.

En lugar de un gradiente de pH en el método de gradiente de pH, el método de sulfato de amonio, que es un método de carga remoto usando un gradiente de ión de sulfato de amonio, es una técnica para incorporar compuestos activos en la fase interna de liposoma al usar un gradiente de ión tal como sulfato de amonio bivalente (ver la Literatura no de Patente 1 y la Literatura de Patente 3).

Además de un gradiente de ión basado en sulfato de amonio, la Literatura de Patente 4 divulga una técnica para incorporar compuestos activos en el liposoma al adicionar ácido borónico junto con el compuesto activo a la fase externa del liposoma.

En lugar de un gradiente de ión basado en sulfato de amonio, la Literatura de Patente 5 divulga una técnica en donde, comparado con el caso donde se utiliza sulfato de amonio, la velocidad de liberación del compuesto activo se mejora al incorporar el compuesto activo en el liposoma utilizando un gradiente de ión de anión de ácido glucurónico.

Así, desde el punto de vista de la relación de atrapamiento, los métodos de carga remotos son excelentes métodos de atrapamiento. Sin embargo, en el caso donde se utilizan métodos de carga remotos, excepto para casos especiales tal como Doxil (una preparación de liposoma de DOX) donde el compuesto activo atrapado en la fase interna del liposoma se cristaliza, hay el problema de que el compuesto activo tiende fugarse del liposoma en el suero sanguíneo, y que la estabilidad de retención del compuesto activo es baja.

Como es descrito en lo anterior, con los métodos técnicos convencionales, la situación actual es que es difícil lograr la coexistencia de una alta relación de atrapamiento del compuesto activo en el liposoma y estabilidad de retención del compuesto activo en el liposoma.

Literatura de la Técnica Previa

Literaturas de Patente

Literatura de Patente 1: Patente Norteamericana No. 5192549, Especificación

Literatura de Patente 2: Publicación Internacional de PCT WO2006/037230, Folleto

Literatura de Patente 3: Patente Norteamericana No. 5316771, Especificación

Literatura de Patente 4: Patente Norteamericana No. 6051251, Especificación

Literatura de Patente 5: Publicación Internacional de PCT WO 2005/046643, Folleto

Literaturas no de Patente

Literatura no de Patente 1: Yasuyuki Sazuka, "Liposome Preparation Method," "New Developments in Liposome Application: Toward the Development of Artificial Cells" (Kazunari Akiyoshi, Shigeru Tsujii, editorial supervision)" NTS, (2005), pp. 33-37.

Literatura no de Patente 2: Mayer LD y colaboradores, Biochimica et Biophysica Acta, (1986), 857: pp. 123-126.

Literatura no de Patente 3: N. Dos Santos y colaboradores, Biochimica et Biophysica Acta, (2004), 166(1): pp. 47-60.

Breve Descripción de la Invención

Problema a ser Resuelto por la Invención

El objetivo de la presente invención es proporcionar una composición de liposoma con una alta relación de atrapamiento y estabilidad de

retención del compuesto activo.

Medios Para Resolver el Problema

Como un resultado de la investigación diligente dirigida en resolver los problemas mencionados en lo anterior, los presente inventores descubrieron, con respecto a una composición de liposoma cuyo compuesto activo es eribulina o su sal farmacológicamente permisible, que la relación de atrapamiento y estabilidad de retención del compuesto activo en la composición de liposoma son extremadamente altas, de esta manera perfeccionando la presente invención.

Específicamente, la presente invención es como sigue.

(1)

Una composición de liposoma que contiene liposoma, y que contiene un compuesto activo en la fase interna de liposoma, en donde el compuesto activo es eribulina o su sal farmacológicamente permisible.

(2)

La composición de liposoma de acuerdo con 1, en donde la composición de liposoma esta en una forma sólida o líquida.

(3)

La composición de liposoma de acuerdo con 1 o 2, en donde la fase interna de liposoma además contiene sal de amonio.

(4)

La composición de liposoma de acuerdo con 3, en donde la concentración de la sal de amonio mencionada en lo anterior es 10 mM o más alta.

(5)

La composición de liposoma de acuerdo con cualquiera de 1 a 4, en donde la fase interna de liposoma además contiene sal, ácido, base y/o aminoácido.

(6)

La composición de liposoma de acuerdo con 5, en donde la concentración de la sal mencionada en lo anterior es 1 a 300 mM.

(7)

La composición de liposoma de acuerdo con 5 o 6, en donde la concentración del ácido mencionado en lo anterior es 1 a 300 mM.

(8)

La composición de liposoma de acuerdo con cualquiera de 5 a 7,

en donde la concentración del aminoácido mencionado en lo anterior es 1 a 300 mM.

(9)

La composición de liposoma de acuerdo con cualquiera de 5 a 8, en donde la concentración de la base mencionada en lo anterior es 1 a 300 mM.

(10)

La composición de liposoma de acuerdo con cualquiera de 1 a 9, en donde la concentración del compuesto activo mencionado en lo anterior es 0.01 a 300 mg/ml.

(11)

La composición de liposoma de acuerdo con cualquiera de 1 a 10, en donde el compuesto activo mencionado en lo anterior es mesilato de eribulina.

(12)

La composición de liposoma de acuerdo con cualquiera de 1 a 11, en donde la fase interna de liposoma además contiene sulfato de amonio, ácido cítrico y un compuesto activo.

(13)

La composición de liposoma de acuerdo con cualquiera de 1 a 12, en donde la fase externa de liposoma contiene azúcar, electrolito y/o aminoácido.

(14)

La composición de liposoma de acuerdo con cualquiera de 1 a 13, en donde la fase externa de liposoma contiene azúcar o electrolito, y aminoácido.

(15)

La composición de liposoma de acuerdo con cualquiera de 13 a 14, en donde la concentración de la azúcar mencionada en lo anterior es 2 a 20%.

(16)

La composición de liposoma de acuerdo con cualquiera de 13 a 15, en donde la concentración del aminoácido mencionado en lo anterior es 1 a 300 mM.

(17)

La composición de liposoma de acuerdo con cualquiera de 1 a 16, en donde la fase externa de liposoma contiene sacarosa o cloruro de sodio, e

histidina.

(18)

La composición de liposoma de acuerdo con cualquiera de 1 a 17, en donde la fase interna de liposoma no contiene sustancialmente ciclodextrina.

(19)

La composición de liposoma de acuerdo con cualquiera de 1 a 18, en donde contiene fosfatidilcolina hidrogenada.

(20)

La composición de liposoma de acuerdo con cualquiera de 1 a 19, en donde el liposoma contiene colesterol.

(21)

La composición de liposoma de acuerdo con cualquiera de 1 a 20, en donde el liposoma contiene condensado de metoxipolietilenglicol.

(22)

La composición de liposoma de acuerdo con 21, en donde el condensado de metoxipolietilenglicol mencionado en lo anterior es condensado de diestearoilfosfatidil etanolamino polietilenglicol.

(23)

La composición de liposoma de acuerdo con cualquiera de 1 a 22, en donde el liposoma contiene fosfatidilcolina hidrogenada, colesterol y condensado de diestearoilfosfatidil etanolamino polietilenglicol.

(24)

La composición de liposoma de acuerdo con 23, que contiene 10 a 80% de la fosfatidilcolina hidrogenada mencionada en lo anterior, 1 a 60% de colesterol mencionado en lo anterior y 0 a 50% del condensado de diestearoilfosfatidil etanolamino polietilenglicol mencionado en lo anterior.

(25)

La composición de liposoma de acuerdo con cualquiera de 1 a 24, en donde el liposoma contiene fosfatidilcolina de soja hidrogenada, colesterol y polietilenglicol 2000-fosfatidiletanolamina.

(26)

Un método de manufactura de la composición de liposoma de acuerdo con cualquiera de 1 a 25, que incluye: una etapa en la cual se proporciona un líquido de dispersión de liposoma que contiene liposoma;

una etapa en la cual el líquido de dispersión de liposoma mencionado en lo anterior se mezcla con el compuesto activo mencionado en lo

anterior; y

una etapa en la cual el compuesto activo mencionado en lo anterior se introduce en la fase interna de liposoma del líquido de dispersión de liposoma mencionado en lo anterior.

(27)

El método de acuerdo con 26, en donde el líquido de dispersión de liposoma mencionado en lo anterior no contiene sustancialmente sal de amonio en la fase externa de liposoma.

(28)

El método de acuerdo con 26 o 27, en donde el pH de la fase externa de liposoma del líquido de dispersión de liposoma mencionado en lo anterior es 3 a 10.

(29)

El método de acuerdo con cualquiera de 26 a 28, en donde el pH de la fase externa de liposoma de líquido a dispersión de liposoma mencionado en lo anterior es 7 a 10.

(30)

El método de acuerdo con 28 o 29, en donde el pH mencionado en lo anterior es el pH de la fase externa de liposoma de líquido de dispersión de liposoma mencionado en lo anterior en la etapa en la cual se mezclan el líquido de dispersión de liposoma mencionado anterior y el compuesto activo mencionado en lo anterior.

(31)

El método de acuerdo con cualquiera de 26 a 30, en donde la etapa en la cual el líquido de dispersión de liposoma mencionado en lo anterior se proporciona incluye: una etapa en la cual se proporciona una solución preparatoria de liposoma que contiene liposoma y que contiene sal de amonio en la fase interna de liposoma y la fase externa de liposoma; en la etapa en la cual la fase externa de liposoma de la solución preparatoria de liposoma mencionada en lo anterior se sustituye o se diluye.

(32)

El método de acuerdo con 31, en donde la etapa en la cual la fase externa de liposoma mencionado en lo anterior se sustituye o se diluye es una etapa en la cual el pH de la fase externa de liposoma se hace más alto que el pH de la fase interna de liposoma.

(33)

El método de acuerdo con 31 o 33, en donde la etapa en la cual la fase externa de liposoma mencionado en lo anterior se sustituye o se diluye es una etapa en la cual la diferencia en el pH de la fase interna de liposoma y el pH de la fase externa de liposoma es 1 a 5.

(34)

El método de acuerdo con cualquiera de 26 a 33, en donde el pH de la fase interna de liposoma mencionado en lo anterior es 3 a 9.

(35)

El método de acuerdo con cualquiera de 26 a 34, en donde el pH de la fase interna de liposoma mencionado en lo anterior es 4 a 9.

(36)

El método de acuerdo con cualquiera de 26 a 35, en donde el pH de la fase interna de liposoma mencionado en lo anterior es 5 a 8.

(37)

El método de acuerdo con cualquiera de 26 a 36, en donde la fase externa de liposoma es una solución que contiene electrolito en la etapa en la cual se introduce el compuesto activo mencionado en lo anterior.

(38)

El método de acuerdo con cualquiera de 26 a 37, en donde el líquido de dispersión de liposoma mencionado en lo anterior sustancialmente no contiene ciclodextrina en la fase interna de liposoma.

(39)

El método de acuerdo con cualquiera de 26 a 38, que además contiene una etapa en la cual se neutraliza el pH de la fase externa de liposoma.

Efecto de la Invención

De acuerdo con la presente invención, es posible ofrecer una composición de liposoma novedosa. La composición de liposoma de la presente invención atrapa un compuesto activo en la fase interna de liposoma con un alto grado de eficiencia, y tiene una alta estabilidad de retención del compuesto activo.

Breve Descripción de los Dibujos

(Fig. 1) muestra los cambios *in vitro* en la concentración de mesilato de eribulina en una composición de liposoma en el suero sanguíneo de rata (37°C).

(Fig. 2) muestra la actividad antitumoral *in vivo* del mesilato de

eribulina debido al liposoma en ratones desnudos que llevan cáncer FaDu.

(Fig. 3) muestra la actividad antitumoral *in vivo* del mesilato de eribulina debido al liposoma en ratones desnudos que llevan cáncer ACHN.

Mejor Modo Para Llevar a Cabo la Invención

La presente invención se describe específicamente por modos para llevar a cabo la invención, pero la presente invención no está limitada a los siguientes modos para llevar a cabo la invención, y se puede llevar a cabo con una variedad de modificaciones.

Los contenidos divulgados en la literatura referenciados en la presente invención son incorporados en la presente invención como referencia.

Definiciones

"Liposoma" significa vesículas cerradas microscópicas que tienen una fase interna encerrada por bicapa de lípido. En la presente invención, el liposoma incluye liposoma de una sola membrana pequeña (SUV: vesícula unilaminar pequeña), liposoma de una sola membrana grande (LUV: vesícula unilaminar grande), liposoma de una sola membrana todavía más grande (GUV: vesícula unilaminar gigante), liposoma de multicapa que tiene múltiples membranas concéntricas (ML V: vesícula multilaminar), liposoma que tiene múltiples membranas que no son concéntricas, sino irregulares (MVV: vesícula multivesicular), etc.

"Fase interna de liposoma" significa una región acuosa encerrada en la bicapa de lípido del liposoma, y se utiliza con el mismo significado como "fase de agua interna" y "fase de agua interna de liposoma". "Fase alterna de liposoma" significa la región no encerrada por la bicapa de lípido de liposoma (esto es, la región aparte de la fase interna y la bicapa de lípido) en el caso en donde el liposoma se dispersa en líquido.

"Composición de liposoma" significa una composición que contiene liposoma y que además contiene mesilato de eribulina en la fase interna de liposoma. En la presente invención, la composición de liposoma incluye formas tanto sólidas como líquidas.

"Líquido de dispersión de liposoma" significa una composición que contiene liposoma, y es una composición que precede la introducción del compuesto activo en la fase interna de liposoma.

"Solución preparatoria de liposoma" significa una composición que contiene liposoma, y es una composición que precede el ajuste de la fase externa de liposoma para propósitos de atrapar mesilato de eribulina en la fase

interna de liposoma.

"Reactivo de liposoma" significa un líquido de dispersión de liposoma, en el caso donde está en una forma líquida, en el caso donde está en una forma sólida, esto significa un reactivo del cual el líquido de dispersión de liposoma se puede obtener por disolución o suspensión en el solvente preescrito. El solvente se describe enseguida. Como es descrito enseguida, un reactivo de liposoma sólido se puede obtener, por ejemplo, el secar un líquido de dispersión de liposoma.

En la presente especificación, el "mezclado de sólido y líquido" incluye la disolución y suspensión de sólido en el líquido, y el mezclado, disolución y suspensión se utilizan de una manera mutuamente intercambiable. De manera similar, el solvente y medio de dispersión también se utilizan de una manera mutuamente intercambiable.

Por otra parte, la composición de liposoma, líquido de dispersión de liposoma, solución preparatoria de liposoma y el reactivo de liposoma de la presente invención sustancialmente no contienen ciclodextrina. "No contiene sustancialmente ciclodextrina" significa que no hay adición de ciclodextrina. Es suficiente si la ciclodextrina no es contenida en una cantidad en la cual la mejora de la solubilidad (solubilidad nominal) del compuesto activo debido a la ciclodextrina es significativamente observable, y aún en el caso donde se adicionan una cantidad en la cual la mejora en la solubilidad del compuesto activo no es significativamente observable, no se excluye de la implementación de la presente invención.

Además, como un modo preferido de la presente invención, "el líquido de dispersión de liposoma que no contiene sustancialmente sal de amonio en la fase externa de liposoma" significa que la sal de amonio no se adiciona a la fase externa de liposoma del líquido de dispersión de liposoma. La adición de sal de amonio en una cantidad que está dentro de intervalo que puede lograr el objetivo de la presente invención no va a ser excluido de la implementación de la presente invención. En el caso donde la sal de amonio es contenida en la fase externa del liposoma de una solución preparatoria de liposoma, es posible preparar un líquido de dispersión de liposoma que no contiene sustancialmente sal de amonio al sustituir o diluir la fase externa de liposoma de la solución preparatoria de liposoma utilizando una solución que no contiene sustancialmente sal de amonio.

(Compuesto activo)

El compuesto activo de la presente invención es eribulina o su sal farmacológicamente permisible (después en la presente alguna vez referida como "eribulina, etc."). No hay limitación particular sobre la sal farmacológicamente permisible mientras que se formen la eribulina y la sal, ya sea sal de ácido inorgánico o sal de ácido orgánico. Por ejemplo, se puede mencionar sal de ácido clorhídrico, sal de ácido sulfúrico, citrato, sal de ácido bromhídrico, sal de ácido yodhídrico, sal de ácido nítrico, bisulfato, sal de ácido fosfórico, sal de ácido super fosfórico, sal de ácido isonicotínico, sal de ácido acético, sal de ácido láctico, sal de ácido salicílico, sal de ácido tartárico, sal de ácido pantoténico, sal de ácido ascórbico, sal de ácido succínico, sal de ácido maleico, sal de ácido fumárico, sal de ácido glucónico, sal de ácido sacarínico, sal de ácido fórmico, sal de ácido benzoico, sal de ácido glutámico, sal de ácido metanosulfónico, sal de ácido etanosulfónico, sal de ácido bencensulfónico, sal de ácido p-toluensulfónico, sal de ácido pamórico, (pamoato) y así sucesivamente. Preferibles entre estas son la sal de ácido clorhídrico, sal de ácido sulfúrico, sal de ácido acético, sal de ácido fosfórico, citrato, sal de ácido mesílico y más preferibles de todos es la sal de ácido mesílico. Esto es, el compuesto activo preferible de la presente invención es mesilato de eribulina. Por otra parte, como la sal farmacológicamente permisible de eribulina, es aceptable usar eribulina y sal de aluminio, calcio, litio, magnesio, zinc [sic], sodio, zinc y dietanolamina. La eribulina o su sal farmacológicamente permisible es el compuesto o su sal registrada en el folleto de la Publicación Internacional de PCT WO 99/65894 o la Patente Norteamericana 62465 (los contenidos registrados en estas patentes son incorporados en la presente por referencia) y tienen acción farmacológica que incluyen acción antitumoral y acción antimetabólica. La eribulina o su sal farmacológicamente permisible exhiben acción antitumoral con respecto a melanoma, fibrosarcoma, leucemia monocítica, cáncer de colon, cáncer ovárico, cáncer de seno, cáncer de hueso, cáncer de próstata, cáncer de pulmón y fibroblastos ras-transformados.

Sin embargo, como compuestos activos que se pueden combinar con eribulina, etc., se puede seleccionar de entre compuestos utilizados en los campos de medicinas (incluyendo fármacos de diagnóstico), productos cosméticos, productos alimenticios y así sucesivamente. Con respecto a los compuestos activos, es aceptable combinar uno o más compuestos diferentes de eribulina, etc.

Como compuestos activos, se pueden mencionar compuestos de

bajo peso molecular, etc. Entre estos, los compuestos usados como agentes antitumorales, agentes antibacterianos, agentes antiinflamatorios, agentes de infarto antimiocardiacos y agente de contraste son adecuados.

Con respecto al peso molecular del compuesto activo, es preferible un intervalo de 100 a 2000, es más preferible un intervalo de 200 a 1500, y es aún más preferible un intervalo de 300 a 1000. Dentro de estos intervalos, la permeabilidad de membrana de liposoma del compuesto activo es generalmente satisfactoria, y la presente invención se puede aplicar adecuadamente.

Los compuestos activos incluyen compuestos solubles en agua y compuestos lipofílicos, y mientras que son más o menos solubles en agua o solventes acuosos, la presente invención se puede aplicar.

No hay limitaciones particulares sobre agentes antitumorales en la presente invención, y se pueden mencionar, por ejemplo, derivados de camptotecina tal como clorhidrato de irinotecan, clorhidrato de nogitecan, exatecan, RFS-2000, lurtotecan, BNP-1350, Bay-383441, PNU-166148, IDEC-132, BN-80915, DB-38, DB-81, DB-90, DB-91, CKD-620, T-0128, ST-1480, ST-1481, DRF-1042, DE-310; derivado de taxano tal como hidruro de docetaxel, docetaxel, paclitaxel, IND-5109, BMS-184476, BMS-188797, T-3782, TAX-1011, SB-RA-31012, SBT-1514 Y DJ-927; ifosfamida, clorhidrato de nimstina, carvocon, ciclofosfamida, dacarbazina, tiotepa, busulfan, melfaran, ranimustina, fosfato de estramustina sódico, 6-mercaptopurina ribosido, enocitabina, clorhidrato de gemcitabina, carmufur, citarabina, ocfosfato de citarabina, tegafur, doxifluridina, hidroxycarbamida, fluorouracilo, metotrexato, mercaptopurina, fosfato de fludarabina, actinomicina D, clorhidrato de aclararubicina, clorhidrato de idarubicina, clorhidrato de pirarubicina, clorhidrato de epirubicina, clorhidrato de daunorubicina, clorhidrato de doxorubicina, epirubicina, pirarubicina, daunorubicina, doxorubicina, clorhidrato de pirarubicina, clorhidrato de bleomicina, zinostatin estimalamer, neocarzinostatin, mitomicina C, sulfato de bleomicina, sulfato de peplomycin, etoposido, tartrato de vinorelbina, sulfato de vincristina, sulfato de vindesina, sulfato de niblastina, clorhidrato de amrubicina, gefinitib, exemestano, capecitabina, TNP-470, TAK-165, KW-2401, KW-2170, KW-2871, KT-5555, KT-8391, TZT-1027, S-3304, CS-682, YM-511, YM-598, TAT-59, TAS-101, TAS-102, TA-106, FK-228, FK-317, E7070, (8E, 12E, 14E)-7[(4-cicloheptipiperazina-1-il)carbonil]oxi-3,6,16,21-tetrahidroxi-610,12,16,20-pentametil-18,19-epoxitricosa-8,12,14-trien-11-ólido (E7107), KRN-700, KRN-

5500, J-107088, HMN-214, SM-11355, ZD-0473, etc. con respecto a los compuestos registrados como sales entre los agentes antitumorales mencionados anterior, cualquier sal es aceptable, y los cuerpos libres también son aceptables. Con respecto a los compuestos registrados como cuerpos libres, cualquier sal es aceptable.

No hay limitaciones particulares sobre agentes antibacterianos, y se pueden mencionar, por ejemplo, anfotericina B, cefotiam hexilo, cefalosporina, cloramfenicol, diclofenaco, etc. Con respecto a compuestos de los agentes antibacterianos mencionados en lo anterior, cualquier sal es aceptable.

No hay limitaciones particulares sobre agentes antiinflamatorios, y se pueden mencionar, por ejemplo, prostaglandinas (PGE1, PGE2), dexametasona, hidrocortisona, piroxicam, indometacina, prednisolona, etc. Con respecto a compuestos de los agentes antiinflamatorios mencionados en lo anterior, cualquier sal es aceptable.

No hay limitaciones particulares sobre agentes de infarto anti-miocárdico y se pueden mencionar, por ejemplo, adenosina, etanolol, pilsicainida, etc. y como agentes de contraste, se pueden mencionar, por ejemplo, iopamidol, ácido ioxáglico, iohexol, iomeprol, etc. Con respecto a los compuestos de los agentes de infarto anti-miocárdico mencionados anterior y agentes de contraste, cualquier sal es aceptable.

(Lípidos)

Es preferible que los constituyentes de membrana del liposoma de la presente invención incluyan fosfolípidos y/o derivados de fosfolípido. Como fosfolípidos y derivados de fosfolípido se pueden mencionar, por ejemplo, fosfatidil etanolamina, fosfatidil colina, fosfatidil serina, fosfatidil inositol, fosfatidil glicerol, cardiolipina, esfingomielina, ceramida fosforiletanolamina, ceramida fosforil glicerol, ceramida fosforil glicerol, fosfato, 1,2-dimiristoil-1,2-deoxifosfatidil colina, plasmalogeno, ácido fosfatídico, etc.

No hay limitaciones particulares sobre residuos de ácido graso en los fosfolípidos y derivados de fosfolípido, y se pueden mencionar, por ejemplo el residuo de ácido graso saturado no insaturado con un número de carbonos de 12 a 20. Específicamente, se pueden mencionar grupos de acilo derivados de ácido graso tal como ácido láurico, ácido mirístico, ácido palmítico, ácido esteárico, ácido oleico y ácido linoleico. También se pueden utilizar fosfolípidos derivados de sustancias naturales tal como la lecitina de yema de huevo y

lecitina de soja, lecitina de yema de huevo parcialmente hidrogenada cuyo residuo de ácido graso insaturado es parcial o completamente hidrogenado (completamente) lecitina de yema de huevo hidrogenada, lecitina de soja parcialmente hidrogenada, lecitina de soja (completamente) hidrogenada, etc.

No hay limitaciones particulares sobre la cantidad de mezclado (fracción en mol) de los fosfolípidos y/o derivados de fosfolípido que se utilizan cuando se prepara el liposoma, pero es preferible de 10 a 80% relativo a la composición de membrana de liposoma completa, y es más preferible 30 a 60%.

Con respecto a los constituyentes de membrana, aparte de los fosfolípidos y/o derivados de fosfolípido, el liposoma de la presente invención también puede incluir esteroides tal como colesterol y colesterol como estabilizadores de membrana, ácidos grasos que tienen grupos acilo saturados e insaturados con un número de carbonos de 8 a 22 y antioxidantes tal como α -tocoferol.

No hay limitaciones particulares sobre la cantidad de mezclado (fracción en mol) de estos esteroides que se utilizan cuando se prepara el liposoma, pero es preferible 1 a 60% relativo a la composición de membrana de liposoma completa, es más preferible 10 a 50% y es aún más preferible 30 a 50%.

Por otra parte, no hay limitaciones particulares sobre la cantidad de mezclado (fracción en mol) de los ácidos grasos, pero es preferible de 0 a 30% relativo a la composición de membrana de liposoma completa, es más preferible 0 a 20% y es aún más preferible 0 a 10%. Con respecto a la cantidad de mezclado (fracción en mol) del antioxidante, es suficiente y se adiciona a una cantidad que puede obtener el efecto antioxidante, pero es preferible 0 a 15% de la composición de membrana de liposoma completa, es más preferible 0 a 10% y es aún más preferible 0 a 5%.

El liposoma de la presente invención también puede contener lípidos funcionales y lípidos modificados como constituyentes de membrana.

Como lípidos funcionales, se pueden mencionar derivados de lípidos retenidos en la sangre, derivados de lípidos sensibles a la temperatura, derivados de lípidos sensibles al pH, etc. Como lípidos modificados se pueden mencionar lípidos de PEG, lípidos de azúcar, lípidos modificados con anticuerpo, lípidos modificados con péptido, etc.

Como derivados de lípidos retenidos en la sangre, se pueden

mencionar, por ejemplo, glicoforina, gangliosido GM1, gangliosido GM3, derivados de ácido glucorónico, derivados de ácido glutámico, derivados de fosfolípido de glicerina, derivados de polietilenglicol (condensado de metoxipolietilenglicol, etc.) tal como N - [carbonil – metoxi polietilenglicol - 2000] - 1,2 – dipalmitoil – sn – glicero – 3 fosfoetanolamina, N - [carbonil – metoxi polietilenglicol - 5000] - 1,2 – dipalmitoil – sn – glicero - 3 – fosfoetanolamina, N - [carbonil – metoxi polietilenglicol - 750] - 1,2 – dipalmitoil – sn – glicero – 3 fosfoetanolamina, N - [carbonil – metoxi polietilenglicol - 2000] - 1,2 – dipalmitoil – sn – glicero - 3 –fosfoetanolamina (MPEG 2000 – distearoil fosfatidil etanolamina), y N - [carbonil – metoxi polietilenglicol - 5000] - 1,2 – diestearoil – sn – glicero – 3 – fosfoetanolamina, que son condensados de fosfoetanolamina y metoxi polietilenglicol. Al tener el liposoma que contiene derivados de lípido con propiedades de retención en la sangre, es posible mejorar la retención en la sangre de liposoma, debido a que el liposoma llega a ser difícil de capturar en el hígado, etc., como una impureza extraña.

Como derivados de lípidos sensibles a la temperatura, se pueden mencionar, por ejemplo, dipalmitoil fosfatidilcolina, etc. Al tener el liposoma que contiene derivados de lípidos sensibles a la temperatura, es posible causar la destrucción de liposoma en temperaturas específicas, y causar cambios en las propiedades superficiales de liposoma. Además, al combinar esto con un incremento en la temperatura en el sitio objetivo del tumor, etc., es posible destruir el liposoma en el sitio objetivo, y liberar el compuesto activo en el sitio objetivo.

Como derivados de lípidos sensibles al pH, se pueden mencionar, por ejemplo, dioleoil fosfatidil etanolamina, etc. Al tener el liposoma que contiene derivados de lípidos sensibles al pH, es posible promover la fusión de membrana de liposoma y endosoma cuando el liposoma se incorpora en las células debido a la endocitosis, y mejorar la transmisión del compuesto activo al tejido celular.

Como lípidos de azúcar, lípidos modificados con anticuerpos y lípido modificados con péptido, se pueden citar lípidos que son enlazados con azúcares, anticuerpos o péptidos que son compatibles con las células objetivo o tejido objetivo. Al utilizar lípidos modificados, el liposoma puede ser transmitido activamente a las células objetivo o tejido objetivo.

No hay limitaciones particulares sobre la cantidad de mezclado (fracción en mol) de derivados de lípido con propiedades de retención en la

sangre utilizados cuando se prepara el liposoma, pero es preferible 0 a 50% de la totalidad de lípidos constituyentes de membranas de liposoma, es más preferible 0 a 30% y es aún más preferible de 0 a 20%.

(Liposoma)

Como es mencionado en lo anterior, el liposoma es una vesícula cerrada microscópica que tiene una fase interna encerrada por una bicapa de lípido.

Idealmente, con respecto al liposoma, a) es preferible que la eribulina, etc. tenga una función de barrera que prevenga su fuga a la fase externa de liposoma después de que la eribulina, etc. es una vez atrapada en la fase interna de liposoma. En el caso, en donde se utiliza como una medicina, es preferible que el liposoma exhiba estabilidad *in vivo*, y que la eribulina etc., tenga una función de barrera que prevenga su escape a la fase externa de liposoma en la sangre cuando el liposoma se administra *in vivo*.

La composición de los constituyentes de membrana para liposoma que tienen tal permeabilidad de membrana en un nivel que permite la aplicación práctica se puede seleccionar apropiadamente por aquellos expertos en la técnica de acuerdo con el compuesto activo, tejido objetivo y los similares mediante la referencia como es necesario en las modalidades descritas enseguida (Huroshi Kikuchi, y colaboradores, "Liposome I—Preparation Method and Assay Method--", Cell Technology (1983), 2(9): pp, 1136-1149, y la literatura de referencia citada en la literatura).

Cuando se utiliza como una medicina, es preferible que la eribulina, etc. sea liberada del liposoma después de que el liposoma alcanza el tejido objetivo, células u organelas intracelulares. Con respecto al liposoma, los constituyentes de membrana por si mismos son ordinariamente biodegradables, y finalmente se descomponen en el tejido objetivo o los similares. Se cree que la eribulina atrapada, etc. es liberada de esta manera. Por otra parte, también es aceptable si el liposoma mismo es incorporado en las células.

No solamente puede la composición de liposoma ser dirigida al tejido objetivo tal como el cáncer sólido, sino también se puede utilizar para transmitir compuestos activos al cáncer hematológico y así sucesivamente. También se puede utilizar como una formulación de liberación lenta, formulación de liberación controlada, etc. en la sangre.

El tamaño de partícula del liposoma se puede ajustar de acuerdo con el objetivo. Por ejemplo, cuando se propone para transmitir liposoma al

tejido canceroso o tejido inflamado mediante el efecto de EPR (Permeabilidad de Retención Aumentada) como un producto de inyección o los similares, es preferible que el tamaño de partícula de liposoma sea de 30 a 400 nm, y es más preferible que el tamaño de partícula sea de 50 a 200 nm. En el caso donde la intención es transmitir el liposoma al macrófago, es preferible que el tamaño de partícula de liposoma sea 30 a 1000 nm, y es más preferible que el tamaño de partícula sea 100 a 400 nm. En el caso donde la composición de liposoma se va a utilizar como una preparación oral o preparación transdérmica, el tamaño de partícula de liposoma se pueden ajustar en varias micras. Se va observar que (1) en el tejido normal, las paredes vasculares sirven como barreras (debido a que las paredes vasculares están densamente constituidas por células endoteliales vasculares) y las micropartículas tales como supermoléculas y el liposoma de tamaño especificado no puede ser distribuido dentro del tejido. Sin embargo, en el tejido enfermo, las paredes vasculares están sueltas (debido a que intersticios existen entre las células endoteliales vasculares) incrementando la permeabilidad vascular, y las supermoléculas y micropartículas se pueden distribuir al tejido extravascular (permeabilidad aumentada). Por otra parte (2) el sistema linfático es bien desarrollado en el tejido normal, pero es conocido que el sistema linfático no es desarrollado en el tejido enfermo, y que las supermoléculas o micropartículas, una vez incorporadas, no son recicladas a través del sistema general, y son retenidas en el tejido enfermo (retención aumentada)—esto es llamado el efecto EPR (Matsumura, Maeda, Cancer Research. (1986), 46: pp. 6387-6392). Consecuentemente, es posible controlar la farmacocinética al ajustar el tamaño de partícula de liposoma.

En la presente invención, el tamaño de partícula de liposoma significa el tamaño de partícula promedio en peso de acuerdo con el método de dispersión de luz dinámica (método de dispersión de luz cuasi-elástica). Aquí, el tamaño de partícula se muestra que es medido por los instrumentos de dispersión de luz dinámica (por ejemplo, Zsatasizer Nano ZS modelo manufacturado por Malvern Instrumets Ltd. y ELS-8000 manufacturado por Otsuka Electronics Co, Ltd). Los instrumentos miden el movimiento Browniano de las partículas, y el tamaño de partícula se determina basado en la teoría metodológica de dispersión de luz dinámica establecida.

No hay limitaciones particulares sobre el solvente de la fase interna de liposoma, y se pueden mencionar, por ejemplo, soluciones reguladoras tal como la solución reguladora de fosfato, solución reguladora de

citrato y soluciones salina fisiológica regulada de fosfato, agua salina fisiológica, medios de cultivo para cultivos celulares, etc. Como el solvente, en el caso donde se utiliza solución reguladora, es preferible que la solución del agente regulador sea 5 a 300 mM, y es más preferible 10 a 100 mM. No hay limitaciones particulares sobre el pH de la fase interna de liposoma, pero es preferible de 3 a 11, y es más preferible 4 a 9.

(Composición de liposoma)

Se ofrece una composición de liposoma de acuerdo con la presente invención. La composición de liposoma contiene liposoma, y además contiene eribulina, etc. en la fase interna de liposoma. Como es mencionado en lo anterior, la composición de liposoma incluye tanto una forma sólida y una forma líquida. En el caso donde el liposoma esta en una forma sólida, este se puede hacer en una forma líquida al disolverlo o suspenderlo en un solvente preescrito como es descrito enseguida. En el caso donde la composición de liposoma es sólida congelada, esta se puede hacer en una forma líquida al fundir al dejarla en reposo a temperatura ambiente.

La concentración de liposoma en la concentración del compuesto activo en la composición de liposoma se puede ajustar apropiadamente de acuerdo con la composición de liposoma objetivo, formulación, etc. En el caso donde la composición de liposoma es una formulación líquida, la concentración de liposoma como la concentración de todos los lípidos que constituyen el liposoma se pueden ajustar en 0.2 a 100 mM, y de preferencia en 1 a 30 mM. La concentración (dosificación) de compuestos activos en el caso donde la composición de liposoma se utiliza como una medicina se describe enseguida. Con respecto a cantidades de ciclodextrina en la composición de liposoma, es preferible que sea menor que un equivalente de 0.1 mol con relación a la eribulina, etc., y es más preferible que sea menor que el límite de detección.

En la composición de liposoma de la presente invención, la eribulina, etc. se puede proporcionar a la bicapa de lípido.

No hay limitaciones particulares sobre el solvente (medio de dispersión) de la composición de liposoma en el caso de donde la composición de liposoma es una formulación líquida, y se puede mencionar, por ejemplo, soluciones reguladoras tal como la solución reguladora de fosfato, solución reguladora de citrato y solución salina fisiológica regulada de fosfato, agua salina fisiológica y medios de cultivo para cultivos celulares. No hay limitaciones particulares sobre el pH de la fase externa de liposoma de la composición de

liposoma, pero es preferible 3 a 11 y es más preferible 4 a 9.

También se puede adicionar lo siguiente a la composición de liposoma: monosacáridos tales como glucosa, glactosa, manosa, fructosa, inositol, ribosa y xilosa; disacáridos tales como lactosa, sacarosa, cellobiosa, trehalosa y maltosa; trisacáridos tal como rafinosa y melizitosa; polisacáridos tal como ciclodextrina; y alcoholes de azúcar tal como eritritol, xilitol, sorbitol, manitol y maltitol; alcoholes polivalentes tales como glicerina, diglicerina, poliglicerina, propilenglicol, polipropilenglicol, etilenglicol, dietilenglicol, trietilenglicol, polietilenglicol, éter monoalquílico de etilenglicol, éter monoalquílico de dietilenglicol, 1,3-butilenglicol. También se puede utilizar combinaciones de azúcar y de alcohol.

Para propósitos de almacenamiento a largo plazo estable del liposoma que es dispersado en el solvente (medio de dispersión), desde el punto de vista de la estabilidad física que incluye coagulación y así sucesivamente, es preferible eliminar el electrolito en el solvente (medio de dispersión) tanto como sea posible. Por otra parte, desde el punto de vista de la estabilidad química de los lípidos, es preferible ajustar el pH del solvente (medio de dispersión) de ácido a la vecindad de neutro 8pH 3.0 a 8.0) y remover el oxígeno resuelto a través del burbujeo de nitrógeno.

No hay limitaciones particulares sobre la concentración del azúcar o alcohol polivalente contenido en la composición de liposoma, pero en un estado donde el liposoma es dispersado en un solvente, por ejemplo, es preferible que la concentración de azúcar sea 2 a 20% (W/V) 5 a 10% (W/V) es más preferible. Con respecto a la concentración de alcohol polivalente, 1 a 5% ((W/V) es preferible y 2 a 2.5% (W/V) más preferible. Estos solventes también se pueden utilizar como la fase externa de liposoma en el líquido de dispersión de liposoma, el sustituir o diluir la fase externa de liposoma de la solución preparatoria de liposoma con este solvente, es posible cambiar la solución de la fase externa de liposoma en estas soluciones.

Es preferible que las formulaciones sólidas de la composición de liposoma incluyan, por ejemplo, monosacáridos tales como glucosa, glactosa, manosa, fructosa, inositol, ribosa y xilosa, disacáridos tales como lactosa, sacarosa, cellobiosa, trehalosa y maltosa; trisacáridos tales como rafinosa y melizitosa; polisacáridos tales como ciclodextrina; y alcoholes de azúcar tales como eritritol, xilitol, sorbitol, manitol y maltitol. Más preferible son mezclas de glucosa, lactosa, sacarosa, trehalosa y sorbitol. Aún más preferibles son

35

mezclas de lactosa, sacarosa y trehalosa. Por este medio, las formulaciones sólidas se pueden almacenar mientras periodos largos. Cuando se congela, es preferible que las formulaciones sólidas mantengan alcoholes polivalentes (soluciones acuosas) tales como glicerina, diglicerina, poliglicerina, propilenglicol, piliprolenglicol, etilenglicol, dietilenglicol, trietilenglicol, polietilenglicol, éter monoalquílico de etilenglicol, éter monoalquílico de dietilenglicol y 1,3-butilenglicol. Con respecto a alcoholes polivalentes (soluciones acuosas), glicerina, propilenglicol y polietilenglicol son preferibles, y glicerina y propilenglicol son más preferibles. Por este medio es posible almacenar establemente la formulación sólida durante periodos largos. Los azúcares y alcoholes polivalentes se pueden utilizar en combinación.

(Método de manufactura de la composición de liposoma)

De acuerdo con la presente invención, se proporciona un método de manufactura para la manufactura de una composición de liposoma que contiene eribulina o su sal farmacológicamente permisible. El método para manufacturar la composición de liposoma incluye: una etapa en la cual se proporciona un líquido de dispersión de liposoma que contiene liposoma; una etapa en la cual el líquido de dispersión de liposoma mencionado en lo anterior se mezcla con el compuesto activo mencionado en lo anterior (eribulina o su sal farmacológicamente aceptable); y una etapa en la cual se introduce el compuesto activo mencionado en lo anterior en la fase interna de liposoma del líquido de dispersión de liposoma mencionado en lo anterior.

Es preferible que la etapa en la cual se proporciona el líquido de dispersión de liposoma que contiene liposoma incluya una etapa en la cual se proporciona una solución preparatoria de liposoma, y una etapa en la cual la fase externa de liposoma de la solución preparatoria de liposoma mencionado en lo anterior se sustituye o se diluye.

La solución preparatoria de liposoma se puede proporcionar, por ejemplo, al preparar liposoma en una solución que contiene sal de amonio. Al preparar la solución preparatoria de liposoma en una solución que contiene sal de amonio, es posible hacer un líquido de dispersión de liposoma que también contiene sal de amonio en la fase interna de liposoma.

No hay limitaciones particulares sobre la solución que contiene sal de amonio que es utilizada cuando se prepara la solución preparatoria de liposoma, y se puede utilizar cualquier solución que contiene sal de amonio.

Como sal de amonio, se puede citar, por ejemplo, cloruro de

amonio, borato de amonio, sulfato de amonio, formiato de amonio, acetato de amonio, citrato de amonio, tartrato de amonio, succinato de amonio y fosfato de amonio. El sulfato de amonio, sulfato de amonio, citrato de amonio, tartrato de amonio y fosfato de amonio son preferibles entre estos; sulfato de amonio, citrato de amonio y tartrato de amonio son más preferibles y sulfato de amonio es mucho más preferible.

Se puede utilizar estas sales de amonio en combinaciones de dos o más.

La concentración de sal de amonio en la solución que contiene sal de amonio se puede ajustar apropiadamente de acuerdo con la cantidad de eribulina, etc., que es atrapada, y entre más alta es mejor; 10 mM o más es preferible; 20 mM o más es más preferible y 50 mM o más es aun más preferible. Con respecto al pH de la solución que contiene sal de amonio, 3 a 9 es preferible, 4 a 9 es más preferible desde el punto de vista del balance de la relación de atrapamiento y estabilidad, y 5 a 8 es aún más preferible.

Un ajustador de pH se puede utilizar con el fin de ajustar el pH de la solución que contiene sal de amonio. No hay limitaciones particulares sobre la concentración de los ajustadores de pH individuales en la solución que contiene sal de amonio, pero 1 a 300 mM es preferibles y 5 a 100 mM es más preferible.

Como el ajustador de pH, se puede mencionar, por ejemplo, aminoácidos tales como arginina, histidina y glicina; ácidos tales como ácido ascórbico, ácido benzoico, ácido cítrico, ácido glutámico, ácido fosfórico, ácido acético, ácido propiónico, ácido tartárico, ácido carbónico, ácido láctico, ácido bórico, ácido maleico, ácido fumárico, ácido málico, ácido adípico, ácido clorhídrico y ácido sulfúrico; sales de los ácidos mencionados en lo anterior tal como la sal de sodio, sal de potasio o sal de amonio; y compuestos alcalinos (base) tal como tris-hidroximetilamino metano, agua amoniada (amoníaco), hidróxido de sodio e hidróxido de potasio. Como ajustadores de pH, el hidróxido de sodio, ácido clorhídrico, agua amoniada, ácido acético, ácido láctico, ácido tartárico, ácido succínico, ácido cítrico y ácido fosfórico son preferibles; hidróxido de sodio, agua amoniada, ácido clorhídrico, ácido acético, ácido cítrico y ácido fosfórico son más preferibles; e hidróxido de sodio, agua amoniada, ácido clorhídrico, ácido cítrico y ácido fosfórico solo aún más preferibles. Los ajustadores de pH se pueden utilizar en combinaciones de dos o más de las sales de amonio. Además, las soluciones reguladoras también se

3X

pueden utilizar como ajustadores de pH, tal como la solución reguladora de fosfato, solución reguladora de citrato y soluciones salina fisiológica regulada de fosfato.

Como la solución preparatoria de liposoma, es mejor usar una solución que se obtiene al preparar liposoma sin inclusión sustancial de ciclodextrina. Como la solución preparatoria de liposoma, la fase interna de liposoma también puede contener, sal, ácido, base y/o aminoácido. En este caso, es preferible que la fase interna de liposoma contenga el compuesto activo, sal de amonio y ácido. Como la sal de amonio, el sulfato de amonio se puede mencionar como el ejemplo preferido. Como el ácido, el ácido cítrico se puede mencionar como el ejemplo preferido.

Con respecto a la preparación de liposoma, se puede mencionar el método de película de lípidos (método de Vórtice), método de evaporación de fase inversa, método ultrasónico, método de pre-vesícula, método de inyección de etanol, método de prensa francesa, método de remoción de ácido cólico, método de lote de Triton X-100, método de fusión Ca^{2+} , método de inyección de éter, método de recosido, método de congelación-descongelación, etc.

Las diversas condiciones (cantidades de constituyentes de membrana, temperatura, etc.), en la preparación de liposoma se pueden seleccionar adecuadamente de acuerdo con el método de preparación de liposoma, composición de liposoma objetivo, tamaño de partícula, etc. (ver Op. Cit, Kikuchi (1983), etc.).

El tamaño de partícula de liposoma se puede ajustar opcionalmente como sea necesario. El tamaño de partícula se puede ajustar, por ejemplo, al conducir extrusión (filtración de extrusión) bajo alta presión utilizando un filtro de membrana de diámetro de poro regular. El ajuste del tamaño de partícula se puede conducir en cualquier tiempo durante la manufactura de la composición de liposoma de la presente invención. Por ejemplo, se puede conducir antes del ajuste de la fase externa de liposoma en la solución preparatoria de liposoma, después del ajuste de la fase externa de liposoma en la solución preparatoria de liposoma, o después de la introducción del compuesto activo en la fase interna de liposoma. Es preferible conducir el ajuste de tamaño de partícula antes de introducir el compuesto activo en la fase interna de liposoma, y es más preferible conducirlo antes de ajustar la fase externa de liposoma en la solución preparatoria de liposoma.

El líquido de dispersión de liposoma se puede obtener al sustituir o

diluir la fase externa de la solución preparatoria de liposoma obtenida. La sustitución de la fase externa de liposoma se puede conducir una vez, o una combinación de varios tipos de métodos de sustitución o dilución se pueden conducir múltiples veces.

Como un método para sustituir la fase externa de liposoma de la solución preparatoria de liposoma, se puede mencionar la diálisis, separación centrífuga y filtración en gel. Al sustituir la fase externa de liposoma, la presente invención se puede implementar de modo que la fase externa de liposoma no contiene sustancialmente ciclodextrina o sal de amonio. Por otra parte, sustituir o diluir la fase externa de liposoma, es posible atrapar eficientemente la eribulina o su sal farmacológicamente permisible en la fase interna de liposoma.

La diálisis se puede conducir, por ejemplo, usando una membrana de diálisis. Como una membrana de diálisis, se puede mencionar una membrana con un corte de peso molecular tal como un tubo de celulosa o Spectra/Por.

Con respecto a la separación centrífuga, la aceleración centrífuga se puede conducir de preferencia a 100,000 g o más alta, y más de preferencia a 300,000 g o más altas. Al sustituir la fase externa de liposoma por centrifugación, también se puede conducir la concentración de liposoma en conjunción con la sustitución de la fase externa de liposoma.

La filtración en gel se puede llevar a cabo, por ejemplo, al conducir el fraccionamiento basado en el peso molecular utilizando una columna tal como Sephadex o Sepharose.

Como el solvente (medio de dispersión) utilizado cuando se sustituye o diluye la fase externa de liposoma, se puede mencionar, por ejemplo, la solución de sacarosa, solución salina y medio de cultivo para cultivo celular. Al usar estos solventes, es posible preparar una composición de liposoma estable.

No hay limitaciones particulares sobre el pH del solvente, pero un intervalo de 2 a 11 se puede ajustar; 3 a 10 es preferible, 6 a 10 es más preferible y 7 a 10 es aún más preferible, como es descrito enseguida, un gradiente de pH se puede utilizar para introducir la eribulina, etc. en la fase interna de liposoma. En este caso, el pH de solvente se puede ajustar de modo que la fase externa de liposoma alcance el pH objetivo.

Un ajustador de pH se puede utilizar con el fin de ajustar el pH en el solvente. No hay limitaciones particulares sobre la concentración de uso, pero

1 a 300 mM es preferible, y 5 a 100 mM es más preferible.

Como el ajustador de pH, se puede mencionar, por ejemplo, aminoácidos tales como arginina, histidina, y glicina; ácidos tales como ácido ascórbico, ácido benzoico, ácido cítrico, ácido glutámico, ácido fosfórico, ácido acético, ácido propiónico, ácido tartárico, ácido carbónico, ácido láctico, ácido bórico, ácido maléico, ácido fumárico, ácido málico, ácido adípico, ácido clorhídrico y ácido sulfúrico; sales de los ácidos mencionados en lo anterior tal como sal de sodio, sal de potasio y sal de amonio; y compuestos alcalinos tal como tris-hidroximetilamino metano, agua amoniata, hidróxido de sodio e hidróxido de potasio. Hidróxido de sodio, ácido clorhídrico, histidina, ácido tartárico, ácido succínico, ácido cítrico y ácido fosfórico son preferibles; hidróxido de sodio, ácido clorhídrico histidina, ácido tartárico, ácido cítrico y ácido fosfórico son más preferibles; e hidróxido de sodio, ácido clorhídrico, histidina y ácido fosfórico son aún más preferibles.

Con el fin de mejorar la relación de atrapamiento de eribulina o su sal farmacológicamente permisible en el liposoma, la relación de atrapamiento se puede incrementar al adicionar una solución (solución de sal) que contiene electrolito a la fase externa de liposoma para incrementar la intensidad iónica. No hay limitaciones particulares sobre el electrolito (sal) contenido en la fase externa de liposoma, pero cloruro de sodio y cloruro de potasio son preferibles, y cloruro de sodio es más preferible. También se puede utilizar solución salina fisiológica, por otra parte, como la fase externa de liposoma del líquido de dispersión de liposoma o los similares, azúcar, electrolito y/o aminoácidos se pueden incluir, y azúcar o electrolito de aminoácidos también se puede incluir. Como azúcar, sacarosa se pueden echar como el ejemplo preferido, como electrolito, la solución salina fisiológica de cloruro de sodio se puede mencionar como ejemplos preferidos, y como aminoácidos, histidina se puede mencionar como el ejemplo preferido.

Es preferible que el líquido de dispersión de liposoma obtenido no contenga sustancialmente el ciclodextrina o sal de amonio en la fase externa de liposoma y la fase interna de liposoma, ver la presente invención, la eribulina o sal y farmacológicamente permisible se puede introducir en la fase interna de liposoma aún en el caso donde la ciclodextrina o sal de amonio tiene por alguna razón que ser adicionada a la fase externa de liposoma de líquido especial de liposoma, y aún cuando la fase externa de liposoma de líquido de dispersión de liposoma contiene ciclodextrina o sal de amonio.

40

Con respecto a la concentración de lípido de liposoma en el líquido de dispersión de liposoma, 1 a 100 mM es preferible, y 1-50 mM es más preferible. Dentro de estos intervalos, es posible formar adecuadamente un número más grande de partículas de liposoma sin deteriorar las propiedades físicas del líquido de dispersión de liposoma.

La composición de liposoma se puede obtener al mezclar el líquido de dispersión de liposoma obtenido y el compuesto activo de eribulina, etc., y al introducir el compuesto activo en la fase interna del liposoma de líquido de dispersión de liposoma. Es preferible que la etapa de introducción incluya una etapa en la cual la permeabilidad de membrana de liposoma se aumente en la solución mezclada del líquido de dispersión de liposoma y el compuesto activo. Por este medio, el atrapamiento de la eribulina, etc. en el liposoma se puede realizar en un período mas corto de tiempo. Sin embargo, aún si no se conducen operaciones particulares para el propósito de aumentar la permeabilidad de membrana de liposoma después del mezclado del líquido de dispersión de liposoma y eribulina, etc., es posible atrapar la eribulina, etc. en el liposoma si se toma el tiempo requerido.

En la etapa en la cual se mezcla la eribulina o su sal farmacológicamente permisible, es posible usar una sustancia disuelta en un solvente o una sustancia sólida como la eribulina, etc. No hay limitaciones particulares sobre el solvente y se puede usar, por ejemplo, una sustancia idéntica a la fase externa de liposoma del líquido de dispersión de liposoma.

En una opción como sea necesario, es posible usar un gradiente de pH en la introducción de eribulina, etc., en la fase interna de liposoma. En este caso, con respecto al pH de la fase interna de liposoma del líquido de dispersión de liposoma, 3 a 9 es preferible, 4 a 9 es más preferible y 5 a 8 es aún más preferible.

Por otra parte, es posible ajustar el pH de la fase externa de liposoma más alto que el pH de la fase interna de liposoma para crear un gradiente de pH. Un gradiente de pH de 1 a 5 es preferible, y 2 a 3 es más preferible.

Además, es posible incrementar la relación de atrapamiento en el liposoma al llevar el pH de la fase externa de liposoma más cercano a la vecindad del pKa de eribulina, etc. 7.5 a 12.5 es preferible, 8.5 a 11.5 es más preferible y 9 a 10.5 es aún más preferible (el pKa de mesilato de eribulina es 9.6).

41

Como la solución preparatoria de liposoma, es óptimo usar una solución que se obtiene al preparar liposoma sin inclusión sustancial de ciclodextrina.

Como un método para aumentar la permeabilidad de membrana de liposoma en la solución mezclada obtenida, se puede mencionar el método de calentamiento de la solución mezclada, el método de adicionar un fluidizador de membrana a la solución mezclada, etc.

En el caso donde se calienta la solución mezclada, el compuesto activo generalmente puede ser más eficientemente producido en la fase interna de liposoma al calentar a temperaturas más altas. Específicamente, es preferible ajustar la temperatura de calentamiento tomando en consideración la estabilidad térmica del compuesto activo y los constituyentes de membrana de liposoma empleados. En particular, es preferible que la temperatura de calentamiento se ajuste a la temperatura de transición de fase de la membrana de bicapa de lípido de liposoma o más alta.

La "temperatura de transición de fase" de la membrana de bicapa de lípido de liposoma significa la temperatura en la cual la absorción de calor inicia (la temperatura cuando comienza la reacción endotérmica) en el análisis térmico diferencial de condiciones de temperaturas elevadas. El análisis térmico diferencial es una técnica que permite el análisis de las propiedades térmicas de las muestras al medir las diferencias de temperatura de una muestra o sustancia de referencia como una función del tiempo o temperatura mientras se cambia la temperatura de la muestra o sustancia de referencia. En el caso donde se conduce el análisis térmico diferencial con respecto a los constituyentes de membrana de liposoma, los componentes de membrana de liposoma fluidizan a medida que se incrementa la temperatura, y se observa la reacción endotérmica. Como es ampliamente conocido en este campo técnico, el intervalo de temperatura en el cual la acción endotérmica se observa grandemente varía de acuerdo con los componentes de membrana de liposoma. Por ejemplo, en el caso donde los componentes de membrana de liposoma consisten de un lípido puro, el intervalo de temperatura en el cual la reacción endotérmica se observa es extremadamente reducido, y la reacción endotérmica frecuentemente se observa dentro de un intervalo de $\pm 1^{\circ}\text{C}$ con relación a la temperatura pico endotérmico. Por otra parte, en el caso donde los componentes de membrana de liposoma consiste de múltiples lípidos, y particularmente en el caso donde los componentes de membrana de liposoma

consiste de lípidos derivados de materiales naturales, en el intervalo de temperatura en el cual la reacción endotérmica se observa debe ser amplio y la reacción endotérmica se observa, por ejemplo, dentro de un intervalo de $\pm 5^{\circ}\text{C}$ con relación a la temperatura pico endotérmico. Esto es, un pico amplio, etc. se observa. De acuerdo con la presente invención, se cree que la fluidización de membrana de liposoma se incrementa, y la permeabilidad de membrana del compuesto activo se incrementa al elevar la temperatura más alta que la temperatura de retención de fase de la membrana de bicapa de lípido de liposoma.

Por ejemplo, aunque dependiente de la estabilidad térmica y así sucesivamente del compuesto activo y los constituyentes de membrana de liposoma empleados, es preferible tener un intervalo de temperatura desde la temperatura de transición de fase de la membrana de bicapa de lípido de liposoma a $+20^{\circ}\text{C}$ de la temperatura de transición de fase; un intervalo de temperatura desde la temperatura de transición de fase a $+10^{\circ}\text{C}$ de la temperatura de transición de fase más preferible; y un intervalo de temperatura desde $+5^{\circ}\text{C}$ de la temperatura de transición de fase a $+10^{\circ}\text{C}$ de la temperatura de transición de fase es aún más preferible.

La temperatura de calentamiento es ordinariamente 20 a 100°C ; 40 a 80°C es preferible y 45 a 65°C es más preferible.

Específicamente, en el caso de una membrana de liposoma cuyos ingredientes principales son di-palmitoil fosfatidilcolina (temperatura de transición de fase como sustancia simple: 41°C) y colesterol, aunque también depende de la composición de la misma, una temperatura de calentamiento de 40 a 60°C es ordinariamente preferible, y 45 a 50°C es más preferible. Por otra parte, en el caso de una membrana de liposoma cuyos ingredientes principales son fosfatidilcolina de soja hidrogenada (HSPC; temperatura de transición de fase como sustancia simple: 50 a 60°C) y colesterol, aunque también depende la composición de la misma como una temperatura de calentamiento del 50 a 70°C es ordinariamente preferible, y 55 a 65°C es más preferible. Sin embargo, estas temperaturas de calentamiento de ninguna manera limita la presente invención.

En la etapa de calentamiento, no hay limitaciones particulares sobre el tiempo en el cual se mantiene la temperatura en o arriba de la temperatura de transición de fase, y esta se puede ajustar apropiadamente de otro intervalo, por ejemplo, de varios segundos a 30 minutos. Tomando en

consideración la estabilidad térmica de compuesto activo y los lípidos así como la producción de más eficientes, es deseable conocido el tratamiento dentro de un tiempo corto. Esto es, es preferible que el período de mantenimiento de temperatura elevada sea de 1 a 30 minutos, y 2 a 5 minutos es más preferible. Sin embargo, estos tiempos de mantenimiento de temperatura de ninguna manera limitan la presente invención.

Por otra parte como es establecido en lo anterior, también es posible aumentar la permeabilidad de membrana de liposoma y adicionar un fluidizador de membrana a la solución mezclada obtenida (esto es, adicionando al lado de fase interna de liposomas). Como un fluidizador de membrana, se pueden mencionar solventes orgánicos, surfactantes, enzimas, etc., que son solubles en solventes acuosos. Más específicamente, como solventes orgánicos, se pueden mencionar, por ejemplo, alcoholes monovalentes tales como alcohol etílico y alcohol bencílico; alcoholes polivalentes tales como glicerina y propilenglicol; solventes polares apróticos tal como dimetil sulfóxido (DMSO). Como surfactantes se pueden mencionar, por ejemplo, surfactantes aniónicos tal como ácido graso sódico, sulfato de monoalquilo y fosfato de monoalquilo; surfactante catiónicos tal como la sal de trimetilamonio de alquilo; surfactantes amfolíticos tal como óxido de dialquildimetilamina y surfactante no iónicos tal como polioxietileno, alquil éter, éter monoglicérido de alquilo y éster de sorbitan de ácido graso. Como enzimas, se pueden mencionar, por ejemplo, colinesterasa y colesterol oxidasa. Aquellos expertos en la técnica pueden ajustar la cantidad de fluidizador de membrana de acuerdo con la composición de los constituyentes de membrana de liposoma, el fluidizador de membrana, etc. y tomando en consideración el grado de eficiencia de atrapamiento del compuesto activo debido a la adición del fluidizador de membrana, la estabilidad de liposoma, etc.

El método de manufactura de la composición de liposoma de la presente invención puede incluir una etapa de ajustar el pH de la fase externa de liposoma de la composición de liposoma obtenida después de la etapa de introducción mencionada en lo anterior.

El pH de la fase externa que es ajustado no es particularmente limitado, pero de preferencia pueden ser 4 a 10, más de preferencia 5 a 9 y aún más de preferencia neutro 6 a 8 desde el punto de vista de estabilidad química del fosfolípido que compone liposoma.

Además, se puede incluir adicionalmente una etapa de secado de

44

la composición de liposoma obtenidas. Esto es, cuando sustituyen una composición de liposoma como una formulación líquida, la composición de liposoma en una forma líquida obtenida de la etapa de introducción mencionado en lo anterior se puede utilizar sin modificación, la composición de liposoma final, o la fase externa liposoma en la composición de liposoma líquida obtenida en la etapa de introducción mencionada anterior se puede ajustar (reemplazar, etc.) para hacer una composición de liposoma final. Cuando se hacen esto, el ajuste de la fase externa de liposoma se puede llevar a cabo de manera similar al ajuste de la fase externa de liposoma en un líquido preparatorio y liposoma. En el caso de la composición de liposoma es una formulación líquida, este se puede utilizar sin modificación adicional.

Además, en el caso donde la composición de liposoma se va a hacer en una preparación líquida, la composición de liposoma líquida obtenida en la etapa de introducción mencionada en lo anterior se puede secar para hacer la composición de liposoma sólida final. El secado por congelación y secado por rocío se puede mencionar como ejemplos de métodos para secar la composición de liposoma. En caso en donde la composición de liposoma es una preparación sólida, esto se puede disolver o suspender de un solvente adecuado y utilizar como una formulación líquida. El solvente para el uso se puede ajustar apropiadamente de acuerdo con el propósito de uso, etc., para la composición de liposoma, y en el caso de usar la composición de liposoma como un producto de inyección, por ejemplo, el solvente es de preferencia agua destilada estéril. En el caso de usar la composición de liposoma como una medicina, el médico o paciente puede inyectar el solvente de un frasquito en el cual se atrapa de preparación sólida, por ejemplo, para hacer la preparación en el tiempo de uso. En el caso donde la composición de liposoma líquida es una preparación sólida congelada como este se puede utilizar como una formulación líquida al almacenar un estado congelado, y regresar a un estado líquido al dejar fundir la temperatura ambiente o al fundir rápidamente con calor en el momento del uso.

(Composiciones Farmacéuticas, etc.)

La composición de liposoma de la presente invención se puede utilizar como una medicina curativa en el campo médico. Específicamente, la composición de liposoma de la presente invención se puede utilizar como una composición farmacéutica antitumoral.

En el caso donde la composición de liposoma de la presente

invención se utiliza como una composición farmacéutica, la composición de liposoma se puede administrar mediante inyección (intravenosa, intraarterial, o inyección local) oralmente, nasalmente, subcutáneamente, pulmonarmente o a través de gotas para ojos, y en particular la inyección local a un grupo dirigido de células u órganos u otra de tal inyección es preferible además de la inyección intravenosa, inyección subcutánea, inyección intracutánea e inyección intraarterial. La tableta, polvo, granulación, jarabe, cápsula, líquido y los similares se pueden dar como ejemplos de la formulación de la composición de liposoma en el caso de administración oral. El producto de inyección, inyección de goteo, gotas para ojos, ungüento, supositorios, suspensión, cataplasma, loción, aerosol, plaster y los similares se pueden dar como ejemplos de formulaciones de la composición de liposoma en el caso de administración oral, y un producto de inyección y agente de infusión de goteo son particularmente preferibles.

La dosificación de la composición farmacéutica difiere notablemente dependiendo del tipo de enfermedad objetivo, el tipo de compuesto activo, así como la edad, sexo y peso del paciente, la severidad de los síntomas, junto con otros factores, pero ordinariamente, la dosis diaria de eribulina o su sal farmacológicamente permisible para adultos no es particularmente restringida, aunque el mesilato de eribulina, que es una sal adecuada, es ordinariamente 0.1 a 10 mg. También, la administración puede ser dividida en más de una dosis por día. Una composición de liposoma que contiene, por ejemplo, 0.01-00 mg/mL eribulina o su sal permisible [error tipográfico] [sic. Farmacológicamente] a la fase interna de liposoma se puede administrar como la composición de liposoma de la presente invención.

(Equipo)

De acuerdo con la presente invención, se proporciona un equipo para preparar la composición de liposoma. El equipo se puede utilizar para preparar la composición de liposoma como una medicina, que se puede utilizar por un médico en la instalación clínica o un paciente.

El equipo incluye un reactivo de liposoma. El reactivo de liposoma puede ser ya sea una forma sólida o líquida. Si el reactivo de liposoma está en una forma líquida, el líquido de dispersión de liposoma mencionado en lo anterior se puede utilizar como el reactivo de liposoma. También, si el reactivo de liposoma está en una forma sólida, el reactivo de liposoma se puede disolver o suspender en un solvente apropiado para obtener el líquido de dispersión de

46

liposoma, y el líquido de dispersión de liposoma mencionado en lo anterior se puede secar para obtener el reactivo de liposoma. El secado se puede llevar a cabo similarmente al secado mencionado en lo anterior de la composición de liposoma. Cuando se utiliza el equipo, si el reactivo de liposoma esta en una forma sólida, el reactivo de liposoma se puede disolver o suspender en un solvente apropiado para hacer el líquido de dispersión de liposoma. Cuando se hace de esta manera, el solvente es similar a la fase externa de liposoma en el líquido de dispersión de liposoma mencionado en lo anterior.

El equipo de la presente invención además contiene eribulina o su sal farmacológicamente permisible (mesilato de eribulina es una sal adecuada). La eribulina o su sal farmacológicamente permisible puede estar ya sea en una forma sólida o líquida (un estado de disuelto o suspendido en un solvente). Cuando se utiliza el equipo, si la eribulina o los similares están en una forma sólida, es preferible que sea disuelta o suspendida en un solvente apropiado para ser una forma líquida. El solvente puede ser apropiadamente ajustado de acuerdo con las propiedades físicas y los similares de la eribulina o los similares, y se pueden hacer similar a la fase externa de liposoma en el líquido de dispersión mencionado en lo anterior, por ejemplo. El equipo de la presente invención puede incluir un compuesto activo diferente de eribulina o su sal farmacológicamente permisible.

En el equipo, el reactivo de liposoma y el compuesto activo se pueden empaquetar separadamente, o pueden estar en formas sólidas y mezclar conjuntamente.

En el caso en donde el reactivo de liposoma está en una forma sólida, sustituyendo los casos de disolución o suspensión para formar un líquido de dispersión de liposoma, en lo anterior, el equipo se puede utilizar al llevar a cabo una etapa similar aquellas de mezclado de líquido de dispersión de liposoma y el compuesto activo y de introducir el compuesto activo en la fase interna de liposoma del líquido de dispersión de liposoma en el método de manufactura de la composición de liposoma mencionado en lo anterior. De esta manera es posible manufacturar una composición de liposoma en la cual un compuesto activo se introduce en la fase interna del reactivo de liposoma.

En el caso en donde el reactivo de liposoma y el compuesto activo están ambos en forma sólida si se empaquetan conjuntamente, la mezcla de reactivo en liposoma y el compuesto activo se disuelve o suspende apropiadamente en un solvente. Cuando se hace de esta manera, el solvente

es similar a la fase externa de liposoma en el líquido de dispersión de liposoma mencionado en lo anterior. De esta manera es posible formar un estado en el cual el líquido de dispersión de liposoma y el compuesto activo se mezclan, después de que se hace el uso posible al llevar a cabo otras etapas de introducción del compuesto activo en la fase interna de liposoma de líquido de dispersión de liposoma en el método de manufactura en la composición de liposoma mencionado en lo anterior.

Modalidades

La presente invención se describe específicamente al dar las modalidades y ejemplos comparativos, pero no se limita a las modalidades enseguida.

(Modalidad 1)

<Preparación de una solución acuosa para la fase interna de liposoma>

396.4 mg de sulfato de amonio y 189.1 mg de monohidrato de ácido cítrico se disolvieron en agua pura, y esto se diluyó a 15 mL para preparar sulfato de amonio 200 mM/ácido cítrico acuoso 60 mM. Después de ajustar 2.5 mL del sulfato de amonio 200 mM/ácido cítrico acuoso 60 mM con amoníaco acuoso a un pH de 5.5, la solución acuosa para la fase interna de liposoma se diluyó a 5 mL con agua pura.

<Preparación del líquido preparatorio de liposoma>

Después de disolver 317.9 mg de fosfatidilcolina de soja hidrogenada (manufacturada por Lipoid), 116.0 mg de colesterol (manufacturado por Sigma) y 130.4 mg de polietilenglicol 2000-fosfatidiletanolamina (manufacturada por Genzyme, MPEG 2000-distearoil fosfatidiletanolamina) en 10 mililitros de cloroformo, esto se suministró precisamente en tres frasquitos, después de lo cual el cloroformo de un frasquito se removió bajo presión reducida en un evaporador rotatorio para crear una película de lípido. 5 mL de la solución acuosa para la fase interna de liposoma se calentó a aproximadamente a 60°C y se adicionó a la película de lípido obtenida, y esto se agitó para preparar un líquido preparatorio de liposoma. Después de tratar el líquido preparatorio de liposoma con ondas ultrasónicas durante 20 minutos, este se granuló con un extrusor (manufacturado por Lipex Biomembranes) calentado a aproximadamente 65° C para obtener el líquido preparatorio de liposoma. El tamaño de partícula de los liposomas en el líquido preparatorio de liposoma obtenido se midió utilizando un

48

método de dispersión de luz dinámica y todos fueron 90 a 100 nm.

<Preparación del líquido de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM (pH = 7.6), sustituyendo la fase externa de liposoma con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM. Después de sustituir la fase externa de liposoma, este se centrifugo durante 30 minutos a 400,00 x g. Después de la centrifugación, esto se redispersó y con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM se utilizó para preparar volumen de 5 mL, que contiene líquido de dispersión de liposoma.

<Preparación de la solución de compuesto activo>

El mesilato de eribulina se disolvió en cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM para obtener 1 mg/mL de mesilato de eribulina.

<Preparación de la composición de liposoma>

0.5 mL de líquido de dispersión de liposoma y 0.5 mL de la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio al 10-mL, y este se incubó durante 3 minutos en 50° C de agua para obtener una composición de liposoma con mesilato de eribulina introducida en los liposomas.

<Medición de la Relación de Atrapamiento>

La relación de atrapamiento se determinó como es descrito enseguida.

La composición de liposoma que atrapa un compuesto activo se ultracentrifugó durante 30 minutos a 400,000 x g. La concentración de compuesto activo en el filtrado se midió con HPLC, cuantificando la cantidad de compuestos activos no atrapados en los liposomas. La relación de atrapamiento se calculó utilizando la fórmula enseguida.

(Fórmula 1)

Relación atrapamiento (%)=

de

Cantidad de compuesto activo en la cantidad total (mg)-cantidad de compuesto activo en el filtrado después de la ultracentrifugación (mg)

X100

Cantidad de compuesto activo en la cantidad total (mg)

La relación de atrapamiento de mesilato de eribulina fue 90.9%.

(Modalidad 2)

<Preparación de la solución acuosa para la fase interna de liposoma>

Similarmente a la Modalidad 1, 264.3 mg de sulfato de amonio y 126.1 mg de monohidrato de ácido cítrico se disolvieron en agua pura, y un matraz graduado se utilizó para diluir esto a 10 mL para preparar sulfato de amonio 200 mM/ácido cítrico acuoso 60 mM. De esto, se tomó 1 mL y se ajustó a un pH de 5.5 con agua amoniada, después de cual se diluyó con agua pura a 2 mL para preparar la solución acuosa para la fase interna de liposoma.

<Preparación del líquido preparatorio de liposoma>

80 mg cada uno de la mezcla de lípido (fosfatidilcolina de soja hidrogenada : colesterol : polietilenglicol 2000-fosfatidiletanolamina=58,6:19:2:22.2 (en peso) se pesó, 2 mL de la solución acuosa para la fase interna de liposoma se calentó a aproximadamente 80° C y se adicionó a la misma, y esto se agitó para preparar el líquido preparatorio de liposoma. Este líquido preparatorio de liposoma se granuló utilizando un extrusor (manufacturado por Lipex Biomembranes) calentado aproximadamente a 80° C para obtener el líquido preparatorio de liposoma.

<Preparación del líquido de dispersión de liposoma>

El líquido preparatorio de liposoma obtenido se diluyó a 10 mL con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM (pH = 7.6), y esto se centrifugó durante 30 minutos a 400,000 x g. Después de la centrifugación, se desechó todo el filtrado. El precipitado se dispersó con el cloruro de sodio 0.9%/solución acuosa de histidina 10 mM, y un matraz graduado se utilizó para preparar 1 mL del líquido, obteniendo el líquido de dispersión de liposoma.

<Preparación de la solución de fármaco>

Mesilato de eribulina (mesilato de eribulina) se disolvió en el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM y se obtuvo 5 mg/mL de solución de mesilato de eribulina.

<Preparación de la composición de liposoma>

0.96 mL del líquido de dispersión de liposoma y 0.24 mL de la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio de 10 mL, y este se incubó durante 3 minutos en 60° C de agua para obtener una composición de liposoma con mesilato de eribulina introducido en los liposomas.

50

<Estabilidad en el plasma sanguíneo de rata>

0.2 mL del mesilato de eribulina preparado atrapado en el liposoma y 1.8 mL de plasma sanguíneo de ratas se mezclaron, y esto se agitó a 37° C utilizando una incubadora de fase líquida. Inmediatamente después de la preparación, el muestreo se realizó en 6 horas, 12 horas, 24 horas, 48 horas y 72 horas después de que se comenzó la agitación, y la cantidad residual de mesilato de eribulina en los liposomas se midió con HPLC.

Los resultados de medición se muestran en la Fig. 1. Como se puede observar en la Fig. 1, se indicó que el mesilato de eribulina se retuvo establemente en el plasma sanguíneo aún durante el lapso de tiempo largo de 120 horas, y fue posible la liberación gradual.

(Modalidad 3)

<Preparación de la solución acuosa para la fase interna de liposoma>

264.3 mg de sulfato de amonio y 126.1 mg de monohidrato de ácido cítrico se disolvieron en agua pura para obtener aproximadamente 15 mL. Después de ajustar el pH a 7.0 con hidróxido de sodio acuoso, esto se diluyó con agua pura a 20 mL para preparar la solución acuosa para la fase interna de liposoma (sulfato de amonio a 100 mM/ácido cítrico 30 mM).

<Preparación del líquido preparatorio de liposoma>

378 mg de una mezcla de lípido (fosfatidilcolina de soja hidrogenada : colesterol : polietilenglicol 2000-fosfatidiletanolamina=58,6:19:2:22.2 (en peso) se pesó, 10 mL de la solución acuosa mencionado en lo anterior o para la fase interna de liposoma se calentó a aproximadamente 80° C y se adicionó a la misma, y esto se agitó para preparar el líquido preparatorio de liposoma. Este líquido preparatorio de liposoma se granuló utilizando un extrusor (manufacturado por Lipex Biomembranes) proporcionado con un filtro de membrana de policarbonato de 50-nm y calentado aproximadamente a 80° C para obtener el líquido preparatorio de liposoma con un tamaño de partícula de aproximadamente 80 nm.

<Preparación del líquido de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM (pH = 7.6), sustituyendo la fase externa de liposoma con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM. Después de

51

sustituir la fase externa liposoma, este se centrifugo durante 30 minutos a 400,00 x g. Después de la centrifugación, esto se redispersó con 96 mg/mL de sacarosa/solución acuosa de histidina de 10 mM (pH = 7.6), y 10 mL de la solución se diluyó a 10n mL para obtener el líquido de dispersión de liposoma.

<Preparación de la solución de fármaco >

Mesilato de eribulina se disolvió con los 96 mg/mL de sacarosa/solución acuosa 10 mM de histidina 10 mM (pH = 7.6) y se obtuvo 5 mg/mL de solución de mesilato de eribulina.

<Preparación de la composición de liposoma>

9.6 mL de líquido de dispersión de liposoma y 1.2 mL de la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio al 10-mL, e hidróxido de sodio se utilizó para ajustar el pH 9.5. Esto se incubó durante 3 minutos en 60° C en agua para obtener una composición de liposoma con mesilato de eribulina introducida en los liposomas. Después del enfriamiento, el cloruro se utilizó para ajustar el pH a 7.5. De manera similar a la modalidad 1, de relación de atrapamiento se midió y se encontró que es 99%.

(Modalidad 4)

<Preparación de la solución acuosa para la fase interna de liposoma>

Similarmente a la Modalidad 1, se preparó sulfato de amonio 100 mM/ácido cítrico 30 mM (pH = 5.5).

<Preparación del líquido preparatorio de liposoma>

Fosfatidilcolina de soja hidrogenada, colesterol y polietilenglicol 2000-fosfatidiletanolamina se pesaron de acuerdo con las cantidades mostradas en la Tabla 1 enseguida. Después de disolver cada uno en 3 mL de cloroformo, el cloroformo se removió bajo presión reducida en un evaporador rotatorio para crear una película de lípido. 10 mL de la solución acuosa preparada para la fase interna de liposoma se calentó a aproximadamente 80° C y se adicionó a la película de lípido obtenida, y esto se agitó para preparar un líquido preparatorio de liposoma. Esto se granuló utilizando un extrusor (manufacturado por Lipex Biomembranes)se calentaron a aproximadamente a 80° C para obtener el líquido preparatorio de liposoma granulado. El tamaño de partícula de los ribosomas en el líquido preparatorio de liposoma obtenido se midió utilizando un método de dispersión de luz dinámica, y Rp. 1 fue 77 nm, Rp. 2 95 nm, Rp. 3 79 nm y Rp. 4 128 nm.

52

(Tabla 1)

Rp.	Fosfatidilcolina de soja hidrogenada	Colesterol	Polietilenglicol 2000- fosfatidiletanolamina
1	234 mg	76 mg	15 mg
2	234 mg	76 mg	15 mg
3	222 mg	73 mg	87 mg
4	222 mg	73 mg	87 mg

<Preparación de la composición de liposoma>

Similarmente a la Modalidad 1, se obtuvo el líquido de dispersión de liposoma. También, mesilato de eribulina se disolvió en cloruro de sodio al 0.9%/solución acuosa de histidina de 10 mM y se obtuvo 5 mg/mL de mesilato de eribulina.

4.8 mL de cada uno de los líquidos de dispersión de liposoma y 0.6 mL de la solución de mesilato de eribulina se mezclaron en recipientes de vidrio de 10 mL, que se incubaron durante 3 minutos en 60° C en agua para obtener composiciones de liposoma con mesilato de eribulina introducido en los liposomas. 24.6 mL del cloruro de sodio a 0.9%/solución acuosa de histidina 10 mM se adicionó a cada una de las composiciones de liposoma, y un filtro de fluoruro de polivinilideno (PVDF) de 0-22-µm se utilizó para filtraciones de esterilización, obteniendo una muestra de administración (concentración de mesilato de eribulina: 0.1 mg/mL). Similarmente la Modalidad 1, la relación de atrapamiento se midió y se confirmó que es por lo menos 90% en cada una de las prescripciones.

Ratones desnudos hembras (UN/UN, Charles River Laboratories Japón, Inc.) se inocularon subcutáneamente con células LOX de melanoma humano, y 11 o 12 días después, las muestras se administraron en las venas caudales para ser 10 mL/kg (1-0 mg/kg para mesilato de eribulina). Una muestra de sangre se tomó y una extracción de tejido de tumor se llevó a cabo con una pulsión cardiaca en periodos fijos después de la administración (15 minutos, 30 minutos, 2, 2, 4, 8, 12, 24, 36 y 48 horas) (n = 3). La sangre se muestreo en un tubo de prueba que contiene heparina, y dentro de 30 minutos del muestreo, la sangre se separó al centrifugar en 1,500 x g durante 10 minutos a 4° C para obtener el plasma sanguíneo. Todo el tejido de tumor se extrajo, se lavó con PBS, y se limpió con papel absorbente de agua, y luego el peso del tejido se pesó inmediatamente y se registró. El tejido se colocó en un

tubo de prueba y se enfrió en agua helada, y luego se almacenaron a -80° C hasta que se llevó a cabo el análisis.

El mesilato de eribulina en el plasma sanguíneo y en el tejido de tumor se midió utilizando el LC/MS/MS.

Los parámetros PK se calcularon utilizando el software de análisis de modelo no de compartimiento (WinNonlin versión 5.0.1). Los resultados de los parámetros PK de plasma sanguíneo y los parámetros PKJ de tejido de tumor de mesilato de eribulina se muestra respectivamente en la Tabla 2 y la Tabla 3.

(Tabla 2)

Rp. 1-4 y parámetros PK de plasma sanguíneo de mesilato de eribulina en ratones portadores de cáncer LOX

Prescripción	AUC ₀₋₁ (ng.hr/mL)	AUC _{0.00} (ng.hr/mL)	CL (mL.hr/kg)	V _{ss} (mL/kg)	T _{1/2} (hr)	MRT (hr)	Relación 1
Rp. 1	253049	258274	3.87	43.99	8.7	11.4	707.1
Rp. 2	176148	177893	5.62	56.40	6.8	10.0	487.0
Rp. 3	228151	233067	4.29	48.93	8.4	11.4	638.1
Rp. 4	221494	230541	4.34	55.88	9.4	12.9	631.2
Mesilato de eribulina	363.02	365.247	24.20	8032	3.7	3.3	1.0

Relación 1 = $AUC_{liposoma \text{ de plasma}} / AUC_{mesilato \text{ de eribulina de plasma}}$

(Tabla 3)

Rp. 1-4 y parámetros PK de plasma sanguíneo de mesilato de eribulina en ratones portadores de cáncer LOX

Prescrip ción	C _[max] (hr)	T _[max] (hr)	AUC _{0.1} (ng.hr/mL)	AUC _{0.00} (ng. hr/mL)	t _{1/2} (hr)	MRT (hr)	TPI (mL/g)	Rela ción
Rp. 1	692.1	4.0	24960.7	34581.8	22.8	38.8	0.13	5.5
Rp. 2	1002.9	8.0	16759.6	22301.1	22.2	34.5	0.13	3.5
Rp. 3	3965.7	12.0	41643.7	46297.3	16.1	23.3	0.20	7.4
Rp. 4	1132.8	12.0	28377.4	45005.6	23.7	44.3	0.20	7.2
Mesilato de eribulina	323.425	0.25	4649.521	6294.283	17.8	27.7	17.23	1.0

Relación 2 = $AUC_{liposoma \text{ de tumor}} / AUC_{mesilato \text{ de eribulina de tumor}}$

A partir de la Tabla 2 y la Tabla 3, se puede observar que la AUC del plasma sanguíneo del tejido de tumor se incrementa en comparación al mesilato de eribulina libre en todas las cuatro composiciones de liposoma Rp. 1 a 4 y por lo tanto, la cantidad de migración del tumor y retención de mesilato de eribulina son mejorados.

(Modalidad 5)

54

<Preparación de la solución acuosa para la fase interna de liposoma>

Similarmente a la Modalidad 1, se preparó sulfato de amonio 100 mM/ácido cítrico acuoso 30 mM (pH = 5.5).

<Preparación del líquido preparatorio de liposoma>

221.8 mg de fosfatidilcolina del soja hidrogena, 72.5 mg de colesterol y 86.9 mg de polietilenglicol 2000-fosfatidiletalamina se pesaron. Después de disolverlos en 3 mL de cloroformo, el cloroformo se removió bajo presión reducida en un evaporador rotatorio y se creó una película de lípido. 10 mL de la solución acuosa creada para la fase interna de liposoma se calentaron a aproximadamente de 80° C y se adicionaron en la película de lípido de obtenida, y esto se agitó para preparar un líquido preparatorio en liposoma. Esto se granuló utilizando un extrusor (manufacturado por Lipex Biomembranas) calentado a aproximadamente a 80° C, y se obtuvo un líquido preparatorio de liposoma granulado. Cuando los tamaños de partícula de los liposomas en el líquido preparatorio de liposoma obtenido se midieron utilizando el método de dispersión de luz dinámica y ellos fueron aproximadamente 90 nm.

<Preparación del líquido de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM (pH = 7.6), sustituyendo la fase externa del liposoma con el cloruro de sodio a 0.9%/solución acuosa de histidina 10 mM. Después de sustituir la fase externa de liposoma, esta se centrifugó durante 30 minutos en 400,000 x g. Después de la centrifugación, esta se redispersó y cloruro de sodio a 0.9%/solución acuosa de histidina a 10 mM, se utilizó para preparar 10 mL de líquido, creando un líquido de dispersión de liposoma.

<Preparación de la solución de fármaco>

Mesilato de eribulina se disolvió en el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM y se obtuvo 1 mg/mL de solución de mesilato de eribulina. También, como muestras de administración de cuerpos libres, la solución de mesilato de eribulina se diluyó con el cloruro de sodio al 0.9%/solución acuosa de histidina a 10 mM y un filtro de PVDF de 0.22- μ m se utilizó para la filtración y esterilización para obtener muestras de administración (concentraciones de mesilato de eribulina: 0.3 mg/mL y 0.4 mg/mL).

<Preparación de la composición de liposoma>

1.8 mL de líquido de dispersión de liposoma y 1.2 mL de la solución de mesilato de eribulina cada uno se mezclaron en un recipiente de vidrio de 10 mL, que se incubó durante 3 minutos en 60° C en agua para obtener una composición de liposoma con mesilato de eribulina introducido en los liposomas. La composición de liposoma obtenida se diluyó con el cloruro de sodio al 0.9%/solución acuosa de histidina de 10 mM (y un filtro de PVDF 0.22- μ m se utilizó para la filtración y esterilización para obtener una muestra de administración (concentraciones de mesilato de eribulina: 0.2 mg/mL) similarmente a la modalidad 1, la relación de atrapamiento se midió y se confirmó que es por lo menos 90%.

FaDu (obtenido de la Colección Americana de Cultivos Tipos) que es una línea de carcinoma de célula escamosa faríngea humana, se cultivó y se dejó crecer en un cultivo MEM que contiene suero fetal bovino al 10%. Las células se separaron del matraz utilizando una solución de Tripsina 0.05%-SDTA y se recolectó. Después del lavado con PBS, la célula se suspendió en PBS para 5×10^7 células/mL se mantuvieron en hielo. 0.1 mL de líquido de suspensión de células se inyectaron subcutáneamente en la porción ventral derecha de los ratones desnudos de 6 semanas de edad (Charles River Laboratories Japón, Inc.). Cada ratón se observó diariamente y notas se hicieron apropiadamente en casos donde se encontraron condiciones anormales. Calibradores se utilizaron para medir el tamaño del tumor a través del tiempo, y el tamaño del tumor se calculó basado en la fórmula de cálculo: eje mayor x (cuadrado de eje menor mg/mL $\div$ 2). En el punto con el tamaño del tumor fue 100 a 200 mm³, los ratones se separaron en grupos tal que los valores promedio de los tamaños de tumor y los pesos corporales de ratón fueron uniformes entre los grupos de prueba (cinco ratones por grupo de prueba), y el fármaco se administró en la vena caudal (0.2 mL/20 g; 3 veces de intervalos de 7 días).

Los cambios resultantes en el volumen de tumor promedio después de la administración de muestra se muestra en la Fig. 2.

Como se muestra en la Fig. 2, un efecto de reducción de tumor no se obtuvo aún en 4 mg/kg, que es la dosis tolerada máxima para cuerpos libres, debido a que FaDu es una línea celular con una baja sensibilidad a mesilato de eribulina. Mientras tanto, en el caso del compuesto de liposoma, un efecto de reducción de tumor claro se encontró aun con la administración de 2 mg/kg, que está abajo de la dosis de tolerancia máxima, indicando que un efecto

farmacológico extremadamente alto se puede obtener aun para tipos de cánceres contra los cuales no se ha tenido éxito con mesilato de eribulina.

(Modalidad 6)

<Preparación de la solución acuosa para la fase interna de liposoma>

Similarmente a la modalidad 1, se preparó sulfato de amonio 100 mM/ácido cítrico acuoso 30 mM (pH = 5.5).

<Preparación de la solución de fármaco>

Similarmente a la modalidad 5, se obtuvieron muestras de administración (concentración de mesilato eribulina: 0.2 mg/mL, 0.3 mg/mL y 0.4 mg/mL) de cuerpos libres.

<Preparación de la composición de liposoma>

Excepto para el uso de la solución acuosa de solución de fase interna de liposoma [*sic*: solución acuosa para la fase interna de liposoma] preparada como es descrito en lo anterior, la composición de liposoma (concentración de mesilato de eribulina: 0.3 mg/mL) se obtuvo similarmente a la modalidad 5. Similarmente a la modalidad 1, la relación de atrapamiento se midió y se encontró que es por lo menos 90%.

ACHN (obtenido de la colección Americana de Cultivos Tipo) que es una línea de células de cáncer renal humano, se cultivó y se dejó crecer en un cultivo MRM que contiene suero fetal bovino al 10%. Las células se separaron del matraz utilizando la solución de Tripsina al 0.05%-EDTA, se recolectaron. Después del lavado con PBS, la célula se suspendieron en PBS para ser 5×10^7 células/mL y luego se mantuvieron en hielo. 0-1 mL de líquido o suspensión de células se inyectaron subcutáneamente en la porción ventral derecha de los ratones desnudos de 6 semanas de (Charles Rivier Laboratories Japón, Inc.). Cada ratón se observó diariamente, y notas se hicieron apropiadamente en casos en donde se encontraron condiciones anormales. Calibradores se utilizaron para medir el tamaño del tumor durante el tiempo, y el tamaño de tumor se calculó basado en la fórmula de cálculo: eje mayor x (eje menor cuadrado $\div$ 2). En el punto con el tamaño del tumor fue 150 a 200 mm³, los ratones se separaron en grupos tal que los valores promedio de los tamaños de tumor y los pesos corporales de ratón fueron uniformes entre los grupos de prueba (cinco ratones por grupo de prueba) y el fármaco se administró en la vena caudal (0.2 mL/20 g; 3 veces en intervalos de 7 días).

Los resultados del cambio en el volumen de tumor promedio

57

después de la administración de muestra se muestran en la Fig. 3.

Como se muestra en la Fig. 3, debido a que SCHN es una línea de células que es resistente a mesilato de eribulina, no se encontró diferencia significativa entre cualquiera de la administración 2 mg/kg, administración 3 mg/kg y grupos de administración de cuerpos libres de 4 mg/kg (dos de tolerancia máxima) y el grupo no tratado 45 días después de inicio de la administración de la muestra. Mientras tanto, en el grupo de administración de composición de liposoma de 3 mg/kg, se encontró un efecto de superación de crecimiento de tumor, y un valor de volumen de tumor menor significativo se indicó para el grupo no tratado y los grupos de administración de cuerpos libres 45 días después del inicio de administración de muestra. Como es así indicado, es posible retardar el crecimiento de un tumor al preparar una formulación liposomal para un tumor para el cual un efecto terapéutico nunca se ha obtenido antes con un mesilato de eribulina.

(Modalidad 7)

<Preparación de la solución acuosa para la fase interna de liposoma>

Los 12 tipos de soluciones acuosas para la fase interna mostradas enseguida en la Tabla 4 se crearon.

<Preparación del líquido preparatorio de liposoma>

120 mg de una mezcla de lípido (fosfatidilcolina de soja hidrogenada : colesterol : polietilenglicol 2000-fosfatidiletanolamina=58.6:19.2:22.2 (en peso) se pesaron en tubos de prueba y 3 mL de cada muestra de la solución acuosa para la fase interna se calentó a 80° C.

El líquido preparatorio de liposoma se granuló utilizando una extrusor calentado a aproximadamente a 80° C, y se obtuvo el líquido preparatorio de liposoma.

<Preparación de la solución de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina de 10 mM, sustituyendo a la fase externa liposomal con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM.

Después de sustituir la fase externa de liposoma, este se centrifugó durante 1 hora en 400,000 x y el filtrado se removió completamente. El secado se resuspendió con 96 mg/mL de sacarosa/solución acuosa de

58

histidina a 10 mM (pH = 7-5) para ser aproximadamente 2 mL.

El tamaño de partícula del líquido de dispersión de liposoma obtenido se midió utilizando un método de dispersión de luz dinámica, y todos fueron aproximadamente 80 nm.

<Preparación de la solución de fármaco>

Mesilato de eribulina se disolvió en 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM y se obtuvo 5 mg/mL de solución de mesilato de eribulina.

<Preparación de la composición de liposoma>

El líquido de dispersión de liposoma y la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio de 10 10-mL tal que el mesilato de eribulina fue 0.2 mg/mL y la concentración de lípido total fue de 16 µmol/mL. Esto se calentó a 25 minutos a 60° C para obtener una composición de liposoma con mesilato de eribulina introducida en los liposomas.

<Medición de la relación de atrapamiento>

La relación de atrapamiento se midió similarmente a la modalidad 1, y los resultados se muestran en la Tabla 4. Como se puede observar en la Tabla 4, sin considerar que sal de amonio se utilizó en la fase interna, se mejoró claramente la relación de atrapamiento de mesilato de eribulina. En particular, la mejora en la relación de atrapamiento fue marcada cuando se utiliza sulfato de amonio, citrato de amonio, fosfato de amonio y tartrato de amonio.

(Tabla 4)

No.	Composición	pH	Presión Osmótica	Relación de atrapamiento (%9
1	50 mM de sulfato de amonio			69.4
2	50 mM de sulfato de sodio			7.2
3	50 mM de acetato de amonio			36.8
4	50 mM de acetato de amonio			10.2
5	50 mM de fosfato de amonio			45.8
6	50 mM de fosfato de sodio			14.6

59

7	50 mM de citrato de amonio	7.5 (ajustado con ácido clorhídrico hidroxido de sodio)	300 mOsm (ajustado con sacarosa)	65.8
8	50 mM de citrato de sodio			8.7
9	50 mM de succinato de amonio			14.7
10	50 mM de succinato de sodio			10.0
11	50 mM de tartrato de amonio			74.7
12	50 mM de tartrato de sodio			11.6

(Modalidad 8)

<Preparación de la solución acuosa para la fase interna de liposoma>

Similarmente a la modalidad 7, la solución acuosa para la fase interna de liposoma se preparó de sulfato de amonio 100 mM/ácido cítrico acuoso 30n mM (pH = 7.5).

<Preparación del líquido preparatorio de liposoma>

Similarmente a la modalidad 7, la solución acuosa mencionada en lo anterior para la fase interna de liposoma se utilizó para preparar un líquido preparatorio de liposoma.

<Preparación del líquido de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM, sustituyendo la fase externa de liposoma con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM.

Después de sustituir la fase externa de liposoma, esto se centrifugó durante 1 hora en 400,000 x g, completamente removiendo el filtrado. El precipitado se resuspendió con 96 mg/mL de solución acuosa de histidina a 10 mM (pH = 7.5), la fase externa en el liposoma se sustituyó con 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM (pH = 7.5) y se obtuvo un líquido de dispersión de liposoma. El tamaño de partícula de líquido de dispersión de liposoma obtenido se midió utilizando un método de dispersión de luz dinámica, y esto fue aproximadamente 80 nm.

El líquido de dispersión de liposoma se suministró en 7 frasquitos,

y sulfato de amonio (ajustado pH de 7.5 utilizando el oxido de sodio acuoso) de una cantidad conocida se adicionó a la fase externa de liposoma tal que los frasquitos tuvieron las concentraciones en la Tabla 5 y un líquido de dispersión de liposoma se obtuvo en el cual el sulfato de amonio en la fase de externa de liposoma fue de una concentración conocida.

<Preparación de la solución de fármaco>

Mesilato de eribulina se disolvió en 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM y se obtuvo 5 mg/mL de solución de mesilato de eribulina.

<Preparación de la composición de liposoma>

El líquido de dispersión de liposoma y la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio de 10-mL tal que el mesilato de eribulina fue 0.2 mg/mL y una concentración de lípido total fue 16 mM. Esto se calentó en 5 minutos a 60° C para obtener una composición de liposoma con mesilato de eribulina introducido en los liposomas.

<Medición de la relación de atrapamiento>

La relación de atrapamiento se midió similarmente a la Modalidad 1, y los resultados se muestran en la Tabla 5. Esto muestra que si aún 0.4 mM de sulfato de amonio esta presente en la fase externa de liposoma, la relación de atrapamiento cae notablemente, y no hay casi atrapamiento si 10 mM de sulfato de amonio está presente.

(Tabla 5)

No.	Fase acuosa interna	Concentración de sulfato de amonio en la fase externa (mM)	Relación de atrapamiento (%)
1	Sulfato de amonio 100 mM ácido cítrico 30 mM pH 0 7.5	0	90.4
2		0.016	90.8
3		0.08	91.3
4		0.4	75.9
5		2	36.8
6		10	16.1
7		50	8.6

(Modalidad 9)

<Preparación de la solución acuosa para fase interna de liposoma>

Similarmente el Ejemplo 7, la solución acuosa para la fase interna de liposoma se preparó de sulfato de amonio 100 mM/ácido cítrico acuoso 30 mM (pH = 7.5).

<Preparación del líquido preparatorio de liposoma>

Similarmente al Ejemplo 7, la solución acuosa mencionada en lo anterior para la fase interna de liposoma se utilizó para preparar el líquido preparatorio de liposoma.

<Preparación de la solución de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM, sustituyendo la fase externa de liposoma con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM.

Después de sustituir la fase externa de liposoma, esto se centrifugo durante 1 hora en 400,000 x g y el filtrado se removió completamente. El precipitado se resuspendió con 96 mg/mL de sacarosa/solución acuosa de histidina de 10 mM (pH = 7.5), la fase externa de liposoma se sustituyó con 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM (pH = 7.5) y se obtuvo el líquido de dispersión de liposoma. El tamaño de partícula de líquido de dispersión de liposoma obtenido se midió utilizando un método de dispersión de luz dinámica, y este fue aproximadamente 80 nm.

<Preparación de la solución de fármaco>

Mesilato de eribulina se disolvió en 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM y se obtuvo 5 mg/mL de solución de mesilato de eribulina.

<Preparación de la composición de liposoma>

El líquido de dispersión de liposoma y la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio de 10-mL tal que el mesilato de eribulina fue 0.2 mg/mL y la concentración de lípido total fue 16 mM. Como se muestra en la Tabla 6, cada pH de la fase externa de liposoma se ajustó utilizando una solución acuosa de hidróxido de sodio 1 M. Esto se calentó durante 25 minutos a 60° C para obtener una composición de liposoma con necesidad de eribulina introducido en los liposomas. Enseguida, ácido clorhídrico se utilizó para ajustar el pH de la fase externa 7.5.

<Medición de la relación de atrapamiento>

La relación de atrapamiento se midió similarmente a la Modalidad 1, y los resultados se muestran en la Tabla 6. Junto con la elevación en el pH de la fase externa de liposoma, la relación de atrapamiento de eribulina se elevó sustancialmente, alcanzar una relación de atrapamiento de casi 100%.

(Tabla 6)

No.	Fase acuosa	pH de fase	Relación de
-----	-------------	------------	-------------

62

	interna	externa	atrapamiento (%)
1	Sulfato de amonio 100 mM ácido cítrico 30 mM pH = 7.5	7.5	72.9
2		8.0	79.8
3		8.5	86.4
4		9.0	92.8
5		9.5	98.5
6		10.0	100.0
7		10.5	99.3

(Modalidad 10)

<Preparación de la solución acuosa para la fase interna de liposoma>

Similarmente al ejemplo 7, la solución acuosa para la fase interna de liposoma se preparó de sulfato de amonio 100 mM/ácido cítrico acuoso 30 mM (pH = 7.5).

<Preparación del líquido preparativo de liposoma>

Similarmente al Ejemplo 7, la solución acuosa mencionada en lo anterior para la fase interna de liposoma se utilizó para preparar el líquido preparatorio de liposoma.

<Preparación de la solución de dispersión de liposoma>

Utilizando columnas Sephadex G-50, el líquido preparatorio de liposoma obtenido se eluyó con cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM, sustituyendo al fase externa de liposoma con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM.

El líquido de dispersión de liposoma se suministró en cuatro frasquitos, que se centrifugaron durante 1 hora a 400,000 x g y el filtrado se removió completamente. El precipitado de dos de los frasquitos se resuspendió con 96 mg/mL de sacarosa/solución acuosa de histidina de 10 mM (pH = 7.5), y la fase externa de liposoma se sustituyó con 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM (pH = 7.5). El precipitado de los dos frasquitos restantes se resuspendió con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM (pH = 7.5) y la fase externa de liposoma se sustituyó con el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM (pH = 7.5). El tamaño de partícula de los líquidos de dispersión de liposoma obtenidos se midió utilizando un método de dispersión de luz dinámica, y todos fueron aproximadamente 80 nm.

<Preparación de la solución de fármaco>

Mesilato de eribulina se disolvió en 96 mg/mL de sacarosa/solución acuosa de histidina 10 mM y se obtuvo 5 mg/mL de solución de mesilato de eribulina. De manera similar, el mesilato de eribulina se disolvió

63

en el cloruro de sodio al 0.9%/solución acuosa de histidina 10 mM y se obtuvo 5 mg/mL de solución de mesilato de eribulina.

<Preparación de la composición de liposoma>

El líquido de dispersión de liposoma y la solución de mesilato de eribulina se mezclaron en un recipiente de vidrio de 10-mL tal que el mesilato de eribulina fue 0.2 mg/mL y la concentración de lípido total fue 16 mM. El pH de la fase externa de liposoma de uno de los dos frasquitos de 96 mg/mL sacarosa/solución acuosa de histidina 10 mM (pH = 7.5), se ajustó a 9.5 al adicionar hidróxido de sodio. De manera similar, el pH de la fase externa de liposoma de uno de los dos frasquitos del cloruro de sodio 0.9%/solución acuosa de histidina 10 mM (pH = 7.5) se ajustó al 9.5 al adicionar hidróxido de sodio. Esto se calentó durante 5 minutos a 60° C para obtener una composición de liposoma con mesilato de eribulina introducido en los liposomas.

<Medición de la relación de atrapamiento>

La relación de atrapamiento se midió similarmente a la Modalidad 1, y los resultados se muestran en la Tabla 7. Comparado con el caso donde la fase externa de liposoma es una sacarosa, que es no electrolito, el caso de cloruro de sodio, que es un electrolito, claramente se obtiene una relación de atrapamiento extremadamente alta. Además del efecto de electrolito, la aplicación del gradiente de pH para hacer la fase externa liposoma un álcali logró una relación de atrapamiento de 100%.

(Tabla 7)

No.	Fase acuosa interna	Composición de fase interna	Relación de atrapamiento (%)
1	Sulfato e amonio 100mM ácido cítrico 30 mM pH = 7.5	96 mg/mL de sacarosa histidina 10mM pH = 7.5	72.9
2		Cloruro de sodio al 0.9% histidina 10mM pH = 7.5	95.9
3		96% mg/mL de sacarosa histidina 10 mM pH = 9.5	97.5
4		Cloruro de sodio al 0.9% histidina 10 mM pH 0 9.5	100.0

La presente solicitud esta basada en una solicitud de patente Japonesa (Solicitud de Patente Japonesa 2009-082521) presentada el 30 de Marzo de 2009, y una Solicitud de Patente Provisional Norteamericana (61/16453), y los contenidos de las mismas se incorporan en la presente como referencia.

64

Campo de Aplicación industrial

La presente invención es capaz de proporcionar un método para manufacturar un liposoma con una alta estabilidad de retención del compuesto activo con una alta relación de atrapamiento.

La composición de liposoma de la presente invención se utiliza favorablemente en aplicaciones terapéuticas a través del efecto farmacológico de la eribulina o su sal farmacológicamente permisible.

Appendix I. Table of Marketed Liposomal Drug Compositions (as of September 2013)

	Brand name	Company	API	Lipids	Others	Formulation	Launch
1	Ambisome	Vestar/NeXstar/ Gilead	Amphotericin B	HSPC/cholesterol/ DSP G/α-Toc	Sucrose/disodium succinate hexahydrate	Lyophilized formulation	1990
2	Amphotec/ A mphocil	LT/Sequus/ALZA, J&J/ Zeneca	Amphotericin B	Cholesteryl sulfate	The liposomal formulation of Amphotec was replaced by the complex with cholesteryl sulfate under clinical trial because of Ambisome's patent	Lyophilized formulation	1993
3	Epaxal /HAVpur/VIR OHEP-A	Crucell/Berna	Inactivated hepatitis A virus(strain RG-SB)	DOPC/DOPE/HA & NA glycoproteins	sodium chloride/ water	Suspension for injection	1994
4	Abelcet	TLC/Elan/Enzon	Amphotericin B	DMPC/DMPG	sodium chloride/ water	Suspensions	1995
5	DaunoXome	Vestar/NeXstar/Gil ead/ Diatos	Daunorubicin citrate	DSPC/cholesterol	sucrose, glycine, calcium chloride dihydrate	Suspensions	1995
6	Doxil/Caelyx	LT/Sequus/ALZA, J&J/Ortho,Scherin g-Plough	Doxorubicin hydrochloride	HSPC/cholesterol/ MPEG-DSPE	ammonium sulphate, histidine, sucrose and hydrochloric acid and/or sodium hydroxide	Suspensions	1995
7	Inflexal V	Crucell/Berna Biotech/Janssen- Cilag	Influenza virus surface antigens	Lecithin	Sodium chloride, disodium phosphate dihydrate, potassium dihydrogen phosphate and water	Suspensions	1997

8	DepoCyte/ Savadar	SlyPharma/Pacira Pharmaceutical	Cytarabine	DOPC/cholesterol/ DPPG/triolein	Sodium chloride and water	Suspensions	1999
9	Myocet	TLC/Elan	Doxorubicin hydrochloride	eggPC/cholesterol	Lactose in lyophilised powder /citric acid, sodium hydroxide and water in dispersion /sodium carbonate and water in solvent	Three-vial system (lyophilised powder / dispersion / solvent)	2001 (Europe)
10	Lipo-Dox	Taiwan Liposome Co(TLC)/TTY Biopharm	Doxorubicin hydrochloride	DSPC/cholesterol/ MPEG-DSPE	unclear	Suspensions	2001 (Taiwan)
11	Visudyne	QLT/Novartis	Verteporfin	eggPG/DMPC	ascorbyl palmitate, butylated hydroxytoluene and lactose	Lyophilized formulation	2001
12	DepoDur/Dep oMorphine	SkyePharma/ Endo/Pacira, EKR	Morphine sulfate	DOPC/cholesterol/ DPPG/ tricaprylin/triolein	sodium chloride, water	Suspensions	2004
13	Marqibo	INEX and Enzon/Ternira/ Talon Therapeutics	Vincristine sulfate	Sphingomyelin/cho lesterol	mannitol, sodium citrate, citric acid, sodium phosphate and sodium chloride	Three-vial system (Vincristine solution, liposome solution and Sodium Phosphate solution)	2008
14	Exparel	Parcira Pharmaceuticals	Bupivacaine	DPPG/cholesterol/ tricaprylin/DEPC	sodium chloride, water	Suspensions	2011

Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors

DARYL C. DRUMMOND,¹ OLIVIER MEYER,² KEELUNG HONG, DMITRI B. KIRPOTIN, AND DEMETRIOS PAPAHA DJOPOULOS
California Pacific Medical Center-Research Institute, Liposome Research Laboratory, San Francisco, California (D.C.D., O.M., K.H., D.K., D.P.); Department of Radiation Oncology, University of California at San Francisco, San Francisco, California (O.M., D.K.); and Department of Cellular and Molecular Pharmacology, University of California at San Francisco, San Francisco, California (D.P.)

This paper is available online at <http://www.pharmrev.org>

I. Introduction	692
II. Pharmacokinetics and biodistribution of liposomes and liposomal drugs	696
A. Effect of liposome size on pharmacokinetic parameters	696
B. Effect of lipid dose on pharmacokinetic parameters	697
C. Effect of liposome charge on pharmacokinetic parameters	698
D. Effect of membrane packing constraints on pharmacokinetic parameters	700
E. Effect of steric stabilization on pharmacokinetic parameters	701
F. Comparison of pharmacokinetic parameters for different liposomal formulations	702
G. Tissue distribution of conventional and sterically stabilized liposomes	704
H. Metabolism and elimination of liposomal doxorubicin	705
III. Accumulation of liposomal drugs in tumors	706
A. Mechanistic rationale for liposome accumulation in tumors: enhanced permeability and retention effect phenomenon	706
1. Effect of microvasculature physiology	707
2. Blood-brain barrier	708
B. Rate and extent of accumulation in tumors	708
C. Hyperthermia and vascular permeability factors for increasing vascular permeability	711
D. Sterically stabilized versus rapid-release conventional liposome carriers	711
IV. Efficacy of liposomal drugs in animal tumor models	712
A. Comparison of efficacy for sterically stabilized and conventional liposomes	712
B. Model dependency of results	714
1. Initial size of tumor	714
2. Rapidly growing versus slowly growing tumors	715
3. Route of administration	715
4. Frequency of injection	715
5. Environment of tumor	715
C. Efficacy with nonanthracyclines	716
D. Multidrug resistance	717
V. Clinical efficacy of liposomal anthracyclines	718
A. AIDS-related Kaposi's sarcoma	718
B. Treatment of breast and ovarian carcinomas	720
VI. Toxicology of liposomal chemotherapy	720
A. Tolerability of liposome components	720
B. Toxicities associated with free drug	721
C. Effect of liposome encapsulation on toxicity profile	721
1. Cardiotoxicity	721
2. Vesicant properties	722
3. Myelosuppression	722
4. Nausea, vomiting, and alopecia	723
5. Hand and foot syndrome (palmar-plantar erythrodysesthesia syndrome)	723

¹ Address for correspondence: Daryl C. Drummond, Ph.D., California Pacific Medical Center-Research Institute, Liposome Research Laboratory, Room 211, 2200 Webster St., San Francisco, CA 94115. E-mail drummond@cooper.cpmc.org

² Present address: TRANSGENE S.A., 67082 Strasbourg Cedex, France.

6. Mucositis	724
7. Reticuloendothelial system impairment and opportunistic infections	724
D. Final comparisons of conventional and sterically stabilized liposomes	725
VII. Stability in plasma and storage	725
A. Physical stability of liposomal drug formulations	725
1. Drug-loading methods	726
2. Physical stability of liposome formulations with nonanthracyclines	727
3. Drug/lipid ratio	728
4. Osmolarity effects	728
5. Stabilizing against aggregation	728
B. Chemical stability of drugs and lipid components	728
VIII. Bioavailability of encapsulated drug	729
A. Release of doxorubicin in tumor	730
B. Active targeting of liposomes	730
C. Hyperthermia and thermosensitive liposomes	733
D. Problems with highly hydrophilic drugs and bioavailability	734
IX. Conclusions	734
A. Sterically stabilized versus rapid-release conventional liposome formulations	734
B. Conventional and sterically stabilized slow-release systems	735
C. Visions for future	735
X. Acknowledgments	736
XI. References	737

I. Introduction

There are many potential barriers to the effective delivery of a drug in its active form to solid tumors. Most small-molecule chemotherapeutic agents have a large volume of distribution on i.v. administration (Speth et al., 1988; Chabner and Longo, 1996). The result of this is often a narrow therapeutic index due to a high level of toxicity in healthy tissues. Through encapsulation of drugs in a macromolecular carrier, such as a liposome, the volume of distribution is significantly reduced and the concentration of drug in the tumor is increased (see *IIF. Comparison of Pharmacokinetic Parameters for Different Liposomal Formulations* and *III. Accumulation of Liposomal Drugs in Tumors*). This results in a decrease in the amount and types of nonspecific toxicities and an increase in the amount of drug that can be effectively delivered to the tumor (Papahadjopoulos and Gabizon, 1995; Gabizon and Martin, 1997; Martin, 1998). Under optimal conditions, the drug is carried within the liposomal aqueous space while in the circulation but leaks at a sufficient rate to become bioavailable on arrival at the tumor. The liposome protects the drug from metabolism and inactivation in the plasma, and due to size limitations in the transport of large molecules or carriers across healthy endothelium, the drug accumulates to a reduced extent in healthy tissues (Mayer et al., 1989; Working et al., 1994). However, discontinuities in the endothelium of the tumor vasculature have been shown to result in an increased extravasation of large carriers and, in combination with an impaired lymphatics, an increased accumulation of liposomal drug at the tumor

(see *III. Accumulation of Liposomal Drugs in Tumors*; Huang et al., 1993; Yuan et al., 1994, 1995; Hobbs et al., 1998). All of these factors have contributed to the increased therapeutic index observed with liposomal formulations of some chemotherapeutic agents (Papahadjopoulos et al., 1991; Gabizon, 1994; Martin, 1998).

A diagram depicting both a conventional liposome (CL)³ and a sterically stabilized liposome (SSL) is shown in Fig. 1. The two types of liposomes share a lipid membrane that is relatively impermeable to both amphipathic and highly water-soluble molecules at physiological temperatures (37°C). This feature is important for the maintenance of stable liposome drug formulations, both during storage and in plasma (see *VII. Stability in Plasma and Storage*). Liposomes composed of a comparably more-fluid membrane are being used as a rapid-

³ CL, conventional liposome; SSL, sterically stabilized liposome; ara-C, 1-β-D-arabinofuranosylcytosine; AUC, area under the curve for concentration versus time; ABV, doxorubicin/bleomycin/vincristine; BV, bleomycin/vincristine; Chol, cholesterol; DOX, doxorubicin; DPPC, 1,2-dipalmitoyl-3-sn-phosphatidylcholine; DPPE, 1,2-dipalmitoyl-3-sn-phosphatidylethanolamine; DPPG, 1,2-dipalmitoyl-3-sn-phosphatidylglycerol; DSPA, 1,2-dipalmitoyl-3-sn-phosphatidic acid; DSPC, 1,2-distearoyl-3-sn-phosphatidylcholine; DSPG, 1,2-distearoyl-3-sn-phosphatidylglycerol; eggPC, phosphatidylcholine derived from egg yolk; H-F, hand and foot; HSPC, hydrogenated soy phosphatidylcholine; ILS, increased life span; L-DOX, liposomal doxorubicin; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEG, polyethylene glycol; PEG-DSPE, N-(polyethylene glycol)distearoylphosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; RES, reticuloendothelial system; SSL DOX, sterically stabilized liposomal doxorubicin; VCR, vincristine; CSF, colony-stimulating factor; POPC, 1-palmitoyl, 2-oleoyl-3-sn-phosphatidylcholine.




FIG. 1. Diagram of a drug-loaded liposome both with (SSL) and without (CL) a PEG coating. The liposome contains a lipid membrane that encapsulates an internal aqueous space used to entrap chemotherapeutic drugs. DOX can be encapsulated at concentrations exceeding its aqueous solubility, forming drug crystals in the liposome interior. Alternatively, some drugs can be carried within the lipid bilayer. Further modifications of the surface through covalent attachment of targeting ligands such as Fab' fragments can result in liposomes that are specifically endocytosed by cancer cells expressing a receptor for that ligand (e.g., the HER2 receptor found on certain breast cancer tumors). The structures of the three most commonly used lipids that compose the lipid bilayer are also given. DSPC (A) or an equivalent, HSPC, is the primary phospholipid component, whereas Chol (B) is the neutral lipid component. PEG-DSPE (C) is incorporated at concentrations of 4 to 6 mol% in SSL formulations.

release system for doxorubicin (DOX) and are described to a limited extent in this review. A liposome also has an internal aqueous space, which can be used to entrap a

variety of chemotherapeutic drugs or diagnostic dyes. We discuss in VII. *Stability in Plasma and Storage* how different drugs are efficiently loaded into this space. The

20

two types of liposomes differ in the presence of the polymer coating [most commonly, polyethylene glycol (PEG)] on the surface of the SSLs but not CLs. This coating provides steric stabilization to the liposome, which is thought to limit binding of serum opsonins as well as direct interactions with cells, most importantly, of the reticuloendothelial system (RES; Allen et al., 1991, 1994; Lasic et al., 1991). The result is enhanced circulation times and increased localization in the tumor (Papahadjopoulos et al., 1991, 1995; Gabizon and Martin, 1997).

Steric stabilization refers to the colloidal stability (Lasic and Needham, 1995; Lasic and Papahadjopoulos, 1996) conferred on the liposome by a variety of hydrophilic polymers or hydrophilic glycolipids (Allen and Chonn, 1987; Papahadjopoulos et al., 1991; Woodle and Lasic, 1992; Allen, 1994; Torchilin et al., 1995; Zalipsky et al., 1996), the best studied of which are PEG and the ganglioside GM₁. An important finding was that SSLs also show a prolonged lifetime in the circulation (Allen and Chonn, 1987; Gabizon and Papahadjopoulos, 1988; Klivanov et al., 1990; Allen et al., 1991; Papahadjopoulos et al., 1991). SSLs then typically refer to any liposomes containing PEG-PE, GM₁, or another of these glycolipids or polymers that has a relatively long half-life in the general circulation. The term "conventional liposomes" has a much broader definition and refers to liposomes composed of a variety of different lipid compositions, but typically the most commonly used of these compositions are very high in phosphatidylcholine (PC) and cholesterol (Chol). The pharmacokinetics and tissue distribution of CLs depend on properties such as size, surface charge, and membrane packing. These factors are discussed in more detail in *II. Pharmacokinetics and Biodistribution of Liposomes and Liposomal Drugs*. However, to perform a careful comparison, we limit this discussion to formulations optimized for increased residence in the circulation, accumulation in tumors, and stability in the plasma. For SSLs, we consider liposomes containing 4 to 6 mol% PEG-DSPE, ~30 mol% Chol, and the remainder hydrogenated soy phosphatidylcholine (HSPC) or distearoylphosphatidylcholine (DSPC; Fig. 1). The size of the carrier is usually 60 to 120 nm. For CLs, the optimized formulations are composed of DSPC and Chol in either a 55:45 or 66:33 M ratio or phosphatidylcholine derived from egg yolk (eggPC)/Chol (3:2) and have a similar average size distribution.

The choice of drug for delivery via liposomes is essential to the success of this approach. Broad generalizations as to the usefulness of a certain liposome composition for the delivery of all chemotherapeutic drugs or as to the superiority of liposomal formulation for all classes of drugs is extremely dangerous considering the present limitations in liposome technology. To be effective as a carrier, a liposome must be able to efficiently balance stability in the circulation with the ability to make the drug bioavailable at the tumor. In choosing a drug, there are several criteria to consider. The drug must have sufficient activity against

the chosen tumor; a drug such as DOX with a relatively broad activity against a variety of different tumor models is an ideal choice in this regard (Young et al., 1981; Doroshaw, 1996). Second, the drug must be efficiently loaded into the liposomal carrier. Ammonium sulfate and pH gradients have been used for remote loading of a variety of amphipathic basic amines, resulting in encapsulation efficiencies of ~100% (Madden et al., 1990; Lasic et al., 1992a; Haran et al., 1993; Cullis et al., 1997). Finally, the drug must be compatible with the carrier; it must be stably transported in the circulation but still released at the tumor. A wide array of different drugs have been encapsulated in liposomes for the treatment of cancer (Fig. 2; Heath et al., 1983; Papahadjopoulos et al., 1991; Allen et al., 1992; Vaage et al., 1993b; Burke and Gao, 1994; Sharma et al., 1995; Jones et al., 1997; Working, 1998). The listed examples illustrate a diversity of different classes of chemotherapeutic drugs, with distinct chemical stabilities, solubility and membrane partitioning properties, modes of action, and modes of drug resistance.

Barenholz and coworkers (Barenholz and Cohen, 1995; Barenholz, 1998) classified these drugs into one of three classes depending on their hydrophobic properties measured as octanol-to-water partition coefficient (K_p): 1) highly hydrophilic drugs such as *N*-(phosphonoacetyl)-L-aspartate, 2) hydrophobic drugs such as paclitaxel, and 3) amphipathic drugs such as DOX, which represent many current chemotherapeutic agents. Liposomal formulations of highly hydrophilic drugs can be limited by the bioavailability of these drugs at the tumor site, which may be prohibitively low due to their extremely low membrane permeability and, therefore, low drug release once the carrier has reached the tumor. Drugs such as 1- β -D-arabinofuranosylcytosine (ara-C) or methotrexate, which are taken by tumor cells using membrane transporters (Plageman et al., 1978; Wiley et al., 1982; Westerhof et al., 1991, 1995; Antony, 1992), may be useful members of this class of drugs, assuming they can be released from the liposome in adequate quantities (Heath et al., 1983; Matthay et al., 1989; Allen et al., 1992). Future improvements in the design of carriers that are destabilized and release the drugs specifically at the tumor site may make their utilization more feasible, as discussed in *VIII. Bioavailability of Encapsulated Drug*. Highly hydrophobic drugs tend to associate mainly with the bilayer compartment of the liposome; this leads to lower entrapment stability due to faster redistribution of the drug to plasma components. However, liposomes may be used with this class of drugs simply as the means to formulate them for i.v. administration rather than using liposome encapsulation to achieve enhanced tumor delivery of the drugs. For example, paclitaxel has formulated into liposomes (Sharma et al., 1995, 1997) but may be equally suitable when formulated as a microemulsion (Wheeler et al., 1994). Liposomes have also used to solubilize and




FIG. 2. Structures of a few chemotherapeutic drugs that have been used with liposomes either in vitro or in vivo. These drugs operate via a variety of different mechanisms; some have different mechanisms of drug resistance and varying physical characteristics that make them more or less compatible for encapsulation in liposomes. At the present time, only formulations of anthracyclines (daunorubicin and DOX) have been sufficiently developed for use in the clinic, although a liposomal VCR formulation is presently under study in clinical trials.

administer hydrophobic photosensitizers for use in photodynamic therapy (Allison et al., 1990; Reddi, 1997).

Considering the present state of liposome technology, amphipathic drugs appear to be the most suitable for liposomal carriers; these drugs include anthracyclines, such as DOX and daunorubicin, and Vinca alkaloids,

such as vincristine (VCR), vinblastine, and vinorelbine (Fig. 2). With this class of drugs, it is possible to tune the drug-release rates to maintain the stability of the formulation in the plasma, yet allow the drug to be released at the tumor site. This is in large part due to the development of gradient-based loading techniques leading to

stable liposomal drug formulations (Nichols and Deamer, 1976; Mayer et al., 1985; Madden et al., 1990; Haran et al., 1993). Indeed, the first liposomal oncology drugs approved for medical use in liposomal form are of the anthracyclines daunorubicin (DaunoXome; Nexstar Pharmaceuticals, Boulder, CO) and DOX [Doxil; Alza Corporation, Palo Alto, CA (CAELYX in Europe)]. DaunoXome is formulated as a CL (DSPC/Chol), whereas Doxil is an SSL formulation (hydrogenated soy PC/Chol/PEG-DSPE; Table 1). Another CL formulation (eggPC/Chol) of DOX (Harris et al., 1998), as well as formulations of other amphipathic drugs, such as VCR (Embree et al., 1998) or cisplatin (Newman et al., 1999), is in preclinical or clinical trials or under Food and Drug Administration consideration for commercial release.

In the remaining sections of this review, we attempt to show how optimization of the balance of circulation lifetimes, drug-induced toxicities, accumulation in tumors, and drug release rates from liposomes results in the most clinically effective formulations. This is accomplished through adjustments of both the pharmacological and physical properties of the liposome, including the injected dose, liposome size, presence of steric stabilization, and lipid composition of the carrier.

II. Pharmacokinetics and Biodistribution of Liposomes and Liposomal Drug

For free DOX, the volume of distribution has been estimated at 25 l/kg, suggesting a significant uptake by tissues (Speth et al., 1988). This large volume of distribution, when combined with the relatively rapid clearance rate from the circulation, results in low drug levels in the tumor and significant toxicity to normal tissues. Liposomes can alter both the tissue distribution and the rate of clearance of a drug by causing the drug to take on the pharmacokinetic parameters of the carrier. Pharmacokinetic parameters of the liposomes depend on physicochemical attributes of the liposomes, such as size, surface charge, membrane lipid packing, and steric stabilization, as well as on the administered dose and route of administration. The pharmacokinetics of both CLs and SSLs have been extensively reviewed (Hwang, 1987; Allen et al., 1995; Allen and Stuart, 1999).

Both slow-release CLs and SSLs have a volume of distribution for DOX not significantly different from the total blood volume (see Table 3), indicating the drug is generally

confined to the systemic circulation. However, after i.v. administration, CLs have saturable, nonlinear kinetics, whereas SSLs have nonsaturable, log-linear kinetics (Hwang, 1987; Allen et al., 1995). The dose-dependent kinetics for CLs result in relatively rapid clearance rates for liposomes at low doses and complicates the calculations of clinical dosages. Clearance of CLs has been suggested by Allen et al. (1995a) to be due to both a high-affinity, low-capacity system, likely the macrophages of the RES, and a low-affinity, high-capacity system. Steric stabilization slows uptake by the high-affinity, low-capacity system, resulting in dose-independent kinetics. The potential mechanisms responsible for the reduced clearance and dose-independent pharmacokinetics of SSLs are described in more detail in IIE. *Effect of Steric Stabilization on Pharmacokinetic Parameters.*

Liposomes are cleared from the circulation by macrophages of the RES, in particular those of the liver and spleen (Gregoriadis, 1976; Weinstein, 1984; Senior, 1987). Opsonization by serum proteins such as the complement C3b fragment, β_2 -glycoprotein I, and the Fc portion of IgG molecules is thought to play a critical role in the recognition and subsequent clearance by RES macrophages (Senior, 1987; Patel, 1992; Devine et al., 1994; Chonn et al., 1995; Devine and Marjan, 1997). The success of a liposome-based approach for drug delivery to sites other than those making up the RES is one that limits the uptake of liposomes by macrophages, either directly by preventing the interaction of liposomes with receptors on the macrophage surface or indirectly by decreasing the binding of serum opsonins. Many studies have concentrated on understanding the mechanisms responsible for regulation of these interactions. These factors are often intricately intertwined, making it impossible to construct sweeping assumptions based on any one factor.

A. Effect of Liposome Size on Pharmacokinetic Parameters

The first aspect of a liposome that affects its disposition is size. Liposomes of a defined size are readily prepared by extrusion of lipid suspensions through filters containing pores of a similar size (Olson et al., 1979; Szoka et al., 1980). Liposomes prepared through this method are slightly larger (20–50%) than the average pore size of the filter. The general trend for liposomes of similar composition is that increasing size translates into more rapid up-

TABLE 1
Commercial liposome formulations of anthracyclines

Drug	Manufacturer	Active Ingredient	Size	Lipid Composition	Drug/Lipid
			nm		w/w
Doxil (CAELYX) ^a	Alza Corporation ^b	DOX	100	HSPC/Chol/PEG-DSPE (56:39:5)	0.125:1
DaunoXome	Nexstar Pharmaceuticals	Daunorubicin	45	DSPC/Chol (2:1)	0.079:1
EVACET (TLC D-99) ^c	The Liposome Company, Inc.	DOX	150	eggPC/chol (55:45)	0.250:1

^a Doxil (DOX) is known as CAELYX in Europe.
^b Originally developed by Sequus Pharmaceuticals, Inc.
^c EVACET was previously known as TLC D-99.

take by the RES (Abra and Hunt, 1981; Hwang, 1987; Senior, 1987). However, although the trend remains the same, the clearance of liposomes is affected to differing extents depending on the composition. For example, DSPC/Chol (3:2) liposomes extruded through 400-nm filters are cleared 7.5 times as fast as liposomes extruded through 200-nm filters, which in turn are cleared 5 times as fast as small unilamellar vesicles (Senior et al., 1985). The inclusion of PEG-DSPE in the liposome composition results in clearance rates that are relatively insensitive to size in the range of 80 to 250 nm (Allen et al., 1989; Liu et al., 1992; Woodle et al., 1992). Now, a 2-fold increase in size from 100 to 200 nm results in only a 54% increase in clearance (Fig. 3; Woodle et al., 1992). A similar dependence of liposome clearance on size was observed for DSPC liposomes stabilized with small quantities of *N*-glutarylphosphatidylethanolamines (Ahl et al., 1997). These liposomes also showed an increased plasma area under the curve (AUC) compared with DSPC/Chol controls, similar to PEG-DSPE-stabilized liposomes. The authors suggested that the aggregation of nonstabilized neutral liposomes may result in an increase in the effective size and, thus, clearance from the circulation via a size-dependent mechanism. Although the dependence of liposome clearance rates on size is relatively less for these two stabilized formulations than for that with CLs, it nevertheless highlights the importance of optimization of liposome size in drug delivery systems not aimed at the RES. For neutral CLs, the window for optimal behavior is considerably nar-

rower, and these data suggest that liposomes should be small enough (preferably <100 nm) but still maintain reasonable drug encapsulation efficiencies.

B. Effect of Lipid Dose on Pharmacokinetic Parameters

The administered dose can also play a significant role in the circulation lifetime of a carrier. CLs are removed from the circulation in a dose-dependent manner, indicating a saturation of the mechanisms responsible for their uptake (Gregoriadis and Senior, 1980; Abra and Hunt, 1981; Senior et al., 1985; Hwang, 1987). Circulation lifetimes typically increase as a function of increasing lipid dose. This effect is likely due to a decreased phagocytic capacity of RES macrophages after the ingestion of high lipid doses or to a saturation of plasma factors that bind to circulating liposomes and result in their opsonization. The fact that liposomes composed of high-phase transition lipids, such as SM/Chol or DSPC/Chol, can more readily saturate RES uptake may indicate that these difficult-to-metabolize lipids saturate metabolic pathways responsible for their destruction (Senior et al., 1985; Hwang, 1987). Alternatively, liposomes have been shown to bind serum proteins in a manner inversely proportional to their blood clearance rates (Chonn et al., 1992; Semple and Chonn, 1996; Semple et al., 1996), giving rise to the hypothesis that the depletion of plasma opsonins at high lipid doses results in an increase in blood circulation half-lives ($T_{1/2}$; Harashima et al., 1993; Oja et al., 1996).

RES blockade can also be achieved by delivering cytotoxic drugs such as DOX or dichloromethylene diphosphonate to RES macrophages (Bally et al., 1990b; Parr et al., 1993; Qian et al., 1994; Buiting et al., 1996). Parr et al. (1997) recently considered the effect of dose on DOX-loaded liposomes. In these experiments, the presence of DOX resulted in a ~1.5- to 2-fold increase in the plasma levels of liposomal lipid at higher doses for SSL DOX compared to CL DOX. In DOX-loaded liposomes, a 10-fold increase in plasma levels of liposomal lipid observed at lower lipid doses (<1 μmol lipid/20–22 g mouse) was reduced to a 3-fold increase at higher doses (>2 μmol lipid/mouse). It should be noted it is at these lower doses that SSL preparations are routinely used. Thus, with SSL DOX, long circulation does not necessarily come at the expense of RES toxicity. The possible implications of the use of dose escalation, and the resulting RES toxicity, simply to achieve long circulation times are described in more detail in VI. *Toxicology of Liposomal Chemotherapy*. This indicates that RES blockade is in part due to the drug and not solely to a saturation of plasma opsonins or inability to metabolize liposomal lipid components.

Steric stabilization with PEG-DSPE offers a unique advantage to liposome delivery in that clearance kinetics become dose independent (Allen and Hansen, 1991; Huang et al., 1992; Woodle et al., 1992). The data in Fig. 4 illustrate the relative effect of liposome dose on




FIG. 3. Effect of liposome size on plasma levels of PEG-DSPE/PC/Chol (0.15:1.85:1 mol/mol/mol). Female adult Sprague-Dawley rats were injected with ^{67}Ga -desferoxamine-loaded liposomes, and blood was drawn at prescribed time points, when ^{67}Ga levels were determined with a gamma counter. From these data, the half-life in the circulation was determined by fitting the data to a single exponential curve (○), and the 24-h time point was recorded (●). The liposomes were prepared by extrusion through polycarbonate filters of defined size as described by Olson et al. (1979), and their size distribution was determined by dynamic light scattering. PC in these liposomes refers to partially hydrogenated egg PC. This figure was adapted from Woodle et al. (1992).

74




FIG. 4. Dependence of circulation $T_{1/2}$ values (▲, △) and plasma AUCs (●, ○) on administered dose. Female ICR mice (three per group) were given a single bolus tail-vein injection of liposomes containing ^{125}I -tyraminylinulin and 0.1 to 10 μmol of phospholipid. Liposomes were composed of either eggPC/Chol (2:1 mol/mol) or SM/eggPC/Chol/PEG-DSPE (1:1:1:0.2 mol/mol/mol). This figure was adapted from Allen and Hansen (1991).

clearance of both an SSL formulation (SM/eggPC/Chol/PEG-DSPE, 1:1:1:0.2) and a CL formulation (eggPC/Chol, 2:1). For the SSLs, the plasma AUC increases linearly, whereas the $T_{1/2}$ remains relatively unchanged. This dose independence was recently shown to extend down to concentrations of lipid as low as 1 $\mu\text{mol/kg}$ in rabbits (Utkhede and Tilcock, 1998). In stark contrast, the plasma AUC for CLs increases slowly at low doses (<2.5 μmol phospholipid/23–27 g mouse) and then increases exponentially with increasing lipid dose. A look at the circulation $T_{1/2}$ of the conventional formulation shows a leveling off of the $T_{1/2}$, indicating a saturation of the mechanism responsible for their clearance. Although the CLs used in this particular study used a fluid-phase phospholipid component, eggPC, similar pharmacokinetics have been seen with DSPC/Chol and SM/Chol liposomes (Beaumier et al., 1983; Hwang, 1987; Chow et al., 1989). In one of these studies (Beaumier et al., 1983), liposome levels in the liver were shown to saturate at the same dose where plasma clearance rates leveled off, consistent with RES saturation being responsible for increased plasma levels at high lipid doses.

C. Effect of Liposome Charge on Pharmacokinetic Parameters

The effect of liposome surface charge on liposome clearance kinetics is an increasingly misused predictive factor of circulation lifetimes. Early studies have shown that the presence of negatively charged lipids in liposomes, including phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylglycerol (PG), results in rapid uptake by the RES (Senior et al., 1985; Senior,

1987). However, this relationship between the presence of charged lipids and circulation lifetimes is extremely complex and cannot be readily explained with simple models in which the presence of an anionic lipid necessitates increased clearance from the circulation. Indeed, it now appears that each lipid must be analyzed separately and in the context of similar liposomes with respect to size, membrane packing constraints, and surface charge density.

A more careful characterization of the effect of surface charge on liposome clearance in mice was conducted using liposomes containing different anionic phospholipids (Gabizon and Papahadjopoulos, 1992). In these experiments, anionic lipids were added to fluid eggPC/Chol liposomes in a 1:10:5 ratio (anionic lipid/eggPC/Chol). Although liposomes containing PG, PA, and PS (PS > PA > PG) were cleared more rapidly than neutral liposomes, the inclusion of other anionic lipids such as the ganglioside GM₁ or phosphatidylinositol (PI) resulted in longer circulation lifetimes. Later, this second group of anionic lipids was shown to include PEG-PE conjugates (Papahadjopoulos et al., 1991; Woodle et al., 1992). The new model then divided negatively charged lipids into those with and those without a sterically shielded negative charge. Those with a sterically hindered charge were cleared more slowly, whereas those without were cleared more rapidly than neutral liposomes of a similar composition. This too may have proved to be too simple of a model.

The last statement concerning a similar composition is extremely important, and the effect of the phase transition of the lipid is intricately interrelated with the effect of charge. 1,2-dipalmitoyl-3-*sn*-phosphatidylglycerol (DPPG)/DSPC/Chol liposomes were previously shown to be cleared more rapidly than DSPC/Chol liposomes in mice (Fig. 5; Lasic et al., 1991; Woodle et al., 1992), and in a separate study, eggPG/DSPC/Chol liposomes were cleared more rapidly than DPPG/DSPC/Chol liposomes (Gabizon et al., 1990). However, DSPC has a gel-to-liquid crystalline phase transition (T_m) of 55°C, whereas the T_m value of DPPG is 41.1°C (Table 2; Boggs et al., 1989). Thus, the replacement of some of the DSPC with DPPG does not necessarily result in liposomes with similar permeability and membrane packing characteristics. Recently, DOX-loaded 1,2-distearoyl-3-*sn*-phosphatidylglycerol (DSPG)/HSPC/Chol liposomes, in which the source of PG was distearoylphosphatidylglycerol (T_m = 53.0; Table 2), were shown to have plasma levels of DOX at 24 h that were greater than twice those of HSPC/Chol liposomes (Gabizon et al., 1996). In addition, the requirement for a high phase transition anionic lipid component may also be necessary for PI, where hydrogenated soy PI is most commonly used as the source of PI in long-circulating liposomes (Gabizon and Papahadjopoulos, 1988; Gabizon et al., 1990). Thus, from these few cases, it appears that that the dependence of long circulation is more related to




FIG. 5. Effect of steric stabilization and lipid composition on plasma levels of liposomes. Extruded liposomes (70–100 nm) loaded with ⁶⁷Ga-deferoxamine were injected by i.v. administration into female Swiss-Webster mice at a dose of 1 μmol of phospholipid per mouse. Blood levels of ⁶⁷Ga were determined by gamma counting 24 h after injection. Lipid molar ratios were 1:10:5 except for eggPC/Chol and DSPC/Chol, both at 10:5, and PEG-DSPE/EPG/eggPC/Chol at 1:3:7:5. This figure was adapted from Woodle et al. (1992) and Lasic et al. (1991).

membrane packing and permeability considerations, and that the inclusion of high-phase transition anionic lipids into solid liposomes can actually increase circulation lifetimes.

However, as was stated previously, all cases must be considered individually. In one study with another anionic phospholipid, PA, liposomes composed of DSPC/1,2-distearoyl-3-*sn*-phosphatidic acid (DSPA)/Chol (3:1:4) were cleared ~10 times faster than DSPC/Chol liposomes (1:1; Senior, 1987). DSPA has a *T_m* value comparable to those of DSPG and DSPC at 58°C, and so for DSPA at least, liposome charge appears to become more important than membrane packing in the determination of rates of uptake. Of course, DSPA was introduced at 25% of the total phospholipid content and has two negative charges per molecule. In the previous example, DSPG was incorporated at only 10% of the total phospholipid and has only one negative charge, consequently adding an additional layer of complexity involving surface charge density. Janoff and coworkers have indeed shown a steep dependence of blood clearance

TABLE 2
Primary gel-to-liquid crystalline phase transitions of different phospholipids

Phosphatidylcholine	Acyl Chain Length, No. of unsaturations	<i>T_m</i>	Reference
		°C	
DSPC	18:0, 18:0	55	Goodwin et al. (1982)
HSPC	16–18 (mixture) ^a	52	Horowitz et al. (1992)
DPPC	16:0, 16:0	42	Papahadjopoulos et al. (1973b)
POPC	16:0, 18:1	−7	Scherer and Seelig (1989)
SLPC	18:0, 18:2	−16.7	Sanchez-Migallon and Aranda (1996)
DOPC	18:1, 18:1	−21	Barton and Gunstone (1975)
eggPC	Mixture ^b	−2.5	Bach et al. (1982)
DSPG	18:0, 18:0	53.0	Surewicz and Epand (1986)
DPPG	16:0, 16:0	41.1	Boggs et al. (1989)
eggPG	Mixture	37	Vincent et al. (1991)
DSPA	18:0, 18:0	58	Krill et al. (1992)

An excellent database containing easily searchable physical properties of numerous lipids can be found at <http://www.lipidat.chemistry.ohio-state.edu>.
DOPC, dioleoylphosphatidylcholine; eggPG, egg phosphatidylglycerol; POPC, 1-palmitoyl, 2-oleoyl phosphatidylcholine; SLPC, 1-stearoyl, 2-linoleoyl phosphatidylcholine.
^a Approximately 18% of the acyl chains are 16 carbons, and 82% are 18 carbons. All unsaturations have been reduced with a hydrogenation reaction.
^b Contains ~34% of 16:0, ~1% of 16:1, ~10.5% of 18:0, ~31% of 18:1, ~17.7% of 18:2, ~3% of 20:4, and ~1.7% of other.

rates on the mol% of the negatively charged component *N*-glutaryl-dipalmitoylphosphatidylethanolamine (*N*-glutaryl-DPPE) in DSPC liposomes (Ahl et al., 1997). The normalized AUC in plasma was greatest at 10 mol% *N*-glutaryl-DPPE and rapidly declined both below and above this value. The authors suggested the small amounts of negatively charged lipids stabilize neutral liposomes against an aggregation-dependent uptake mechanism. All of these examples point to the reality that different liposomes, and even comparable liposomes with different phospholipid headgroups of similar charge, may have very different mechanisms responsible for their uptake (Daemen et al., 1997).

An even more intriguing question is raised based on these analyses. Have CLs really been optimized? Are small DSPC/Chol liposomes really the most efficient liposomal carriers in the absence of steric stabilization? At least three studies have suggested that the inclusion of small amounts (10 mol%) of certain negatively charged lipids such as DSPG or *N*-acylated phosphatidylethanolamines (Park et al., 1992; Gabizon et al., 1996; Ahl et al., 1997) actually increase circulation *T_{1/2}* even further. Additional studies will be needed to elucidate the exact nature of this stabilizing effect and determine more carefully the dependence of this stabilization on the structure of the stabilizing lipid and such parameters as membrane packing. Whether these liposomes would offer any improvements over SSLs remains to be seen, but at least one study has suggested that some DOX-loaded anionic liposome formulations demonstrate an efficacy similar to that of SSL DOX (Gabizon et al., 1996).

76

D. Effect of Membrane Packing Constraints on Pharmacokinetic Parameters

The effect of bilayer fluidity and the relative nature of the lipid components can have a considerable impact on the clearance from the circulation of both the liposome and the associated drug. These effects can either be direct effects, such as inhibition of penetration and thus binding of serum proteins (Papahadjopoulos et al., 1973b), or indirect effects, such as stabilization of the drug formulation to reduce the rate of drug leakage (VII. *Stability in Plasma and Storage*). The presence of Chol probably has one of the most important roles in the maintenance of membrane bilayer stability and long circulation times in vivo (Gregoriadis and Davis, 1979; Senior and Gregoriadis, 1982; Senior, 1987). In the absence of Chol, CLs are destabilized by HDL particles (Chobanian et al., 1979; Damen et al., 1980) and upon release, their components can be readily eliminated from the circulation. For liposomes with and without Chol, clearance rates were shown to negatively correlate with increased stability in plasma (Senior and Gregoriadis, 1982). The presence of steric stabilization makes the need for Chol less apparent for empty liposomes, but for drug-loaded liposomes, Chol is necessary for maintenance of the drug in the liposomal interior. The phospholipid component also plays a prominent role in the maintenance of high plasma levels of liposomes. DSPC/Chol and SM/Chol liposomes have higher $T_{1/2}$ values in the circulation compared with more fluid liposomes containing eggPC or even 1,2-dipalmitoyl-3-*sn*-phosphatidylcholine (DPPC; Gregoriadis and Senior, 1980; Senior, 1987). This is presumably due to the decreased affinity of these liposomes for serum opsonins required for their uptake. To be most effective, the PC component must have a phase transition that is significantly above 37°C. An inspection of the gel-to-liquid-crystalline phase transitions (T_m) of a variety of different PC molecules (Table 2) shows the T_m value for eggPC is below 37°C, whereas DPPC has a T_m value of only a few degrees above (with a pretransition at 37°C). However, both DSPC and HSPC have a T_m value that is ~15–17°C higher than 37°C. Thus, at 37°C, HSPC- and DSPC-containing liposomes have a considerably more rigid membrane bilayer that resists penetration of serum opsonins than do eggPC- or DPPC-containing formulations. It is no surprise, then, that these liposomes tend to be the most stable in the circulation and display the longest circulation lifetimes.

Sphingomyelin (SM) has an added effect on circulation lifetimes. SM/Chol and SM/DSPC/Chol liposomes were both shown to have longer circulation lifetimes than DSPC/Chol (Hwang, 1987; Allen et al., 1991), indicating an additional stabilizing effect of SM. SM can form intermolecular hydrogen bonds with neighboring Chol molecules (Schmidt et al., 1977; Sankaram and Thompson, 1990), resulting in greater stability and a

decreased ability of plasma proteins to insert into liposomal membranes.

The rate of elimination of a liposomal drug from the circulation is also dependent on the rate of drug leakage from the carrier. Because drugs considered for liposome encapsulation often have circulation times significantly shorter than the liposomal carrier, premature release can lead to an apparent increase in the rate of elimination of the liposomal drug from the circulation. In DOX-loaded SSLs (SSL DOX) with HSPC, DPPC, or eggPC as the phospholipid component of the formulation, a correlation was observed among the phase transition (T_m) of the phospholipid component, the stability of the formulation in in vitro plasma stability tests, and plasma levels of the drug in vivo (Fig. 6 and Table 2; Gabizon et al., 1993). Liposomes containing high-phase transition lipids formed more stable formulations, which were better able to retain their drug and showed apparent increases in drug circulation lifetimes. A similar result was seen by Mayer and coworkers using CLs and DOX (Bally et al., 1990b). A more detailed explanation of the different factors responsible for maintaining a stable formulation of different drugs in the plasma is given in VII. *Stability in Plasma and Storage*.

The conclusions that can be drawn from these data differ for CLs and SSLs. For CLs, a membrane composed




FIG. 6. Dependence of plasma drug levels on liposome composition. SSL DOX lipid formulations containing different species of phosphatidylcholine were injected into Sabra female mice (four per group) at a dose of 10 mg/kg DOX. The molar ratio of PEG-DSPE/PC/Chol was kept constant at 0.75:9.25:8 for each formulation, whereas the species of the PC component was varied. The different PCs used were HSPC, DPPC, and eggPC. HSPC/Chol (10:8) liposomes were used as a CL control. DOX measurements were taken 24 h after drug administration. This figure was adapted from Gabizon et al. (1993).

of Chol and high-phase transition phospholipids appears to be imperative for maintaining long circulation times and subsequent delivery of high levels of liposomes to solid tumors (see *III. Accumulation of Liposomal Drugs in Tumors*). SSLs are more pliable and can be used with fluid-phase lipids to obtain long circulation times and high tumor levels of liposomes. For both types of liposomes, the lipid composition of the liposome membrane is essential in maintaining a stable encapsulation of the drug while in the circulation. For most amphipathic drugs that are either weak acids or weak bases (the majority of classic chemotherapeutic agents), this is of considerable importance because these drugs will more rapidly leak from the carrier while in the circulation, unless high-phase transition lipids are used.

E. Effect of Steric Stabilization on Pharmacokinetic Parameters

Original attempts to mimic the surface of red blood cells by including the sterically hindered GM₁ or PI in liposome preparations led to the development of long-circulating liposomes (Allen and Chonn, 1987; Gabizon and Papahadjopoulos, 1988; Gabizon et al., 1990). Later, PEG-DSPE was substituted for GM₁ or PI (Klibanov et al., 1990; Allen et al., 1991; Papahadjopoulos et al., 1991). A common misconception is that the attachment of PEG to the surface of a liposome prevents liposome uptake by the RES; rather, it simply reduces the rate of uptake. One of the most significant advantages of SSLs is the nonsaturable, log-linear pharmacokinetics, as described previously. SSLs likely resist uptake by the high-affinity, low-capacity RES macrophages, resulting in increased circulation lifetimes (Allen et al., 1995a). Like CLs, the primary site of accumulation for SSLs is also the spleen and liver (Huang et al., 1992). However, the rate of accumulation in these tissues is considerably slower than that for CLs. Plasma levels of PEG-DSPE containing liposomes are increased 2- to 2.5-fold over DSPC/Chol (2:1) CLs and 7- to 10-fold over eggPC/Chol (2:1) liposomes in mice (Fig. 5; Lasic et al., 1991; Woodle et al., 1992). As mentioned earlier, CLs containing anionic lipids or those containing unsaturated lipid components, such as eggPC, are removed more readily from the circulation than those containing high-phase transition phospholipids (SM/Chol or DSPC/Chol). However, in the presence of PEG-DSPE, liposomes containing some charged lipids or low-phase transition phospholipids are found in plasma after 24 h at similar levels to those containing neutral high-phase transition phospholipids (Fig. 5). The presence of steric stabilization thus allows for the rate of clearance to be relatively independent of the remaining lipid composition for "empty" liposomes (Lasic et al., 1991; Woodle et al., 1992).

This is not inclusive of all phospholipid components. Both GM₁ and PEG-DSPE were unable to prevent liposomes containing PS from being cleared rapidly from the circulation (Allen et al., 1988, 1991), indicating that

some membrane components may confer a very powerful propensity for a type of liposome being recognized and taken up by the RES. In addition, although the lipids composing the majority of the liposome may not have a direct effect on the removal of the liposomal carrier itself, they may have an indirect effect on clearance of the encapsulated drug. As previously described, when amphipathic drugs such as DOX are loaded into these liposomes, the rate of leakage from the liposome can become the rate-limiting step for clearance of the drug from the circulation if liposomes are not optimized to prevent leakage. The dose independence of liposome clearance, reduced recognition and clearance of liposomes by the RES, and flexibility in lipid compositions that can provide considerable advantages for SSLs that make them more desirable for an assortment of different applications.

The mechanism by which steric stabilization of liposomes increases their longevity in the circulation has been extensively discussed (Lasic et al., 1991, 1992; Needham et al., 1992a, 1999; Allen, 1994; Lasic and Martin, 1995). The basic concept of this discussion has been that a flexible-chained hydrophilic polymer or a glycolipid, such as PEG or GM₁, which occupies the space immediately adjacent to the liposome surface ("periliposomal layer"), tends to exclude other macromolecules from this space. Consequently, access and binding of blood plasma opsonins to the liposome surface are hindered, and thereby interactions of RES macrophages with such liposomes are inhibited. The exclusion of extraneous macromolecules from the periliposomal layer creates steric hindrance ("steric stabilization effect"), which is manifested as increased interbilayer repulsive forces and results in an increased interbilayer separation of PEG-decorated bilayers compared with unmodified ones (Lasic et al., 1992b; Needham et al., 1992b). Ganglioside GM₁ has less effect on the interbilayer separation compared with PEG. Measurements of streptavidin-induced agglutination rate of biotinylated SSLs demonstrated that the steric barrier decreased with decreasing PEG chain length and at higher PEG lengths (PEG M_r = 1900 and 5000) was significantly greater than that produced by GM₁ (Mori et al., 1991).

Several studies have argued that the presence of PEG or GM₁ does in fact lead to both a decreased extent and rate of binding of plasma proteins to liposomes (Senior et al., 1991; Chonn et al., 1992; Blume and Cevc, 1993; Semple and Chonn, 1996), although direct experimental evidence is not abundantly clear for PEG-DSPE-containing liposomes. In two earlier studies in which decreased protein binding or opsonic activity was shown for SSLs, the incubation of PEG-stabilized liposomes with plasma components was completed in 2 to 15 min (Allen et al., 1994; Semple and Chonn, 1996). Another study showed similar findings in vivo after a 2-min incubation but approximately equivalent levels of bound protein for a CL and a PEG-stabilized liposome formulation after 30

min (Harvie et al., 1996). Chonn et al. (1992) have previously shown a correlation of protein-binding levels in CLs and GM₁-containing liposomes to in vivo circulation lifetimes, which is consistent with the observations seen with SSLs. Thus, decreased binding of serum opsonins by GM₁-containing liposomes can result in decreased opsonin activation, as has been shown for complement factor C3 (Chonn et al., 1992), or reduced uptake by macrophages (Wassef et al., 1991; Alving and Wassef, 1992). Finally, reduced clearance may be partially due to steric hinderance for the binding of liposome-bound opsonins to their receptors on RES macrophages (Klibanov et al., 1991; Mori et al., 1991; Allen, 1994). Allen and coworkers have suggested that the elimination of SSLs may occur via the same mechanism as CLs, after a slow removal of PEG-DSPE from the membrane (Allen et al., 1991; Allen, 1994). Blume and Cevc (1993) suggested that SSLs may simply require longer to bind the opsonins necessary for uptake by the RES. The net effect of these phenomena is that by sterically hindering the approach to the liposome surface by large molecules or cells, liposomes can attain longer circulation lifetimes, allowing them greater time to accumulate in tumors.

F. Comparison of Pharmacokinetic Parameters for Different Liposomal Formulations

SSL DOX has a long half-life in the circulation compared with free DOX (Table 3). Pharmacokinetic data for free DOX are best described by a biexponential fit with a rapid distribution phase and a slow terminal elimination phase. The majority of free DOX is eliminated in the initial rapid phase. With SSL DOX, a major portion of the plasma AUC is attributed to the prolonged terminal phase (Papahadjopoulos and Gabizon, 1995; Gabizon and Martin, 1997). Half-lives in rats were found to be between 22 and 23.6 h (Mayhew et al., 1992; Working and Dayan, 1996), whereas those in humans approximated 45 h (Gabizon et al., 1994). For conventional formula-

tions in humans, the terminal $T_{1/2}$ is significantly shorter: from 6.7 to 25 h for TLC D-99 and from 2.8 to 8.3 h for DaunoXome. Although the $T_{1/2}$ was found to be independent of dose for SSL DOX, it increased with increasing dose for both DaunoXome and TLC D-99. Recently, the dose-independence of SSL DOX at very high concentrations of drug, 60 mg/m², was called into question when it was reported that a decreased rate of clearance was observed at these higher doses (Martin, 1998). This may result from a drug-induced toxicity to macrophages responsible for their elimination, similar to the effect described by others with CLs (Bally et al., 1990b; Parr et al., 1997). The increased $T_{1/2}$ values of liposomal drugs relative to free drugs were also consistent with a decreased rate of clearance of the liposomal carriers. DOX is cleared 560 times slower in humans when encapsulated in SSLs, and daunorubicin is cleared 35 to 56 times slower with DaunoXome, a CL formulation, compared with the free drugs. The stable encapsulation of drug within the liposome, combined with the large size of the carrier, likely prevents filtration and removal of the drug by the kidneys.

It should be emphasized that the AUCs that are typically referred to in this discussion are based on drug that is for the most part nonbioavailable. It is entrapped inside the carrier and unable to elicit any response. Thus, the term "AUC," which is commonly used by those in the liposome field of study, for liposomal drugs may appear a little misleading to some because it does not truly represent the pool of bioavailable drug in the plasma or in the tumor. Several studies have shown for DOX that >95% of the drug remains liposome associated in the plasma (Gabizon et al., 1994; Martin, 1998). A technical limitation in the ability to accurately measure the rate at which drug is released from the carrier has also prevented us from expressing true AUC measurements for bioavailable drug in the tumor. The AUC measurements typically being referred to are of total

TABLE 3
Pharmacokinetic parameters of SSL DOX in various animals

Animal Model	Formulation	Dose	$T_{1/2}$	AUC	V_d	CL
		mg/kg	h	mg * l/h	ml	ml/h
Rats ^a	SSL DOX	1.0	$T_1 = 1.8$ $T_2 = 23.6$	683	13	0.4
	Free DOX	0.9	$T_1 = 0.16$ $T_2 = 29.1$	11.1	1,014	24.3
Male Sprague-Dawley rats ^b	HSPC/Chol/PEG-DSPE (37:20:3)	6.0	$T_1 = 2.8$ $T_2 = 22$	2,769	18	0.5
	Free epirubicin	6.0	0.23	15	3,700	111
Rabbits ^a	SSL DOX	1.0	$T_1 = 0.5$ $T_2 = 21.3$	368	176	6
	Free DOX	1.0	$T_1 = 0.03$ $T_2 = 4.07$	1	13,651	2,536
Dogs ^{a,c}	SSL DOX	1.5	$T_1 = 0.20$ $T_2 = 25.9$	656	596	15.5
	SSL DOX	0.5	27 ± 5	304 ± 118	1000 ± 100	25.2 ± 7.2

T_1 , half-life associated with the first exponent of elimination; T_2 , half-life associated with the second exponent of elimination; V_d , volume of distribution; CL, total plasma clearance.

^a Working and Dayan (1996).

^b Mayhew et al. (1992).

^c Gabizon et al. (1993).

drug, including both liposome and free drug. Depending on the lipid composition used and the rate of clearance in the particular organ or compartment being studied, these relative amounts may vary significantly.

The increased $T_{1/2}$ values of liposomal drugs translate into an increased AUC for Doxil in plasma compared with the free drug (Tables 3 and 4). In rats, the AUC for Doxil is >60 times that of free DOX, and this increase is elevated to a 368-fold increase in rabbits (Working and Dayan, 1996). In humans, the AUC is increased by 250 to 600 times in the case of Doxil over free DOX, 20 to 30 times in the case of TLC D-99, and ~60-fold in the case of DaunoXome (Table 4; Conley et al., 1993; Cowens et al., 1993; Gabizon et al., 1994). The smaller plasma AUCs for DaunoXome and TLC D-99 relative to Doxil may reflect both the shorter circulation times of the carriers, as a result of the lack of steric stabilization, and their increased rate of drug leakage. Even doses greater than three times those used for DOX were unable to provide comparable plasma levels of the relevant anthracycline (609 mg*/h/liter for 25 mg/m² DOX and 375.3 mg*/h/liter for 80 mg/m² daunorubicin). For TLC D-99, plasma AUCs reached their maximum value at 50.5 ± 44.9 mg*/h/liter, 10-fold lower than that for Doxil. Mayer and coworkers recently demonstrated they could obtain plasma AUCs for DOX in mice from 27 to 57% of those obtained with an SSL formulation by encapsulating DOX in DSPC/Chol liposomes and injecting them at

the relatively high doses of 20 mg/kg DOX and 100 mg/kg lipid (Parr et al., 1997; Bally et al., 1998; Mayer et al., 1998). Assuming that a stable formulation can be prepared with SSLs (this is not always the case as will be seen with liposomal VCR), the data suggest that plasma drug levels, and thus the total AUC, will always be greater with SSL formulations. Although there is little debate on this particular point, there is a significant amount of debate over whether higher plasma levels necessitate a more favorable clinical outcome. This question is a complex one, and a considerable part of the remainder of this review focuses on how and whether this question can be answered.

The volume of distribution for free DOX is high in all species examined, indicating a wide tissue distribution. The small molecular size and amphipathic nature of the free drug allow it to rapidly distribute to both healthy and diseased tissues. However, when administered in liposomal form, the volume of distribution was reduced >60-fold to values approximating the plasma volume, suggesting that both DaunoXome and Doxil are restricted to the central compartment (Gabizon et al., 1993; Tables 3 and 4). The relatively large size of liposomal carriers (45–150 nm) prevents them from passing through the 2-nm pores found in the endothelium of blood vessels in most healthy tissues or even the 6-nm pores found in postcapillary venules (Seymour, 1992). In addition to the size of the carrier, the stability of the

TABLE 4
Pharmacokinetic parameters of CL and SSL DOX in humans

Formulation	Dose	$T_{1/2}$	AUC	V_d	Cl	Reference
	mg/m ²	h	mg * h/l	l	l/h	
SSL DOX	25	3.2 (0.2–5.4)	609	4.1	0.08	Gabizon et al. (1994)
		45.2 (20.8–59.1)	(227–887)	(3.0–6.5)	(0.05–0.21)	
		1.4 (0.2–7.3)	902	5.9	0.09	Gabizon et al. (1994)
Free DOX	25	45.9 (29.3–74.0)	(335–2497)	(2.3–10.1)	(0.03–0.24)	Gabizon et al. (1994)
		0.07 (0.05–0.09)	1.0	254	45.3	
		8.7 (3.6–13.3)	(0.7–1.3)	(126–393)	(39.7–48.6)	Gabizon et al. (1994)
SSL DOX	50	0.06 (0.06–0.08)	3.5	365	25.3	
		10.4 (5.4–26.8)	(2.6–6.0)	(131–501)	(13.3–35.2)	Working and Dayan (1996)
		5.6	577	4.7	0.07	
TLC D-99	20	56.6				Cowens et al. (1993)
		0.71 ± 0.37	30.4 ± 32.5	21.4 ± 14.0	23.5 ± 15.6	
		8.2 ± 6.2				
		0.29 ± 0.09	19.7 ± 17.7	18.8 ± 10.7	23.3 ± 15.7	
		6.68 ± 2.94				
TLC D-99	30	0.37 ± 0.16	50.5 ± 44.9	8.2 ± 3.0	9.0 ± 7.8	Conley et al. (1993)
		25.0 ± 22.5				
		0.45 ± 0.60	14.1 ± 16.6	14.6 ± 7.8	21.8 ± 15.5	
		13.5 ± 6.6				
		0.2 ± 0.1	30.4 ± 25.8	7.1 ± 4.0	9.8 ± 10.7	
DSPC/Chol (2:1) (daunorubicin)	20	25.1 ± 35.5				Gill et al. (1995)
		2.8	16.9	3.75	0.942	
		3.8	57.2	4.1	0.858	
		4.0	120.1	3.7	0.630	
		8.3	301.1	2.9	0.402	
Free daunorubicin	80	5.2	375.3	2.9	0.396	Forssen and Ross (1994) Embree et al. (1998)
		0.77	10.33	1055	13.38	
		1.95 ± 1.67	6.5 ± 0.6	4.35 ± 0.84		
		22.5 ± 9.85				
		7.2 ± 4.8	40.2 ± 17.2	2.26 ± 0.47		
DSPC:Chol (55:45) (VCR)	2.0	99.3 ± 17.2				

Errors are expressed as either a range (in parentheses) or as a S.D., depending on the source of the data. For expression of half-lives of elimination, the top value is the half-life associated with the first exponent of elimination, and the bottom value is the half-life associated with the second exponent of elimination.
 $T_{1/2}$, half-life elimination of drug from the circulation; V_d , volume of distribution; Cl, total plasma clearance.

formulation can also have an effect on the volume of distribution. If drug leaks from the liposome before leaving the circulation, then the free drug can readily redistribute to healthy tissues. A comparison of Doxil or DaunoXome, both of which contain high-phase transition phospholipids (DSPC or HSPC), with TLC D-99, which contains the highly unsaturated eggPC, shows a significantly higher volume of distribution (4- to 5-fold at 25 mg/m²) for the latter (Table 4). This indicates that DOX was released more rapidly from the carrier with TLC D-99 and has distributed more extensively into normal tissues than for more stable preparations with lower leakage rates. The consequences of this are an alteration in the toxicity profile and lower tumor levels of the drug. A more thorough review of the factors that contribute to the stability of a formulation in the plasma is given in VII. *Stability in Plasma and Storage.*

G. Tissue Distribution of Conventional and Sterically Stabilized Liposomes

Due in part to the size of the carrier, L-DOX has an altered tissue distribution compared with free DOX (Tables 5 and 6). Free DOX has a wide distribution, accumulating in most tissues to a significant extent. L-DOX preferentially accumulates in areas containing a discontinuous microvasculature, such as tumors, or in organs containing the macrophages of the RES, such as liver and spleen. This altered distribution reduces the concentration of drug at potential sites of toxicity, such as the heart. A comparison of the biodistribution of free drug and that encapsulated in both CLs and SSLs is given in Tables 5 and 6. When DOX levels are reported as peak levels of drug in various tissues, a significant increase in DOX is found in healthy tissues, such as kidneys, heart, and lung when administered as free DOX compared with both CL and SSL DOX (Table 5). L-DOX shows increased levels in blood, liver, spleen, and tumor (Table 5). In the liver, SSLs were found almost exclusively in Kupffer cells and rarely in the more abundant hepatocytes (Huang et al., 1992; Litzinger et al., 1994). This is consistent with the role of Kupffer cells in removing liposomes from the circulation and suggests less damage to liver tissue than if delivered to parenchymal cells. However, in addition to macrophages, other investigators have demonstrated a significant uptake of liposomes by a low-affinity, high-capacity system involving hepatocytes in a manner dependent on both the size of the liposomes and the presence of PEG-DSPE (Scherphof et al., 1994). The nature of this discrepancy is unclear but may involve problems in detection of liposomes in hepatocytes by some methods. From these data, it appears as though liposomes preferentially accumulate in tumor and tissues of the RES, whereas free DOX distributes more uniformly between the various tissues.

Although peak drug levels indicate L-DOX reaches healthy tissues to a reduced extent, when tissue drug

TABLE 5
Tissue distribution of DOX in animals treated with L-DOX

Animal Model	Liposome Formulation	Time h	Dose ^a mg/kg	Plasma µg/ml	Spleen	Liver	Skin	Heart	Lung	Kidney
Nude mice (N87 tumor implants) ^b Rats ^c	HSPC/Chol/PEG-PE (92.5:70:7.5)	72	10	12.89	7.18 ± 1.41	15.84 ± 1.58	5.36 ± 0.35	2.37 ± 0.46	1.59 ± 0.33	1.70 ± 0.11
	HSPC/Chol/PEG-PE (56.4:38.3:5.3)	24	1		1.27 ± 0.11	1.67 ± 0.16	0.46 ± 1.1	1.67 ± 0.55	2.71 ± 0.49	3.61 ± 0.40
	Free DOX	0.5	1		2.56 ± 0.33	134 ± 20.2	0.46 ± 0.06	2.21 ± 0.17	16.5 ± 4.1	17.3 ± 6.2
Female CD1 mice ^d	eggPC/Chol (55:45) 200 nm	5	20	14.3 ± 3.8	995.1 ± 284.7	137.5 ± 10.7		4.1 ± 2.2	11.4 ± 3.4	13.1 ± 2.1
	DSPC/Chol (55:45) 230 nm	5	20	27.4 ± 3.2	832.2 ± 64.8	25.8 ± 3.7		2.4 ± 1.2	29.9 ± 5.8	35.5 ± 7.9
	Free DOX	5	20	0.09 ± 0.04	39.0 ± 8.3	68.7 ± 3.7		15.5 ± 3.4	30.9 ± 0.6	98.5 ± 6.4
Female BDF1 mice ^e	DSPC/Chol (55:45) (100 nm)	C _{max}	10	140.5 ± 5.3	259.8 ± 7.8	59.5 ± 2.4		7.8 ± 1.5		
	Free DOX	C _{max}	7.5	2.7 ± 0.3	13.5 ± 1.4			35.1 ± 1.8		

C_{max} is the peak concentration of drug achieved, and it varied as a function of time.

^a Dose is given in mg/kg DOX.

^b Gabizon et al. (1997).

^c Working and Dayan (1996).

^d Mayer et al. (1989).

^e Krishna and Mayer (1997).

Errors are provided where available.

TABLE 6
Tissue AUC values after i.v. administration of various liposomal and free drugs

Animal Model	Liposome Formulation	Dose ^a mg / kg	Plasma μg · h / ml	Tumor	Spleen	Liver μg · h / g	Heart	Lung	Kidney
BALB/c mice with C26 colon carcinoma ^{b,d}	DSPC/Chol/GM ₁ (2:1:0.2)	5		662.2	1974	1299	83.25	141.5	241.8
Female BDF1 mice ^e	DSPC/Chol (2:1)	5		256.2	3348	1757	31.98	28.3	40.48
	DSPC/Chol (55:45)	10	1095.2	470.6	8923.8	2444.5	67		1265.6
	Free DOX	7.5	1.3	73.8	496.9	874.9	820.4		1258.1
BALB/c mice with colon C26 carcinoma ^f	PEG-PE/DSPC/Chol (6:47:47)	5	809.5	169.6	320.3	309.4	41.9	91.4	132.0
BALB/c mice with P1798 lymphosarcoma ^g	DSPC/Chol (1:1)	5	342.8	50.1	365.5	341.4	41.2	67.5	72.4
	Free DOX	5	1	18.1	178.1	168.8	63.2	106.4	146.1
	DSPC/Chol (2:1) (62 nm)	20	2275.6	2470.5	3596.2	693.6	265.1	685.0	1237.2
	Free daunorubicin	20	10	245.1	2213.4	335.5	249.9	612.2	976.8
BDF ₁ mice ^h (mitoxantrone)	DSPC/Chol	10	1970		12630	4832		178	751
	DSPC/Chol/PEG-PE	10	4863		7242	4302		218	697

AUC was calculated from either 0–96 h,^d 1–24 h,^f by the trapezoidal rule,^{e, h} or 0–48 h.^g

^a Dose is given in mg/kg DOX.

^b Data were collected using encapsulated ⁶⁷Ga as the tracer. The tissue distribution is expressed as percent of injected dose per gram of tissue versus time (h).

^c 10–15 μmol of phospholipid/kg.

^d Huang et al. (1992). Data were collected using encapsulated ⁶⁷Ga as the tracer. The tissue distribution is expressed as percent of injected dose per gram of tissue versus time (h) after injection.

^c Krishna and Mayer (1997).

^f Unezaki et al. (1995).⁸ Forssen et al. (1992).

^h Chang et al. (1997).

levels are reported as the AUC, even in healthy tissues, tissue drug levels approach those for free DOX (Table 6). DOX delivered via CLs accumulates to a reduced extent in non-RES tissues compared with delivery by SSLs. This is most likely a result of the reduced circulation lifetimes of CLs. The AUC for tumors is still between 2.5- and 10-fold greater than that for free DOX. A more detailed comparison of the extents of accumulation in tumors is given in *IIIB. Rate and Extent of Accumulation in Tumors*. In one of the earliest comparisons of SSLs (GM₁) versus CLs (Huang et al., 1992), liposome levels in tumor (followed with encapsulated ⁶⁷Ga) were greater than twice those of DSPC/Chol liposomes (Table 6). The levels in spleen and liver for DSPC/Chol liposomes were 1.35 to 1.7 times those of the GM₁-containing formulation, reflecting their more rapid uptake by the RES. In the three healthy non-RES tissues measured (heart, lung, and kidneys), liposome levels were significantly greater for the SSL formulation, suggesting that longer circulation also leads to higher AUCs for liposomes in healthy tissues. The few comparative studies with L-DOX or mitoxantrone showed either insignificant differences or slightly elevated AUCs in healthy tissues for SSLs relative to the CL formulation (Table 6; Unezaki et al., 1995; Chang et al., 1997). In all cases, the total AUC was either comparable or decreased for the liposomal form compared with the free drug. Considering that the overall exposure for these tissues is approaching equivalent amounts for free and encapsulated drug, it might be reasonable to expect the level of toxicity in these tissues to be similar. However, some acute toxicities are dependent on peak levels of the drug, and liposomal drugs accumulate in these tissues at a much slower rate than the free drug. In addition, the liposomal drug is not completely bioavailable, and thus the effective concen-

tration of the drug in these tissues is considerably reduced. In one study, a histological section of cardiac muscle showed accumulation of liposomes only within blood vessels between muscle fibers and not within the muscle itself, indicating that liposomes were unable to extravasate in the heart to areas where they may do considerable damage (Working et al., 1994). This is discussed in greater detail in VI. *Toxicology of Liposomal Chemotherapy*.

H. Metabolism and Elimination of Liposomal Doxorubicin

Anthracyclines are metabolized in human plasma to a variety of both active and inactive metabolites (Takanashi and Bachur, 1976; Fig. 7). The reduction in DOX by an aldo-ketoreductase results in the formation of the most prominent metabolite, doxorubicinol (**II**), in plasma, bile, and urine (Takanashi and Bachur, 1976). A two-electron reduction in DOX with subsequent elimination of the sugar results in the inactive metabolite, a 7-deoxyaglycone (**V**; Takanashi and Bachur, 1976; Doroshaw, 1996). In several studies, researchers looked for the presence of DOX metabolites in plasma and urine after the administration of L-DOX (Gabizon et al., 1991, 1994; Northfelt et al., 1996). Although several of the more common metabolites (doxorubicinol and glucuronide and sulfate derivatives of 4-dimethyl,7-deoxyaglycones) were observed in urine, they were at diminished levels (2.5%) compared with the administration of free DOX (11%; Gabizon et al., 1994). In two separate studies (Gabizon et al., 1994; Northfelt et al., 1996), doxorubicinol (**II**) was not observed in plasma at any time after the administration of SSL DOX. This is not surprising considering that the liposomal membrane protects its contents from inactivation by plasma enzymes. The importance of a stable formulation is essential in

82




FIG. 7. Metabolism of DOX in vivo. DOX (I) can be converted to either inactive (deoxyaglycones; III or V) or active (doxorubicinol; II) metabolites in the circulation. Initially, DOX is converted to doxorubicinol (II), DOX aglycone (III), or deoxydoxorubicin aglycone (V), although the preferred pathway is for the metabolism to II. Doxorubicinol (II) is the primary metabolite found in both plasma and urine. Doxorubicinol can be further metabolized to doxorubicinol aglycone (IV) or deoxydoxorubicinol aglycone (VI), with metabolism to VI being the preferred pathway. Finally, VI can be converted to more polar metabolites such as o-sulfate or o-glucuronide derivatives. A notable advantage of liposomes is that they are able to protect their contents from metabolism and inactivation in the circulation, thus allowing higher levels of the parent compound to arrive at the tumor site. This figure was modified from Takanashi and Bachur (1976).

maintaining this advantage. In formulations containing unsaturated phospholipids, DOX leaks rapidly from the liposome and doxorubicinol was detected in plasma at times as short as 30 min (Gabizon et al., 1991; Embree et al., 1993). Although small amounts of DOX metabolites have been observed in tumor and tumor exudates (Gabizon et al., 1994; Siegal et al., 1995), its protection from inactivation by plasma enzymes almost certainly increases the percentage of drug that arrives in the active form at the tumor site.

L-DOX is eliminated in the urine at a much slower rate than free DOX (Vaage et al., 1998). In a mouse model, free DOX was found in urine samples as readily as 15 min and up to 48 h after the administration of the drug. SSL DOX was not detected in the urine until almost 1 h and could still be detected up to 5 days after drug administration. This is consistent with a controlled-release mechanism for the liposome-encapsulated drug, where the drug is released from its carrier at a very slow rate.

An understanding of the mechanisms responsible for maintaining high circulating levels of drug in the plasma is essential to design carriers that remain in the circulation sufficiently long to have a high probability of accumulating in tumors. Nevertheless, long circulation time is only one aspect of liposomes that results in their preferential antitumor activity. If liposomes were unable to preferentially accumulate in tumors, they would be useful only as a controlled-release type of therapy. This is increasingly available through mechanical

means, and thus there is minor clinical importance for the development of liposomes for this purpose. However, the fact that liposomes do accumulate preferentially in tumors allows them to be passively targeted and gives rise to substantial increases in antitumor efficacy. In *III. Accumulation of Liposomal Drugs in Tumors*, we review the various mechanisms responsible for the uptake of liposomes into tumors and how they may be exploited for further increasing drug delivery to tumors in the future.

III. Accumulation of Liposomal Drugs in Tumors

A. Mechanistic Rationale for Liposome Accumulation in Tumors: Enhanced Permeability and Retention Effect Phenomenon

The accumulation of liposomes or large macromolecules in tumors is a result of a "leaky" microvasculature and an impaired lymphatics supporting the tumor area (Matsumura and Maeda, 1986, 1989; Huang et al., 1992; Seymour, 1992; Yuan et al., 1994; Jain, 1996). This effect is often referred to as the enhanced permeability and retention effect ("EPR phenomenon"; Matsumura and Maeda, 1986, 1989). With gold-labeled liposomes, both extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions were demonstrated (Huang et al., 1993). The principal pathway for the movement of liposomes into the tumor interstitium is via extravasation through the discontinuous endothelium of the tumor microvasculature, and transcytosis is thought to be a relatively minor pathway. Once in the

tumors, nontargeted liposomes are localized in the interstitium surrounding the tumor cells (Huang et al., 1992; Yuan et al., 1994). Liposomes were not seen within tumor cells, although they were observed in resident tumor macrophages. The limited distribution of liposomes within the tumor interstitium results from a high interstitial pressure and a large interstitial space compared with normal tissues (Jain, 1989, 1990). Large tumors are more difficult to treat than small ones, in part because of the resulting increase in interstitial pressure, which prevents access of drugs to the necrotic core (Jain, 1990). Recently, liposomes were shown to penetrate the tumor more uniformly after the addition of an internalizing anti-HER2 Fab' fragment to the liposome surface (Papahadjopoulos et al., 1999) or by combining liposomal delivery with local hyperthermia. The extravasation and accumulation of liposomes into tumors are depicted in Fig. 8. Targeting to endocytic pathways may also increase the bioavailability of some drugs by degrading the liposomal carrier in the late endosome

or lysosome. These advances are discussed in more detail in *VIII. Bioavailability of Encapsulated Drug*.

The rate of accumulation and subsequent removal of liposomal drugs are affected by a variety of factors. The absence of functioning lymphatics, in combination with a high interstitial pressure, results in the trapping of liposomes within the tumor area (Yuan et al., 1994). The result is a relatively slow rate of elimination from the tumor. Several reports suggest that the observed elimination of L-DOX from the tumor is more likely due to the release of free drug from the carrier and its subsequent metabolism and diffusion from the tumor. In a brain tumor model, 7-deoxyaglycone metabolites were observed at 96 and 120 h after injection, when tumor drug levels were starting to decrease (Siegal et al., 1995). In a separate experiment, tumor levels of DOX and a nonexchangeable lipid marker, [^3H]cholesteryl hexadecyl ether, were measured at identical times (Goren et al., 1996). Although the lipid marker continued to accumulate over the entire time course, 100 h, to a maximum of ~6% of the injected dose/g of tumor, DOX levels reached a maximum after 24 h of ~5% of the injected dose/g tumor and then slowly decreased. This suggests that after the trapping of the liposomal carrier in the tumor area, DOX is made bioavailable and attains its own separate rate of elimination.

1. Effect of Microvasculature Physiology. Liposomes are able to enter tumors due to a discontinuous tumor microvasculature, where pore sizes vary between 100 to 780 nm in size (Yuan et al., 1995; Hobbs et al., 1998). The junctions in the vascular endothelium of healthy tissues vary depending on the type of tissue (Seymour, 1992). In most tissues, including connective tissue and tissues of the muscle, heart, brain, and lung, intercellular tight junctions result in openings of <2 nm. These openings can approach 6 nm in postcapillary venules and are considerably smaller than the size of liposomal carriers (65–125 nm; Seymour, 1992; Lum and Malik, 1994). Organs or tissues with discontinuous endothelium, such as the fenestrated endothelium of the kidney glomerulus or the sinusoidal endothelium of the liver and spleen, can have junctions ranging from 40 to 60 nm for the former and up to 150 nm for the latter (Seymour, 1992). Most liposome formulations are larger than the threshold required for glomerular filtration. As described in *II. Pharmacokinetics and Biodistribution of Liposomes and Liposomal Drug*, it is the macrophages residing in the liver and spleen that are responsible for the removal of liposomes from the circulation and, thus, the other two major sites of accumulation. However, unlike in tumor tissue, where they become effectively trapped, if liposomes are able to avoid uptake by macrophages, then they are free to pass in and out of the liver and spleen. The selective accumulation in tumors is thus made possible by the impervious nature of the endothelium of most healthy tissues.




FIG. 8. Scheme showing accumulation of liposomes and drug in tumors. a, slow-release liposomes are able to carry some drugs securely in the circulation. b, rapid-release liposomes leak their drug, to a greater extent in the circulation. The drug is then free to diffuse and take on the pharmacokinetics of the free drug. c, the continuous endothelium of healthy tissues prevents leakage of liposomes into these tissues. d, however, the tumor vasculature is discontinuous with gaps ranging from 100 to 780 nm, allowing liposomes to extravasate and reach the tumor interstitium. e, nontargeted liposomes accumulate in the tumor interstitium, where they eventually leak their drug. f, DOX can then enter nearby tumor cells and accumulate in the nucleus where it elicits its cytotoxic effects. g, targeted liposomes also accumulate in tumors, but on entering the tumor area are endocytosed by tumor cells. This likely results in breakdown of the carrier in the lysosome and an increased delivery of DOX to the nucleus. h, in addition, HER2-targeted liposomes have been shown to distribute within the tumor, increasing the access of DOX to tumor cells deep within the tumor mass. Hyperthermia in combination with SSL DOX was shown to result in a similar distribution (not drawn to scale).

84

Vascular permeability in tumors is heterogeneous with respect to tumor type, location of the vessel within the tumor, and the tumor microenvironment (Yuan et al., 1994; Fukumura et al., 1997; Hobbs et al., 1998). The enhanced permeability and retention effect has been described for a variety of large macromolecules and drug carriers (Matsumura and Maeda, 1986, 1989; Maeda, 1991; Huang et al., 1992; Seymour, 1992; Yuan et al., 1994). Permeability and angiogenesis are also dependent on various growth factors and the microenvironment from which those growth factors are released or act on (Collins et al., 1993; Roberts and Palade, 1995; Dellian et al., 1996). The best studied of these is vascular permeability factor, also known as vascular endothelial growth factor. Vascular permeability factor also is an angiogenic factor; it helps to recruit new blood vessels to support the tumor (Folkman, 1985; Collins et al., 1993; Roberts and Palade, 1995). Basic fibroblast growth factor was shown in another study to increase vascular permeability, although its effects may be secondary to those of vascular endothelial growth factor (Dellian et al., 1996). The availability of these growth factors in different tumor environments will affect the accumulation of large macromolecules and liposomal carriers in tumors.

2. Blood-Brain Barrier. The blood-brain barrier represents a formidable barrier for drug delivery to the central nervous system. Tight junctions, the lack of fenestrations, and a low transcellular pinocytic index severely limit the accumulation of macromolecules in the brain (Levin et al., 1980; Seymour, 1992). Surprisingly, several groups have been able to show that even tumors located in the brain have a "leaky" microvasculature, although pore sizes are significantly smaller (100–380 nm) than those seen with tumors located elsewhere in the body (200–780 nm; Siegal et al., 1995; Hobbs et al., 1998). In a brain tumor model, Gabizon and coworkers were able to show high levels of SSL DOX accumulation in the tumor (Siegal et al., 1995). Fischer rats injected with SSL DOX at a dose of 6 mg/kg showed maximal accumulation at 48 h of 10 to 11 μg DOX/g of tumor tissue. This was 15-fold higher than the levels observed after the administration of an identical dose of free DOX (0.8 μg /g at 4 h), which were not different from levels found in the normal brain (contralateral hemisphere). There was no accumulation of SSL DOX in the contralateral hemisphere, and in brain tissue immediately adjacent to the tumor, levels were <2 μg /g tissue up to 70 h after injection but gradually increased to a maximum of 4 μg /g at 120 h. These results suggest that even in the tightly regulated central nervous system, a high tumor vascular permeability can be exploited for carrier-mediated drug delivery.

B. Rate and Extent of Accumulation in Tumors

The rate and extent of drug accumulation in tumors vary depending on dose, formulation, and tumor type

(Table 7; Gabizon et al., 1996; Goren et al., 1996; Harsanyi et al., 1997; Parr et al., 1997). Drug accumulation in tumor is most often measured at single time points, commonly either 24 or 48 h. In some studies, the free drug is measured at shorter times, such as 1 h, due to its earlier peak of accumulation. Data comparing the degree of drug accumulation in tumors for free and liposomal drug at single time points are given in Table 7. Peak DOX levels are 3- to 15-fold greater in tumors when delivered via liposomes compared with the free drug. A comparison of CL versus SSL DOX showed an approximately equivalent accumulation in three tumor models when administered at high doses (20–55 mg/kg; Mayer et al., 1997; Parr et al., 1997; Table 7). When administered at lower doses (5–10 mg/kg), SSLs accumulated to a greater extent in tumors (Huang et al., 1992; Unezaki et al., 1995; Gabizon et al., 1996). The similar accumulation in the first study is probably an underestimate due to the taking of 24 h as the only or final time point, whereas significant tumor accumulation with SSL DOX occurs after this time. The effect of both dose and formulation is indirectly a result of their effect on liposome circulation lifetimes and on formulation stability. As described in *II. Pharmacokinetics and Biodistribution of Liposomes and Liposomal Drug*, the kinetics of SSL clearance are log linear and dose independent, which allow for significant concentrations of the liposomal drug to be in the circulation, even at low doses (Allen et al., 1995a). CLs, on the other hand, display saturable dose-dependent kinetics that result in rapid clearance of the liposomal drug at lower doses but a much slower rate of clearance, and thus higher blood levels at higher doses (Hwang, 1987; Allen et al., 1995a). It is postulated that at these lower doses, the large differences in circulation lifetimes between SSLs and CLs would result in a larger reservoir of liposomes available to enter the tumor in the case of SSLs. However, at higher doses, as saturation of the mechanisms responsible for liposome clearance occurs, the extent of these differences should be reduced. Using a variety of different lipid compositions with varying circulation lifetimes, a good correlation was observed between increasing lifetimes and high liposome levels in tumors (Gabizon and Papahadjopoulos, 1988). This relationship may prove to be overly simplistic. As factors such as drug-induced RES blockade and high liposome dose bring clearance rates of differing formulations closer together, poorly understood effects of liposome composition and physical properties (e.g., size) on rates of extravasation may begin to become important. Recent evidence suggests that CL formulations may accumulate in tumors at a more rapid rate than SSLs, but due to lower circulation lifetimes, they give rise to lower overall extents of accumulation (Gabizon et al., 1996; Mayer et al., 1998).

Gabizon et al. (1996) were the first to show that liposomes with decreased circulation lifetimes may accumulate in tumors at a more rapid rate. Later, Mayer and


TABLE 7
Accumulation of liposomes in tumors

Animal and Tumor Model	Formulation	Dose	Time	Accumulation
		mg/kg	h	µg/g
CD2F ₁ mice (P-1798 lymphosarcoma) ^a	DaunoXome	20	24	39.57 ± 15.38
	Free daunorubicin	20	24	2.02 ± 1.42
B6C3F1 mice (MA16C mammary adenocarcinoma) ^a	DaunoXome	20	24	19.98 ± 8.77
	Free daunorubicin	20	24	8.41 ± 1.11
Fischer rats (fibrous histiocytoma) ^b	Doxil	6	48	10.92
	Free DOX	6	4	0.8
Female C3H/HeJ mice (FSa-R fibrosarcoma) ^c	DSPC/Chol (55:45), 100 nm	20	24	16.3 ± 2.3
	DSPC/Chol/PEG-DSPE (50:45:5)	20	24	15.7 ± 1.7
Female C3H/HeJ mice (FSa-N fibrosarcoma) ^c	Free DOX	20	1	7.8 ± 3.1
	DSPC/Chol (55:45), 100 nm	20	24	23.9 ± 2.7
BDF1 mice (Lewis lung carcinoma) ^d	DSPC/Chol/PEG-DSPE (50:45:5)	20	24	32.1 ± 4.7
	Free DOX	20	1	12.8 ± 1.2
Shionogi mice (SC115 mammary carcinoma) ^e	DSPC/Chol (55:45), 100 nm	55	168	143.8 ± 18.2
	DSPC/Chol/PEG-DSPE (50:45:5)	55	168	133.0 ± 11.9
BALB/c mice (M109 carcinoma) ^f	TLC D-99	13	24	10.2 ± 3.6
		6.5	24	5.5 ± 1.1
		6.5	24	1.9 ± 0.08
	Doxil	5	48	6.5 ± 4
		10	48	16 ± 17.3
		20	48	42 ± 39.3
	Free DOX	5	3	3.6 ± 2.1
		10	3	5.2 ± 2.1
BALB/c female mice (J6456 ascites) ^g	PEG-DSPE/HSPC/Chol	10	24	5.9 ± 3.4
	DSPG/HSPC/Chol	10	24	4.2 ± 2.95
	HSPI/HSPC/Chol	10	24	5.3 ± 1.4
	HSPC/Chol	10	24	1.8 ± 0.13
BALB/c female mice (M-109 carcinoma) ^g	Free DOX	10	24	<0.05
	PEG-DSPE/HSPC/Chol	10	24	17.4 ± 8.8
	DSPG/HSPC/Chol	10	24	17.4 ± 6.1
	HSPC/Chol	10	24	19.7 ± 5.0
	Free DOX	10	24	2.2 ± 0.6
Humans (various carcinomas) ^h		mg/m ²		
	Doxil	25	3-7 days	0.44
		50	3-7 days	0.69
	Free DOX	25	4-24	0.051
Humans (Kaposi's sarcoma lesions, biopsy specimens) ⁱ	DaunoXome	20	24	1.07
		40	24	1.06
Humans (Kaposi's sarcoma lesions, biopsy specimens) ^j	Doxil	10	72	2.06 ± 0.42
		20	72	1.61 ± 0.80
		40	72	7.71 ± 2.72
	Free DOX	10	72	0.18 ± 0.07
		20	72	0.31 ± 0.16
		40	72	0.82 ± 0.18

The composition, size, and drug/lipid ratio for daunorubicin and DOX are listed in Table 1. When available, the time of analysis was the time of maximal accumulation.
^a Forssen et al. (1992).
^b Siegal et al. (1995).
^c Mayer et al. (1997).
^d Parr et al. (1997).
^e Mayer et al. (1990a).
^f Gabizon et al. (1997).
^g Gabizon et al. (1996).
^h Gabizon et al. (1994).
ⁱ Forssen and Ross (1994).
^j Northfelt et al. (1996).

coworkers proposed the use of a factor termed “tumor accumulation efficiency” (T_e), defined as the AUC of the drug in the tumor divided by the AUC in the plasma, to determine the efficiency of extravasation for a given liposome formulation (Mayer et al., 1997, 1998; Parr et al., 1997). In several different tumor models, the T_e value was 1.5- to 3-fold higher for DSPC/Chol formulations than the sterically stabilized equivalent (Mayer et al., 1997, 1998; Parr et al., 1997). The effect of steric stabilization on the rate of tumor accumulation is still controversial; at least one study that used videomicroscopy to follow fluorescently labeled liposomes showed a higher permeability for SSLs (Yuan et al., 1994). In

another study, CL DSPC/Chol (55:45) liposomes delivered at 20 mg/kg to two fibrosarcoma models showed elevated drug levels in the tumor for CLs at 4 h but for SSLs at 24 h (Mayer et al., 1997). The initially increased rate of accumulation may be due to a higher permeability of the tumor microvasculature to CLs, but the later increase in SSL accumulation likely reflects the disappearing pool of CLs in the circulation, relative to SSLs. The role of long-circulating properties and tissue uptake rate on the expected efficacy of a liposomal drug after i.v. bolus administration may be explored using a two-compartment open pharmacokinetic model (Scheme 1; Welling, 1986).



SCHEME 1.

The amount of liposomes in the blood compartment (A_b) and in the selected tissue [e.g., tumor (A_t)] is governed by the following set of equations and boundary conditions:

$$dA_b/dt = -(k_e + k_i)A_b + k_oA_t \quad (1)$$

$$dA_t/dt = k_iA_b - k_oA_t \quad (2)$$

$$A_b(0) = A_0; \quad A_b(\infty) = 0 \quad (3)$$

$$A_t(0) = A_t(\infty) = 0 \quad (4)$$

This set of linear differential equations with constant coefficients allows simple analytical solution resulting in somewhat cumbersome formulas for $A_b(t)$ and $A_t(t)$ (Welling, 1986). Assuming that drug efficacy correlates with the tissue exposure to the liposomes, which, in turn, is characterized by AUC, we need only calculate AUC for blood and tumor:

$$AUC_b = 1/V_b \int_0^\infty A_b dt \quad (5)$$

$$AUC_t = 1/V_t \int_0^\infty A_t dt \quad (6)$$

where V_b and V_t are physical volumes of the blood and tumor compartments, respectively.

After integration of right and left parts of eqs. 1 and 2 from zero to infinity and applying boundary conditions, we obtain:

$$(k_e + k_i) \cdot V_b \cdot AUC_b - k_o \cdot V_t \cdot AUC_t = A_0 \quad (7)$$

$$k_i \cdot V_b \cdot AUC_b - k_o \cdot V_t \cdot AUC_t = 0 \quad (8)$$

and, finally:

$$AUC_t = A_0 \cdot k_i / (k_e \cdot k_o \cdot V_t) \quad (9)$$

$$T_e = (AUC_t) / (AUC_b) = (k_i \cdot V_b) / (k_o \cdot V_t) \quad (10)$$

In these equations, "blood elimination" first order rate constant k_e includes all processes that lead to the removal of the carrier from the blood, including excretion, phagocytic clearance, and distribution into organs and tissues other than the tumor. Interestingly, T_e , perhaps deceptively termed "tumor accumulation efficiency" (Mayer et al., 1997, 1998), does not include liposome longevity in the circulation (characterized by k_e) as a

factor and is determined essentially by the liposome uptake rate into the tumor. On the contrary, tumor AUC correlates not only with the liposome uptake (uptake rate constant k_i) but also with the liposome longevity in circulation (blood elimination constant k_e). These equations point out the importance of another process, often neglected: the rate of liposome elimination from the tumor (k_o). Liposome elimination from the tumor, which appears to be slower than tumor uptake and blood elimination, is poorly understood and awaits adequate experimental investigation.

The above simple model of liposome pharmacokinetic behavior can be modified for the case in which liposomes are not recycled from the tumor into the blood but instead are metabolized in situ. In this case, the effects of liposome uptake rate by the tumor and circulation longevity on the tumor AUC are similar to the previous model:

$$AUC_t = A_0 k_i / (k_e + k_i) / (k_o V_t) \quad (11)$$

and the expression for T_e is exactly the same as eq. 10.

Thus, within the framework of these models, circulation longevity of liposomes is not a factor in tumor accumulation efficiency, T_e , but rather is an important factor in the determination of overall tumor exposure to the drug.

In light of this controversy, a complicated question remains. If the permeability is increased for CLs, what is the overall significance of a 1.5- to 3-fold increase in permeability, taking into consideration the difference in circulation lifetimes? As expected, when the T_e was calculated for free DOX at 24 h after injection, the result was a 2.8-fold increase over that for an HSPC/Chol formulation (Gabizon et al., 1996). This is not surprising considering the small molecular size of the free drug and its rapid redistribution into tissues. However, the extent of accumulation in the tumor is greater for the liposomal formulation, as is the tumor AUC calculated at extended times. The overall tumor AUC appears to be a more relevant indicator of the effectiveness of a drug delivery system in liposomes where drug release from the liposome is similar. Mayer et al. (1998) showed two examples where the tumor AUC was slightly greater for CL formulations. One of these examples compared SM/Chol versus SM/Chol/PEG-PE formulations of VCR, where the concentrations of PEG-DSPE used were shown to result in a destabilization of the formulation and, consequently, lower amounts of drug available for delivery to the tumor (Webb et al., 1995). A second example was completed with DOX-loaded liposomes (Mayer et al., 1997). An important consideration when considering at total accumulation in tumors is the duration in which the AUC was calculated. The tumor AUC levels for all the examples given were calculated over the time period of 0 to 24 h. Other work, with substantially lower doses of SSL DOX, has shown that maximum tumor accumu-

lation does not occur until 48 h or longer in some cases and that a substantial portion of the tumor drug level-versus-time curve exists after 24 h in all cases (Papahadjopoulos et al., 1991; Vaage et al., 1994a; Siegal et al., 1995; Gabizon et al., 1996, 1997; Goren et al., 1996). In addition, the peak time of accumulation is conceivably even later considering the large doses (20 mg/kg) used in these studies. Thus, the tumor AUC levels reported by Mayer and coworkers are likely biased in favor of CLs by limiting the calculation to the first 24 h. Finally, although it is theoretically possible to increase circulation lifetimes to a sufficiently high level to achieve an advantage from the proposed increased rate of extravasation, the conditions required to do so may not be pharmacologically relevant. The doses required to obtain the needed circulation lifetimes (20–55 mg/kg) are 4 to 20 times larger than those being used in current studies with SSL DOX and will likely result in substantial toxicity if administered in multiple doses (see VI. *Toxicology of Liposomal Chemotherapy*).

Although differences in the rates of extravasation may not be sufficiently great to obtain a true advantage for CLs over SSLs, it is nevertheless an important parameter to keep in mind when designing drug delivery systems. Liposome size may be another important parameter that affects accumulation in tumors. Several studies have shown that the permeability of large macromolecules is independent of size as long as the translocating molecule is much smaller than the pore size in the endothelium of the tumor microvasculature (Yuan et al., 1995; Hobbs et al., 1998). However, even small liposomes (100 nm) are between 13 and 100% of the average pore size found in tumor endothelium, and liposomes (100 nm) have already been shown to have a reduced permeability compared with fluorescently labeled BSA molecules. Although a study with carefully sized liposomes has yet to be completed, theoretically these data suggest that even small changes in liposome size (50 nm) may significantly affect the rate of accumulation in tumors. A DSPC/Chol (2:1) formulation containing daunorubicin shows maximal accumulation in a lymphosarcoma solid tumor mouse model at 8 h with a subsequent elimination rate similar to free daunorubicin (Forssen et al., 1992). This initial rate of drug accumulation in this study is far more rapid than that seen with other CL or SSL DOX formulations (Gabizon et al., 1997; Mayer et al., 1997) and may be due to the smaller size (50 nm compared with 100 nm for the DOX-loaded liposomes), although differences in tumor type or drug-leakage rates cannot be ruled out. In situ fluorescence measurements for an identical small formulation showed a slower rate of accumulation, similar to that of other larger CL formulations (Forssen et al., 1996), thus complicating this interpretation. A carefully designed study that considered the effect of liposome size (50-nm increments) on tumor accumulation rates or vascular permeability would help test this hypothesis.

C. Hyperthermia and Vascular Permeability Factors for Increasing Vascular Permeability

Differences in vascular permeability have been exploited in two different ways to increase accumulation of liposomes in diseased tissues. Permeability of the tumor microvasculature was increased with the use of local hyperthermia, resulting in increased tumor levels of SSL DOX (Huang et al., 1994; van Bree et al., 1996). Hyperthermia can also result in increased rates of drug release from specially engineered thermosensitive liposomes (see VIII.C. *Hyperthermia and Thermosensitive Liposomes*; Gaber et al., 1995, 1996). In a second example, substance P was used in an inflammation model to increase vascular permeability and, thus, the extents of liposome accumulation (Rosenecker et al., 1996; Zhang et al., 1998). In both of these examples, increased accumulation in the diseased tissue resulted from a direct effect on the tumor microvasculature. It may prove advantageous in future studies to increase accumulation in tumors by altering liposome surface properties or vascular permeability directly to promote extravasation.

D. Sterically Stabilized versus Rapid-Release Conventional Liposome Carriers

In addition to using liposomes as slow-release liposomal carriers, such as SSL DOX, they can be used as rapid-release systems, such as TLC D-99. The low-phase transition phospholipid component, eggPC, of rapid-release liposomal carriers allows the drug to leak more quickly from the liposome, at least partially while in the circulation (Bally et al., 1990b; Gabizon et al., 1993). Although slow-release liposomal carriers accumulate in tumors on a time scale similar to or greater than the release of DOX from the carrier, rapid-release systems can release their drug to a greater extent before reaching the tumor, where it can diffuse into the tumor as the free drug. It should be emphasized that “slow” and “rapid” are relative terms, and the magnitude of the leakage rates will ultimately be determined by the physicochemical properties of both the drug and the carrier. The release of DOX in the plasma for TLC D-99 can be demonstrated by considering the drug/lipid ratio, which drops from 0.29 to $<0.05 \mu\text{g DOX}/\mu\text{g lipid}$ in 24 h (Harasym et al., 1997). Approximately 58% of the drug was released from the carrier within the first hour. The differences in tumor accumulation show that the drug slowly accumulates in tumors when delivered via slow-release liposomal carriers (Papahadjopoulos et al., 1991; Bally et al., 1994; Gabizon et al., 1996, 1997), likely reflecting delivery of the intact liposome-encapsulated drug. In rapid-release CL liposomal carriers, DOX accumulated rapidly in the tumor and levels remained constant for up to 72 h at levels 2- to 3-fold greater than that achieved with free DOX (Harasym et al., 1997). Due to the increased leakage of DOX in the circulation, the drug presumably reaches normal tissues at a faster rate as

88

well (Mayer et al., 1989), although levels at very early times were not measured. When rates of lipid and DOX accumulation were compared, DOX delivered via rapid-release carriers reached peak levels by 1 h, whereas lipid levels did not peak until 48 h. With slow-release carriers, the initial rate of tumor accumulation is similar for lipid and drug (Bally et al., 1994; Goren et al., 1996), but at later times, tumor drug levels decrease upon drug release from the carrier and subsequent metabolism and redistribution (Goren et al., 1996). Drug can thus accumulate in tumor via several different mechanisms, although the primary mechanism for delivery by slow-release liposomal carriers is via extravasation of liposome plus drug through a discontinuous microvasculature. Studies of the effects of various factors (e.g., size, charge, tumor microenvironment, regulation by growth factors) on the permeability and distribution of liposomes within the tumor will help engineer liposomes for more effective delivery of their contents in the tumor. With the exception of one study (Yuan et al., 1994), few studies have considered the movement of liposomes through the tumor interstitium. The long distances and high interstitial pressure make this an obstacle that may prove as important as the permeability of the tumor vasculature.

IV. Efficacy of Liposomal Drugs in Animal Tumor Models

SSL DOX has been examined for antitumor efficacy in a variety of different tumor models, including a human lung tumor xenograft (Williams et al., 1993), human pancreatic carcinoma xenograft (Vaage et al., 1997), mouse lymphoma (Gabizon et al., 1996, 1997, 1998), rat brain sarcoma (Siegal et al., 1995; Gabizon et al., 1997), mouse colon carcinoma (Papahadjopoulos et al., 1991; Huang et al., 1992; Mayhew et al., 1992), prostatic tumor xenografts (Vaage et al., 1994a; Working et al., 1994), mouse mammary carcinomas (Mayer et al., 1990a; Forssen et al., 1992; Vaage et al., 1992), ovarian carcinoma xenograft (Vaage et al., 1993a), and an HER2-overexpressing human breast carcinoma xenograft (Park et al., 1997). The combination of a broad activity of DOX to a wide assortment of different cancers and the common mechanistic rationale for liposomal accumulation in solid tumors (see *IIIA. Mechanistic Rationale for Liposome Accumulation in Tumors: Enhanced Permeability and Retention Effect Phenomenon*) results in a drug formulation with substantial antitumor efficacy compared with the free drug and relatively independent of the type or location of the tumor. Even in a brain tumor model where the blood-brain barrier is thought to severely limit drug accumulation, SSL DOX showed a significant increase in mean survival times compared with free DOX (189% compared with 126%; Siegal et al., 1995; Gabizon et al., 1997). Efficacy results in a variety of different liposome formulations and tu-

mor models are listed in Table 8. There are possible exceptions to these observations that may result in different liposome formulations being more suitable for the treatment of different cancers, depending on circumstances. These potential exceptions are described later.

In critical evaluation of previous studies using liposomal anthracyclines, one must be careful of comparisons drawn between CL and SSL formulations. All too often, the CL formulation being referred to is of a suboptimal formulation, containing either unsaturated lipids that allow the drug to leak rapidly from the carrier or negatively charged lipids that facilitate their clearance from the circulation. Under exceedingly complex conditions, such as in vivo drug delivery, where a variety of factors can influence pharmacokinetics, stability, extravasation into tumors, and clinical efficacy, it is best for comparisons to be drawn where a minimum number of variables, ideally only one, are altered at any one time.

A. Comparison of Efficacy for Sterically Stabilized and Conventional Liposomes

There are few studies that directly compare small neutral CLs and SSLs in therapeutic efficacy studies (Huang et al., 1992; Unezaki et al., 1995; Gabizon et al., 1996; Chang et al., 1997; Mayer et al., 1997; Parr et al., 1997). With the exception of one study that targets splenic and liver tumors (Chang et al., 1997), these comparisons are usually divided into one of two experimental designs. We examine the results and relevance of each of these experimental designs individually. In the first design, liposomes are injected at a dose of ≤ 10 mg/kg DOX and show significant improvement in therapeutic efficacy for SSL DOX compared with both free DOX and CL L-DOX (L-DOX; Table 8; Huang et al., 1992; Unezaki et al., 1995; Gabizon et al., 1996). Using a BALB/c mouse C26 colon carcinoma model, an increased life span (ILS) of 48.3% for SSL DOX was observed compared with 5.1% for DSPC/Chol liposomes and -4.2% for free DOX when administered as a single dose at 10 mg/kg (Huang et al., 1992). When SSL DOX or SSL-epirubicin was injected at either a single dose of 10 mg/kg DOX or three weekly doses of 6 or 9 mg/kg DOX, tumors regressed to a nonmeasurable size over time, whereas free drug administered at an identical dose and schedule only slightly delayed tumor growth compared with controls. This was similar to the first efficacy study completed with a Stealth® liposomal drug formulation showing increased therapeutic efficacy of SSL-epirubicin compared with free epirubicin (Papahadjopoulos et al., 1991). Epirubicin is a DOX analog that shows markedly reduced cardiac toxicity compared with DOX. In this study, both an increase in life span and an inhibition of tumor growth were noted with three weekly injections of SSL-epirubicin (6 mg/kg epirubicin), whereas free epirubicin had only minimal effects. Unfortunately, due to the significantly decreased ILS of the CL formulation, neither study examined the effect of CL DOX or

TABLE 8
Efficacy studies in animals

Animal Model	Formulation	Dose	ILS ^a	p
		mg/kg	%	
Fischer rats (fibrous histiocytoma) ^f	Doxil	8	65	<.0003
	Free DOX	8	35	<.05
	Doxil	5 × 3	89	<.00001
CD2F ₁ mice (P-1798 lymphosarcoma) ^g	Free DOX	5 × 3	23	<.05
	DaunoXome	20	15	<.05
	Free daunorubicin	20	54	<.05
B6C3F ₁ mice (MA16C mammary adenocarcinoma) ^g	DaunoXome	20	>217	<.05
	DaunoXome	2	100	<.05
	Free daunorubicin	20	94	
Nude mice (ovarian HEY cancer) ^g	Doxil	9	40	<.001
	Free DOX	9	-50	
Female BALB/c mice (C26 colon carcinoma) ^h	PEG-DSPE/HSPC/Chol (DOX)	10	48.3	
	DSPC/Chol (2:1)	10	5.1	NS
	Free DOX	10	-4.2	NS
BALB/c mice (J6456 lymphoma)	Doxil	10 (i.v.)	116	<.0001
	Free DOX	10 (i.v.)	21	<.0001
	Doxil	10 (i.p.)	60.5	<.0001
	Free DOX	10 (i.p.)	60.5	<.0001
Female BALB/c mice (C26 colon carcinoma) ^h	PEG-DSPE/HSPC/Chol (DOX)	10	-7	
	DSPC/Chol (1:1)	10	21	
	Free DOX	10	114	
BALB/c mice (M-109 carcinoma) ^h	PEG-DSPE/DSPC/Chol (DOX)	10	168	<.05
	PEG-DSPC/DPPC/Chol	10	118	
	DSPG/HSPC/Chol	10	168	<.1
	HSPC/Chol	10	94	
	Free DOX	10	97	
BALB/c mice (J6456 lymphoma) ^h	PEG-DSPE/DSPC/Chol (DOX)	15	144	<.01
	DSPG/HSPC/Chol	15	197	<.01
	Free DOX	15	19	
BALB/c mice (C26 colon carcinoma) ^h	PEG-DSPC/DSPC/Chol (epirubicin)	6 × 3	148 ^b	
	Free epirubicin	6 × 3	20	
BDF1 mice (P388 lymphoma) ^h	DSPC/Chol (55:45) (VCR)	3	38	<.05
	SM/Chol (55:45)	3	214	<.05
	Free VCR	3	>445	<.05
B6D2F1 mice (P388 leukemia) ^h (i.p.)	PEG-DSPE/DSPC/Chol (VCR)	2	199	<.01 ^c
	Free VCR	2	79	<.01 ^c
BDF1 mice (L1210 tumors) ^g	DSPC/Chol (mitoxanthrone)	20	189	
	DMPC/Chol	20	>590	
	Free mitoxanthrone	10 ^d	98	
B6D2F1 mice (L1210 leukemia) ^g (i.v.)	PEG-DSPE/DSPC/Chol (ara-c)	50	138	
	PEG-DSPE/DSPC/Chol/SM	50	197	
	PG/DSPC/Chol	50	160	
	Free ara-C (24-h infusion)	50	90	

The composition, size, and drug/lipid ratio for DaunoXome and Doxil are listed in Table 1.
^a ILS, mean survival: 100 × treated/control - 100.
^b ILS was calculated only from mean survival time of mice dying before day 120 (there were 6 of 10 long-term survivors for >120 days).
^c Between-treatment groups at same dose level; other p values are between treatment and control groups.
^d The mean survival time for free mitoxanthrone.
^e Siegal et al. (1995).
^f Forssen et al. (1992).
^g Vaage et al. (1994b).
^h Huang et al. (1992).
ⁱ Cabanes et al. (1998).
^j Unezaki et al. (1995).
^k Gabizon et al. (1996).
^l Mayhew et al. (1992).
^m Webb et al. (1995).
ⁿ Allen et al. (1995b).
^o Lim et al. (1997).
^p Allen et al. (1992).

CL-epirubicin on tumor growth. At the concentrations of DOX (6–9 mg/kg) and liposomes (50–75 mg/kg phospholipid) used in these studies, clearance rates are likely too rapid to observe a significant therapeutic result for CLs. Two additional studies completed with a comparable experimental design showed similar results to those observed earlier (Unezaki et al., 1995; Gabizon et al., 1996). In an almost identical design (including the tumor and animal model), Unezaki et al. (1995) showed a 6-fold increase in the percent ILS for SSLs compared

with CLs (Table 8). This correlated to a >3-fold decrease in tumor AUC levels for DOX when encapsulated in CLs (Table 6). Gabizon et al. (1996) completed one of the most thorough and careful studies of the effect of lipid composition on therapeutic efficacy. In this study, five different liposome compositions were evaluated for therapeutic efficacy and tumor accumulation in two different tumor models (J6456 lymphoma and M-109 carcinoma, a murine lung metastasis model). The number of variables was kept to a minimum to allow for careful com-

parisons, and even rates of accumulation in tumors were measured in some instances, rather than simply measuring DOX levels at single time points. At a single dose of 10 mg/kg, a linear correlation between circulation lifetimes and antitumor efficacy could not be found. Liposomes with similar but still reduced lifetimes (HSPI/HSPC/Chol, DSPG/HSPC/Chol, GM₁/HSPC/Chol) compared with PEG-DSPE/HSPC/Chol liposomes had a similar therapeutic efficacy. In one example, DSPG/DSPC/Chol liposomes were shown to have plasma levels at 24 h, approximately half that seen for PEG-DSPE/HSPC/Chol liposomes but an identical degree of accumulation in tumor and percent ILS. This was not shown to be an artifact of the type of tumor investigated, in that both the J6456 lymphoma and M-106 carcinoma gave similar results. Interestingly, the one liposome composition that showed significantly less efficacy was HSPC/Chol. Plasma levels were between one fourth and one half of the closest formulation and this translated into a reduced percent ILS (168 versus 94%) in both tumor models. For the conditions examined in this study, SSLs certainly showed a greater accumulation in tumors and an increase in therapeutic efficacy compared with neutral CLs (HSPC/Chol). However, the far more interesting result, obtained with other negatively charged formulations, demonstrated that longer circulation times do not necessitate greater tumor accumulation and efficacy.

In a second experimental design, liposomes were injected as a single dose of 20 to 55 mg/kg DOX and showed approximately equivalent therapeutic efficacy for SSL DOX and CL DOX (Table 8; Mayer et al., 1997; Parr et al., 1997). At these high doses, the circulation lifetimes for the CL formulation are markedly elevated due to a toxic effect on RES macrophages, and initial rates of tumor accumulation appear to be greater for CLs than for SSL. The rates of tumor accumulation favor the SSL formulation at later times, likely due to the more rapidly disappearing pool of CLs. In both of these studies, tumor growth rates were slowed to comparable extents with SSL DOX and CL DOX. There was no significant difference in either study. However, a serious question is raised in one of these studies due to the significant activity of free DOX (Mayer et al., 1997). This may be due to the nature of the tumor investigated: either methylcholanthrene-induced or "spontaneously" arising fibrosarcoma. In any case, there is no significant difference between free and liposome encapsulated DOX with one tumor, and free DOX actually appears more efficacious in the second tumor investigated. This stands in stark contrast to most other studies with L-DOX in which a significant therapeutic advantage is gained by liposome encapsulation. In the other study, L-DOX was used at a concentration (55 mg/kg), 5.5-fold greater than that used with previous studies with SSL DOX (Parr et al., 1997). This raises serious toxicological concerns, which are addressed in VI. *Toxicology of Liposomal Che-*

motherapy. Even at these concentrations, tumor growth continued rapidly after a short delay. It is unlikely that the animals would tolerate multiple injections of the drug at these doses. The authors appear to make logical arguments as to why RES blockade and an increased permeability of the tumor microvasculature to CLs could give rise to similar therapeutic efficacy. However, the experiments in these two reports appear to be unconvincing because of the unrealistically high doses of drug being administered, and a more careful set of experiments on the effect of dose on tumor accumulation, toxicity, and therapeutic efficacy in already established tumor models may prove to be more persuasive. In addition, even at the elevated doses used in these studies, little information is given concerning the types and degree of severity of different toxicities. This appears to be an especially important concern considering the doses under investigation.

B. Model Dependency of Results

There are a number of characteristics of animal and tumor models, and the study design in general, that may influence the observed results for a given formulation in efficacy studies; these include such factors as the initial size of the tumor before the start of treatment, the growth rate of the tumor, the route of administration, the frequency of injection, and the tumor microenvironment. Investigators should be aware of how these factors potentially influence the observed efficacy of a particular liposomal drug, as well as comparisons between different formulations. Each of these characteristics is examined in detail here.

1. Initial Size of Tumor. The size of the tumor is an important determinant in its ability to be treated. As mentioned in III. *Accumulation of Liposomal Drugs in Tumors*, the tumor microvasculature varies depending on the size of the tumor. Vascular permeability has been shown to increase with increasing tumor size, and some very small lesions (<1–2 mm) appear to be avascular (Folkman, 1971, 1990; Blasberg et al., 1981; Zhang et al., 1992). Thus, some extremely small tumors may not be particularly amenable to treatment with liposomal drugs that require extravasation for activity. In other instances, small tumors may coopt already existing blood vessels (Holmgren et al., 1995; Pezzella et al., 1997; Holash et al., 1999). A more relevant problem occurs as tumors increase to very large sizes; the necrotic regions in the interior of large tumors have a reduced vascular density and an increased interstitial pressure compared with the surface of the tumor (Jain, 1987, 1990; Jain and Baxter, 1988; Baxter and Jain, 1990). The result is a reduced access of liposome-associated drug, which enters the tumor via extravasation, to certain areas of the tumor. Experiments can be effectively biased toward a favorable therapeutic outcome by choosing to start the drug administration at early times when the tumor size is small (<0.1 cm³). Several studies

have shown a difference in the SSL DOX or CL DOX to free DOX efficacy depending on the day of treatment relative to tumor inoculation (Huang et al., 1992; Vaage et al., 1992; Cabanes et al., 1998). Of course, this applies to treatment with free drug as well; tumors treated early after tumor inoculation can be considerably easier to treat than those whose for which treatment was delayed (Huang et al., 1992). Recently, most experiments completed in our laboratory have used 0.20 to 0.25 cm³ as the size at which treatments are begun.

2. Rapidly Growing versus Slowly Growing Tumors. Certain tumor models may give ambiguous results with long-circulating liposomes due to their rapid doubling times (Allen et al., 1992; Papahadjopoulos and Gabizon, 1995). Both L1210 and P388 leukemias in mice fit into this category. In these two models, the cells divide more rapidly than liposomes can distribute to tumors and release their contents. With fast growing tumors, liposomes that accumulate in tumors or release their contents more rapidly may be more efficacious. Thus, although DPPC/Chol or PEG-DSPE/DPPC/Chol liposomes may release their contents too rapidly to be effective against slower growing tumors, they may show greater efficacy than the slow-releasing HSPC/Chol liposomes in these tumor models. Allen et al. (1992) have shown that formulations with increased release rates of encapsulated ara-C were more efficacious in the treatment of mice injected with rapidly growing L1210 leukemia cells (Table 8). In addition, if CLs do accumulate more rapidly in tumors, they may have an advantage over SSLs, even if the long-term accumulation is not as great. As mentioned previously, the rate of liposome accumulation in tumors remains a point of controversy and must be more thoroughly studied. Of course, the rates of tumor drug accumulation and drug release rates from liposomes must be of a similar magnitude to be the most effective in the delivery of bioavailable drug to tumors. If liposomes release most of the drug before reaching the tumor or are taken up so rapidly by the RES that they cannot accumulate in tumors to a significant extent, then the effective concentration of bioavailable drug in the tumor will still be less than that for long-circulating liposomes. Most solid tumors targeted in animal studies grow at a sufficiently slow rate, as to be compatible with long-circulating liposomes.

The difference in tumor doubling times between human and animal tumor models may also play a role in the effectiveness of a particular type of liposomal treatment. The animal tumor models described in many of these studies have doubling times on the order of days to a few weeks. Most human tumors have doubling times on the order of weeks to months, a substantial increase compared with that seen in animals. In slowly growing tumors, small differences in the rate liposomes accumulate in tumors, or the rate at which the drug becomes bioavailable (i.e., is released from the carrier) will have less impact on efficacy than in rapidly growing tumors,

where the overall flux of bioavailable drug through the tumor is more likely to determine treatment success. The move from animals to humans should favor SSLs, where liposomes continue to accumulate in tumors for days after administration.

3. Route of Administration. The route of administration is another important variable when considering the relative therapeutic enhancement provided by liposomes in the treatment of cancer. The i.v. route is the commonly used route of administration for liposomal drugs due primarily to its ability to reach distant sites of metastasis. Because the vasculature of even tumor metastasis requires angiogenesis and increased vascular permeability to obtain the nutrients required for its rapid growth, delivery via the i.v. route allows the drug to be simultaneously targeted to all sites of primary growth or metastases. Delivery via other routes may reduce the amount of drug that effectively reaches the tumor and thus decrease the efficacy of the drug. In a mouse J6456 lymphoma model, SSL DOX injected i.v. was shown to increase the ILS from 121 to 215 ($p < .0001$) compared with free DOX at 10 mg/kg (Table 8; Cabanes et al., 1998). When administered by i.p. injection, the life spans were identical (ILS = 60.5%) for free and L-DOX, showing that a considerable difference in effectiveness does exist depending on the site of administration.

4. Frequency of Injection. The frequency of drug injection is also likely to have an effect on the therapeutic response. CLs require high doses of both lipid (>100 mg/kg) and drug (>20 mg/kg) to obtain comparable tumor levels of drug to SSL DOX (see *IIIB. Rate and Extent of Accumulation in Tumors*; Mayer et al., 1997; Parr et al., 1997). At these high doses, repeated injections may not be possible due to nonspecific toxicities. In addition to the toxicities associated with the drug, Allen et al. (1984) have shown that multiple injections of free liposomes at high doses also cause significant toxicity to liver and spleen (see *VIA. Tolerability of Liposome Components*). The dose independence of SSL DOX allows liposomes to be administered at low doses on a schedule that varies from once a week to once every 4 weeks. This is likely necessary to keep tumor drug levels high and thus maintain a greater efficacy. If CLs are found to have similar efficacy at a single high dose, then the next step will be to show that this similarity in efficacy can be maintained after multiple injections without compromising the reduced toxicity of the drug.

5. Environment of Tumor. The site of tumor implantation is also important in determination of the relative efficacy of a liposomal drug formulation. Tumors vary in permeability, vascular density, and response to local permeability or growth factors depending on the micro-environment of the tumor (Dellian et al., 1996; Fukumura et al., 1997; Hobbs et al., 1998). Tumors implanted s.c. have different properties from those implanted in the liver or in the brain. Tumors found in the liver and

92

spleen may be more susceptible to drug delivered by CLs than tumors in other areas of the body, due to the ability of CLs to localize rapidly and preferentially in these organs. Drug released from macrophages may kill neighboring tumor cells through the bystander effect (Storm et al., 1988). This underscores the question as to why more studies have not been completed with liver metastatic models. Early studies completed with DOX loaded in PG- or PS-containing liposomes demonstrated an enhanced activity toward liver metastasis of colon carcinomas (Mayhew et al., 1987) or lymphomas (Gabizon et al., 1993) compared with free DOX. These, or similar, liposome formulations were ineffective against a variety of cancers located elsewhere in the body (Gabizon et al., 1990). The close proximity of liver metastasis to Kupffer cells responsible for liposomal drug uptake may make tumor models more sensitive to treatment with liposomal drug therapy and alter the characteristics necessary for effective treatment.

Allen et al. (1992) showed that mice injected i.v. with L1210 leukemia cells were treated more effectively after the encapsulation of ara-C in liposomes than by a 24-h infusion of free ara-C, presumably because liposomes can more efficiently deliver the drug to liver or splenic tumors. In the same study, liposomes that released ara-C at a faster rate were shown to have the greatest activity (Table 8). This same group used liposomal VCR to show that depending on the route of tumor implantation for L1210 leukemic cells, drugs may benefit from either a more rapid or a slower release from the liposomal carrier (Allen et al., 1995b). These authors concluded that peritoneal or s.c. tumors may be more amenable to slow-release systems, whereas intravascular cancers are better treated with rapid-release systems. Another rather elegant study used liposomal mitoxantrone encapsulated in different liposome formulations to show that liposomes that rapidly release their contents may be more efficacious than slow-release formulations in two such tumor models (Lim et al., 1997). L1210 and P388 cells seed preferentially in the liver and spleen when injected i.v. (Lim et al., 1997). In this study, mitoxantrone delivered via DMPC/Chol liposomes (rapid-release liposomes) were considerably more effective than when delivered via DSPC/Chol liposomes (Table 8; >590 versus 189% ILS), suggesting the rapid leakage of drug from the former carrier may facilitate the cytotoxic activity of the drug in this model. In addition, CLs (DSPC/Chol) were shown to have a similar percent ILS compared with SSL-mitoxantrone at both 10 and 20 mg/kg (Table 8; Chang et al., 1997). Although SSL-mitoxantrone may distribute to the tumors themselves to a greater extent, the high concentration of mitoxantrone in the liver and spleen, due to its rapid uptake by RES macrophages in these organs, may provide higher overall concentrations of bioavailable drug after its release from these macrophages. Unlike DOX, mitoxantrone was unable to increase the circulation lifetime

by poisoning RES macrophages. The studies suggest that distribution to the liver and spleen may favor a good therapeutic response with CLs programmed to release the encapsulated drug at a faster rate than experienced with solid DSPC/Chol or PEG-DSPE/DSPC/Chol liposomes. Although these experiments show that proximity of tumors to RES macrophages may alter the characteristics needed to engineer effective liposomal drug delivery vehicles for their treatment, it should be noted that both L1210 and P388 tumors are fast growing tumors that likely favor rapid drug release for the reasons mentioned earlier. It would be interesting for the authors to repeat these experiments with slower growing tumors to see whether a more general relationship truly exists between tumor environment and drug-release characteristics.

C. Efficacy with Nonanthracyclines

There have been several *in vivo* therapeutic efficacy studies completed with drugs other than anthracyclines. SSL-cisplatin (SPI-77) is presently being developed by Alza Corporation (Palo Alto, CA; formerly Sequus Pharmaceuticals, Inc., Menlo Park, CA). Although details are limited, SSL-cisplatin proved more efficacious than free cisplatin in both Lewis lung carcinoma and C26 colon carcinoma tumor models (Working et al., 1998; Newman et al., 1999), delaying tumor growth in one model by >30 days compared with 3.7 for free cisplatin. In another study, SSLs were used to deliver ara-C in a murine L1210/C2 leukemia model (Allen et al., 1992). Encapsulation in SSLs increased the percent ILS from 90 to 197%. The liposomes were shown to act as a slow-release depot for drug, and the increased therapeutic efficacy was thought to result primarily from this effect and not preferential accumulation in tumors. These liposomes were not optimized for long circulation and high tumor accumulation because the liposomes were prepared by reversed-phase evaporation followed by extrusion through 0.4- μ m-pore filters, giving liposomes in excess of 400 nm.

Several studies have been completed with liposomal paclitaxel (Sharma et al., 1995, 1996, 1997). In two of these studies, liposomal paclitaxel showed significant activity against human ovarian tumor xenografts, inhibiting tumor growth (Sharma et al., 1995, 1997). The liposomes in these studies incorporated paclitaxel into liposomes at low drug/lipid ratios (1:33), much lower than that used for DOX (see Table 1), likely a result of the drug being carried in the liposomal membrane and not encapsulated within its internal aqueous space, as is DOX. This is consistent with the physicochemical properties of the drugs, where hydrophobic drugs such as paclitaxel would be expected to reside in the hydrophobic membrane core and amphipathic drugs, such as DOX, can be loaded by remote-loading techniques (see *VIIA1. Drug-Loading Methods*) to high concentrations in the encapsulated aqueous space. The pharmacokinetic pa-

93

parameter associated with the drug were similar for liposomal paclitaxel and paclitaxel formulated with Cremophor EL, suggesting that liposomes in this formulation are simply acting as a drug-solubilizing agent (Sharma et al., 1997), and the drug rapidly redistributes to other hydrophobic sites after administration. The high toxicity of the Cremophor EL vehicle makes delivery by liposomal solubilization therapeutically beneficial, due to the low toxicity of the liposomal carrier (see VIA. *Tolerability of Liposome Components*). However, because this formulation acts as an extremely rapid-release liposomal carrier, it differs from slow-release systems, which selectively accumulate in tumors and release their contents on a more compatible time scale. A lipophilic cisplatin derivative, *cis*-bis-neodecanoato-*trans*-*R,R*-1,2-diaminocyclohexaneplatinum(II), has also shown some promise when incorporated into liposomal membranes (Mori et al., 1996). This prodrug reverts to the active drug after hydrolysis.

Finally, liposomal VCR has been the most thoroughly studied nonanthracycline liposome formulation in vivo. VCR is an alkaloid derived from *Vinca rosea* that has been used clinically for the treatment of various types of cancer (Carter and Livingston, 1976). Like other *Vinca* alkaloids, VCR exerts its antitumor activity by inhibiting cell division via interactions with tubulin (Owells et al., 1976). The major dose-limiting toxicities of VCR is a peripheral neurotoxicity (Rowinsky and Donehower, 1996). VCR exhibits low solubility in aqueous solution at physiological pH and relatively high permeability to membranes. Due to physicochemical similarities with DOX, methods of drug loading in liposomes developed for DOX could be efficiently used for VCR; this is discussed in more detail in VIIA1. *Drug-Loading Methods*.

For CL formulations, the exchange of DSPC ($T_m > 37^\circ\text{C}$) for eggPC ($T_m \ll 37^\circ\text{C}$) increased the circulation lifetime of VCR by $>100\%$ (Mayer et al., 1990b, 1993). Despite this advance, no significant difference in the toxicity profile were observed compared with free VCR in dogs, although a moderate reduction in toxicity could be observed in mice (Kanter et al., 1994). However, the drawback of liposomal drug retention was still to be overcome because 85 to 90% of encapsulated VCR leaked from DSPC/Chol liposomes within 24 h of i.v. administration (Boman et al., 1994). Webb et al. (1995) showed that drug retention was increased after the substitution of SM for DSPC, and this translated into a significant improvement in efficacy in BDF1 mice bearing P388 tumors (214 versus 38% ILS for SM- and DSPC-containing liposomes, respectively). This demonstrates the importance of maintaining a stable formulation for the effective use of liposomes as a drug delivery system and that a particular lipid composition is not necessarily the best for all drugs, even if both are amphipathic in nature. Each drug must be considered individually.

SSL formulations of VCR in which liposomes were coated with GM₁ showed highly efficient cures of mice with P388 leukemia (Boman et al., 1994). When PEG

was used as the stabilizing agent, liposomal VCR showed efficient antitumoral activity in s.c. and i.p. solid tumors but did not improve efficacy on rapidly growing i.v. disseminated leukemias (Allen et al., 1995b). This study also did not find a significant difference in the LD₅₀ of SSLs and free VCR in mice, with both having an LD₅₀ of ~ 2.5 mg/kg (Allen et al., 1995b). In this study, pharmacokinetic studies comparing SL- and CL-VCRs were performed using EPG/HSPC/Chol liposomes as a CL formulation. Although similar in surface charge to the SSL formulation, the presence of the exposed negative charge in EPG results in a relatively rapid clearance of the CL formulation from the circulation, essentially accentuating the differences between CLs and SSLs. Other studies have used a similar CL control with studies of L-DOX delivery (Mayhew et al., 1992; Vaage et al., 1992; Williams et al., 1993; Sakakibara et al., 1996). In our opinion, the use of small neutral CL formulations as a control when comparing SSL and CL formulations may be more accurate and informative as to the extent of the differences between optimized formulations of both SSLs and CLs. Finally, combination therapy, using SSL VCR and DOX, gave highly efficient stop growth and disappearance of mammary carcinoma MC2 bearing mice at doses for which no toxic systemic side effects could be detected (three weekly injections of 1.3 and 6 mg/kg for liposomal VCR and DOX, respectively; Vaage et al., 1993b).

D. Multidrug Resistance

Multidrug resistance can severely limit the effectiveness of some types of chemotherapy. Although drug resistance can take on many forms, one of the most common comes in the form of the multidrug resistance transporter, a membrane-spanning ATPase located in the plasma membrane and responsible for the efflux of positively charged amphipathic drugs from the cell (Endicott and Ling, 1989; Pastan and Gottesman, 1991; Gottesman and Pastan, 1993). Overexpression of P-glycoprotein (Pgp170) in tumor cells can lead to a marked decrease in sensitivity to drugs such as DOX. The delivery of L-DOX has resulted in the effective treatment of a number of chemotherapy refractory cancers both in animal models and in the clinic (Treat et al., 1990; Vaage et al., 1994b; Muggia et al., 1997; Northfelt et al., 1997). This has raised some questions as to whether L-DOX is able to sensitize tumor cells and thus partially reverse multidrug resistance.

Results in cell culture suggested that drug resistance could be partially reversed by treatment with L-DOX, although these cells were still significantly less sensitive than non-drug-resistant cell lines (Richardson and Ryman, 1982; Thierry et al., 1989; Rahman et al., 1992). The mechanism responsible for liposome-mediated partial reversal of drug resistance is not well understood. Several of the formulations used in these studies contain negatively charged phospholipid components, such as

94

phosphatidylserine (Fan et al., 1990) or cardiolipin (Thierry et al., 1989; Oudard et al., 1991; Rahman et al., 1992), which may act to directly regulate the P-glycoprotein transporter. Alternatively, they may act to provide sustained high levels of drug to the resistant cells over long periods of time (Allen, 1998), or if endocytosed, they may deliver the drug internally where it doesn't immediately reach the P-glycoprotein transporters located in the plasma membrane (Mickisch et al., 1992). Apart from cell sensitization, liposomal drug delivery may help overcome a broader range of drug resistance due to favorable pharmacokinetics. Thus, the increased response rates in these refractory patients may have to do with the increased concentration of drug that accumulates in the tumor after treatment with L-DOX. In any event, although the fact that L-DOX appears to be more effective against refractory patients is an encouraging observation, the likelihood that DOX delivered via liposomes will completely reverse multidrug resistance is low. Thus, to more effectively treat patients resistant to a particular type of chemotherapy, it will be important to combine L-DOX with other presently used chemotherapeutic agents or develop additional liposomal chemotherapeutic agents, with nonoverlapping mechanisms of drug resistance.

V. Clinical Efficacy of Liposomal Anthracyclines

There are three forms of L-DOX or daunorubicin being manufactured by different pharmaceutical companies. The properties of these formulations are given in Table 1. Doxil and DaunoXome have been approved for the treatment of AIDS-related Kaposi's sarcoma and are being evaluated in clinical trials for the treatment of a variety of cancers (Eckardt et al., 1994; Gill et al., 1995; Muggia et al., 1997; Ranson et al., 1997; Martin, 1998; Northfelt et al., 1998; Schmidt et al., 1998). The Liposome Company, Inc. has recently completed several large phase II and phase III clinical trials using EVACET (also known as TLC D-99) for the treatment of metastatic breast cancer and is now awaiting approval for the drug by the Food and Drug Administration (Harris et al., 1998; Swenson et al., 1998; Valero et al., 1999). The data obtained from trials thus far suggest that all three liposomal drugs offer a significant therapeutic benefit compared with the free drug and often compared with current chemotherapy combinations indicated for the studied form of cancer. Liposomal drugs can be therapeutically beneficial based on their ability to decrease nonspecific toxicities associated with the drug, a process referred to as toxicity buffering, or by being more efficacious against a specific type of cancer, increasing the response frequency, average time to relapse, or response duration. DaunoXome and Doxil have been shown to offer similar or greater efficacy, and decreased levels of most toxicities (see VI. *Toxicology of Liposomal Chemotherapy*; Table 9) compared with free DOX and standard

chemotherapy regimens (Gabizon et al., 1994; Gill et al., 1995, 1996; Muggia et al., 1997; Ranson et al., 1997; Martin, 1998; Northfelt et al., 1998; Stewart et al., 1998). EVACET was shown to decrease most toxicities and has a similar response frequency to DOX alone (Batist et al., 1998; Harris et al., 1998).

This review focuses primarily on PC/Chol CLs and SSLs. There have been several earlier clinical studies with alternative formulations, mostly containing small quantities of negatively charged lipids, but due to their unproven clinical utility they are not discussed further in this review. The reader is referred to the following references for information on these studies (Gabizon et al., 1989, 1991; Treat et al., 1990; Rahman et al., 1992; Gabizon, 1998). In addition, efficacy can be dependent on a variety of different patient characteristics; these include such characteristics as sex, age, prior chemotherapy treatments, degree of disease severity, presence of metastatic disease, and overall performance status. The reader is encouraged to return to the original citations to obtain information concerning these characteristics because a detailed evaluation of the complete clinical findings is beyond the scope of this review.

A. AIDS-Related Kaposi's Sarcoma

Kaposi's sarcoma is the most common neoplasm associated with AIDS (Northfelt, 1994). It is characterized by painful and disfiguring cutaneous lesions that can also have tumor-associated lymphedema. Some patients have visceral involvement, including gastrointestinal and pulmonary nodules. Single-agent standard chemotherapy is relatively ineffective. Until recently, combination regimens, including bleomycin/VCR (BV) or DOX/bleomycin/VCR (ABV), were most commonly used as a front-line defense (Gill et al., 1990, 1994). Both liposomal daunorubicin and SSL DOX have shown significant activity against Kaposi's sarcoma in a number of phase II and III clinical trials (Presant et al., 1993; Simpson et al., 1993; Gill et al., 1995, 1996; Harrison et al., 1995; Girard et al., 1996; Amantea et al., 1997; Coukell and Spencer, 1997; Northfelt et al., 1997, 1998; Stewart et al., 1998). Response rates have varied from 25 to 73.5% depending on patient characteristics and trial design. Many of the results from these trials are listed in Table 9.

Recently, Doxil (20 mg/m²) was shown to compare very favorably with either the ABV (20 mg/m²:10 mg/m²:1 mg) or BV (15 IU/m²:2 mg) regimens (Northfelt et al., 1998; Stewart et al., 1998). The overall response rate in the ABV comparison was 45.9% for Doxil and 24.8% for the ABV arm (Northfelt et al., 1998). Doxil showed an overall response rate of 58.7% compared with 23.3% for the BV arm (Stewart et al., 1998). In both of these studies, the duration of response was similar for both arms of the study. In addition to the superiority in response rate achieved with Doxil, both studies reported a significant decrease in certain toxicities and greater

TABLE 9
Phase II and III clinical studies with L-DOX

Cancer ^a	Liposome Formulation ^b	Dose	Schedule	Total Responses	Complete Response	Response Duration
		mg/m ²		%		days
Kaposi's sarcoma (n = 16) ^c	Doxil	20	×3 wk	75		98
Kaposi's sarcoma (n = 24) ^d (patients failed standard chemotherapy)	DaunoXome	40	×2 wk	54.2	8.3	84
Kaposi's sarcoma (n = 22) ^e	DaunoXome	50–60	×2 wk	55	5	
Kaposi's sarcoma (n = 34) ^f	Doxil	20	×3 wk	73.5	5.8	63
Kaposi's sarcoma (n = 29) ^g	Free DOX	20	×2 wk	48	3	105
Kaposi's sarcoma (n = 116) ^h	DaunoXome	40	×2 wk	25	2.5	175
	ABV	10, 15 U, 1 mg	×2 wk	28	0.9	168
Kaposi's sarcoma (n = 30) ⁱ	DaunoXome	40	×2 wk	73		153
Kaposi's sarcoma (n = 29) ^j	DaunoXome	40	×2 wk	45		70
Kaposi's sarcoma (n = 53) ^k (patients failed standard chemotherapy)	Doxil	20	×3 wk	36	1.8	128
Ovarian carcinoma (n = 35) ^{c, n}	Doxil	40–50	×3 wk	25.7	2.9	180
Metastatic breast carcinoma (n = 64) ^o	Doxil	45–60	3–4 wk	31	6.3	270
Kaposi's sarcoma (n = 40) ^p	Doxil	20	×3 wk	70		
Kaposi's sarcoma (n = 121) ^q	Doxil	20	×3 wk	58.7	5.8	160.4
	BV	15 IU/m ² , 2 mg	×3 wk	23.3	0.8	156.7
Kaposi's sarcoma (n = 133) ^r	Doxil	20	×2 wk	45.9	0.8	90
	ABV	20, 10, 1 mg	×2 wk	24.8		92
Metastatic breast carcinoma (n = 69) ^s	TLC D-99	75	×3 wk	33	3	
Metastatic breast carcinoma (n = 69) ^t	Free DOX	75	×3 wk	28	1	
	TLC D-99/ CPA/5-FU ^c	60, 500, 500	×3 wk ^d	68	5	

CPA, cyclophosphamide; 5-FU, 5-fluorouracil.
^a Values are number of accessible patients.
^b The composition, size, and drug/lipid ratio for DaunoXome and Doxil are listed in Table 1.
^c Patients failed to respond to platinum- and paclitaxel-based regimens.
^d Both CPA and TLC D-99 were administered on day 1, and 5-FU was administered on days 1 and 8.
^e Simpson et al. (1993).
^f Presant et al. (1993).
^g Gill et al. (1995).
^h Harrison et al. (1995).
ⁱ Gill et al. (1991).
^j Gill et al. (1996).
^k Girard et al. (1996).
^l Uthayakumar et al. (1996).
^m Northfelt et al. (1997).
ⁿ Muggia et al. (1997).
^o Ranson et al. (1997).
^p Amantea et al. (1997).
^q Stewart et al. (1998).
^r Northfelt et al. (1998).
^s Harris et al. (1998).
^t Valero et al. (1999).

patient compliance with the liposomal drug. Similar to patients receiving daunorubicin (Gill et al., 1996), patients receiving Doxil developed more opportunistic infections than those receiving the standard chemotherapy regimens (Stewart et al., 1998). The toxicological advantages are described in more detail in VI. *Toxicology of Liposomal Chemotherapy*.

DaunoXome was also compared with the ABV regimen in a large randomized trial (232 patients; Gill et al., 1996). DaunoXome (40 mg/m²) was found to have an overall response rate of 25 compared with 28% for the ABV arm (10 mg/m²:15 U:1 mg) and an almost identical response duration (175 versus 168 days). Although DaunoXome did not appear to have any advantage over the ABV regimen in terms of response rate, patients receiving DaunoXome experienced less alopecia (8 versus 36%) and neuropathy (13 versus 41%) but a slightly

greater incidence of opportunistic infections. Other differences in toxicities observed were not statistically significant.

An indirect comparison of Doxil and DaunoXome suggests that Doxil is significantly more active against Kaposi's sarcoma than DaunoXome. Although DaunoXome is comparable in response rate to the ABV regimen, Doxil shows a considerable increase in response rate compared with both ABV and BV regimens. The response duration was shorter for the Doxil study completed by Stewart et al. (1998). However, the duration of response was likely underestimated due to the inclusion of stable disease as an endpoint for response and the restriction in this study of a maximum number of six cycles of drug therapy (Bennett et al., 1998). Toxicities also appeared to favor Doxil over DaunoXome. This is not surprising, considering the DaunoXome dose was

twice that of Doxil (40 versus 20 mg/m²) and injections (every 2 weeks versus every 3 weeks) of daunorubicin were given at a higher frequency. In the treatment of Kaposi's sarcoma at least, SSLs appear to be far more efficient drug-delivery vehicles than CLs. Although DOX and DaunoXome are very similar in mechanism of action, pharmacokinetic parameters, and toxicological profiles, the difference in the encapsulated drug precludes us from making any definitive statements concerning the superiority of SSLs based on these observations. In addition, the weak immune system and increased susceptibility to opportunistic infections of AIDS patients prevent escalation of the daunorubicin dose to dosages that may allow for longer circulation lifetimes of CLs.

B. Treatment of Breast and Ovarian Carcinomas

L-DOX was suggested to have greater activity against breast and ovarian cancers, which are typically only moderately sensitive to DOX, due to the enhanced tumor accumulation of the drug. In patients with advanced ovarian cancer, who were refractory toward paclitaxel- and platinum-based regimens, Doxil was shown to have a response rate of 25.7% and a response duration of 180 days (Table 9; Muggia et al., 1997). This favorable response rate was significantly greater than that for free DOX in similar patients (<10%; Young et al., 1981), and there were fewer problems with patient compliance due to reduced toxicities (Alberts and Garcia, 1997).

Two studies have been completed with SSL DOX (Doxil) and CL DOX (TLC D-99) in metastatic breast cancer patients (Table 9; Ranson et al., 1997; Harris et al., 1998). Response rates were similar in the two studies (31% for Doxil and 33% for TLC D-99). The response rate of free DOX was 29% in the randomized phase III study comparing TLC D-99 and free DOX (both at 75 mg/m²). This response rate for free DOX was similar to that described previously in similar patients (Young et al., 1981). It will be interesting to do a more detailed comparison of Doxil and TLC D-99 when the full results from the clinical trials with TLC D-99 are published. Pharmacokinetic and tumor accumulation considerations would theoretically favor Doxil. However, TLC D-99 is administered at a dose of 75 mg/m² compared with 45 mg/m² for Doxil (both are administered every 3 weeks). Thus, the higher dose and increased rate of drug release from the carrier at the tumor may contribute to its similar activity. The principal reason for the decreased dose in the case of Doxil is the high incidence of hand and foot (H-F) syndrome associated with Doxil at elevated doses (60 mg/m²). In both studies with ovarian and breast cancers, H-F syndrome was dose limiting (Muggia et al., 1997; Ranson et al., 1997). H-F syndrome is characterized by dermal lesions on both the palms of the hand and soles of the feet and is also found in patients receiving prolonged infusions of some chemotherapeutic agents. This toxicity is described in more detail in VI. *Toxicology of Liposomal Chemotherapy*. If

the severity of H-F syndrome can be controlled by means other than dose reduction, then the administration of a similar dose will almost certainly give rise to an enhanced therapeutic effect. Mucositis, another significant toxicity in patients treated with Doxil, causing dose modification in some patients (Muggia et al., 1997; Ranson et al., 1997). The plasma AUC of TLC D-99 at elevated doses (Cowens et al., 1993; Embree et al., 1993) is far below the plasma AUC of Doxil at 25 or 50 mg/kg DOX (Table 4; Gabizon et al., 1994). These results emphasize the fact that the long circulating property of SSLs is not the only factor responsible for increased levels of efficacy with liposomal drugs. A mechanism by which DOX is at least partially released from the liposome in the circulation, avoiding the high peak levels of drug responsible for some types of toxicities, is most likely responsible for the increased therapeutic effect of TLC D-99. Thus, the altered toxicity profile of TLC D-99 allows the dose to be escalated to a point at which the efficacy is comparable to Doxil. The long-term effects of this dose escalation on the cumulative cardiotoxicity of DOX, compared with Doxil, are unknown. However, recent results did show a significant reduction in the cardiotoxicity when TLC D-99 was compared with free DOX (Batist et al., 1998). The reader is also referred to other reviews on the clinical activity of both Doxil (Gabizon, 1994, 1998; Coukell and Spencer, 1997; Muggia, 1997; Martin, 1998) and DaunoXome (Forssen and Ross, 1994; Schmidt et al., 1998) for additional analysis of the clinical data.

VI. Toxicology of Liposomal Chemotherapy

A. Tolerability of Liposome Components

"Empty" CLs or SSLs are usually considered nontoxic unless administered at very high doses (Storm et al., 1993; Working and Dayan, 1996). This is one of the characteristics that makes them attractive as a drug delivery vehicle and is not surprising because they are typically composed of natural lipids and small amounts of well-tolerated synthetic stabilizers (PEG-DSPE). At very high doses (multiple injections at a dose of ≥ 100 mg/kg lipid), liposomes have been shown to result in an impairment of RES function, hepatomegaly, granulomas, and splenomegaly (Allen et al., 1984, 1987; Allen and Smuckler, 1985; Storm et al., 1993). However, these effects are usually considered irrelevant due to the dose-limiting effects of the encapsulated drug. PEG is considered nontoxic at the degree of polymerization (1900–5000 Da) used to prepare SSLs and is excreted unmetabolized in the urine (Carpenter et al., 1971). Toxicity studies completed with PEG-DSPE micelles at a concentration 30-fold greater than that applied in a standard dose of SSL DOX demonstrated no deaths or clinical signs of toxicity (Working and Dayan, 1996). In addition, the various types of toxicities observed with SSL DOX treatment in animals are consistent with

those for free DOX, although at significantly reduced levels (Working and Dayan, 1996). Although for SSL DOX these results suggest that the lipid components have little if any effect on the overall toxicity profile, the picture for CLs is less clear. SSL DOX is typically administered at a total lipid dose of 8 to 54 mg/kg (1–6 mg/kg DOX) in rats or mice, with subsequent injections occurring between 3 days and 4 weeks. However, using CL a number of recent studies have used a single bolus injection of 100 to 300 mg/kg total lipid and 20 to 55 mg/kg DOX (Mayer et al., 1989, 1997; Parr et al., 1997). One of these studies showed minimal improvements in therapeutic efficacy over free DOX (Mayer et al., 1997). If multiple injections are to be used, then the toxicity of the lipid component may eventually become important; this will require further study.

In addition, an increasing lipid dose has been shown to deplete plasma of various proteins (Senior, 1987; Oja et al., 1996). Both the quantities and types of protein bound to liposomes are dependent on the lipid composition (Senior, 1987; Oja et al., 1996). Although the identity and significance of all the depleted proteins are unclear, it is possible that their loss will result in a disruption of normal homeostasis. Although toxicities related specifically to high lipid doses might prove to be relevant in some situations, in most instances the toxicity of the encapsulated drug is considered to be far more limiting.

B. Toxicities Associated with Free Drug

For the treatment of cancer, liposomal drug delivery has primarily involved the use of anthracyclines such as DOX or daunorubicin (Gabizon, 1994; Papahadjopoulos and Gabizon, 1995; Martin, 1998) or *Vinca* alkaloids such as VCR (Vaage et al., 1993b; Allen et al., 1995b; Webb et al., 1995). A few studies have chosen alternative drugs such as paclitaxel (Sharma et al., 1996, 1997), ara-C (Allen et al., 1992), methotrexate (Matthay et al., 1989; Jones and Hudson, 1993), or cisplatin derivatives (Perez-Soler et al., 1990; Mori et al., 1996), but preclinical toxicological results with these drugs are limited at the present time. Because the toxicity profile of a liposomal drug is primarily dependent on the encapsulated drug rather than the lipids, it is first important to understand the toxicities associated with the free drug. With free DOX, myelosuppression is considered dose limiting (Legha et al., 1987; Speth et al., 1988; Doroshaw, 1996). However, the therapy-limiting toxicity is considered to be cardiotoxicity and results after a high cumulative dose of the drug (Von Hoff et al., 1979; Doroshaw, 1996). High peak levels of DOX in the plasma have been shown to correlate with an increased risk of cardiac toxicity. When delivered by bolus injection, the most commonly used total cumulative dose of DOX is 450 to 500 mg/m², where the risk of cardiac toxicity is between 1 and 10% (Doroshaw, 1996). There is significant evidence that DOX delivered by continuous infu-

sion displays similar efficacy but reduced toxicity, with cumulative doses up to 1100 mg/m² delivered without signs of cardiac toxicity (Legha et al., 1987; Hortobagyi et al., 1989). Although drug-induced congestive heart failure is the most significant concern due to its very poor prognosis, it is lethal in 60% of patients (Von Hoff et al., 1979); there are several other important toxicities associated with anthracyclines.

DOX-induced myelosuppression and alopecia are also delayed toxicities but are independent of the rate of drug administration (Speth et al., 1988; Doroshaw, 1996). Recent work has shown that myelosuppression can be partially combated with the use of colony-stimulating factors (granulocyte-CSF and granulocyte-macrophage-CSF), which stimulate activation and proliferation of hematopoietic cells (Vose and Armitage, 1995; Petros and Peters, 1996; Henry, 1997; Lieschke et al., 1997; Nemunaitis, 1997; Clemons et al., 1998). These growth factors are currently being used to allow dose intensification of conventional chemotherapy by effectively reducing one of the most common dose-limiting toxicities. Another toxicity associated with anthracyclines is a severe necrosis of the skin adjacent to the site of injection due to injection related drug extravasation (Von Hoff et al., 1979; Doroshaw, 1996). The resulting lesions are difficult to treat, and extreme care should be taken to prevent infection at these sites. Nausea, vomiting, and mucositis, including gastrointestinal toxicity and stomatitis, are additional toxicities resulting from chemotherapy with anthracyclines (Speth et al., 1988; Doroshaw, 1996). Finally, H-F syndrome, which is characterized by severe dermal lesions on the soles of the feet and the palms of the hand, is seen in patients receiving long-term continuous infusions of free DOX (Lokich and Moore, 1984; Vogelzang and Ratain, 1985). As discussed in *Effect of Liposome Encapsulation on Toxicity Profile*, although encapsulation of anthracyclines in liposomes does not alter the types of toxicities observed, the severity can be significantly reduced due to the resulting alterations in the pharmacokinetics and tissue distribution of the drug. In addition to these alterations, toxicity buffering is also a result of the relatively slow release of the DOX from the liposome, giving rise to relatively low peak levels of the free drug in the circulation.

C. Effect of Liposome Encapsulation on Toxicity Profile

1. Cardiotoxicity. The toxicity profile for L-DOX is altered due to the changes in pharmacokinetics described previously in *II. Pharmacokinetics and Biodistribution of Liposomes and Liposomal Drug*. Drug encapsulation in either SSLs or CLs eliminated or significantly reduced the amount of cardiotoxicity compared with the free drug (Table 10; Olson et al., 1982; Herman et al., 1983; Balazsovits et al., 1989; Working and Dayan, 1996; Working et al., 1999). This is thought to be due to the inability of liposomes to cross the endothelial cell barrier in the heart and the low bioavailabil-

TABLE 10
Toxicities associated with free and L-DOX

Toxicity	Effect of Liposome Encapsulation
Cardiac toxicity	Reduced or not observed
Myelosuppression	Reduced (to a greater extent with SSLs)
Mucositis	Slightly increased with Doxil
Alopecia	Reduced or not observed
Severe local tissue necrosis after drug extravasation	Reduced
Nausea and vomiting	Reduced or not observed
H-F syndrome	Observed with Doxil or with continuous infusion of free DOX

ity of the free drug due to its encapsulation in liposomes (Gabizon, 1994, 1997). Indeed, in tissue sections of cardiac muscle, liposomes are found exclusively in the blood vessels and not in the muscle fibers (Working et al., 1994), suggesting that most of the drug is not bioavailable in the myocardium. A comparison of cardiotoxicity in beagle dogs showed a higher incidence of cardiomyopathy and vacuolization of cardiac muscle fibers when administered as the free drug compared with TLC D-99, confirming a protective effect of liposomal encapsulation on cardiotoxicity (Kanter et al., 1993). A similar cardioprotective effect was seen with SSL DOX in both rabbits and beagle dogs (Working and Dayan, 1996; Working et al., 1999). Compared with the considerable damage observed to the myocardium of beagle dogs treated with free DOX (cumulative dose of 10 mg/kg), no histological indication of cardiotoxicity was seen when treated with the same cumulative dose of SSL DOX (Working et al., 1999).

Clinical data are limited due to the relatively low cumulative dose of DOX delivered in most studies. In one phase I study, four patients received a total cumulative dose of >500 mg/m². There was no clinical cardiotoxicity or decrease in the resting left ventricular ejection fraction in any of these patients (Casper et al., 1997). In a recent study with TLC D-99 for the treatment of metastatic breast cancer (75 mg/m² every 3 weeks), 16% of patients on TLC D-99 had a cardiac event (either a problem with the electrocardiogram or a decrease in left ventricular ejection fraction), but there were no instances of congestive heart failure, compared with 25% of patients with cardiac events and three instances of congestive heart failure for patients receiving free DOX (Batist et al., 1998). Although significant compared with free DOX, this reduction in cardiotoxicity is not as great as expected for stable liposomes that show reduced drug leakage in the plasma. Patients with a cumulative dose of liposomal daunorubicin between 600 and 1000 mg/m², including one patient with a cumulative dose of >1000 mg/m², showed no evidence of cardiotoxicity (Gill et al., 1995). Recently, endomyocardial biopsy was used to demonstrate significantly less DOX-induced cardiac damage in patients receiving SSL DOX

(cumulative doses of 440–840 mg/m²) compared with two earlier studies with free DOX (cumulative doses of 174–671 mg/m²; Berry et al., 1998). In another study, patients receiving 40 to 50 mg/m² Doxil every 3 to 4 weeks for the treatment of refractory ovarian cancer showed no decrease in the left ventricular ejection fraction (Muggia et al., 1997); this included nine patients who received >550 mg/m². A similar response was seen with breast cancer patients treated with Doxil (Ranson et al., 1997), with only 1 of 71 patients showing a decrease in the ejection fraction of >10%. It should be noted that the average administered dose in this final study was only 179 mg/m² (45–399 mg/m²), which is well below the recommended maximum cumulative dose for free DOX. From these limited studies, it appears that Doxil, TLC D-99, and DaunoXome are significantly less cardiotoxic than the free drugs. However, the data available thus far are unable to indicate conclusively a benefit for one liposomal formulation over another. A more thorough study of the cardiotoxicity at higher cumulative doses is needed to establish a new recommended cumulative dose for liposomal formulations.

2. *Vesicant Properties.* The vesicant effect seen with free DOX is also markedly reduced by encapsulation in eggPC/Chol- (Balazsovits et al., 1989) or HSPC- (Gabizon et al., 1993; Oussoren et al., 1998) containing liposomes. Mice injected s.c. with free DOX showed severe necrosis, acanthosis, edema, and inflammatory infiltration when free DOX was injected, whereas only a mild edema and inflammatory infiltration were observed with SSL DOX (Gabizon et al., 1993). This suggests liposomes are able to effectively protect the skin from vesicant damage due to DOX until the carrier can be drained from the injection site by the lymph and the blood.

3. *Myelosuppression.* The toxicity of DOX-loaded liposomes is extremely sensitive to the rate of drug leakage from the liposome in the circulation, and thus the lipid composition (Mayer et al., 1989; Bally et al., 1990a; Oussoren et al., 1998). Liposomes composed of Chol and high-phase transition phospholipids such as DSPC or SM have rigid membranes and retain the drug well in the circulation. However, when DSPC is replaced by the more fluid eggPC, DOX is able to more readily transverse the membrane and be released into the general circulation (Hwang, 1987; Mayer et al., 1989; Gabizon et al., 1993). The free drug is generally considered responsible for most types of toxicity. Indeed, the calculated LD₅₀ decreased almost 3-fold from 161 to 57 mg/kg DOX when going from DSPC/Chol (55:45) to eggPC/Chol (55:45) liposomes (Mayer et al., 1989). It should be noted, however, that the LD₅₀ for eggPC/Chol (55:45) liposomes was still greater than two times that for free DOX, indicating that even encapsulation in “leaky” liposomes provides some degree of toxicity buffering. The effect of DOX on myelosuppression was also greater when encapsulated in eggPC/Chol liposomes compared with in

DSPC/Chol liposomes (Bally et al., 1990a). The decrease and recovery in the number of bone marrow cells (90% reduction on day 3) and in spleen weight were similar for free DOX and DOX-loaded eggPC/Chol liposomes (100 nm) administered at a dose of 20 mg/kg. DOX-loaded DSPC/Chol liposomes depressed the number of bone marrow cells by only 40% and were around normal levels on day 7. The effect on spleen weight was less severe, causing a 23% reduction on day 1 that returned to normal by day 14, compared with a 50% reduction for free DOX or DOX-loaded eggPC/Chol liposomes. An unusual finding was that DOX-loaded DSPC/Chol liposomes caused extended reductions in peripheral white blood cell counts (leukopenia) that were ~50% below initial values on day 14, a time at which mice treated with eggPC/Chol L-DOX had nearly returned to normal. From this study, eggPC/Chol L-DOX showed little improvement over free DOX in terms of myelosuppression. A similar study in dogs showed that free drug and TLC D-99 resulted in similar levels of myelosuppression (Kanter et al., 1993). This translated into the clinic where neutropenia and leukopenia were the most common adverse effects for both DaunoXome and TLC D-99 (Conley et al., 1993; Gill et al., 1996) and was dose limiting for TLC D-99 (Conley et al., 1993; Cowens et al., 1993; Casper et al., 1997). Myelosuppression could be partially controlled by the addition of colony-stimulating factors for bone marrow support (Casper et al., 1997).

4. *Nausea, Vomiting, and Alopecia.* Alopecia, mucositis, nausea, and vomiting were observed at all doses (75–105 mg/m²) of TLC D-99 (Casper et al., 1997) but were less severe than free DOX when compared at a dose of 75 mg/m² (Harris et al., 1998). Although grade 3 and 4 alopecia, nausea, and vomiting were observed for DaunoXome delivered at 40 mg/m² every 2 weeks, it was usually <2 to 3%. Alopecia, nausea, and vomiting was rare in patients treated with Doxil at a concentration of 45 to 60 mg/m² (Muggia et al., 1997; Ranson et al., 1997). Myelosuppression was mild, occurring in most cycles at a grade of 2 or less (Ranson et al., 1997). Toxicity benefits were also observed in patients treated for AIDS-related Kaposi's sarcoma, where the combination of free Adriamycin, bleomycin, and VCR produced more instances and greater severity of most toxicities than Doxil (Northfelt et al., 1998).

5. *Hand and Foot Syndrome (Palmar-Plantar Erythrodysesthesia Syndrome).* One of the most significant toxicities for SSL DOX is a condition consisting of dermal lesions referred to as H-F syndrome (Gordon et al., 1995; Uziely et al., 1995; Amantea et al., 1999). This same condition was previously described in patients receiving long continuous infusions of 5-fluorouracil, DOX, or vinorelbine (Lokich and Moore, 1984; Vogelzang and Ratain, 1985; Hoff et al., 1998) but is not observed in patients receiving chemotherapy by bolus injection. This particular toxicity, also called palmar-plantar erythrodysesthesia syndrome, is most likely a toxic effect of

DOX on the rapidly dividing keratinocytes. Histological sections of the affected areas showed significant hyperkeratosis and parakeratosis in the stratum corneum of the epidermis (Gordon et al., 1995). Interruption of chemotherapy results in desquamation and reepithelialization of the affected areas and was complete within 3 to 7 weeks after the discontinuation of treatment (Gordon et al., 1995; Uziely et al., 1995). Interestingly, when free DOX is delivered via continuous infusion, the reversal of this syndrome was complete within 1 to 2 weeks after the discontinuation of treatment (Vogelzang and Ratain, 1985). There has been little success in reversing this toxicity without discontinuation of treatment. Discontinuation of treatment often leads to relapse of the cancer (Uziely et al., 1995). One promising strategy for the treatment of H-F syndrome without interruption of treatment involves the use of the strong reductant DHM3, which converts anthracyclines to the inactive 7-deoxyglycone (Averbuch et al., 1985, 1986, 1988; Dorr, 1990). This agent was studied because of its capacity to reduce the vesicant effect observed with free DOX at the site of injection, but it may be useful in treating this syndrome as well. In other studies, the oral administration of pyridoxine (vitamin B₆) was shown to reduce the severity of H-F syndrome, resulting in fewer delays or discontinuations of treatment (Vukelja et al., 1989, 1993; Fabian et al., 1990; Vail et al., 1998). Topical dimethyl sulfoxide may be another method of reducing skin toxicity resulting from treatment with SSL DOX. It was previously shown to reduce vesicant damage in patients administered free DOX (Olver et al., 1988; Bertelli et al., 1995). The use of peripheral vasoconstrictors, such as ergotamine, may also potentially reduce the severity of H-F syndrome in patients treated with SSL DOX. Ergotamine is presently used in the treatment of migraine headaches (Perrin, 1995; Silberstein, 1997), but its ability to constrict blood vessels in peripheral tissues may restrict blood flow, and thus the accumulation of SSL DOX in the skin of the hands and feet. The choice and subsequent modification of the dose intensity appear to be the current anecdotal strategy for reducing the seriousness of this toxicity (Uziely et al., 1995; Ranson et al., 1997). The further study and use of compounds such as DHM3, pyridoxine, ergotamine, and dimethyl sulfoxide in combination with SSL DOX will potentially allow for dose intensification and increased antitumor efficacy.

It is possible that liposome-mediated drug delivery results in a slow-release mechanism of DOX into the tissues that mimics the effect seen with continuous infusion chemotherapy. Drug delivered by bolus injection may saturate mechanisms responsible for its uptake by the skin, where a majority of the drug can be removed from the circulation by alternative pathways: a wide tissue distribution and rapid excretion in the bile. A continuous infusion of free drug or slow release of DOX from SSL DOX results in lower peak levels of the drug in

the circulation and possibly increased uptake by the skin. Alternatively, several studies have shown that long-circulating liposomes accumulate to a limited degree in skin (Gabizon et al., 1990, 1997), where slow release in the near vicinity of keratinocytes can give rise to their toxicity. Although H-F syndrome is a serious concern, the dosage and treatment schedule can be adjusted to minimize this toxicity and still maintain a high antitumor efficacy compared with standard chemotherapy regimens (45 mg/m² every 3 weeks; Ranson et al., 1997).

6. Mucositis. Mucositis was also slightly increased in patients treated with SSL DOX (Gabizon et al., 1994; Uziely et al., 1995; Alberts and Garcia, 1997). Like H-F syndrome, mucositis is increased by prolonged infusion of free DOX, so its increased incidence is not surprising (Alberts and Garcia, 1997). Stomatitis was dose limiting at single doses of >70 mg/m² in one study (Uziely et al., 1995), but at the doses used presently (45 mg/m² every 3 weeks), it is mild. Although most toxicities are greatly reduced with SSL DOX, those toxicities normally associated with prolonged infusions of the free drug seem to manifest themselves in SSL DOX, most likely as a result of the long circulation lifetimes.

7. Reticuloendothelial System Impairment and Opportunistic Infections. Despite claims to the contrary (Mayer et al., 1998), several studies have shown that both SSL and CL DOX can impair the phagocytic activity of liver macrophages (Kupffer cells), as well as significantly deplete their total numbers in rats, with the use of clinically relevant doses of L-DOX (Allen et al., 1984; Daemen et al., 1995, 1997). Mayer et al. (1998) referenced a dose of liposomal DOX (2 mg/kg) relevant in some studies with SSL DOX but <10-fold the dose of CL DOX used in studies from their laboratory (Mayer et al., 1997; Parr et al., 1997). Thus, at clinically relevant concentrations of CL DOX, macrophage toxicity and depletion do appear to be serious concerns. This is not surprising because the primary route of clearance for liposomal DOX of either form is via splenic or liver macrophages (Hwang, 1987; Senior, 1987), whereas free DOX is primarily excreted in the bile (Benjamin et al., 1974; Speth et al., 1988). Thus, their preferential accumulation at these sites might be expected to result in a toxic effect. RES impairment is a serious concern, especially in immunocompromised patients, where it is the first-line defense against bacterial or fungal infections. In addition to the increased susceptibility to infection (Qian et al., 1994), macrophage toxicity has been shown to result in a decreased ability to fight metastatic growth (Levy and Wheelock, 1974; Roh et al., 1992; Heuff et al., 1993). Although in theory this is a logical concern, there are at least two studies that suggest that L-DOX may enhance the efficacy in the treatment of liver metastatic cells due to its increased localization in the liver (Gabizon et al., 1983; Mayhew et al., 1987).

Male Wag/Rij or female R-strain albino rats treated with DOX-loaded DSPC/Chol (55:45) liposomes at a dose of 5 mg/kg DOX showed a reduced ability to phagocytose unloaded liposomes (70% after a single injection or 90% after three injections) or *Klebsiella pneumoniae* bacteria (Daemen et al., 1995). A decrease in the total number of macrophages by 56 or 85% for rats treated with two or three injections of L-DOX, respectively, was also observed. Placebo liposomes (25 μ mol lipid/kg) or free DOX (5 mg/kg) had no measurable effect on phagocytic activity, indicating this toxicity was carrier dependent. The dose of L-DOX used to produce a therapeutic effect with DSPC/Chol liposomes has been from 20 to 55 mg/kg DOX in rats (Mayer et al., 1997; Parr et al., 1997), or 4- to 11-fold greater than the dose used in these studies (and 10-fold greater than the dose quoted by Mayer et al., 1998). The effects at 20 to 55 mg/kg DOX would be expected to be even greater and thus significantly inhibit RES function in both liver and spleen. The saturable pharmacokinetics, shown in *II. Pharmacokinetics and Biodistribution of Liposomes and Liposomal Drug* to be responsible for increased circulation lifetimes of high concentrations of CLs, results from a partial toxicity to RES macrophages. In these studies, liposomes of identical composition and size, but lacking DOX, had more rapid clearance rates, indicating the toxicity was due to DOX (Mayer et al., 1998).

Two studies have been carried out with SSL DOX (Daemen et al., 1997; Storm et al., 1998). The first study used doses and schedules similar to those chosen for the study with CL DOX mentioned earlier (Daemen et al., 1997). Male Wag/Rij rats received a single or two or three injections, at 3-day intervals, of 5 mg/kg SSL DOX. The maximum tolerated dose for SSL DOX in humans is 60 mg/m² DOX at 4-week intervals for patients with Kaposi's sarcoma (Uziely et al., 1995; Coukell and Spencer, 1997), which translates to ~1.5 mg/kg DOX in rats.

It should be noted that the liposomes used in the studies with a CL formulation were ~200 nm, almost twice that of optimized formulations (Daemen et al., 1995). The lipid composition of a second study, eggPC/Chol/PEG-DSPE (55:45:5), raises questions about the bioavailability of the drug due to the source of phosphatidylcholine chosen (Daemen et al., 1997). Although these studies suggest macrophage toxicity may be a serious concern, due to the size dependence of clearance for CLs (Hwang, 1987; Senior, 1987) and the increased bioavailability of DOX from egg PC-containing SSL DOX (Gabizon et al., 1993), a study comparing the effects of optimized L-DOX formulations on splenic and liver macrophages toxicity is warranted.

Clinically, CL daunorubicin (DaunoXome) is only indicated for advanced HIV-related Kaposi's sarcoma due to the short time until observance of opportunistic infections in treated patients compared with controls (145 versus 371 days; White, 1997). In a second case, SSL DOX was responsible for one case of fatal hepatic failure

in an AIDS patient with impaired liver function (Hengge et al., 1993). Both of these cases suggest that toxicity to liver macrophages impairs bacterial or viral clearance. Although immunocompromised patients represent a special class of patients, not necessarily representative of the majority of cancer patients, the injected dose used in these studies was several fold-less than the dose needed to obtain the desired RES blockade effect required by Mayer et al. (1998). At these levels, even healthy patients may experience liver toxicity. Although this, of course, is speculative, it does suggest the need for additional toxicity studies in animals, specifically looking at the effect of L-DOX administration on RES and liver function. These studies may be more informative if formulations were optimized for size and composition of both CL and SSL DOX and at a range of relevant doses.

D. Final Comparisons of Conventional and Sterically Stabilized Liposomes

An additional problem when using CLs is the difficulty in predicting the effects of drug encapsulation on the different types of toxicity in humans based on earlier animal studies. As was mentioned previously, one of the most important advantages of steric stabilization is the dose independence provided by this particular carrier. Differences in serum opsonins between species, and thus rates of uptake by various tissues, may be more radically affected by CLs. Differences in pharmacokinetic parameters and toxicity profiles may differ not only between different animal species but also between different strains of the same animal model. Scid and immunodeficient nude mice are commonly used in antitumor efficacy studies. Scid mice have less efficient scavenging systems than normal mice and deficient DNA repair mechanisms. The high concentrations of L-DOX required to maintain long circulation times with CLs may prove especially toxic to these strains of mice and preclude their use. Even with SSLs, the dose must be scaled down significantly (1–2 mg/kg) to prevent significant drug-induced toxicities (Williams et al., 1993). This is possible with the dose-independent pharmacokinetics of SSL DOX but may not be possible with CL L-DOX.

The toxicology studies reviewed here show that liposome encapsulation offers significant protection against many common toxicities of anticancer drugs (Table 10). The degree of protection is higher when the liposomes leak their contents less readily. H-F syndrome and mucositis appear to be the most significant obstacle preventing dose escalation of the long-circulating Doxil. In animals, the dose of DOX being used in CLs (20 mg/kg) is between 3 and 20 times that being used with SSLs (1–6 mg/kg). Although some nonspecific toxicities may be slightly reduced for CL DOX (DSPC/Chol) compared with SSL DOX, DOX is unlikely to be tolerated at even three times the dose of SSL DOX in humans. The resulting increased levels of toxicity observed at the doses required to obtain long circulation will likely prevent

their use in multidose regimens at these concentrations. It is unknown whether the drug-induced RES blockade required to obtain long circulation times will be maintained at schedules requiring lower doses and multiple injections.

In any event, independent of the liposome formulation, entrapment of DOX inside liposomes significantly alters the toxicity profile of DOX. This altered profile makes the liposomal drugs more tolerable, preventing patients from leaving treatments due to unbearable toxicities. Another related issue is the increased quality of life. Although alopecia, nausea, and vomiting are severe with many standard chemotherapeutic agents, they are rare or significantly reduced among patients treated with L-DOX. The toxicity buffering provided by liposomes is a considerable improvement in itself over standard chemotherapy.

VII. Stability in Plasma and Storage

The stability of drug-loaded liposomes over time is an important concern in pharmaceutical formulations. Stability can refer to several different aspects of a liposomal drug formulation: chemical stability of both drug and lipid components, colloidal stability, and drug retention. For applications of liposomes where specific delivery of liposome-associated drug to solid tumors is desired, liposomes must substantially retain their contents while in the circulation (Senior, 1987). In other applications, such as the delivery of photosensitizers to tumors in photodynamic therapy, liposome-associated photosensitizers immediately redistribute to other hydrophobic sites, such as plasma lipoproteins in the circulation, which in turn accumulate in tumors (Allison et al., 1990; Reddi, 1997). Various factors can affect the relative stabilities of such preparations in the presence of plasma. This plasma-induced destabilization is exquisitely sensitive to the lipid composition of the liposome. To be more attractive for pharmaceutical development, liposomal drug formulations also must be stable during prolonged storage. Liposomes have either been stored preloaded with DOX, as is the case for PEG-coated liposomes, or as “empty” liposomes that are loaded by a pH gradient immediately before injection (Madden et al., 1990; Haran et al., 1993; Lasic et al., 1995; Cullis et al., 1997). Compositions containing more fluid lipid components, such as eggPC, require remote-loading just before injection, due to a high level of leakage during storage.

A. Physical Stability of Liposomal Drug Formulations

For amphipathic drugs that can readily cross membranes, there are a variety of factors that can influence the stability of a liposomal formulation. The presence of Chol and saturated phospholipids appear to be the most important factors for reducing membrane permeability of these drugs (Bally et al., 1990b; Gabizon et al., 1993). Other factors, such as the drug-loading method, which

can result in internal concentrations of the drug exceeding the aqueous solubility of the free drug, also act to stabilize the formulation.

Cholesterol appears to be especially important in stabilization of liposomes to the effects of plasma components such as HDL (Mayhew et al., 1979; Allen and Cleland, 1980). In addition, several early studies have indicated that Chol was essential for controlling the permeability properties of membranes to ions or small molecules (Papahadjopoulos et al., 1972, 1973a,b). The presence of Chol in a 1:1 ratio with PG and PC was shown to reduce the amount of ara-C leakage observed in the presence of serum from 88 to 28% after 24 h in one study (Mayhew et al., 1979). HDL has been shown to destabilize pure PC liposomes by catalyzing the net exchange of PC from liposomes to HDL particles (Scherphof et al., 1978; Chobanian et al., 1979; Damen et al., 1980). The addition of Chol to liposome formulations results in an increase in plasma stability, inhibiting transfer of lipid components to plasma lipoproteins (Allen, 1981; Damen et al., 1981).

In vitro stability studies using human plasma or serum have some inherent limitations. Plasma is often isolated in the presence of calcium chelators to prevent blood coagulation and results in some uncertainty because calcium can often modulate interactions of proteins with membrane surfaces and, with some formulations, interact with membranes directly, causing destabilization. Although plasma can be isolated in the presence of heparin, heparin may also affect protein interactions with membranes. In addition, there is considerable interpatient variability in the levels of plasma proteins and lipoproteins, adding another level of complexity to these in vitro studies. The most relevant studies of liposome stability are completed in vivo, simultaneously monitoring the concentrations of both the encapsulated drug and a nonexchangeable lipid marker. With chemotherapeutic drugs, such as DOX, that are removed rapidly from the circulation, the drug/lipid ratio becomes an excellent measure of the stability of the formulation. Measurement of free and L-DOX after cation exchange or size-exclusion chromatography is not reflective of liposome stability because the free drug is rapidly removed from the circulation, resulting in an underestimation of the amount of drug leakage.

The in vivo leakage of DOX from DSPC/Chol (55:45) and eggPC/Chol (55:45) was measured in mice by following the clearance of a lipid label [³H]cholesterylhexadecyl ether and DOX from the circulation (Bally et al., 1990b; Mayer et al., 1998). Although the DSPC/Chol formulation proved relatively stable, releasing <10% of the encapsulated DOX in 24 h, the eggPC/Chol formulation released almost 50% of its DOX within 1 h and ~70% by 4 h. A PEG-DSPE/HSPC/Chol DOX formulation appears to have even greater stability with little apparent leakage in the first 24 h and <10% leakage up to 72 h after injection (Gabizon et al., 1993). It should be

noted that in the first study, DOX was loaded into liposomes by the pH gradient method of Mayer, Cullis, and coworkers, whereas in the second study, DOX was loaded according to the ammonium sulfate method. These loading methods are discussed in more detail in VIIA1. *Drug-Loading Methods*. However, differences in the loading methods, including a more rapid dissipation of the pH gradient, in the case of first method, and the formation of a stable drug-sulfate gel in the liposome interior of liposomes loaded using the ammonium sulfate method (Lasic et al., 1992a, 1995), may result in greater stability for liposomes loaded with DOX via the second method (Frézard, 1994; Frézard et al., 1994). Because the kinetics of tumor accumulation are more rapid than the rate of DOX release from liposomes loaded via either method, it is not known whether a further increase in stability is desirable or may simply act to limit the bioavailability of the drug in the tumor. Also, for amphipathic compounds such as DOX the choice of a saturated phospholipid component, such as DSPC or HSPC, is essential in maintaining a stable formulation in the circulation. The substitution of SM for phosphatidylcholine may also increase the liposome stability of some drug formulations (Parr et al., 1994; Webb et al., 1995). Intermolecular hydrogen bonding between the Chol hydroxyl group and the neighboring amide nitrogen of SM gives rise to a tightly packed bilayer that likely resists drug permeation (Schmidt et al., 1977; Smaby et al., 1996).

1. Drug-Loading Methods. A diagram depicting the ammonium sulfate remote-loading procedure is given in Fig. 9 (Haran et al., 1993; Lasic et al., 1995). Lipids are typically hydrated to form suspensions in high concentrations of ammonium sulfate (250 mM) and subsequently extruded to the desired size. Unencapsulated ammonium sulfate is removed (for example using a size-exclusion column), and the drug is added to the liposomes. Although ammonia can freely pass through membranes in its neutral form, sulfate is trapped in the liposomal lumen. When ammonia moves out of the liposome going with the concentration gradient, a hydrogen ion is left behind and a self-sustaining pH gradient is formed; DOX moves in its neutral form in the opposite direction and becomes protonated, eventually forming an insoluble salt with the entrapped sulfate anions. The resulting gel helps stabilize the drug in the interior. The cooling that occurs after the loading step, which is performed at 55–60°C, also likely plays a role in solidifying the drug precipitate, and thus increasing the stability of the formulation. A pH gradient strategy for loading weak bases was reported initially by Nichols and Deamer (1976) and later used extensively by Cullis and coworkers, with a pH gradient to drive the accumulation of drugs into liposomes (Mayer et al., 1985; Madden et al., 1990; Harrigan et al., 1993; Cullis et al., 1997). Weak acids can be loaded in an analogous manner using calcium acetate or reverse pH gradients (Clerc and Baren-




FIG. 9. Ammonium sulfate-loading procedure for weak bases. Liposomes are first prepared in the presence of ammonium sulfate (250 mM). On removal of the exterior ammonium sulfate on a size-exclusion column, DOX is added to the extraliposomal media. Ammonium sulfate can dissociate to two ammonium cations and one sulfate anion. Ammonia (NH_3) is free to cross the liposomal membrane, giving rise to a pH gradient across the membrane. DOX in its uncharged form can then cross the liposome membrane and form an insoluble gel under acidic conditions with the remaining sulfate anion on cooling, effectively trapping it in the liposomal interior. The concentration of DOX in the liposomal lumen can reach concentrations in excess of the aqueous solubility of DOX. This loading procedure can be applied to a variety of weak bases, such as those composing the anthracyclines, *Vinca* alkaloids or camptothecins. However, the stability of the complex formed with sulfate and thus the gel in the liposomal lumen may help determine the overall stability of the formulation.

holz, 1995; Cullis et al., 1997). These gradients also help stabilize formulations and reduce leakage during storage and while in the circulation. The small difference between DSPC/Chol (55:45) and HSPC/Chol/PEG-DSPE (92.5:70:7.5) in the observed amount of in vivo DOX leakage is possibly due to differences in the remote loading procedure (Gabizon et al., 1993; Mayer et al., 1998). Most studies with SSLs typically use ammonium sulfate gradients to entrap amphiphatic basic amines such as DOX, whereas studies using CLs prefer the pH gradient method (Madden et al., 1990; Haran et al., 1993; Lasic et al., 1995; Cullis et al., 1997).

2. *Physical Stability of Liposome Formulations with Nonanthracyclines.* An excellent review recently described the relationship of drug structure and physical properties of the liposomal membrane to drug-loading efficiencies and the stability of liposome-drug formulations (Barenholz, 1998). The drugs described thus far are considered membrane active, meaning they are amphiphatic in nature and able to insert into and transverse both artificial and biological membranes. Other drugs, such as *N*-(phosphonoacetyl)-L-aspartate, have a more polar character and are unable to freely transverse membranes (Heath and Brown, 1989). Stable liposome formulations with such drugs can include monounsaturated or polyunsaturated phospholipid components that

were previously considered undesirable with drugs such as DOX or VCR. However, although it becomes easier to prepare stable formulations with highly water-soluble drugs, it also becomes more difficult to release the drug from the carrier at the tumor site where it can elicit its desired response. This aspect is investigated in more detail in VIII. *Accumulation of Liposomal Drugs in Tumors.* An additional concern with highly water-soluble drugs is how to entrap them at very high efficiencies in liposomal carriers. Methods for entrapping amphiphatic drugs using a pH gradient or ammonium sulfate gradient are dependent on the partition coefficient of the drug between the aqueous phase and the liposomal membrane (Lasic et al., 1995; Cullis et al., 1997). Amphiphatic drugs that partition to a greater extent in the liposomal membrane are more readily entrapped in the liposomal interior. Highly water-soluble drugs are likely to be loaded only by passive encapsulation, which is limited by the entrapped volume, and with 100-nm vesicles rarely exceeds 95% of the total volume (Szoka and Papahadjopoulos, 1978; Mayer et al., 1985).

It should be emphasized that results obtained with DOX cannot necessarily be extrapolated to other drugs, even those similar in chemical structure. For example, VCR-loaded liposomes loaded by the pH gradient method are significantly less stable in the circulation, losing ~85% of the encapsulated drug in a 24-h period (Mayer et al., 1998). Apparent rates of elimination of VCR and ara-C are also affected by membrane stability (Mayhew et al., 1979; Webb et al., 1995). When SM and Chol are included in these formulations to reduce leakage of the drug, the drug shows higher plasma levels and reduced rates of elimination from the circulation.

The presence of PEG-DSPE may decrease the stability of some liposomal drug formulations (Webb et al., 1995, 1998). SM/Chol liposomes containing entrapped VCR were shown to rapidly leak VCR in the circulation in the presence of PEG-DSPE. We have observed reduced loading of vinorelbine, another *Vinca* alkaloid, at high mol% value of PEG-DSPE (5–6 mol%; Kirpotin et al., 1999a). However, reducing the concentration of PEG-DSPE to 3 mol% significantly increased the loading efficiency. Thus, the stability dilemma observed with some drugs in the presence of PEG-DSPE may be overcome by simply reducing the concentration of PEG-DSPE, but the effect of reducing the concentration of PEG-DSPE has on the pharmacokinetics of the liposome remains to be seen. A simple increase in the molecular weight of PEG used from 2000 to 5000 may result in a similar degree of protection to that observed with the lower molecular weight PEG at a higher mol% value. Alternatively, Mayer and coworkers suggested the stability problem is a consequence of the negative charge found at the membrane interface with PEG-DSPE (Webb et al., 1998). The exchange of PEG-DSPE for a neutral PEG-ceramide con-

jugate resulted in greater stability of liposomal VCR preparation.

3. Drug/Lipid Ratio. An optimal drug/lipid ratio is known to be important in the development of a stable formulation. The drug/lipid ratio should be as high as possible to maximize the payload of drug reaching the tumor without compromising stability. The maximum amount of drug loaded per liposome is dependent on the method used for drug loading, the size of the liposome, and the presence of trapping components such as acidic lipids to which the drug can bind. Because the latter two factors are traditionally associated with negative effects on pharmacokinetic parameters, the drug-loading method is the most readily adjustable. For passive encapsulation of daunorubicin in CLs, the concentration achieved was 0.079 $\mu\text{g drug}/\mu\text{g lipid}$. For remote loading via a simple pH gradient, the most effective concentration reached was 0.250 $\mu\text{g drug}/\mu\text{g lipid}$, and for remote-loading using an ammonium sulfate gradient, it was 0.125 $\mu\text{g drug}/\mu\text{g lipid}$ (Table 1). Drug/lipid ratios that are too high can also form less stable formulations, presumably due to the dissipation of the pH gradient during drug loading (Mayer et al., 1990c, 1993). These results emphasize the care needed in optimization of drug-loading methods to prepare stable liposomes and at the same time maximize encapsulation efficiencies.

4. Osmolarity Effects. Several studies have investigated the role of osmolarity on the development of stable liposomal drug formulations (Allen et al., 1992, 1995b; Mui et al., 1993, 1994). Allen et al. (1992) showed that entrapped ara-C was released more rapidly when entrapped under hyperosmotic conditions, and its release was characterized by initially rapid kinetics, followed by a slower second rate of leakage. This is consistent with the work of Madden and coworkers, who showed that osmotic lysis results in only partial release of liposomal contents and that after resealing of the liposome membrane, the liposomal lumen remains hyperosmotic (Mui et al., 1993, 1994). VCR-loaded SSLs loaded using an ammonium citrate gradient were relatively stable (leakage $T_{1/2} = 84$ h) when loaded under iso-osmotic conditions (125 mM ammonium citrate; Allen et al., 1995). In contrast, 90% of the encapsulated VCR was released after 24 h from DSPC/Chol liposomes loaded via the pH gradient method under hyperosmotic conditions (400 mM sodium citrate; Boman et al., 1994). A fine balance may exist between the osmotic stability of the liposome, residual pH gradients after loading, and the formation of drug precipitates in the liposomal lumen. For the pH gradient drug-loading method, a high buffer capacity is typically required in the intravesicular medium to maintain a reasonable pH gradient and obtain high amounts of drug loading (Mayer et al., 1990c; Boman et al., 1993; Cullis et al., 1997). High concentrations of DOX form gel-like precipitates with low osmotic activity (Lasic et al., 1992a; Haran et al., 1993). For example, DOX loaded into PEG-DSPE/DSPC/Chol or DSPC/Chol liposomes,

using either the pH (400 mM sodium citrate) or ammonium sulfate (250 mM ammonium sulfate) gradient method, is stably encapsulated in the presence of plasma. However, other drugs that form less stable complexes or gels may still have a considerable osmotic gradient, after the drug-loading process, that can increase further during drug loading (Boman et al., 1993). For instance, both daunorubicin and VCR have a considerably greater aqueous solubility than DOX (Madden et al., 1990), and both leak at a faster rate than DOX (Boman et al., 1993; Haran et al., 1993; Mayer et al., 1993). Other factors, such as the pK_a of titratable groups on the drug, a more rapid dissipation of the pH gradient, and the ability of the soluble form of the drug to partition more readily into the liposome membrane, as opposed to drug precipitates or crystals, also likely play a role in the decreased stability of such formulations relative to DOX (Madden et al., 1990; Mayer et al., 1993; Cullis et al., 1997).

5. Stabilizing against Aggregation. Although more solid CLs composed of DSPC and Chol leak drug very slowly, they are difficult to work with due to increased flocculation and aggregation over time (Crommelin, 1984; Gamon et al., 1989; Barenholz et al., 1993). Early preparations were often stabilized with small quantities of negatively charged lipids such as PG to prevent aggregation from occurring during storage (Gabizon et al., 1983, 1986, 1989). However, as was previously discussed, the presence of certain anionic phospholipids increases the rate of clearance from the circulation (Hwang, 1987; Senior, 1987). The presence of PEG on the surface provides a steric barrier that prevents liposome aggregation. PEG-coated liposomes are stable with respect to both size and drug-encapsulation over the period of many months to years when stored below the phase transition of the PC component (Haran et al., 1993; Lasic and Needham, 1995).

B. Chemical Stability of Drugs and Lipid Components

Thus far, we have been primarily concerned with the physical stability of liposomal drug formulations, either in storage or in the circulation. However, another important concern is the chemical stability of both the drug and lipid components (Barenholz et al., 1993). Are the drugs and lipid components compatible with the remote loading techniques used? If ligand-mediated targeting results in endocytosis of the liposome, is the drug stable in the low pH environment of late endosomes and lysosomes or in the presence of degradative enzymes present in these structures? These are important questions that must be answered when designing a liposomal drug delivery system. When ara-C-loaded liposomes were targeted to cells in vitro, the uptake and delivery to the lysosome resulted in degradation of the drug (Huang et al., 1993). In contrast, DOX is relatively stable and able to escape the harsh conditions of the lysosome intact (Barenholz et al., 1993).

Many drugs and lipids are susceptible to base hydrolysis. A calcium-acetate gradient has been used to load amphipathic weak acids into liposomes (Clerc and Barenholz, 1995). This method presumably generates a very high internal pH. When using this method, the stability of the drug must be considered. DOX, paclitaxel, topotecan, and other drugs can be hydrolyzed under basic conditions (Ringel and Horwitz, 1987; Barenholz et al., 1993; Burke et al., 1993; Chabner and Longo, 1996). The lactone ring of topotecan is readily hydrolyzed at even neutral pH, giving rise to serious stability concerns under basic conditions (Burke et al., 1993; Subramanian and Muller, 1995), although entrapment in liposomes with an acidic interior has been shown to stabilize topotecan formulations (Burke and Gao, 1994). Finally, the fatty acid esters are sensitive to both acid and base hydrolysis giving rise to membrane-destabilizing lysolipids under certain conditions (Barenholz et al., 1993; Zuidam et al., 1995). It is wise to analyze the lipid components of a newly developed liposome formulation by thin-layer chromatography or HPLC to be confident in the chemical stability of the lipids used.

Lipid peroxidation is another important concern for unsaturated lipid components. Lipid peroxidation can be initiated by a variety of different factors and can lead to the formation of membrane-destabilizing secondary oxidation products such as 4-hydroxynonenal and malondialdehyde (Frankel, 1987a,b; Barenholz et al., 1993). Phospholipids containing diunsaturated fatty acyl chains such as linoleic, linolenic, or arachidonic acid are particularly susceptible to lipid peroxidation due to the ready abstraction of hydrogen radicals from doubly allylic carbons (Frankel, 1980, 1985). Linolenate- and arachidonate-containing phospholipids are the most likely to form complex secondary oxidation products that are particularly damaging to membranes (Frankel, 1987a,b). This brings up an important point concerning the use of unsaturated lipids. There may be liposomal drug delivery scenarios in which a more fluid membrane is preferred. When the use of unsaturated lipids is required, it is the gel-to-liquid crystalline phase transition (T_m) that is often an excellent predictor of bilayer fluidity. Table 2 gives the primary phase transitions for several different phosphatidylcholines. Increasing the acyl chain length gives rise to a higher T_m whereas increasing the number of unsaturations decreases the T_m . Thus, a lipid component with the desired T_m can be found by balancing the acyl chain length and the number of unsaturations found in a particular phospholipid component. eggPC is a widely used fluid phase lipid component that is in the liquid crystalline state at physiological temperatures. Unfortunately, it also contains a high proportion of fatty acyl groups with multiple unsaturations (18% with two olefins and 3% with four olefins), making it particularly susceptible to oxidation. As can be seen from Table 2, POPC has a comparable T_m value with only one olefin in one of the two acyl chains.

eggPC was originally used because it was readily available and relatively inexpensive. It is now being used for mostly historic reasons, because most investigators prefer to continue using what is familiar to them in the literature. However, improvements in organic synthetic methods for phospholipids have led to the increased availability of synthetic lipids such as POPC and resulted in a cost that is comparable to the natural product. Combined with an increased chemical stability, POPC becomes a far more appropriate candidate for use as the unsaturated lipid component of a liposome formulation than eggPC.

The stability of a liposomal formulation is dependent on many physical and chemical factors, ranging from the individual drug and lipid components to the stable encapsulation of the drug within the carrier. A rigorous undertaking is necessary in developing any new liposomal drug formulation to ensure these stability considerations are addressed. In *VIII. Bioavailability of Encapsulated Drug*, we discuss how to balance stability in the circulation with release from the carrier on reaching the tumor.

VIII. Bioavailability of Encapsulated Drug

It is important to emphasize that most of the work described thus far has been concerned with drugs considered to be membrane active. They are amphipathic in nature and able to transverse the bilayer at a rate dependent on the physical properties of the membrane, as well as any ionic or pH gradients across the membrane (Madden et al., 1990; Lasic et al., 1995; Cullis et al., 1997). Other drugs, such as ara-C, are more water soluble and after a slow release from the carrier (Allen et al., 1992) can be taken up by specific transporters located in the plasma membrane of tumor cells, such as the nucleoside transporter (Plageman et al., 1978; Wiley et al., 1982) or the reduced folate carrier (Westerhof et al., 1991, 1995; Antony, 1992). The bioavailability of such compounds is dependent on how readily they are able to escape their liposomal carrier. We define bioavailability in the case of liposomal carriers as the amount of free drug that is able to escape the confines of the carrier and is thus available for redistribution to neighboring tissues and tumor. A fine balance is required to prevent premature leakage in the circulation, and thus nonspecific toxicities, but still allow for release of the drug on reaching the tumor. For DOX-loaded slow-release liposomes (PEG-DSPE/HSPC/Chol or DSPC/Chol), the drug is thought to leak very slowly and thus be similar to a slow infusion of the drug specifically near the cancerous cells (Horowitz et al., 1992; Vaage et al., 1998). Using scanning confocal fluorescence microscopy to look at s.c. implants of a prostate carcinoma xenograft, DOX delivered via SSL DOX was shown to reside immediately adjacent to tumor capillaries and venules at early times (1 h; Vaage et al., 1998). At 24 h,

DOX had leaked from the liposome and was found within the tumor in a pattern indicating diffusion away from the capillaries and venules. Free DOX was found deep within the tumor at 1 h but was nearly undetectable at 24 h. This is likely due to both elimination and metabolism of the drug, as well as fluorescence quenching after intercalation of the drug into nucleic acids (Gigli et al., 1988). These results indicate that DOX does become bioavailable on reaching the tumor, where it slowly and continuously bombards the nearby cancer cells with low levels of the cytotoxic agent. Thus far, most detailed studies have used anthracyclines for delivery studies. Although the antitumor cytotoxicity of drugs such as anthracyclines and ara-C are less dependent on peak levels of the drug, cytotoxicity of other drugs may show a considerably greater dependence on peak levels of the drug, and hence the rate at which the drug is released from its carrier. Consequently, the selection of drugs with these properties or the selective increase in the rate of release at the tumor site will be very important in designing an effective carrier.

A. Release of Doxorubicin in Tumor

The mechanisms responsible for liposome breakdown and drug release in tumors have not been well elucidated. Several potential mechanisms have been proposed, but all are highly speculative and little direct evidence has been provided, primarily due to technical difficulties associated with monitoring drug release in vivo. Some of the properties of the tumor microenvironment believed to play a role in liposome destabilization include the slightly acidic pH found in interstitial fluids surrounding tumors, lipases released from dying tumor cells, inflammatory cells present in response to tumor release factors, enzymes, and oxidizing agents (Martin, 1998). In addition, phagocytic cells residing in tumors could metabolize liposomes and release free DOX, killing neighboring tumor cells via the bystander effect (Storm et al., 1988). The effect of local interstitial media on DOX leakage from SSL DOX was investigated in an in vitro study (Gabizon, 1995). Although leakage in plasma was relatively slow ($T_{1/2} \sim 100$ h), liposomes incubated in the presence of fluid obtained from pleural malignant effusions leaked DOX at a significantly elevated rate. Another investigator suggested that ammonium sulfate used to remote loaded DOX could also catalyze liposome breakdown, although a logical rationale for its mechanism was not provided (Lasic, 1993). With SSLs, a certain amount of PEG-DSPE can be released from the liposome over time, allowing liposomes to undergo more interactions with neighboring cells and or plasma components. Finally, it may be possible that DOX passively crosses the liposome membrane and that as the DOX-sulfate gel is gradually destabilized by loss of more and more drug, the drug release is accelerated. Finding methods to selectively destabilize liposomal drug formulations in the tumor area is a major challenge to the

liposome field, which if overcome could lead to substantial increases in drug bioavailability at the tumor site and subsequent increased efficacy.

The release of DOX from eggPC/Chol liposomes is rapid compared with liposomes composed of HSPC/Chol or DSPC/Chol (Bally et al., 1990b; Gabizon et al., 1993). eggPC/Chol liposomes release a significant portion of their drug before reaching the tumor and thus act as a rapid-release system (Harasym et al., 1997), in contrast to the more stable formulations that act as slow-release systems and are the focus of this review.

B. Active Targeting of Liposomes

Although clearly more beneficial than the use of free DOX, one disadvantage of SSL DOX or L-DOX is that cancer cells deep within the tumor are not readily reached with high concentrations of drug and are given an opportunity to select for drug-resistant cells. One strategy for increasing drug bioavailability and distribution within the tumor has been to target liposomes to internalizing receptors. Liposomes have been targeted to cells via small molecules (Lee and Low, 1994, 1995), sugar molecules (Spanjer and Scherphof, 1983; Banerjee et al., 1996), serum proteins (Afzelius et al., 1989; Brown and Silviu, 1990; Lundberg et al., 1993), and antibodies (Heath et al., 1983; Debs et al., 1987; Matthay et al., 1989; Maruyama et al., 1990a; Allen et al., 1995c; Lopes de Menezes et al., 1998) or antibody fragments (Park et al., 1995; Kirpotin et al., 1997b). Recently, HER2-targeted immunoliposomes were shown to distribute within solid tumors and not simply in the extracellular space surrounding the tumor blood vessels (Kirpotin et al., 1997a, 1999a; Park et al., 1997). Release of the drug within the tumor itself presumably increases the bioavailability of the drug to the more-difficult-to-reach cells within the solid tumor mass. Indeed, this property is most likely responsible for the increased therapeutic effect observed with these carriers, as there was no overall increase in liposome localization to the tumor (Fig. 10).

Active targeting of pharmaceuticals is often perceived as a means of getting increased amounts of drug into the diseased site. However, the passive trapping of liposomes due to a discontinuous tumor microvasculature, the lack of a functioning lymphatics, and a high interstitial pressure result in a rate-limiting accumulation of liposomal drug in solid tumors. It is unlikely that active targeting to cell surface proteins of solid tumors that are not internalized will offer a significant therapeutic benefit. When anti-HER2-targeted immunoliposomes are prepared with an antibody that is not internalized, there was no increase in therapeutic efficacy compared with nontargeted liposomes (Goren et al., 1996). Similar to the results seen with the internalizing anti-HER2 Fab' fragment (Kirpotin et al., 1998; Park et al., 1998a,b), there was no increase in tumor levels of the targeted liposomes compared with nontargeted liposomes (Goren




FIG. 10. Tissue distribution of anti-HER2 targeted SSLs (□) and non-targeted SSLs (rhbox) in nude mice with breast cancer xenografts. Xenografts were derived from both HER2-overexpressing (BT-474) and HER2-negative (MCF-7) cell lines. The biodistribution was determined at 24 h by following ^{67}Ga -labeled liposomes after injection of 1 μmol of phospholipid via the tail vein in nude mice. This figure was adapted from Kirpotin et al. (1998).

et al., 1996). Vingerhoeds et al. (1996) also failed to show increased efficacy of noninternalizing immunoliposomes targeted against the OA3 antigen present on 90% of human ovarian carcinomas. Some investigators have even suggested that cell surface binding by itself may serve to limit the distribution of liposomes within the tumor (Weinstein et al., 1987; Jain, 1989). Allen et al. (1995c) showed that SSL DOX was more effective than sterically stabilized immunoliposomal DOX targeted against a carbohydrate epitope on an ovarian cancer cell line grown s.c. in nude mice. The authors suggested the reduced activity may be due in part to the binding-site barrier. However, the circulation $T_{1/2}$ values of the immunoliposomes in this study were significantly shorter than those for the nontargeted SSL, and there was no evidence presented showing that these liposomes were internalized, giving rise to two alternative explanations for the reduced activity. Furthermore, this study used whole antibodies for targeting. In our studies with the anti-HER2 antibody, antibody fragments were used: either Fab' or single chain FV fragments (Fig. 11; Park et al., 1995, 1998a,b; Kirpotin et al., 1998; Papahadjopoulos et al., 1999). In addition to the advantages associated with reduced immunogenicity of antibody fragments, the reduced avidity of the fragments for their cell sur-

face targets may serve to reduce the binding-site barrier, allowing a deeper penetration of the carrier within the tumor. A deeper penetration of antibody fragments compared with full antibodies has been previously attributed to both the reduced size of the molecule and a reduced avidity for its target (Fujimori et al., 1989; Yokota et al., 1992). This, of course, is speculation, and additional studies must be completed to determine more precisely the mechanisms responsible for regulation of the tumor penetration of targeted liposomes.

Allen and coworkers have also been successful in targeting liposomes to a lung metastatic cancer model, where cancer cells travel through the blood and localize in the lung as small tumor colonies (0.5 mm; Ahmad et al., 1993; Allen et al., 1995c). An increased localization to tumor-bearing lungs was seen with targeted immunoliposomes compared with nontargeted SSL, and this correlated with a significant decrease in the tumor burden of mice treated with immunoliposomes (Ahmad et al., 1993). Cancer cells in this metastatic model differ greatly compared with the solid tumors described earlier due to their small size and the greater accessibility of liposomes to their receptor. This same group has also been successful in targeting liposomes against hematological cancers, such as B cell malignancies (Allen et al., 1995c; Lopes de Menezes et al., 1998), where the tumor cells are also more available for binding to targeted liposomes. Huang and coworkers have targeted the pulmonary endothelium using antibodies directed against the lung endothelial protein thrombomodulin (Maruyama et al., 1990a,b; Mori et al., 1993, 1995). This type of organ-specific targeting allows liposome-associated drug to be delivered near the site of tumors located in the lung, where on their disassociation from the carrier they can act on neighboring tumor cells (Mori et al., 1995). The greater accessibility of the receptors in each of these approaches offers a significant advantage for targeted therapies compared with the treatment of solid tumors.

The choice of targeting ligand is important when designing targeted liposomes. The ligand should be relatively specific for cancer cells, especially in contrast to cells readily accessible in the general circulation, where many passes may occur before extravasation into tumors. Second, as mentioned, the epitope bound should result in internalization of the liposome. Binding to a receptor that is known to be endocytosed does not necessitate endocytosis, especially in the case of antibodies or antibody fragments (Goren et al., 1996). Ligands, such as folate, for internalized receptors usually induce endocytosis, but binding of a protein or peptide to an unrelated part of the receptor may simply constrain the carrier on the membrane surface. An additional problem with the attachment of targeting molecules to the surface of liposomes is that they may increase liposome clearance by tissues other than the tumor. For instance, early studies indicated antibody-targeted liposomes are




FIG. 11. Effect of tumor cell targeting on the localization of SSLs in HER2-overexpressing human breast cancer xenografts (BT-474). A and B, nontargeted SSLs. C and D, anti-HER2 SSL. Liposomes labeled with entrapped colloidal gold were injected i.v. into the mice with s.c. xenograft tumors (200–300 mm³ in size) at the dose of 5 mmol of phospholipid/animal. Twenty-four hours later, the tumors were harvested, and liposomes were visualized on tumor sections by the silver enhancement method. Liposomes appear as bright dots on the dark field images (B and D) or as black grains on the matching bright-field images counterstained with light H&E (A and C). Nontargeted liposomes are concentrated in the interstitial spaces within the cells with characteristic macrophage morphology. HER2-targeted SSL are more uniformly dispersed throughout the tumor tissue and often found within tumor cells.

rapidly removed from the circulation by macrophages of the RES (Debs et al., 1987). This was likely due to recognition of the Fc portion of the antibody by Fc receptors located on the surface of macrophages (Aragnol and Leserman, 1986; Raghavan and Bjorkman, 1996) or by recognition of noncompatible portions of the antibody by antibodies of the humoral immune system. The recent endeavors with Fab' targeted liposomes do not contain the Fc region of the antibody and are prepared from humanized versions of the antibody (Park et al., 1995; Kirpotin et al., 1997b). Indeed, these immunoliposomes have a nearly identical tissue distribution as that of nontargeted SSL DOX (Fig. 10). A more in-depth description of these immunoliposomes and the various properties necessary for their optimization is given in several recent reviews (Kirpotin et al., 1997a, 1998; Park et al., 1997). There also are many reviews describing the methods for preparing and applying other targeted liposomes (Allen and Moase, 1996; Allen et al., 1997, 1998; Forssen and Willis, 1998; Park et al.,

1998a,b). The most relevant aspect of targeted liposomes is that targeting to internalizing receptors can potentially increase the bioavailability of the drug. It can accomplish this by altering the intratumoral distribution of the liposome and thus increasing the percentage of cells exposed to the drug. This effect has only been observed for HER2-targeted immunoliposomes and may very well differ depending on the targeting ligand.

Liposomes targeted to internalizing receptors have shown considerably greater tumor cell cytotoxicity both in vitro and in vivo (Heath et al., 1983; Huang et al., 1983; Berinstein et al., 1987; Matthey et al., 1989; Lee and Low, 1995; Park et al., 1995, 1997; Lopes de Menezes et al., 1998). This may be due in part to an increased bioavailability after transport of the liposomes to lysosomes, where degradative enzymes can breakdown the liposomal membrane and release the drug. Many studies have demonstrated degradation of both lipid and either encapsulated or bound protein after internalization by macrophages (Dijkstra et al., 1984;

Storm et al., 1988; Derksen et al., 1988). Increased release of DOX from liposomes was observed after uptake by peritoneal macrophages, and collected supernatants were shown to have considerable growth-inhibitory activity (Storm et al., 1988). The degradation rate was dependent on the lipid composition of the liposomes, with liposomes containing high-phase transition phospholipids (slow release) being degraded more slowly than those containing low-phase transition phospholipids (rapid release; Storm et al., 1988). However, intracellular processing may vary depending on the cell type and may be significantly different in tumor cells compared with phagocytes such as macrophages. For example, two studies have shown that T cells are able to process liposome-delivered drugs more rapidly than B cells (Machy et al., 1982; Lopes de Menezes et al., 1998). Nevertheless, several other cell types, such as fibroblasts, endothelial cells, and tumor cells, have demonstrated processing of liposomes or their components after internalization (Straubinger et al., 1983; Jett et al., 1985; Trubetskaya et al., 1988; Chu et al., 1990). Internalization of liposomal drugs has also been suggested to increase efficacy by limiting diffusion of the drug away from the cancer cells (Allen et al., 1998). This is especially a concern in the turbulent environment of the general circulation or peritoneal cavity (Allen and Moase, 1996). Both of these factors likely play a role in the increased efficacy observed with actively targeted liposomes. Regardless of the mechanism, targeting to internalizing receptors appears to increase the growth-inhibitory effects of some liposomal drugs.

Methotrexate or other reduced folates are good candidates for delivery via this kind of targeted approach. Due to the relatively low pK^a of the 2' carboxyl group, methotrexate and its derivatives are not readily protonated and thus cannot passively transverse artificial or biological membranes. The result of this is relatively stable liposome formulations of reduced folates such as methotrexate, which are significantly less likely than even anthracyclines to leak prematurely in the circulation and cause nonspecific toxicities. These reduced folates enter the cell by reduced folate carriers located in the plasma membrane (and membranes of endosomes and lysosomes) of certain cells (Kamen et al., 1991; Westerhof et al., 1995). Reduced folate carriers are up-regulated in a variety of different tumor models, as is expected considering the rapid growth rate of cancerous cells (Westerhof et al., 1991; Weitman et al., 1992a; Ross et al., 1994). After the delivery to late endosome and lysosomes where the carrier is degraded and methotrexate is released, methotrexate can be transported by the reduced folate carrier into the cytosol, where it can elicit its cytotoxic action on folate-requiring enzymes (Weitman et al., 1992b; Antony, 1996). A number of in vitro studies with methotrexate or methotrexate- γ -aspartate have shown a marked dependence of cytotoxicity on targeting to endocytic pathways (Heath et al., 1983;

Matthay et al., 1986, 1989; Bernstein et al., 1987; Straubinger et al., 1988; Singh et al., 1989). An additional advantage of the development of a liposomal formulation of a drug such as methotrexate is that the modes of drug resistance to methotrexate and anthracyclines are markedly different. Consequently, a combination of targeted liposomal methotrexate with targeted or nontargeted DOX may provide an even greater chance for long-term survival. Of course, this is a technical advantage of the use of antifolates with targeted liposomes. The first and most obvious consideration is that the type of cancer is sensitive to antifolates.

C. Hyperthermia and Thermosensitive Liposomes

Hyperthermia has also been used to increase the bioavailability of liposomal drugs in the tumor area. In addition to simply increasing the amount of liposomes that enter the tumor area (see *IIIC. Hyperthermia and Vascular Permeability Factors for Increasing Vascular Permeability*), hyperthermia makes the distribution of liposomes within the tumor more uniform, increasing the bioavailability of the released drug to cells within the tumor (Kirpotin et al., 1999b). This is similar to the effect seen with HER2-targeted immunoliposomes. Hyperthermia can also be used to increase drug bioavailability via a second mechanism. Liposomes can be rendered thermosensitive by replacing some of the DSPC lipid component with DPPC, resulting in an increased leakage of the encapsulated material (Yatvin et al., 1978; Gaber et al., 1995, 1996; Wu et al., 1997) when heated to 42°C. This effect was found to be dependent on the presence of plasma proteins. At 37°C these liposomes are stable and do not release DOX. However, heating to 42°C for 30 min results in a release of >60% of the encapsulated DOX (Gaber et al., 1995). The combination of hyperthermia and L-DOX appears to be a very promising strategy for the treatment of cancer due to its ability to enhance three important characteristics of liposomal drug delivery: tumor accumulation, intratumoral distribution, and bioavailability. One study has already demonstrated increased therapeutic efficacy for DOX-loaded thermosensitive liposomes used in conjunction with hyperthermia (Huang et al., 1994). Different regimens and treatment schedules are currently being investigated for their effect on efficacy and tolerability. The strategy used here illustrates another important aspect of the optimization of liposomal drug delivery. Currently, it is difficult to resolve even the complex relationships existing between various liposome properties (size, charge, permeability characteristics) and pharmacological factors (dose, route of administration) regulating liposome delivery in vivo. Although these relationships have been the primary focus of this review, the future holds a need for elucidation of the complex processes responsible in vivo for regulating tumor permeability and the movement of liposomes within the tumor after extravasation. The ability to manipulate

these processes will undoubtedly provide a greater avenue for increasing drug bioavailability in vivo for difficult-to-treat solid tumors.

A diagram depicting the accumulation and distribution of liposomes in tumors is given in Fig. 8. After extravasation through large pores in the tumor microvasculature, liposomes accumulate in the tumor interstitium. Here they can release their encapsulated drug slowly, where it can be taken up by neighboring tumor cells. Targeted liposomes can also obtain a deeper tissue distribution after endocytosis or transcytosis of the carrier and thus expose a greater area of the tumor to the drug. In addition, liposomes targeted to endocytic pathways are destabilized by lysosomal enzymes, releasing the drug within the tumor cells, where it can act on intracellular targets.

D. Problems with Highly Hydrophilic Drugs and Bioavailability

As mentioned in VII. *Stability in Plasma and Storage*, it is relatively easy to prepare stable liposome formulations with polar drugs that are unable to permeate membranes. However, the usefulness of these liposomes is more limited due to present limitations in the ability to make these drugs bioavailable at the tumor site. Increased delivery of highly hydrophilic drugs (Chu and Szoka, 1992) or oligonucleotides (Woodle et al., 1997) to the site of action is not sufficient in itself to obtain an enhanced therapeutic effect. On arrival, the drug must both be released by the carrier and be taken up by the cells of interest. Drugs that can be recognized and transported by plasma membrane transporters, such as ara-C and methotrexate (Plageman et al., 1978; Wiley et al., 1982; Kamen et al., 1991), may be useful if they can be released from the carrier (Allen et al., 1992). In the case of methotrexate, liposome targeting and internalization likely give rise to increased drug release, and thus greater cytotoxicity (Heath et al., 1983; Matthay et al., 1989). After internalization, the drug can be subsequently transported by an internal anion transporter into the cytosol (Kamen et al., 1991).

Several approaches are being studied to improve the bioavailability of this class of drugs. pH sensitive liposomes composed of unsaturated phosphatidylethanolamines and mildly acidic amphiphiles have been the most thoroughly studied (Straubinger et al., 1985; Chu et al., 1990; Litzinger and Huang, 1992). The problem with this approach is that these formulations are readily stabilized by plasma components, which insert into the membrane bilayer and reduce the liposome's sensitivity to pH (Liu and Huang, 1989, 1990; D. C. Drummond and D.-L. Daleke, unpublished observations). Recently, two approaches have been attempted to induce acid-mediated leakage of water-soluble content markers. The first is the development of pH-sensitive lipid-anchored copolymers (Meyer et al., 1998b). Incorporation of these polymers into eggPC/Chol liposomes was shown to result

in substantial leakage of a water-soluble content marker (pyranine), when the pH was lowered below 5.5. Unlike other pH-sensitive liposomes, release of the marker is not due to fusion but rather to a collapse of the polymer at the phase transition and subsequent collapse of the liposomes or resulting local defects in the membrane that allow for contents leakage. The second approach is the design of cleaveable PEG-DSPE conjugates (Kirpotin et al., 1996). PEG-DSPE is known to stabilize 1,2-dideoyl-3-*sn*-phosphatidylethanolamine containing membranes and prevent fusion of liposomes (Holland et al., 1996a,b; Basanez et al., 1997). Release of PEG from the surface with a sulfhydryl- or an acid-sensitive trigger gives a fusion-competent liposome, capable of releasing its contents. Programming release of PEG-lipid conjugates from the liposome surface through adjustment of the acyl chain composition has been another mechanism for release of the stabilizing polymer (Holland et al., 1996b; Webb et al., 1998). Some groups have even attempted to destabilize liposomes using enzymes that can cleave peptides or sugars from the liposome surface (Pinaduwege and Huang, 1988; Pak et al., 1997) or by using pH-sensitive peptides (Parente et al., 1988, 1990). Finally, water-soluble polyanions such as oligonucleotides have been complexed with cationic lipids and then delivered effectively to the nucleus of target cells (Zelphati and Szoka, 1996; Meyer et al., 1998a). Although some progress has been made with these systems in vitro and in cell culture, they are still a considerable way from being useful in an in vivo application.

If this class of drugs is to be used in vivo, it will undoubtedly be in the context of SSLs. To be readily released from the liposome, highly water-soluble compounds will likely require the use of fluid phase liposomes. Although low-phase transition lipids such as 1,2-dideoyl-3-*sn*-phosphatidylethanolamine, eggPC, or POPC can be incorporated into SSLs and still remain long circulating, CLs containing these lipids are rapidly removed from the circulation (see IID. *Effect of Membrane Packing Constraints on Pharmacokinetic Parameters*). Thus, steric stabilization provides more flexibility for the type of drug class that can be delivered to tumors with liposomes.

IX. Conclusions

A. Sterically Stabilized versus Rapid-Release Conventional Liposomal Formulations

In theory, slow-release systems that effectively deliver their drug to tumors and release the drug in the near vicinity of tumor cells are more advantageous, and thus should be more therapeutically efficacious, than a rapid-release system where the drug is released from the carrier to a significant extent while in the circulation. When used at equivalent doses, there are no known instances where DOX-loaded eggPC/Chol liposomes (TLC D-99) were shown to be more efficacious than SSL DOX. How-

ever, by definition, efficacy is not dependent on dose, and at present TLC D-99 can be administered at higher doses than Doxil due to the dose-limiting toxicity of H-F syndrome. In the treatment of patients with metastatic breast cancer, TLC D-99 was shown to have an almost identical response rate as reported for Doxil (Ranson et al., 1997; Harris et al., 1998) but had to be delivered at a dose 70% greater than used for Doxil (75 versus 45 mg/m² every 3 weeks). Although both formulations are undoubtedly better than free DOX due to decreased toxicities, better patient compliance, and an increased quality of life, drug delivered via sterically stabilized slow-release systems offers two significant advantages. First, because a comparable therapeutic response requires higher doses of DOX to be administered in the case of TLC D-99, cumulative toxicities such as cardiotoxicity are likely to be higher. In addition, due to significant leakage of the drug in the central compartment, compared with the tumor for DOX, more bioavailable drug likely reaches the heart and other healthy tissues. Initially, the large improvements over free DOX will likely make these differences seem minor in comparison. Nevertheless, as L-DOX becomes more widely accepted and replaces free DOX in treatment regimens, these differences in the new higher limits placed on cumulative doses of L-DOX will become important.

A second advantage of slow-release liposomes is that they are more amenable to active targeting of solid tumors. Because eggPC/Chol liposomes release a large proportion of their contents before reaching the tumor, a significantly reduced advantage would be gained by targeting than would be expected for slow-release liposomes. The use of hyperthermia to increase extravasation of liposomes would also benefit more using slow-release systems, where the increased uptake and distribution of drug-loaded liposomes in the tumor would result in a greater increase in overall tumor drug levels. If the drug is released to a greater extent in the circulation, then the drug takes on the pharmacokinetics of the free drug and would not benefit as substantially from hyperthermia, which alters further the pharmacokinetics of the carrier. If hyperthermia were used in conjunction with thermosensitive liposomes to trigger the release of contents, then heat would be administered after accumulation of the drug in the tumor and would in effect reversibly trigger the transformation of liposomes from a slow-release to a very rapid-release system. In addition, the rapid-release liposomes have reduced circulation lifetimes compared with slow-release liposomes, especially SSLs. Liposomes with longer circulation lifetimes would be expected to benefit more from hyperthermia, which has its effect on increasing passive targeting. Future improvements in liposome design by preparing triggerable liposomes that are slow-release systems whereas in the plasma but revert to rapid-release systems on reaching the tumor will presumably result in the most efficacious formulation.

Finally, efficacy results have not shown thus far a favorable response rate for TLC D-99 over Doxil, and potential remedies are presently under consideration for reducing the severity of H-F syndrome. If these are effective, then dose escalation of Doxil will undoubtedly provide a greater therapeutic response.

B. Conventional and Sterically Stabilized Slow-Release Systems

Small, neutral, and solid CLs for drug delivery appear to be limited in their potential usefulness as a drug delivery vehicle if compared with SSL formulations at a similar dose. The dose-independent clearance kinetics of PEG-modified liposomes provides these carriers with a unique ability to remain in the circulation long enough for a therapeutically relevant concentration of drug to accumulate in tumors but at low enough concentrations to avoid certain nonspecific toxicities. However, as mentioned, H-F syndrome limits the dose of SSL DOX that can be administered and thus CLs (DSPC/Chol) may be administered at a dose high enough to give rise to similar tumor concentrations of drug. One potential problem with CL formulations is that increased circulation times and high intratumoral drug concentrations are dependent on drug-induced toxicity to RES macrophages. This presents a problem that has not been adequately addressed: susceptibility to opportunistic infections. In addition, the requirement of long circulation times on drug-induced toxicity would depend heavily on the drug that is formulated. Some drugs such as mitoxantrone are unable to enhance circulation lifetimes by this approach. For delivery of liposomal drug to solid tumors, slow-release CLs are also limited to the delivery of amphipathic drugs that are able to freely transverse the bilayer. SSLs offer the potential advantage of being able to be modified to increase the bioavailability of a variety of drugs whereas maintaining their long circulation times. Thus, CLs appear to be more limited in applicability to very specific conditions, whereas SSLs appear to be more flexible.

The development of SSLs has shifted the focus of liposome research away from improved CL formulations for long circulation. The question of whether CLs have been truly optimized was raised in *IIC. Effect of Liposome Charge on Pharmacokinetic Parameters*. There is at least some evidence to suggest they have not been. If this is the case, then a careful study of the rate of accumulation in tumors, formulation stability, toxicity, and efficacy will have to be completed to determine whether they can be effectively used as carriers of anti-neoplastic drugs in vivo. This new generation of CLs may provide a plausible alternative to SSLs if carefully optimized.

C. Visions for Future

Liposomal drugs have been suggested to be the long-awaited "magic bullet" cancer therapy due to their abil-

112

ity to accumulate selectively in the tumor (Matsumura and Maeda, 1986; Maeda and Matsumura, 1989). However, the problem remains that not all cancers and not all patients respond to the "bullet" equivalently. The drug being delivered by liposomes plays an important role in the response achieved. Multidrug resistance has led to significant obstacles in the ability of standard chemotherapy regimens to cure cancer (Chapman and Powis, 1993; Chabner and Longo, 1996). Many studies have shown that combinations of chemotherapeutic agents with nonoverlapping mechanisms of drug resistance may provide a greater opportunity for treating cancer more effectively. Liposomal drugs have the advantage of continually bombarding the cancer cells with low doses of standard chemotherapy and possible overwhelming drug transporters responsible for pumping drugs such as anthracyclines out of the cell (Richardson and Ryman, 1982; Thierry et al., 1989; Rahman et al., 1992). Even with this possibility in mind, it is unlikely that tumors resistant to DOX will be completely eradicated using only L-DOX. One prominent member of the liposome field of study has continually and quite understandably raised the important question, "When are we ever going to get out of the A's" (Szoka, 1998), referring, of course, to the four most studied liposomal drugs: ara-C, anthracyclines, aminoglycosides, and amphotericin B (a potent antifungal agent). It is an excellent question and one that deserves a considerable amount of thought. Liposomes provide an efficient vehicle for delivery of anticancer agents to tumors, but it will almost certainly be necessary to use combinations of different drugs to provide the most effective treatment. Several studies have addressed this concern (Vaage et al., 1993b; Fonseca et al., 1995; Mitsuyasu et al., 1997; Valero et al., 1999). In one study, combination therapy with low doses of both SSL DOX and SSL-VCR was shown to be more effective in the treatment of MC2 mammary tumors than higher doses of either liposomal drug alone (Vaage et al., 1993b). Other studies have reported the combination of L-DOX with other free drugs (Fonseca et al., 1995; Mitsuyasu et al., 1997; Valero et al., 1999). Additional studies that attempt to encapsulate drugs with nonoverlapping modes of drug resistance and significant activity against a particular form of cancer in liposomes or combine free drugs with nonoverlapping modes of drug resistance with presently developed liposomal drugs are needed and may result in more effective drug regimens for the treatment of a variety of difficult-to-treat cancers.

What liposomal drugs should be developed next? This is a difficult question and is dependent on several different variables; including the type of cancer and its response to a particular drug, the stability of the liposome formulation in the circulation, the ability to make the drug bioavailable at the tumor site, and the mode of drug resistance. There is no one correct answer, and investigators are encouraged to be both creative and

thorough in their selection and development of other drug formulations. Although methods for liposome targeting using tumor-specific ligands, for increasing extravasation of liposomes into tumors (hyperthermia) and for increasing the bioavailability of the drug selectively at the tumor site, will in all probability increase the overall therapeutic index of a drug such as L-DOX, there is no doubt an important need to develop liposomal formulations of other drugs. These attempts are currently being made in our laboratory (Kirpotin et al., 1999a) and those of others (Allen et al., 1995b; Chang et al., 1997; Colbern et al., 1998; Embree et al., 1998; Gelmon et al., 1999; Newman et al., 1999; Vaage et al., 1999) with an assortment of well-studied chemotherapeutic agents.

Increasing the efficiency of L-DOX by altering its accumulation in tumor or its distribution within tumors or by increasing its bioavailability selectively within the tumor are important strategies being investigated by many in the field. We have concentrated on two approaches to achieve these goals: local hyperthermia and specific targeting to tumor cell-specific epitopes that internalize on binding. The encouraging preclinical studies with HER2-targeted immunoliposomes are in part a result of the long circulation lifetimes provided by steric stabilization combined with the increased bioavailability resulting from endocytosis of the targeted carrier. Anti-HER2 immunoliposomes are presently being considered (HER2 overexpressing) for the treatment of aggressive forms of breast cancer in clinical trials. In addition, Allen and coworkers have recently shown promising preclinical results with SSL immunoliposomes targeted to B cell malignancies using an anti-CD19 antibody (Lopes de Menezes et al., 1998).

The field of liposomal chemotherapy brings together a broad arena of scientific disciplines, including such varied practices as membrane biophysics, chemistry, biochemistry, cell biology, pharmaceutical technology, tumor physiology, toxicology, and clinical oncology. To be successful, scientific groups in the liposome field need to operate at the interface of these various disciplines and take as many of these practices into consideration when rationally designing a drug-carrier system, including the liposomes described in this review. It is hoped that this review will serve as a focal point from which future improvements in liposome technology can be made and, at the same time, as a reminder of how far we have come. The development of additional liposomal drug formulations should be aided by the advancements of the past, many of which are described in this review, but with the realization that no one formulation is ideal for all classes or even subclasses of drugs. The ability to be creative and to adapt what we have learned thus far will determine the success of this field in the future.

Acknowledgments. This work was supported in part by grants from the National Institutes of Health (1-RO1-CA72452 and 1-RO1-

CA71653-01), by Grant SB96-23 from the University of California Biotechnology STAR Program, and by the California Breast Cancer Research Program (2CB-0004). D.D. is supported by a postdoctoral fellowship from the Breast Cancer Research Program of the University of California (Grant 4FB-0154). We thank our exceptional network of collaborators, including Dr. Christopher C. Benz, Dr. John W. Park, and Dr. James D. Marx, for their continued efforts in helping advance the use of liposomes as a drug delivery vehicle for the treatment of various cancers. The complexity of the liposome field requires expertise from a wide array of different scientific disciplines to be successful, and the efforts of these scientists and clinicians are invaluable to many exciting advances. We also thank Dr. Francis Szoka and Victoria Champion for carefully reviewing this manuscript before its submission.

This review was one of several projects that Dr. Papahadjopoulos was working on at the time of his sudden death in September 1998. Dr. Papahadjopoulos was a pioneer in the field of liposome-mediated drug delivery and an integral part of many major breakthroughs in the liposome field. His contributions started with basic membrane biophysics, leading to an understanding of the basic principles that would allow us to use these artificially prepared membranes as drug carriers, and evolved into the clinic with the development of Doxil, a liposome-based chemotherapeutic. Those contributions intervening are far too numerous to list here, and the full impact of his career on the oncology and liposome fields awaits time's trials. His dedication to the treatment of cancer and, more specifically, breast cancer ensured us all of a greater meaning for our research and for our lives. He remains an inspiration to all of us who remain in his laboratory (The Liposome Research Laboratory) at California Pacific Medical Center and, we are sure, to many others in the field as well.

REFERENCES

Abra RM and Hunt CA (1981) Liposome disposition in vivo. III. Dose and vesicle-size effects. *Biochim Biophys Acta* **666**:493-503.

Afzelius P, Demant EJF, Hansen GH and Jensen PB (1989) Covalent modification of serum transferrin with phospholipid and incorporation into liposomal membranes. *Biochim Biophys Acta* **979**:231-238.

Ahl PL, Bhatia SK, Meers P, Roberts P, Stevens R, Dause R, Perkins WR and Janoff AS (1997) Enhancement of the in vivo circulation lifetime of L- α -distearoylphosphatidylcholine liposomes: Importance of liposomal aggregation versus complement opsonization. *Biochim Biophys Acta* **1329**:370-382.

Ahmad I, Longenecker M, Samuel J and Allen TM (1993) Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. *Cancer Res* **53**:1484-1488.

Alberts DS and Garcia DJ (1997) Safety aspects of pegylated liposomal doxorubicin in patients with cancer. *Drugs* **54** (Suppl 4):30-35.

Allen TM (1981) A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. *Biochim Biophys Acta* **640**:385-397.

Allen TM (1994) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. *Adv Drug Del Rev* **13**:285-309.

Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect in the future. *Drugs* **56**:747-756.

Allen TM, Ahmad I, Lopes de Menezes DE and Moase EH (1995c) Immunoliposome-mediated targeting of anti-cancer drugs in vivo. *Biochem Soc Trans* **23**:1073-1079.

Allen TM and Chonn A (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. *FEBS Lett* **223**:42-46.

Allen TM and Cleland LG (1980) Serum-induced leakage of liposome contents. *Biochim Biophys Acta* **597**:418-426.

Allen TM and Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. *Biochim Biophys Acta* **1068**:133-141.

Allen TM, Hansen CB, Kao GY, Ma J, Marjan JMJ, Demenezes DL, Moase EH, Qi W and Stuart D (1997) Antibody-targeted liposomes: Prospects and problems. *Adv Drug Del Rev* **24**:243.

Allen TM, Hansen CB and Lopes de Menezes DE (1995a) Pharmacokinetics of long-circulating liposomes. *Adv Drug Del Rev* **16**:267-284.

Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. *Biochim Biophys Acta* **1066**:29-36.

Allen TM, Hansen C and Rutledge J (1989) Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. *Biochim Biophys Acta* **981**:27-35.

Allen TM, Hansen CB and Stuart DD (1998) Targeted sterically stabilized liposomal drug delivery, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 545-565, Elsevier Science BV, New York.

Allen TM, Mehra T, Hansen C and Chin YC (1992) Stealth liposomes: An improved sustained release system for 1- β -D-arabinofuranosylcytosine. *Cancer Res* **52**:2431-2439.

Allen TM and Moase EH (1996) Therapeutic opportunities for targeted liposomal drug delivery. *Adv Drug Del Rev* **21**:117-133.

Allen TM, Murray L, Alving CR and Moe J (1987) Effects of the murine mononuclear phagocyte system of chronic administration of liposomes containing cytotoxic drug or lipid A compared with empty liposomes. *Can J Physiol Pharmacol* **65**:185-190.

Allen TM, Murray L, MacKeigan S and Shah M (1984) Chronic liposome administration in mice: Effects on reticuloendothelial function and tissue distribution. *J Pharmacol Exp Ther* **229**:267-275.

Allen TM, Newman MS, Woodle MC, Mayhew E and Uster PS (1995b) Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. *Int J Cancer* **62**:199-204.

Allen TM and Smuckler EA (1985) Liver pathology accompanying chronic liposome administration in mouse. *Res Commun Chem Pathol Pharmacol* **50**:281-290.

Allen TM and Stuart DD (1999) Liposome pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes, in *Liposomes: Rational Design* (Janoff AS ed) pp 63-87, Marcel Dekker, Inc, New York.

Allen TM, Williamson P and Schlegel RA (1988) Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. *Proc Natl Acad Sci USA* **85**:8067-8071.

Allison BA, Pritchard PH, Richter AM and Levy JG (1990) The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. *Photochem Photobiol* **52**:501-507.

Alving CR and Wassef NM (1992) Complement-dependent phagocytosis of liposomes: Suppression by "stealth" lipids. *J Liposome Res* **2**:383-395.

Amantea M, Newman MS, Sullivan TM, Forrest A and Working PK (1999) Relationship of dose intensity to the induction of palmar-plantar erythrodysesthesia by pegylated liposomal doxorubicin in dogs. *Hum Exp Toxicol* **18**:17-26.

Amantea MA, Forrest A, Northfelt DW and Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. *Clin Pharmacol Ther* **61**:301-311.

Antony AC (1992) The biological chemistry of folate receptors. *Blood* **79**:2807-2820.

Antony AC (1996) Folate receptors. *Annu Rev Nutr* **16**:501-521.

Aragón D and Leserman LD (1986) Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. *Proc Natl Acad Sci USA* **83**:2699-2703.

Averbuch SD, Boldt M, Gaudiano G, Stern JB, Koch TH and Bachur NR (1988) Experimental chemotherapy-induced skin necrosis in swine: Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. *J Clin Invest* **81**:142-148.

Averbuch SD, Gaudiano G, Koch TH and Bachur NR (1985) Radical dimer rescue of toxicity and improved therapeutic index of adriamycin in tumor-bearing mice. *Cancer Res* **45**:6200-6204.

Averbuch SD, Gaudiano G, Koch TH and Bachur NR (1986) Doxorubicin-induced skin necrosis in the swine model: Protection with a novel radical dimer. *J Clin Oncol* **4**:88-94.

Bach D, Miller IR and Sela BA (1982) Calorimetric studies on various gangliosides and ganglioside-lipid interactions. *Biochim Biophys Acta* **686**:233-239.

Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonnell M, Ginsberg RS and Falk RE (1989) Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. *Cancer Chemother Pharmacol* **23**:81-86.

Bally MB, Lim H, Cullis PR and Mayer LD (1998) Controlling the drug delivery attributes of lipid-based drug formulations. *J Liposome Res* **8**:299-335.

Bally MB, Masin D, Nayar R, Cullis PR and Mayer LD (1994) Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. *Cancer Chemother Pharmacol* **34**:137-146.

Bally MB, Nayar R, Masin D, Cullis PR and Mayer LD (1990a) Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. *Cancer Chemother Pharmacol* **27**:13-19.

Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR and Mayer LD (1990b) Liposomes with entrapped doxorubicin exhibit extended blood residence times. *Biochim Biophys Acta* **1023**:133-139.

Banerjee G, Nandi G, Mahato SB, Pakrashi A and Basu MK (1996) Drug delivery system: Targeting of pentamidine to specific sites using sugar grafted liposomes. *J Antimicrob Chemother* **38**:145-150.

Barenholz Y (1998) Design of liposome-based drug carriers: From basic research to application as approved drugs, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 545-565, Elsevier Science BV, New York.

Barenholz Y, Amselem S, Goren D, Cohen R, Gelvan D, Samuni A, Golden EB and Gabizon A (1993) Stability of liposomal doxorubicin formulations: Problems and prospects. *Med Res Rev* **13**:449-491.

Barenholz Y and Cohen R (1995) Rational design of amphiphile-based drug carriers and sterically stabilized carriers. *J Liposome Res* **5**:905-932.

Barton PG and Gunstone FD (1975) Hydrocarbon chain packing and molecular motion in phospholipid bilayers formed from unsaturated lecithins: Synthesis and properties of sixteen positional isomers of 1,2-dioctadecenyl-sn-glycero-3-phosphorylcholine. *J Biol Chem* **250**:4470-4476.

Basanez G, Goni FM and Alonso A (1997) Poly(ethylene glycol)-lipid conjugates inhibit phospholipase C-induced lipid hydrolysis, liposome aggregation and fusion through independent mechanisms. *FEBS Lett* **411**:281-286.

Batist G, Winer E, Navari R, Rovira D and Azarnia N (1998) Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomized trial of metastatic breast carcinoma (MBC) (Abstract). *Proc Am Soc Clin Oncol* **17**:115.

Baxter LT and Jain RK (1990) Transport of fluid and macromolecules in tumors. II. Role of heterogeneous pressure and convection. *Microvasc Res* **40**:246-263.

Beaumer PL, Hwang KJ and Slattery JT (1983) Effect of liposome dose on the elimination of small unilamellar sphingomyelin/cholesterol vesicles from the circulation. *Res Commun Chem Pathol Pharmacol* **39**:277-289.

Benjamin RS, Wiernik PH and Bachur NR (1974) Adriamycin. *Ann Intern Med* **81**:414-415.

Bennett CL, Golub RM, Stinson TJ, Aboulafia DM, von Roenn J, Bogner J, Goebel FD and Stewart S (1998) Cost-effectiveness analysis comparing liposomal anthra-

114

- cyclines in the treatment of AIDS-related Kaposi's sarcoma. *J Acquir Immune Defic Syndr Hum Retrovirol* 18:460-465.
- Berinstein N, Matthay KK, Papahadjopoulos D, Levy R and Sikic BI (1987) Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition. *Cancer Res* 47:5954-5959.
- Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A and Martin FJ (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. *Ann Oncol* 9:711-716.
- Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venurini M, Del Mastro L, Garrone O, Rosso R and Dini D (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. *J Clin Oncol* 13:2851-2855.
- Blasberg RG, Kobayashi T, Patlak CS, Shinohara M, Miyoaka M, Rice JM and Shapiro WR (1981) Regional blood flow, capillary permeability, and glucose utilization in two brain tumor models: Preliminary observations and pharmacokinetic implications. *Cancer Treat Rep* 65 (Suppl 2):3-12.
- Blume G and Ceve G (1993) Molecular mechanism of the lipid vesicle longevity in vivo. *Biochim Biophys Acta* 1146:157-168.
- Boggs JM, Wang HY, Rangaraj G and Tummier B (1989) Interdigitation of phosphatidylcholine and phosphatidylethanolamine mixed with complexes of acidic lipids and polymyxin B or polymyxin B nonapeptide. *Biochim Biophys Acta* 985: 199-210.
- Boman NL, Masin D, Mayer LD, Cullis PR and Bally MB (1994) Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. *Cancer Res* 54:2830-2833.
- Boman NL, Mayer LD and Cullis PR (1993) Optimization of the retention properties of vincristine in liposomal systems. *Biochim Biophys Acta* 1152:253-258.
- Brown PM and Silvius JR (1990) Mechanisms of delivery of liposome-encapsulated cytosine arabinoside to CV-1 cells in vitro: Fluorescence-microscopic and cytotoxicity studies. *Biochim Biophys Acta* 1023:341-351.
- Buiting AMJ, Zhou F, Bakker JAJ, Rooijen Nv and Huang L (1996) Biodistribution of clodronate and liposomes used in the liposome mediated macrophage "suicide" approach. *J Immunol Methods* 192:55-62.
- Burke TG and Gao X (1994) Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. *J Pharm Sci* 83:967-969.
- Burke TG, Mishra AK, Wani M and Wall ME (1993) Lipid bilayer partitioning and stability of camptothecin drugs. *Biochemistry* 32:5352-5364.
- Cabanes A, Tzemach D, Goren D, Horowitz AT and Gabizon A (1998) Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. *Clin Cancer Res* 4:499-505.
- Carpenter CP, Woodside MD, Kinkead ER, King JM and Sullivan LJ (1971) Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. *Toxicol Appl Pharmacol* 18:35-40.
- Carter SK and Livingston RB (1976) Plant products in cancer chemotherapy. *Cancer Treat Rep* 60:1141-1156.
- Casper ES, Schwartz GK, Sugarman A, Leung D and Brennan MF (1997) Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. *J Clin Oncol* 15:2111-2117.
- Chabner BA and Longo DL (1996) *Cancer Chemotherapy and Biotherapy: Principles and Practice*, Lippincott-Raven, Philadelphia.
- Chang CW, Barber L, Ouyang C, Masin D, Bally MB and Madden TD (1997) Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. *Br J Cancer* 75:169-177.
- Chapman DE and Powis G (1993) Tumor cell drug metabolism and drug resistance, in *Drug Resistance in Oncology* (Teicher B ed) pp 413-459, Marcel Dekker, Inc, New York.
- Chobanian JV, Tall AR and Brecher PI (1979) Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoprotein. *Biochemistry* 18:180-187.
- Chonn A, Semple SC and Cullis P (1992) Association of blood proteins with large unilamellar liposomes in vivo: Relation to circulation lifetimes. *J Biol Chem* 267:18759-18765.
- Chonn A, Semple SC and Cullis PR (1995) β 2-Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. *J Biol Chem* 270:25845-25849.
- Chow DD, Essien HE, Padki MM and Hwang KJ (1989) Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. *J Pharmacol Exp Ther* 248:506-513.
- Chu C-J, Dijkstra J, Lai M-Z, Hong K and Szoka FC (1990) Efficiency of cytoplasmic delivery by pH sensitive liposomes to cells in culture. *Pharm Res* 7:824-834.
- Chu C-J and Szoka FC (1992) Antiviral activity and pharmacokinetics of liposome-encapsulated phosphonoformate in Rauscher murine leukemia virus-infected mice. *J Liposome Res* 2:67-92.
- Clemons M, Gharif R and Howell A (1998) The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors. *Cancer Treat Res* 24:173-184.
- Clerc S and Barenholz Y (1995) Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. *Biochim Biophys Acta* 1240:257-265.
- Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E and Saville (1998) Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (Stealth) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. *Clin Cancer Res* 4:3077-3082.
- Collins PD, Connolly DT and Williams TJ (1993) Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. *Br J Pharmacol* 109:195-199.
- Conley BA, Egorin MJ, Whitacre MY, Carter DC and Zuhowski EG (1993) Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. *Cancer Chemother Pharmacol* 33:107-112.
- Coukell AJ and Spencer CM (1997) Polyethylene glycol-liposomal doxorubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. *Drugs* 53:520-538.
- Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilikiewicz F, Ginsberg R and Petrelli N (1993) Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). *Cancer Res* 53:2796-2802.
- Crommelin DJ (1984) Influence of lipid composition and ionic strength on the physical stability of liposomes. *J Pharm Sci* 73:1559-1563.
- Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD and Fenske DB (1997) Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. *Biochim Biophys Acta* 1331:187-211.
- Daemen T, Hofstede G, Kate MTT, Bakker-Woudenberg IAJM and Scherphof G (1995) Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. *Int J Cancer* 61:716-721.
- Daemen T, Regts J, Meesters M, Ten Kate MT, Bakker-Woudenberg IAJM and Scherphof GL (1997) Toxicity of doxorubicin entrapped within long-circulating liposomes. *J Control Release* 44:1-9.
- Damen J, Dijkstra J, Regts J and Scherphof G (1980) Effect of lipoprotein-free plasma on the interaction of human plasma high density lipoprotein with egg yolk phosphatidylcholine liposomes. *Biochim Biophys Acta* 620:90-99.
- Damen J, Regts J and Scherphof G (1981) Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins: Dependence on cholesterol content and phospholipid composition. *Biochim Biophys Acta* 665:538-545.
- Debs RJ, Heath TD and Papahadjopoulos D (1987) Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration. *Biochim Biophys Acta* 901:183-190.
- Dellian M, Witwer BP, Salehi HA, Yuan F and Jain RK (1996) Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor/vascular permeability factor, and host microenvironment. *Am J Pathol* 149:59-71.
- Devine DV and Marjan JMJ (1997) The role of immunoproteins in the survival of liposomes in the circulation. *CRC Crit Rev Ther Drug Carrier Syst* 14:105-131.
- Devine DV, Wong K, Serrano K, Chonn A and Cullis PR (1994) Liposome-complement interactions in rat serum: Implications for liposome survival studies. *Biochim Biophys Acta* 1191:43-51.
- Dijkstra J, van Galen WJM, Hulstaert CE, Kalicharan D, Roerdink FH and Scherphof GL (1984) Interaction of liposomes with Kupffer cells in vitro. *Exp Cell Res* 150:161-176.
- Doroshaw JH (1996) Anthracyclines and anthracenediones, in *Cancer Chemotherapy and Biotherapy: Principles and Practice* (Chabner BA and Longo DL eds) pp 409-433, Lippincott-Raven Publishers, Philadelphia.
- Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. *Blood Rev* 4:41-60.
- Eckardt JR, Campbell E, Burris HA, Weiss GR, Rodriguez GI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenberg ML, Ross ME and Von Hoff DD (1994) A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. *Am J Clin Oncol* 17:498-501.
- Embrece L, Gelmon KA, Lohr A, Mayer LD and Goldman AJ (1993) Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. *J Pharm Sci* 82:627-634.
- Embrece L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB and Mayer LD (1998) Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. *Cancer Chemother Pharmacol* 41:347-352.
- Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. *Annu Rev Biochem* 58:137-171.
- Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S and Stephens R (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. *Invest New Drugs* 8:57-63.
- Fan D, Bucana CD, O'Brian CA, Zwelling LA, Seid C and Fidler IJ (1990) Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. *Cancer Res* 50:3619-3626.
- Folkman J (1971) Tumor angiogenesis: Therapeutic implications. *N Engl J Med* 285:1182-1186.
- Folkman J (1985) Tumor angiogenesis. *Adv Cancer Res* 43:175-203.
- Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* 82:4-6.
- Fonseca GA, Valero V, Buzdar A, Walters R, Willey J, Benjamin R, Ewer M, Mackay B, Gordon D and Hortobagyi G (1995) Decreased cardiac toxicity of TLC D-99 (liposomal doxorubicin) in the treatment of metastatic breast carcinoma (MBC) (Abstract). *Proc Am Soc Clin Oncol* 14:99.
- Forssen E and Willis M (1998) Ligand-targeted liposomes. *Adv Drug Delivery Rev* 29:249-271.
- Forssen EA, Coulter DM and Proffitt RT (1992) Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. *Cancer Res* 52:3255-3261.
- Forssen EA, Male-Brune R, Adler-Moore JP, Lee MJA, Schmidt PG, Krasieva TB, Shimizu S and Tromberg BJ (1996) Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome®) within tumor tissue. *Cancer Res* 56:2066-2075.
- Forssen EA and Ross ME (1994) DaunoXome® treatment of solid tumors: Preclinical and clinical investigations. *J Liposome Res* 4:481-512.
- Frankel EN (1980) Lipid oxidation. *Prog Lipid Res* 19:1-22.
- Frankel EN (1985) Chemistry of free radical and singlet oxidation of lipids. *Prog Lipid Res* 23:197-221.
- Frankel EN (1987a) Biological significance of secondary lipid oxidation products. *Free Radic Res Commun* 3:213-225.
- Frankel EN (1987b) Secondary products of lipid oxidation. *Chem Phys Lipids* 44:73-85.

- Frézard F (1994) Fluorimetric determination in biological fluids of the release kinetics of liposome-entrapped doxorubicin. *J Liposome Res* 4:1063-1073.
- Frézard F, Santaella C, Montisci M-J, Vierling P and Riess JG (1994) Fluorinated phosphatidylcholine-based liposomes: H⁺/Na⁺ permeability, active doxorubicin encapsulation and stability in human serum. *Biochim Biophys Acta* 1194:61-68.
- Fujimori K, Covell DG, Fletcher JE and Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')₂, and Fab in tumors. *Cancer Res* 49:5656-5663.
- Fukumura D, Yuan F, Monsky WL, Chen Y and Jain RK (1997) Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. *Am J Pathol* 151:679-688.
- Gaber MH, Hong K, Huang SK and Papahadjopoulos D (1995) Thermosensitive sterically stabilized liposomes: Formulation and in vitro studies on the mechanism of doxorubicin release by bovine serum and human plasma. *Pharm Res* 12:1407-1416.
- Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW and Papahadjopoulos D (1996) Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks. *Int J Radiat Oncol Biol Phys* 36:1177-1187.
- Gabizon A, Catane R, Uziely B, Kaufman B and Safra T (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. *Cancer Res* 54:987-992.
- Gabizon A, Chemla M, Tzemach D, Horowitz AT and Goren D (1996) Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. *J Drug Target* 3:391-398.
- Gabizon A, Chisin R, Amselem S, Druckmann S, Cohen R, Goren D, Fromer I, Peretz T, Sulkes A and Barenholz Y (1991) Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. *Br J Cancer* 64:1125-1132.
- Gabizon A, Goren D, Fuks Z, Barenholz Y and Dagan A (1983) Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. *Cancer Res* 43:4730-4735.
- Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A and Siegal T (1997) Long-circulating liposomes for drug delivery in cancer therapy: A review of bio-distribution studies in tumor-bearing animals. *Adv Drug Del Rev* 24:337-344.
- Gabizon A and Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. *Drugs* 54 (Suppl 4):15-21.
- Gabizon A, Meshorer A and Barenholz Y (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. *J Natl Cancer Inst* 77:459-469.
- Gabizon A and Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumors. *Proc Natl Acad Sci USA* 85:6949-6953.
- Gabizon A and Papahadjopoulos D (1992) The role of surface charge and hydrophilic groups on liposome clearance in vivo. *Biochim Biophys Acta* 1103:94-100.
- Gabizon A, Peretz T, Sulkes A, Amselem S, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S and Barenholz Y (1989) Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study. *Eur J Cancer Clin Oncol* 25:1795-1803.
- Gabizon A, Price DC, Huberty J, Bresalier RS and Papahadjopoulos D (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. *Cancer Res* 50:6371-6378.
- Gabizon AA (1994) Liposomal anthracyclines. *Hematol Oncol Clin North Am* 8:431-450.
- Gabizon AA (1995) Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. *Adv Drug Del Rev* 16:285-294.
- Gabizon AA (1998) Clinical trials of liposomes as carriers of chemotherapeutic agents: synopsis and perspective, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 625-634, Elsevier Science BV, New York.
- Gabizon AA, Barenholz Y and Bialer M (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. *Pharm Res* 10:703-708.
- Gamon BL, Virden JW and Berg JC (1989) The aggregation kinetics of an electrically stabilized dipalmitoylphosphatidylcholine vesicle system. *J Colloid Interface Sci* 132:125-138.
- Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P and Mayer LD (1999) Phase I study of liposomal vincristine. *J Clin Oncol* 17:697-705.
- Gigli M, Doglia SM, Millot JM, Valentini L and Manfait M (1988) Quantitative study of doxorubicin in living cell nuclei by microspectrofluorimetry. *Biochim Biophys Acta* 950:13-20.
- Gill P, Rarick M, Bernstein-Singer M, Harb M, Espina BM, Shaw V and Levine A (1990) Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. *Am J Clin Oncol* 13:315-319.
- Gill PS, Espina BM, Muggia F, Cabriaes S, Tulpule A and Esplin JA (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. *J Clin Oncol* 13:996-1003.
- Gill PS, Miles SA, Mitsuyasu RT, Montgomery T, McCarthy S, Espina BM, Feldstein M and Levine AM (1994) Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. *AIDS* 8:1695-1699.
- Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, Bernstein-Singer M, Akil B, Espina BM, Krailo M and Levine A (1991) Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. *Am J Med* 90:427-433.
- Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, Vonroenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC and Ross ME (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 14:2353-2364.
- Girard PM, Bouchaud O, Goetschel A, Mukwaya G, Eestermans G and Ross M (1996) Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. *AIDS* 10:753-757.
- Goodwin GC, Hammond K, Lyle IG and Jones MN (1982) Lectin-mediated agglutination of liposomes containing glycophorin: Effects of acyl chain length. *Biochim Biophys Acta* 689:80-88.
- Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR and VonRoenn J (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. *Cancer* 75:2169-2173.
- Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y and Gabizon A (1996) Targeting of stealth liposomes to erbB-2 (Her2) receptor: In vitro and in vivo studies. *Br J Cancer* 74:1749-1756.
- Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem* 62:385-427.
- Gregoriadis G (1976) The carrier potential of liposomes in biology and medicine. *N Engl J Med* 295:704-710.
- Gregoriadis G and Davis C (1979) Stability of liposome in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. *Biochem Biophys Res Commun* 89:1287-1293.
- Gregoriadis G and Senior J (1980) The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. *FEBS Lett* 119:43-46.
- Haran G, Cohen R, Bar LK and Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphatic weak bases. *Biochim Biophys Acta* 1151:201-215.
- Harashima H, Sakata K and Kiwada H (1993) Distinction between depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes. *Pharm Res* 10:606-610.
- Harasym TO, Cullis PR and Bally MB (1997) Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. *Cancer Chemother Pharmacol* 40:309-317.
- Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ and Cullis PR (1993) Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. *Biochim Biophys Acta* 1149:329-338.
- Harris L, Winer E, Batist G, Rovira D, Navaria R and Lee L (1998) Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC) (Abstract). *Proc Am Soc Clin Oncol* 17:124.
- Harrison M, Tomlinson D and Stewart S (1995) Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 13:914-920.
- Harvie P, Désormeaux A, Bergeron M-C, Tremblay M, Beauchamp D, Poulin L and Bergeron MG (1996) Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine. *Antimicrob Agents Chemother* 40:225-229.
- Heath TD and Brown CS (1989) Liposome dependent delivery of N-(phosphonyl)-L-aspartic acid to cells in vitro. *J Liposome Res* 1:303-317.
- Heath TD, Montgomery JA, Piper JR and Papahadjopoulos D (1983) Antibody-targeted liposomes: Increase in specific toxicity of methotrexate-γ-aspartate. *Proc Natl Acad Sci USA* 80:1377-1381.
- Hengge UR, Brockmeyer NH, Rabhofer R and Goos M (1993) Hepatic failure with liposomal doxorubicin. *Lancet* 341:383-384.
- Henry D (1997) Haematological toxicities associated with dose-intensive chemotherapy: The role for and use of recombinant growth factors. *Ann Oncol* 8:S7-S10.
- Herman EH, Rahman A, Ferrans VJ, Vick JA and Schein PS (1983) Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. *Cancer Res* 43:5427-5432.
- Heuff G, Oldenburg HSA, Boutkan H, Visser JJ, Beelen RHJ, Van Rooijen N, Dijkstra CD and Meyer S (1993) Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. *Cancer Immunol Immunother* 37:125-130.
- Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP and Jain RK (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. *Proc Natl Acad Sci USA* 95:4607-4612.
- Hoff PM, Valero V, Ibrahim N, Willey J and Hortobagyi GN (1998) Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. *Cancer* 82: 965-969.
- Holash J, Maisonnier PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD and Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science (Wash DC)* 284:1994-1998.
- Holland JW, Cullis PR and Madden TD (1996a) Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer forming lipids. *Biochemistry* 35:2610-2617.
- Holland JW, Hui C, Cullis PK and Madden TD (1996b) Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. *Biochemistry* 35:2618-2624.
- Holmgren L, O'Reilly MS and Folkman J (1995) Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nat Med* 1:149-153.
- Horowitz AR, Barenholz Y and Gabizon AA (1992) In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. *Biochim Biophys Acta* 1109:203-209.
- Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B and Benjamin RS (1989) Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. *Cancer* 63:37-45.
- Huang A, Kennel SJ and Huang L (1983) Interactions of immunoliposomes with target cells. *J Biol Chem* 258:14034-14040.
- Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D and Friend DS (1993) Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV Tat gene. *Am J Pathol* 143:10-14.
- Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ and Papahadjopoulos D (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. *Cancer Res* 52:6774-6781.

- Huang SK, Stauffer PR, Hong K, Guo JWH, Phillips TL, Huang A and Papahadjopoulos D (1994) Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. *Cancer Res* 54:2186-2191.
- Hwang KJ (1987) Liposome Pharmacokinetics, in *Liposomes: From Biophysics to Therapeutics* (Ostro MJ ed) pp 109-156, Marcel Dekker, Inc, New York.
- Jain R (1987) Transport of molecules in the tumor interstitium: A review. *Cancer Res* 47:3039-3051.
- Jain RK (1989) Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. *J Natl Cancer Inst* 81:570-576.
- Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. *Cancer Res* 50 (3 Suppl):814s-819s.
- Jain RK (1996) Delivery of molecular medicine to solid tumors. *Science (Wash DC)* 271:1079-1080.
- Jain RK and Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. *Cancer Res* 48:7022-7032.
- Jett M, Chudzik J, Alving CR and Stanacev NZ (1985) Metabolic fate of liposomal phosphatidylinositol in murine tumor cells: Implications for the mechanism of tumor cell cytotoxicity. *Cancer Res* 45:4810-4815.
- Jones CB, Clements MK, Wasi S and Daoud SS (1997) Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. *Cancer Chemother Pharmacol* 40:475-483.
- Jones M and Hudson MJH (1993) The targeting of immunoliposomes to tumour cells (A431) and the effects of encapsulated methotrexate. *Biochim Biophys Acta* 1152: 231-242.
- Kamen BA, Smith AK and Anderson RGW (1991) The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. *J Clin Invest* 87:1442-1449.
- Kanter PM, Bullard GA, Ginsberg RA, Pilkievicz FG, Mayer LD, Cullis PD and Pavelic ZP (1993) Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. *In Vivo* 7:17-26.
- Kanter PM, Klaich GM, Bullard GA, King JM, Bally M and Mayer LD (1994) Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats, and dogs. *Anticancer Drugs* 5:579-590.
- Kirpotin D, Hong K, Mullah N, Papahadjopoulos D and Zalipsky S (1996) Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). *FEBS Lett* 388:115-118.
- Kirpotin D, Park JW, Hong K, Zalipsky S, Li W-L, Carter P, Benz CC and Papahadjopoulos D (1997b) Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. *Biochemistry* 36:66-75.
- Kirpotin DB, Park JW, Demetozos K, Meyer O, Colbern G, Uster P and Hong K (1999a) Stealth liposomal vinorelbine: Synthesis, stability and antitumor activity against human breast and lung cancer xenografts (Abstract). *Proc Am Assoc Cancer Res* 40:417.
- Kirpotin DB, Park JW, Hong K, Shao Y, Colbern G, Zheng W-W, Meyer O, Benz CC and Papahadjopoulos D (1998) Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 325-345, Elsevier Science BV, New York.
- Kirpotin DB, Park JW, Hong K, Shao Y, Shalaby R, Colbern G, Benz CC and Papahadjopoulos D (1997a) Targeting of liposomes to solid tumors: The case of sterically stabilized anti-HER2 immunoliposomes. *J Liposome Res* 7:391-417.
- Kirpotin DB, Stauffer PS, Diedrich CJ, Hong K, Shao Y, Park JW, Benz CC and Papahadjopoulos D (1999b) Optimization of liposome uptake by human breast cancer xenografts in response to hyperthermia. 18th Annual Meeting of North American Hyperthermia Society; 1999 April 8-10; Philadelphia.
- Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP and Huang L (1991) Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposomes binding to target. *Biochim Biophys Acta* 1062:142-148.
- Klibanov AL, Maruyama K, Torchilin VP and Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett* 268: 235-237.
- Krill SL, Knutson K and Higuchi WI (1992) Ethanol effects on the stratum corneum lipid phase behavior. *Biochim Biophys Acta* 1112:273-280.
- Krishna R and Mayer LD (1997) Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. *Cancer Res* 57:5246-5253.
- Lasic D and Martin F (1995) *Stealth Liposomes*, CRC Press, Boca Raton, FL.
- Lasic DD (1993) *Liposomes: From Physics to Applications*, Elsevier, New York.
- Lasic DD, Ceh B, Stuart MCA, Guo L, Frederik PM and Barenholz Y (1995) Transmembrane gradient driven phase transitions within vesicles: Lessons for drug delivery. *Biochim Biophys Acta* 1239:145-156.
- Lasic DD, Frederik PM, Stuart MCA, Barenholz Y and McIntosh TJ (1992a) Gelation of liposome interior: A novel method for drug encapsulation. *FEBS Lett* 312:255-258.
- Lasic DD, Martin FJ, Gabizon A, Huang SK and Papahadjopoulos D (1991) Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. *Biochim Biophys Acta* 1070:187-192.
- Lasic DD and Needham D (1995) The "stealth" liposome: A prototypical biomaterial. *Chem Rev* 95:2601-2628.
- Lasic DD and Papahadjopoulos D (1996) Liposomes and copolymers in drug and gene delivery. *Curr Opin Solid State Mater Sci* 1:392-400.
- Lasic DD, Woodle MC and Papahadjopoulos D (1992b) On the molecular mechanism of steric stabilization of liposomes in biological fluids. *J Liposome Res* 2:335-353.
- Lee RJ and Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. *J Biol Chem* 269:3198-3204.
- Lee RJ and Low PS (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. *Biochim Biophys Acta* 1233:134-144.
- Legha SS, Hortobagyi GN and Benjamin RS (1987) Anthracyclines, in *Cancer Chemotherapy by Infusion* (Lokich JJ ed) pp 130-144, Precept Press, Inc, Chicago.
- Levin VA, Patlak CS and Landahl HD (1980) Heuristic modeling of drug delivery to malignant brain tumors. *J Pharmacokinet Biopharm* 8:257-275.
- Levy MH and Wheelock EF (1974) The role of macrophages in defense against neoplastic disease. *Adv Cancer Res* 20:131-163.
- Lieschke GJ, Foote M and Morstyn G (1997) Hematopoietic growth factors in cancer chemotherapy. *Cancer Chemother Biol Response Modif* 17:363-389.
- Lim HJ, Masin D, Madden TD and Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. *J Pharmacol Exp Ther* 281:566-573.
- Litzinger DC, Buiting AMJ, van Rooijen N and Huang L (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. *Biochim Biophys Acta* 1190:99-107.
- Litzinger DC and Huang L (1992) Phosphatidylethanolamine liposomes: Drug delivery, gene transfer, and immunodiagnostic applications. *Biochim Biophys Acta* 1113:201-227.
- Liu D and Huang L (1989) Role of cholesterol in the stability of the pH-sensitive, large unilamellar liposomes prepared by the detergent dialysis method. *Biochim Biophys Acta* 981:254-260.
- Liu D and Huang L (1990) pH-sensitive, plasma-stable liposomes with relatively prolonged residence in circulation. *Biochim Biophys Acta* 1022:348-354.
- Liu D, Mori A and Huang L (1992) Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM₁-containing liposomes. *Biochim Biophys Acta* 1104:95-101.
- Lokich JJ and Moore C (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. *Ann Intern Med* 101:798-800.
- Lopes de Menezes DE, Pilarski LM and Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. *Cancer Res* 58:3320-3330.
- Lum H and Malik AB (1994) Regulation of vascular endothelial barrier function. *Am J Physiol* 267:L223-L241.
- Lundberg B, Hong K and Papahadjopoulos D (1993) Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. *Biochim Biophys Acta* 1149:305-312.
- Machy P, Barbet J and Leserman LD (1982) Differential endocytosis of T and B lymphocyte surface molecules evaluated with antibody-bearing fluorescent liposomes containing methotrexate. *Proc Natl Acad Sci USA* 79:4148-4152.
- Madden TD, Harrigan PR, Tai LCL, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinish LW and Cullis PR (1990) The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. *Chem Phys Lipids* 53:37-46.
- Maeda H (1991) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. *Adv Drug Del Rev* 6:181-202.
- Maeda H and Matsumura Y (1989) Tumorotropic and lymphotropic principles of macromolecular drugs. *CRC Crit Rev Ther Drug Carrier Syst* 6:193-210.
- Martin FJ (1998) Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 635-688, Elsevier Science BV, New York.
- Maruyama K, Holmberg E, Kennel SJ, Klibanov A, Torchilin VP and Huang L (1990a) Characterization of in vivo immunoliposome targeting to pulmonary endothelium. *J Pharm Sci* 79:978-984.
- Maruyama K, Kennel SJ and Huang L (1990b) Lipid composition is important for highly efficient target binding and retention of immunoliposomes. *Proc Natl Acad Sci USA* 87:5744-5748.
- Matsumura Y and Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent SMANCS. *Cancer Res* 46:6387-6392.
- Matthay KK, Abai AM, Cobb S, Hong K, Papahadjopoulos D and Straubinger RM (1989) Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. *Cancer Res* 49:4879-4886.
- Matthay KK, Heath TD, Badger CC, Bernstein ID and Papahadjopoulos D (1986) Antibody-directed liposomes: Comparison of various ligands for association, endocytosis, and drug delivery. *Cancer Res* 46:4904-4910.
- Mayer LD, Bally MB, Cullis PR, Wilson SL and Emerman JT (1990a) Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. *Cancer Lett* 53:183-190.
- Mayer LD, Bally MB, Hope MJ and Cullis PR (1985) Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. *Biochim Biophys Acta* 816:294-302.
- Mayer LD, Bally MB, Loughrey H, Masin D and Cullis PR (1990b) Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. *Cancer Res* 50:575-579.
- Mayer LD, Cullis PR and Bally MB (1998) Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes, in *Medical Applications of Liposomes* (Papahadjopoulos D and Lasic D, eds) pp 231-257, Elsevier Science BV, New York.
- Mayer LD, Dougherty G, Harasym TO and Bally MB (1997) The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. *J Pharmacol Exp Ther* 280:1406-1414.
- Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR and Bally MB (1993) Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia. *Cancer Chemother Pharmacol* 33:17-24.
- Mayer LD, Tai LCL, Bally MB, Mitlenes GN, Ginsberg RS and Cullis PR (1990c) Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. *Biochim Biophys Acta* 1025:143-151.
- Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR and Bally MB (1989)

11X

- Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. *Cancer Res* 49:5922-5930.
- Mayhew E, Rustum YM, Szoka F and Papahadjopoulos D (1979) Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. *Cancer Treat Rep* 63:1923-1928.
- Mayhew EG, Goldrosen MH, Vaage J and Rustum YM (1987) Effects of liposome-entrapped doxorubicin in liver metastases of mouse colon carcinomas 26 and 38. *J Natl Cancer Inst* 78:707-713.
- Mayhew EG, Lasic D, Babbar S and Martin FJ (1992) Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. *Int J Cancer* 51:302-309.
- Meyer O, Kirpotin D, Hong K, Sternberg B, Park JW, Woodle MC and Papahadjopoulos D (1998a) Cationic liposomes coated with polyethylene glycol as carriers of oligonucleotides. *J Biol Chem* 273:15621-15627.
- Meyer O, Papahadjopoulos D and Leroux J-C (1998b) Copolymers of N-isopropylacrylamide can trigger pH sensitivity to stable liposomes. *FEBS Lett* 421:61-64.
- Mickisch GH, Rahman A, Pastan I and Gottesman MM (1992) Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. *J Natl Cancer Inst* 84:804-805.
- Mitsuyasu R, von Roenn J, Krown S, Kaplan L and Testa M (1997) Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286 (Abstract). *Proc Am Soc Clin Oncol* 16:55.
- Mori A, Kennel SJ and Huang L (1993) Immunotargeting of liposome containing lipophilic antitumor prodrugs. *Pharm Res* 10:507-514.
- Mori A, Kennel SJ, Waalkes MvB, Scherphof GL and Huang L (1995) Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model. *Cancer Chemother Pharmacol* 35:447-456.
- Mori A, Klivanov AL, Torchilin VP and Huang L (1991) Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. *FEBS Lett* 284:263-266.
- Mori A, Wu S-P, Han I, Khokhar AR, Perez-Soler R and Huang L (1996) In vivo antitumor activity of *cis*-bis-neodecanoato-*trans*-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. *Cancer Chemother Pharmacol* 37:435-444.
- Muggia FM (1997) Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. *Drugs* 54:22-29.
- Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muterspach L, Garcia A, Burnett A and Greco FA (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. *J Clin Oncol* 15:987-993.
- Mui BL-S, Cullis PR, Evans EA and Madden TD (1993) Osmotic properties of large unilamellar vesicles prepared by extrusion. *Biophys J* 64:443-453.
- Mui BL-S, Cullis PR, Pritchard PH and Madden TD (1994) Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. *J Biol Chem* 269:7364-7370.
- Needham D, Hristova K, McIntosh TJ, Dewhirst M and Lasic DD (1992a) Polymer-grafted liposomes: Physical basis for the "stealth" property. *J Liposome Res* 2:411-430.
- Needham D, McIntosh TJ and Lasic DD (1992b) Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. *Biochim Biophys Acta* 1108:40-48.
- Needham D, Zhelev DV and McIntosh TJ (1999) Surface chemistry of the sterically stabilized PEG-liposome, in *Liposomes: Rational Design* (Janoff AS ed) pp 13-62, Marcel Dekker, Inc, New York.
- Nemunaitis J (1997) A comparative review of colony-stimulating factors. *Drugs* 54:709-729.
- Newman MS, Colbern GT, Working PK, Engbers C and Amantea M (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. *Cancer Chemother Pharmacol* 43:1-7.
- Nichols JW and Deamer DW (1976) Catecholamine uptake and concentration by liposomes maintaining pH gradients. *Biochim Biophys Acta* 455:269-271.
- Northfelt DW (1994) AIDS-related Kaposi's sarcoma: Still a problem, still an opportunity. *J Clin Invest* 12:1109-1110.
- Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C and Mamelek RD (1997) Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. *J Clin Oncol* 15:653-659.
- Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Mond CD, Mamelek RD and Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. *J Clin Oncol* 16:2445-2451.
- Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA and Kaplan LD (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. *J Clin Pharmacol* 36:55-63.
- Oja CD, Semple SC, Chonn A and Cullis PR (1996) Influence of dose on liposome clearance: Critical role of blood proteins. *Biochim Biophys Acta* 1281:31-37.
- Olson F, Hunt CA, Szoka FC, Vail WJ and Papahadjopoulos D (1979) Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. *Biochim Biophys Acta* 557:9-23.
- Olson F, Mayhew E, Maslow D, Rustum Y and Szoka F (1982) Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. *Eur J Cancer Clin Oncol* 18:167-176.
- Oliver IN, Aisner J, Hamant A, Buchanan L, Bishop JF and Kaplan RS (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline. *J Clin Oncol* 6:1732-1735.
- Oudard S, Thierry A, Jorgensen TJ and Rahman A (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. *Cancer Chemother Pharmacol* 28:259-265.
- Oussoren C, Eling WMC, Crommelin DJA, Storm G and Zuidema J (1998) The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. *Biochim Biophys Acta* 1369:159-172.
- Owells RJ, Hartke CA, Dickerson RM and Hains FO (1976) Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. *Cancer Res* 36:1499-1502.
- Pak CC, Ali S, Janoff AS and Meers P (1997) Triggerable liposome fusion by enzymatic cleavage of a novel peptide-lipid conjugate. *Biochim Biophys Acta* 1372:13-27.
- Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthey K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C and Martin FJ (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. *Proc Natl Acad Sci USA* 88:11460-11464.
- Papahadjopoulos D, Cowden M and Kimelberg H (1973a) Role of cholesterol in membranes: Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. *Biochim Biophys Acta* 330:8-26.
- Papahadjopoulos D and Gabizon AA (1995) Sterically stabilized (Stealth®) liposomes: Pharmacological properties and drug carrying potential in cancer, in *Liposomes as Tools in Basic Research and Industry* (Philippot JR and Schuber F eds) pp 177-188, CRC Press, Boca Raton, FL.
- Papahadjopoulos D, Jacobson K, Nir S and Isac T (1973b) Phase transitions in phospholipid vesicles: Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. *Biochim Biophys Acta* 311:330-348.
- Papahadjopoulos D, Kirpotin DB, Park JW, Hong K, Shao Y, Shalaby R, Colbern G and Benz CC (1999) Targeting of drugs to solid tumors using anti-HER2 immunoliposomes. *J Liposome Res* 8:425-442.
- Papahadjopoulos D, Nir S and Oki S (1972) Permeability properties of phospholipid membranes: Effect of cholesterol and temperature. *Biochim Biophys Acta* 266:561-583.
- Parente RA, Nadasdi L, Subbarao NK and Szoka FC (1990) Association of a pH-sensitive peptide with membrane vesicles: Role of amino acid sequence. *Biochemistry* 29:8713-8719.
- Parente RA, Nir S and Szoka FC Jr (1988) pH-dependent fusion of phosphatidylcholine small vesicles: Induction by a synthetic amphipathic peptide. *J Biol Chem* 263:4724-4730.
- Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D and Benz CC (1995) Development of anti-p185^{HER2} immunoliposomes for cancer therapy. *Proc Natl Acad Sci USA* 92:1327-1331.
- Park JW, Hong K, Kirpotin DB, Papahadjopoulos D and Benz CC (1997) Immunoliposomes for cancer treatment. *Adv Pharmacol* 40:399-435.
- Park JW, Kirpotin D, Hong K, Colbern G, Shalaby R, Shao Y, Meyer O, Nielson U, Marks J, Benz CC and Papahadjopoulos D (1998a) Anti-HER2 immunoliposomes for targeted drug delivery. *Med Chem Res* 8:383-391.
- Park JW, Kirpotin D, Hong K, Zheng W, Shao Y, Meyer O, Benz CC and Papahadjopoulos D (1998b) Sterically stabilized immunoliposomes: Formulations for delivery of drugs and genes to tumor cells in vivo, in *Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems* (Gregoriadis G and McCormack B eds) pp 41-47, Plenum Press, New York.
- Park YS, Maruyama K and Huang L (1992) Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. *Biochim Biophys Acta* 1108:257-260.
- Parr MJ, Ansell SM, Choi LS and Cullis PR (1994) Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. *Biochim Biophys Acta* 1195:21-30.
- Parr MJ, Bally MB and Cullis PR (1993) The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. *Biochim Biophys Acta* 1168:249-252.
- Parr MJ, Masin D, Cullis PR and Bally MB (1997) Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects of coating liposomes with poly(ethylene glycol). *J Pharmacol Exp Ther* 280:1319-1327.
- Pastan I and Gottesman MM (1991) Multidrug resistance. *Annu Rev Med* 42:277-286.
- Patel HM (1992) Serum opsonins and liposomes: Their interaction and opsonophagocytosis. *CRC Crit Rev Ther Drug Carrier Syst* 9:39-90.
- Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Raber MN and Khokhar AR (1990) Phase I clinical and pharmacologic study of liposome-entrapped *cis*-bis-neodecanoato-*trans*-R,R-1,2-diaminocyclohexaneplatinum (II). *Cancer Res* 50:4252-4259.
- Perrin VL (1995) Clinical pharmacokinetics of ergotamine in migraine and cluster headache. *Clin Pharmacokinet* 10:334-352.
- Petros WP and Peters WP (1996) Colony-stimulating factors, in *Cancer Chemotherapy and Biotherapy: Principles and Practice* (Chabner BA and Longo DL eds) pp 639-654, Lippincott-Raven Publishers, Philadelphia.
- Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter G, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M and Rilke F (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. *Am J Pathol* 151:1417-1423.
- Pinnaduwage P and Huang L (1988) β -Galactosidase-induced destabilization of liposome composed of phosphatidylethanolamine and ganglioside GM1. *Biochim Biophys Acta* 939:375-382.
- Plageman PGW, Marz R and Wohlhueter RM (1978) Transport and metabolism of deoxycytidine and 1- β -D-arabinofuranosyl-cytosine into cultured Novikoff rap hep-

atoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. *Cancer Res* 38:978-989.

Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J and Presant J (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. *Lancet* 341:1242-1243.

Qian Q, Jutila MA, Van Rooijen N and Cutler JE (1994) Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. *J Immunol* 152:5000-5008.

Raghavan M and Bjorkman PJ (1996) Fc receptors and their interactions with immunoglobulins. *Annu Rev Cell Dev Biol* 12:181-220.

Rahman A, Husain SR, Siddiqui J, Verma M, Agresti M, Center M, Safa AR and Glazer RI (1992) Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. *J Natl Cancer Inst* 84:1909-1915.

Rahman A, Treat J, Roh JK, Potkul LA, Alvord WG, Forst D and Woolley PV (1990) A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. *J Clin Oncol* 8:1093-1100.

Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D and Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. *J Clin Oncol* 15:3185-3191.

Reddi E (1997) Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumors. *J Photochem Photobiol B* 37:189-195.

Richardson VJ and Ryman BE (1982) Effect of liposomally trapped antitumor drugs on a drug-resistant mouse lymphoma in vivo. *Br J Cancer* 45:552-558.

Ringel I and Horwitz SB (1987) Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. *J Pharmacol Exp Ther* 242:692-698.

Roberts WG and Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced endothelial growth factor. *J Cell Sci* 108:2369-2379.

Roh MS, Kahky MP, Oyedeji C, Klostergaard J, Wang L, Curley SA and Lotzová E (1992) Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. *Clin Exp Metastasis* 10:317-327.

Rosenecker J, Zhang W, Hong K, Lausier J, Geppetti P, Yoshihara S, Papahadjopoulos D and Nadel JA (1996) Increased liposome extravasation in selected tissues: Effect of substance P. *Proc Natl Acad Sci USA* 93:7236-7241.

Ross JF, Chaudhuri PK and Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. *Cancer* 73:2432-2443.

Rowinsky EK and Donehower RC (1996) Antimicrotubule agents, in *Cancer Chemotherapy and Biotherapy: Principles and Practice* (Chabner BA and Longo DL eds) pp 263-296, Lippincott-Raven Publishers, Philadelphia.

Sanchez-Migallon MP and Aranda FJ (1996) Interaction between α -tocopherol and heteroacid phosphatidylcholines with different amounts of unsaturation. *Biochim Biophys Acta* 1279:251-258.

Sankaram MB and Thompson TE (1990) Interaction of cholesterol with various glycerophospholipids and sphingomyelin. *Biochemistry* 29:10670-10675.

Scherer PG and Seelig J (1989) Electric charge effects on phospholipid headgroups. Phosphatidylcholine in mixtures with cationic and anionic amphiphiles. *Biochemistry* 28:7720-7728.

Scherphof G, Roerdink F, Waite M and Parks J (1978) Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. *Biochim Biophys Acta* 542:296-307.

Scherphof GL, Morselt H and Allen TM (1994) Intrahepatic distribution of long-circulating liposomes containing poly(ethylene glycol) distearoylphosphatidylethanolamine. *J Liposome Res* 4:213-228.

Schmidt CF, Barenholz Y and Thompson TE (1977) A nuclear magnetic resonance study of sphingomyelin in bilayer systems. *Biochemistry* 16:2649-2656.

Schmidt PG, Adler-Moore JP, Forssen EA and Proffitt RT (1998) Unilamellar liposomes for anticancer and antifungal therapy, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 703-731, Elsevier Science BV, New York.

Semple SC and Chonn A (1996) Liposome-blood protein interactions in relation to liposome clearance. *J Liposome Res* 6:33-60.

Semple SC, Chonn A and Cullis PR (1996) Influence of cholesterol on the association of plasma proteins with liposomes. *Biochemistry* 35:2521-2525.

Senior J, Crawley JCW and Gregoriadis G (1985) Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. *Biochim Biophys Acta* 839:1-8.

Senior J, Delgado C, Fisher D, Tilcock C and Gregoriadis G (1991) Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles. *Biochim Biophys Acta* 1062:77-82.

Senior J and Gregoriadis G (1982) Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. *Life Sci* 30:2123-2136.

Senior JH (1987) Fate and behaviour of liposomes in vivo: A review of controlling factors. *CRC Crit Rev Ther Drug Carrier Syst* 3:123-193.

Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. *CRC Crit Rev Ther Drug Carrier Syst* 9:135-187.

Sharma A, Mayhew E, Bolesak L, Cavanaugh C and Harmon P (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. *Int J Cancer* 71:103-107.

Sharma A, Sharma US and Straubinger RM (1996) Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. *Cancer Lett* 107:265-272.

Sharma A, Straubinger RM, Ojima I and Bernacki RJ (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. *J Pharm Sci* 84:1400-1404.

Siegel T, Horowitz A and Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. *J Neurosurg* 83:1029-1037.

Silberstein SD (1997) The pharmacology of ergotamine and dihydroergotamine. *Headache* 37 (Suppl 1):S15-S25.

Simpson JK, Miller RF and Spittle MF (1993) Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. *Clin Oncol* 5:372-374.

Singh M, Ghose T, Faulkner G, Kralovec J and Mezei M (1989) Targeting of methotrexate-containing liposomes with a monoclonal antibody against human renal cancer. *Cancer Res* 49:3976-3984.

Smaby JM, Momsen M, Kulkarni VS and Brown RE (1996) Cholesterol-induced interfacial area condensations of galactosylceramides and sphingomyelins with identical acyl chains. *Biochemistry* 35:5696-5704.

Spanjer HH and Scherphof GL (1983) Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo. *Biochim Biophys Acta* 734:40-47.

Speth PAJ, van Hoesel QGCM and Haanen C (1988) Clinical pharmacokinetics of doxorubicin. *Clin Pharmacokinet* 15:15-31.

Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleghaw J and Dezube BJ (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. *J Clin Oncol* 16:683-691.

Storm G, Oussoren C, Peeters PAM and Barenholz Y (1993) Tolerability of liposomes in vivo, in *Liposome Technology* (Gregoriadis G ed) pp 345-383, CRC Press, Inc, Boca Raton, FL.

Storm G, Steerenberg PA, Emmen F, Waalkes MvB and Crommelin DJA (1988) Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. *Biochim Biophys Acta* 965:136-145.

Storm G, ten Kate MT, Working PK and Bakker-Woudenberg IA (1998) Doxorubicin entrapped in sterically stabilized liposomes: Effects on bacterial blood clearance capacity of the mononuclear phagocyte system. *Clin Cancer Res* 4:111-115.

Straubinger RM, Düzgünes N and Papahadjopoulos D (1985) pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. *FEBS Lett* 179:148-154.

Straubinger RM, Hong K, Friend DS and Papahadjopoulos D (1983) Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles. *Cell* 32:1069-1079.

Straubinger RM, Lopez NG, Debs RJ, Hong K and Papahadjopoulos D (1988) Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. *Cancer Res* 48:5237-5245.

Subramanian D and Muller MT (1995) Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. *Oncol Res* 7:461-469.

Surewicz WK and Epand RM (1986) Phospholipid structure determines the effects of peptides on membranes: Differential scanning calorimetry studies with pentagastin-related peptides. *Biochim Biophys Acta* 856:290-300.

Swenson CE, Freitag J and Janoff AS (1998) The Liposome Company: Lipid-based pharmaceuticals in clinical development, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 689-702, Elsevier Science BV, New York.

Szoka F, Olson F, Heath T, Vail W, Mayhew E and Papahadjopoulos D (1980) Preparation of unilamellar liposomes of intermediate size (0.1-0.2 μ m) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. *Biochim Biophys Acta* 601:559-571.

Szoka F and Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. *Proc Natl Acad Sci USA* 75:4194-4198.

Szoka FC (1998) Commentary: Rantosomes and ravesomes. *J Liposome Res* 8:vii-ix.

Takanashi S and Bachur NR (1976) Adriamycin metabolism in man: Evidence from urinary metabolites. *Drug Metab Dispos* 4:79-87.

Thierry AR, Jorgensen TJ, Forst D, Belli JA, Dritschilo A and Rahman A (1989) Multidrug resistance in Chinese hamster cells: Effect of liposome encapsulated doxorubicin. *Cancer Commun* 1:311-316.

Torchilin V, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P and Veronese B (1995) The synthetic hydrophilic polymers for steric protection of liposome in vivo. *J Pharm Sci* 84:1049-1053.

Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV and Rahman A (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. *J Natl Cancer Inst* 82:1706-1710.

Trubetskaya OV, Trubetskoy VS, Domogatsky SP, Rudin AV, Popov NV, Danilov SM, Nikolayeva MN, Klibanov AL and Torchilin VP (1988) Monoclonal antibody to human endothelial cell surface internalization and liposome delivery in cell culture. *FEBS Lett* 228:131-134.

Unezaki S, Mauryama K, Ishida O, Suganaka A, Jun-ichi H and Iwatsuru M (1995) Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). *Int J Pharm* 126:41-48.

Uthayakumar S, Bower M, Money-Kyrle J, Muyschondt C, Youle M, Hannon F, Phillips R, Gazzard BG and Boag F (1996) Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. *AIDS* 10:515-519.

Utkhed DR and Tilcock CP (1998) Effect of lipid dose on the biodistribution and blood pool clearance kinetics of PEG-modified technetium-labeled lipid vesicles. *J Liposome Res* 8:381-390.

Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM and Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. *J Clin Oncol* 13:1777-1785.

Vaage J, Barberá-Guillem E, Abra R, Huang A and Working P (1994a) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. *Cancer* 73:1478-1484.

Vaage J, Donovan D, Colbern G, Uster P and Working P (1999) Tumor uptake and therapeutic effects of drugs encapsulated in long-circulating pegylated liposomes (Abstract). *Proc Am Assoc Cancer Res* 40:418.

Vaage J, Donovan D, Loftus T, Abra R, Working P and Huang A (1994b) Chemoprevention and therapy of mouse mammary carcinomas with doxorubicin encapsulated in sterically stabilized liposomes. *Cancer* 73:2366-2371.

Vaage J, Donovan D, Mayhew E, Abra R and Huang A (1993a) Therapy of human

ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. *Cancer* 72:3671-3675.

Vaage J, Donovan D, Mayhew E, Uster P and Woodle MC (1993b) Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. *Int J Cancer* 54:959-964.

Vaage J, Donovan D, Uster P and Working P (1997) Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. *Br J Cancer* 75:482-486.

Vaage J, Donovan D, Working P and Uster P (1998) Cellular distribution of DOXIL® within selected tissues, assessed by confocal laser scanning microscopy, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 275-282, Elsevier Science BV, New York.

Vaage J, Mayhew E, Lasic D and Martin F (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. *Int J Cancer* 51:942-948.

Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ and Obradovich JE (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: A randomized, double blind clinical trial using a canine model. *Clin Cancer Res* 4:1567-1571.

Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW and Hortobagyi GN (1999) Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. *J Clin Oncol* 17:1425-1434.

van Bree C, Krooshoop JJ, Riethbroek RC, Kipp JB and Bakker PJ (1996) Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. *Cancer Res* 56:563-568.

Vincent JS, Revak SD, Cochrane CG and Levin IW (1991) Raman spectroscopic studies of model human pulmonary surfactant systems: Phospholipid interactions with peptide paradigms for the surfactant protein SP-B. *Biochemistry* 30:8395-8401.

Vingerhoeds MH, Steenberg PA, Hendriks JJGW, Dekker LC, van Hoeseel QGCM, Crommelin DJA and Storm G (1996) Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. *Br J Cancer* 74:1023-1029.

Vogelzang NJ and Ratain MJ (1985) Cancer chemotherapy and skin changes. *Ann Intern Med* 103:303-304.

Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozenzweig M and Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 91:710-717.

Vose JM and Armitage JO (1995) Clinical applications of hematopoietic growth factors. *J Clin Oncol* 13:1023-1035.

Vukelja SJ, Baker WJ, Burris HA, Keeling JH and Von Hoff D (1993) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. *J Natl Cancer Inst* 85:1432-1433.

Vukelja SJ, Lombardo FA, James WD and Weiss RB (1989) Pyroxidine for palmar-plantar erythrodysesthesia syndrome. *Ann Intern Med* 111:688-689.

Wassef NM, Matyas GR and Alving CR (1991) Complement-dependent phagocytosis of liposomes by macrophages: Suppressive effects of "stealth" lipids. *Biochem Biophys Res Commun* 176:866-874.

Webb MS, Harasym TO, Masin D, Bally MB and Mayer LD (1995) Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. *Br J Cancer* 72:896-904.

Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR and Mayer LD (1998) Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine. *Biochim Biophys Acta* 1372:272-282.

Weinstein JN (1984) Liposomes as drug carriers in cancer therapy. *Cancer Treat Rep* 68:127-135.

Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM and Keenan AM (1987) The pharmacology of monoclonal antibodies. *Ann NY Acad Sci* 507:199-210.

Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V and Zurawski VR (1992a) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. *Cancer Res* 52:3396-3401.

Weitman SD, Weiberg AG, Coney LR, Zurawski VR, Jennings DS and Kamen BA (1992b) Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. *Cancer Res* 52:6708-6711.

Welling PG (1986) *Pharmacokinetics: Processes and Mathematics*, American Chemical Society, Washington, DC.

Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijkse G, Jackman AL and Schornagel JH (1991) Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: Role of carrier- and receptor-mediated transport systems. *Cancer Res* 51:5507-5513.

Westerhof GR, Rijnbouts S, Schornagel JH, Pinedo HM, Peters GJ and Jansen G (1995) Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate binding protein. *Cancer Res* 55:3795-3802.

Wheeler JJ, Wong KF, Ansell SM and Bally MB (1994) Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. *J Pharm Sci* 83:1558-1564.

White RM (1997) Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma. *AIDS* 11:1412-1413.

Wiley JS, Jones SP, Sawyer WH and Paterson ARP (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. *J Clin Invest* 69:479-489.

Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ and Bankert RB (1993) Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. *Cancer Res* 53:3964-3967.

Woodle MC and Lasic DD (1992) Sterically stabilized liposomes. *Biochim Biophys Acta* 1113:171-199.

Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, Martin FJ and Papahadjopoulos D (1992) Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. *Biochim Biophys Acta* 1105:193-200.

Woodle MC, Raynaud FI, Dizik M, Meyer O, Huang SK, Jaeger AJ, Brown BD, Brown BD, Judson IR and Papahadjopoulos D (1997) Oligonucleotide pharmacology and formulation: G3139 anti-bcl2 phosphorothioate in stealth liposomes and gel implants. *Nucleosides Nucleotides* 16:1731-1734.

Working PK (1998) Pre-clinical studies of lipid-complexed and liposomal drugs: AMPHOTEC®, DOXIL®, and SPI-77, in *Medical Applications of Liposomes* (Lasic DD and Papahadjopoulos D eds) pp 605-624, Elsevier Science BV, New York.

Working PK and Dayan AD (1996) Pharmacological-toxicological expert report: CAELYX® (Stealth® liposomal doxorubicin HCl) (Foreword). *Hum Exp Toxicol* 15:751-785.

Working PK, Newman MS, Huang SK, Mayhew E, Vaage J and Lasic DD (1994) Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). *J Liposome Res* 4:667-687.

Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z and Turner N (1998) Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. *Toxicol Sci* 46:155-165.

Working PK, Newman MS, Sullivan T and Yarrington J (1999) Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating pegylated liposomes. *J Pharmacol Exp Ther* 289:1128-1133.

Wu NZ, Braun RD, Gaber MH, Lin GM, Ong ET, Shan SQ, Papahadjopoulos D and Dewhirst MW (1997) Simultaneous measurement of liposome extravasation and content release in tumors. *Microcirculation (Lond)* 4:83-101.

Yatvin MB, Weinstein JN, Dennis WH and Blumenthal R (1978) Design of liposomes for enhanced local release of drugs by hyperthermia. *Science (Wash DC)* 202:1290-1293.

Yokota T, Milenic DE, Whitlow M and Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. *Cancer Res* 52:3402-3408.

Young RC, Ozols RF and Myers CE (1981) The anthracycline antineoplastic drugs. *N Engl J Med* 305:139-153.

Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin V and Jain R (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. *Cancer Res* 55:3752-3756.

Yuan F, Lwunig M, Huang SK, Berk DA, Papahadjopoulos D and Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. *Cancer Res* 54:3352-3356.

Zalipsky S, Hansen CB, Oaks JM and Allen TM (1996) Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. *J Pharm Sci* 85:133-137.

Zelphati O and Szoka FC (1996) Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. *Pharm Res* 13:1367-1372.

Zhang W, Guo L, Nadel JA and Papahadjopoulos D (1998) Inhibition of tracheal vascular extravasation by liposome-encapsulated albuterol in rats. *Pharm Res* 15:455-460.

Zhang R, Price JE, Fujimaki T, Bucana CD and Fidler IJ (1992) Differential permeability of the blood-brain barrier in experimental brain metastasis produced by human neoplasms implanted in nude mice. *Am J Pathol* 141:1115-1124.

Zuidam NJ, Gouw HKME, Barenholz Y and Crommelin DJA (1995) Physical (in) stability of liposomes on chemical hydrolysis: The role of lysophospholipids and fatty acids. *Biochim Biophys Acta* 1240:101-110.